

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number
WO 02/30860 A2

(51) International Patent Classification⁷: **C07C 49/17**,
49/245, 49/258, 49/185, A61K 31/12, 31/122, 31/185,
31/21, 31/275, 31/095, 31/33, 31/66, A61P 9/00, C07C
49/82, 49/86, 49/782, 49/215, 49/723, 49/743, 49/747,
49/507, 50/30, 261/04, C07F 9/09, 9/24, 9/44, C07C
69/716, 69/738, 309/24, 309/07

Daniela; 3920 N.W. 23rd Street, Gainesville, FL 32605
(US).

(74) Agent: **INSOGNA, Anthony, M.**; Pennie & Edmonds
LLP, 1155 Avenue of the Americas, New York, NY 10036
(US).

(21) International Application Number: PCT/US01/31872

(22) International Filing Date: 11 October 2001 (11.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/239,232 11 October 2000 (11.10.2000) US

(71) Applicant: **ESPERION THERAPEUTICS, INC.**
[US/US]; 3621 S. State Street, 695 KMS Place, Ann
Arbor, MI 48108 (US).

(72) Inventors: **DASSEUX, Jean-Louis, H.**; 7898 Huron
Oak Drive, Brighton, MI 48116 (US). **ONICIU, Carmen,**


(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

[Continued on next page]

(54) Title: KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES

Effect of One Week of Daily Oral Gavage Treatment with Compound B on Lipoprotein
Total Cholesterol in Chow-Fed Male Sprague-Dawley Rats



(57) Abstract: The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.



WO 02/30860 A2



Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**KETONE COMPOUNDS AND COMPOSITIONS
FOR CHOLESTEROL MANAGEMENT AND RELATED USES**

5

1. Field of The Invention

The present invention relates to ketone compounds; compositions comprising the ketone compounds; and methods for treating or preventing a disease or disorder, such as cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, Alzheimer's Disease, Syndrome X, a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. The ketone compounds and compositions of the invention may also be used to reduce the fat content of meat in livestock and reduce the cholesterol content of eggs.

15

2. Background of The Invention

Obesity, hyperlipidemia, and diabetes have been shown to play a causal role in atherosclerotic cardiovascular diseases, which currently account for a considerable proportion of morbidity in Western society. Further, one human disease, termed "Syndrome X" or "Metabolic Syndrome", is manifested by defective glucose metabolism (insulin resistance), elevated blood pressure (hypertension), and a blood lipid imbalance (dyslipidemia). *See e.g. Reaven, 1993, Annu. Rev. Med. 44:121-131.*

The evidence linking elevated serum cholesterol to coronary heart disease is overwhelming. Circulating cholesterol is carried by plasma lipoproteins, which are particles of complex lipid and protein composition that transport lipids in the blood. Low density lipoprotein (LDL) and high density lipoprotein (HDL) are the major cholesterol-carrier proteins. LDL is believed to be responsible for the delivery of cholesterol from the liver, where it is synthesized or obtained from dietary sources, to extrahepatic tissues in the body. The term "reverse cholesterol transport" describes the transport of cholesterol from extrahepatic tissues to the liver, where it is catabolized and eliminated. It is believed that plasma HDL particles play a major role in the reverse transport process, acting as scavengers of tissue cholesterol. HDL is also responsible for the removal of non-cholesterol lipid, oxidized cholesterol and other oxidized products from the bloodstream.

Atherosclerosis, for example, is a slowly progressive disease characterized by the accumulation of cholesterol within the arterial wall. Compelling evidence supports the

belief that lipids deposited in atherosclerotic lesions are derived primarily from plasma apolipoprotein B (apo B)-containing lipoproteins, which include chylomicrons, CLDL, IDL and LDL. The apo B-containing lipoprotein, and in particular LDL, has popularly become known as the "bad" cholesterol. In contrast, HDL serum levels correlate inversely with coronary heart disease. Indeed, high serum levels of HDL are regarded as a negative risk factor. It is hypothesized that high levels of plasma HDL are not only protective against coronary artery disease, but may actually induce regression of atherosclerotic plaque (*e.g.*, see Badimon *et al.*, 1992, *Circulation* 86:(Suppl. III)86-94; Dansky and Fisher, 1999, *Circulation* 100:1762-3.). Thus, HDL has popularly become known as the "good" cholesterol.

2.1. Cholesterol Transport

The fat-transport system can be divided into two pathways: an exogenous one for cholesterol and triglycerides absorbed from the intestine and an endogenous one for cholesterol and triglycerides entering the bloodstream from the liver and other non-hepatic tissue.

In the exogenous pathway, dietary fats are packaged into lipoprotein particles called chylomicrons, which enter the bloodstream and deliver their triglycerides to adipose tissue for storage and to muscle for oxidation to supply energy. The remnant of the chylomicron, which contains cholesteryl esters, is removed from the circulation by a specific receptor found only on liver cells. This cholesterol then becomes available again for cellular metabolism or for recycling to extrahepatic tissues as plasma lipoproteins.

In the endogenous pathway, the liver secretes a large, very-low-density lipoprotein particle (VLDL) into the bloodstream. The core of VLDL consists mostly of triglycerides synthesized in the liver, with a smaller amount of cholesteryl esters either synthesized in the liver or recycled from chylomicrons. Two predominant proteins are displayed on the surface of VLDL, apolipoprotein B-100 (apo B-100) and apolipoprotein E (apo E), although other apolipoproteins are present, such as apolipoprotein CIII (apo CIII) and apolipoprotein CII (apo CII). When a VLDL reaches the capillaries of adipose tissue or of muscle, its triglyceride is extracted. This results in the formation of a new kind of particle called intermediate-density lipoprotein (IDL) or VLDL remnant, decreased in size and enriched in cholesteryl esters relative to a VLDL, but retaining its two apoproteins.

In human beings, about half of the IDL particles are removed from the circulation quickly, generally within two to six hours of their formation. This is because IDL particles bind tightly to liver cells, which extract IDL cholesterol to make new VLDL and bile acids.

The IDL not taken up by the liver is catabolized by the hepatic lipase, an enzyme bound to the proteoglycan on liver cells. Apo E dissociates from IDL as it is transformed to LDL. Apo B-100 is the sole protein of LDL.

Primarily, the liver takes up and degrades circulating cholesterol to bile acids, which
5 are the end products of cholesterol metabolism. The uptake of cholesterol-containing particles is mediated by LDL receptors, which are present in high concentrations on hepatocytes. The LDL receptor binds both apo E and apo B-100 and is responsible for binding and removing both IDL and LDL from the circulation. In addition, remnant receptors are responsible for clearing chylomicrons and VLDL remnants (*i.e.*, IDL).
10 However, the affinity of apo E for the LDL receptor is greater than that of apo B-100. As a result, the LDL particles have a much longer circulating life span than IDL particles; LDL circulates for an average of two and a half days before binding to the LDL receptors in the liver and other tissues. High serum levels of LDL, the "bad" cholesterol, are positively associated with coronary heart disease. For example, in atherosclerosis, cholesterol derived
15 from circulating LDL accumulates in the walls of arteries. This accumulation forms bulky plaques that inhibit the flow of blood until a clot eventually forms, obstructing an artery and causing a heart attack or stroke.

Ultimately, the amount of intracellular cholesterol liberated from the LDL controls cellular cholesterol metabolism. The accumulation of cellular cholesterol derived from
20 VLDL and LDL controls three processes. First, it reduces the cell's ability to make its own cholesterol by turning off the synthesis of HMGCoA reductase, a key enzyme in the cholesterol biosynthetic pathway. Second, the incoming LDL-derived cholesterol promotes storage of cholesterol by the action of cholesterol acyltransferase ("ACAT"), the cellular enzyme that converts cholesterol into cholesteryl esters that are deposited in storage
25 droplets. Third, the accumulation of cholesterol within the cell drives a feedback mechanism that inhibits cellular synthesis of new LDL receptors. Cells, therefore, adjust their complement of LDL receptors so that enough cholesterol is brought in to meet their metabolic needs, without overloading (for a review, see Brown & Goldstein, In, The Pharmacological Basis Of Therapeutics, 8th Ed., Goodman & Gilman, Pergamon Press,
30 New York, 1990, Ch. 36, pp. 874-896).

High levels of apo B-containing lipoproteins can be trapped in the subendothelial space of an artery and undergo oxidation. The oxidized lipoprotein is recognized by scavenger receptors on macrophages. Binding of oxidized lipoprotein to the scavenger receptors can enrich the macrophages with cholesterol and cholesteryl esters independently
35 of the LDL receptor. Macrophages can also produce cholesteryl esters by the action of

ACAT. LDL can also be complexed to a high molecular weight glycoprotein called apolipoprotein(a), also known as apo(a), through a disulfide bridge. The LDL-apo(a) complex is known as Lipoprotein(a) or Lp(a). Elevated levels of Lp(a) are detrimental, having been associated with atherosclerosis, coronary heart disease, myocardial infarction, stroke, cerebral infarction, and restenosis following angioplasty.

2.2. Reverse Cholesterol Transport

Peripheral (non-hepatic) cells predominantly obtain their cholesterol from a combination of local synthesis and uptake of preformed sterol from VLDL and LDL. Cells expressing scavenger receptors, such as macrophages and smooth muscle cells, can also obtain cholesterol from oxidized apo B-containing lipoproteins. In contrast, reverse cholesterol transport (RCT) is the pathway by which peripheral cell cholesterol can be returned to the liver for recycling to extrahepatic tissues, hepatic storage, or excretion into the intestine in bile. The RCT pathway represents the only means of eliminating cholesterol from most extrahepatic tissues and is crucial to maintenance of the structure and function of most cells in the body.

The enzyme in blood involved in the RCT pathway, lecithin:cholesterol acyltransferase (LCAT), converts cell-derived cholesterol to cholesteryl esters, which are sequestered in HDL destined for removal. LCAT is produced mainly in the liver and circulates in plasma associated with the HDL fraction. Cholesterol ester transfer protein (CETP) and another lipid transfer protein, phospholipid transfer protein (PLTP), contribute to further remodeling the circulating HDL population (see for example Bruce *et al.*, 1998, *Annu. Rev. Nutr.* 18:297-330). PLTP supplies lecithin to HDL, and CETP can move cholesteryl ester made by LCAT to other lipoproteins, particularly apoB-containing lipoproteins, such as VLDL. HDL triglyceride can be catabolized by the extracellular hepatic triglyceride lipase, and lipoprotein cholesterol is removed by the liver via several mechanisms.

Each HDL particle contains at least one molecule, and usually two to four molecules, of apolipoprotein (apo A-I). Apo A-I is synthesized by the liver and small intestine as preproapolipoprotein which is secreted as a proprotein that is rapidly cleaved to generate a mature polypeptide having 243 amino acid residues. Apo A-I consists mainly of a 22 amino acid repeating segment, spaced with helix-breaking proline residues. Apo A-I forms three types of stable structures with lipids: small, lipid-poor complexes referred to as pre-beta-1 HDL; flattened discoidal particles, referred to as pre-beta-2 HDL, which contain only polar lipids (*e.g.*, phospholipid and cholesterol); and spherical particles containing both

polar and nonpolar lipids, referred to as spherical or mature HDL (HDL₃ and HDL₂). Most HDL in the circulating population contains both apo A-I and apo A-II, a second major HDL protein. This apo A-I- and apo A-II-containing fraction is referred to herein as the AI/AII-HDL fraction of HDL. But the fraction of HDL containing only apo A-I, referred to herein
5 as the AI-HDL fraction, appears to be more effective in RCT. Certain epidemiologic studies support the hypothesis that the AI-HDL fraction is antiatherogenic (Parra *et al.*, 1992, *Arterioscler. Thromb.* 12:701-707; Decossin *et al.*, 1997, *Eur. J. Clin. Invest.* 27:299-307).

Although the mechanism for cholesterol transfer from the cell surface is unknown, it
10 is believed that the lipid-poor complex, pre-beta-1 HDL, is the preferred acceptor for cholesterol transferred from peripheral tissue involved in RCT. Cholesterol newly transferred to pre-beta-1 HDL from the cell surface rapidly appears in the discoidal pre-beta-2 HDL. PLTP may increase the rate of disc formation (Lagrost *et al.*, 1996, *J. Biol. Chem.* 271:19058-19065), but data indicating a role for PLTP in RCT is lacking. LCAT
15 reacts preferentially with discoidal and spherical HDL, transferring the 2-acyl group of lecithin or phosphatidylethanolamine to the free hydroxyl residue of fatty alcohols, particularly cholesterol, to generate cholesteryl esters (retained in the HDL) and lysolecithin. The LCAT reaction requires an apolipoprotein such as apo A-I or apo A-IV as an activator. ApoA-I is one of the natural cofactors for LCAT. The conversion of cholesterol to its HDL-
20 sequestered ester prevents re-entry of cholesterol into the cell, resulting in the ultimate removal of cellular cholesterol. Cholesteryl esters in the mature HDL particles of the AI-HDL fraction are removed by the liver and processed into bile more effectively than those derived from the AI/AII-HDL fraction. This may be due, in part, to the more effective binding of AI-HDL to the hepatocyte membrane. Several HDL receptors have been
25 identified, the most well characterized of which is the scavenger receptor class B, type I (SR-BI) (Acton *et al.*, 1996, *Science* 271:518-520). The SR-BI is expressed most abundantly in steroidogenic tissues (*e.g.*, the adrenals), and in the liver (Landshulz *et al.*, 1996, *J. Clin. Invest.* 98:984-995; Rigotti *et al.*, 1996, *J. Biol. Chem.* 271:33545-33549). Other proposed HDL receptors include HB1 and HB2 (Hidaka and Fidge, 1992, *Biochem J.*
30 15:161-7; Kurata *et al.*, 1998, *J. Atherosclerosis and Thrombosis* 4:112-7).

While there is a consensus that CETP is involved in the metabolism of VLDL- and LDL-derived lipids, its role in RCT remains controversial. However, changes in CETP activity or its acceptors, VLDL and LDL, play a role in "remodeling" the HDL population. For example, in the absence of CETP, the HDL becomes enlarged particles that are poorly
35 removed from the circulation (for reviews on RCT and HDL, See Fielding & Fielding,

1995, *J. Lipid Res.* 36:211-228; Barrans *et al.*, 1996, *Biochem. Biophys. Acta.* 1300:73-85; Hirano *et al.*, 1997, *Arterioscler. Thromb. Vasc. Biol.* 17:1053-1059).

5 2.3. Reverse Transport of Other Lipids

HDL is not only involved in the reverse transport of cholesterol, but also plays a role in the reverse transport of other lipids, *i.e.*, the transport of lipids from cells, organs, and tissues to the liver for catabolism and excretion. Such lipids include sphingomyelin, oxidized lipids, and lysophosphatidylcholine. For example, Robins and Fasulo (1997, *J. Clin. Invest.* 99:380-384) have shown that HDL stimulates the transport of plant sterol by the liver into bile secretions.

2.4. Peroxisome Proliferator Activated Receptor Pathway

15 Peroxisome proliferators are a structurally diverse group of compounds that, when administered to rodents, elicit dramatic increases in the size and number of hepatic and renal peroxisomes, as well as concomitant increases in the capacity of peroxisomes to metabolize fatty acids via increased expression of the enzymes required for the β -oxidation cycle (Lazarow and Fujiki, 1985, *Ann. Rev. Cell Biol.* 1:489-530; Vamecq and Draye, 1989, *Essays Biochem.* 24:1115-225; and Nelali *et al.*, 1988, *Cancer Res.* 48:5316-5324).

20 Chemicals included in this group are the fibrate class of hypolipidemic drugs, herbicides, and phthalate plasticizers (Reddy and Lalwani, 1983, *Crit. Rev. Toxicol.* 12:1-58).

Peroxisome proliferation can also be elicited by dietary or physiological factors, such as a high-fat diet and cold acclimatization.

Insight into the mechanism whereby peroxisome proliferators exert their pleiotropic effects was provided by the identification of a member of the nuclear hormone receptor superfamily activated by these chemicals (Isseman and Green, 1990, *Nature* 347:645-650). This receptor, termed peroxisome proliferator activated receptor α (PPAR $_{\alpha}$), was subsequently shown to be activated by a variety of medium and long-chain fatty acids. PPAR $_{\alpha}$ activates transcription by binding to DNA sequence elements, termed peroxisome proliferator response elements (PPRE), in the form of a heterodimer with the retinoid X receptor (RXR). RXR is activated by 9-cis retinoic acid (*see* Kliewer *et al.*, 1992, *Nature* 358:771-774; Gearing *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 90:1440-1444, Keller *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 90:2160-2164; Heyman *et al.*, 1992, *Cell* 68:397-406, and Levin *et al.*, 1992, *Nature* 355:359-361). Since the discovery of PPAR $_{\alpha}$, additional

isoforms of PPAR have been identified, *e.g.*, PPAR_β, PPAR_γ and PPAR_δ, which have similar functions and are similarly regulated.

PPREs have been identified in the enhancers of a number of gene-encoding proteins that regulate lipid metabolism. These proteins include the three enzymes required for peroxisomal β-oxidation of fatty acids; apolipoprotein A-I; medium-chain acyl-CoA dehydrogenase, a key enzyme in mitochondrial β-oxidation; and aP2, a lipid binding protein expressed exclusively in adipocytes (reviewed in Keller and Whali, 1993, *TEM*, 4:291-296; *see also* Staels and Auwerx, 1998, *Atherosclerosis* 137 Suppl:S19-23). The nature of the PPAR target genes coupled with the activation of PPARs by fatty acids and hypolipidemic drugs suggests a physiological role for the PPARs in lipid homeostasis.


2.5. Current Cholesterol Management Therapies

None of the commercially available cholesterol management drugs has a general utility in regulating lipid, lipoprotein, insulin and glucose levels in the blood. Thus, compounds that have one or more of these utilities are clearly needed. Further, there is a clear need to develop safer drugs that are efficacious at lowering serum cholesterol, increasing HDL serum levels, preventing coronary heart disease, and/or treating existing disease such as atherosclerosis, obesity, diabetes, and other diseases that are affected by lipid metabolism and/or lipid levels. There is also a clear need to develop drugs that may be used with other lipid-altering treatment regimens in a synergistic manner. There is still a further need to provide useful therapeutic agents whose solubility and Hydrophile/Lipophile Balance (HLB) can be readily varied.

Citation or identification of any reference in Section 2 of this application is not an admission that such reference is available as prior art to the present invention.

3. Summary of The Invention

In one embodiment, the invention relates to a compound of formula I:



I


or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, stereoisomer, diastereomer, racemate, geometric isomer or mixtures thereof wherein:

- (a) each occurrence of Z is independently CH_2 , $\text{CH}=\text{CH}$, or phenyl, wherein each occurrence of m is independently an integer ranging from 1 to 9, but when Z is phenyl then its associated m is 1;
- 5 (b) G is $(\text{CH}_2)_x$, $\text{CH}_2\text{CH}=\text{CHCH}_2$, $\text{CH}=\text{CH}$, CH_2 -phenyl- CH_2 , or phenyl, wherein x is 2, 3, or 4;
- (c) W^1 and W^2 are independently L, V, $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_c-\text{C}(\text{R}^3)(\text{R}^4)-(\text{CH}_2)_n-\text{Y}$, or $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_c-\text{V}$, wherein c is 1 or 2 and n is an independent integer ranging from 0 to 4;
- 10 (d) each occurrence of R^1 and R^2 is independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl or when W^1 or W^2 is $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_c-\text{C}(\text{R}^3)(\text{R}^4)-\text{Y}$, then R^1 and R^2 can both be H;
- 15 (e) R^3 is H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_1-C_6) alkoxy, phenyl, benzyl, Cl, Br, CN, NO_2 , or CF_3 ;
- (f) R^4 is OH, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_1-C_6) alkoxy, phenyl, benzyl, Cl, Br, CN, NO_2 , or CF_3 ;
- 20 (g) L is $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_n-\text{Y}$; where n is an independent integer ranging from 0 to 4;
- (h) V is


25

30

35



(i) each occurrence of Y is independently OH, COOH, CHO, COOR⁵, SO₃H,



where:

5

(i) R⁵ is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C₁-C₆)alkoxy, or phenyl groups,

(ii) each occurrence of R⁶ is independently H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, or (C₂-C₆)alkynyl and is unsubstituted or substituted with one or two halo, OH, C₁-C₆alkoxy, or phenyl groups; and

10

- (iii) each occurrence of R^7 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;

5

provided that:

10

- (i) if G is $(CH_2)_x$, x is 4, each occurrence of Z is CH_2 , each occurrence of m is 4, and W^1 is $-CH(CH_3)CO_2H$, then W^2 is not the same as W^1 ;

- (ii) if G is CH_2 -phenyl- CH_2 , each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(CH_3)_2CH(CO_2CH_2CH_3)_2$, then W^2 is not the same as W^1 ;

15

- (iii) if G is CH_2 -phenyl- CH_2 , each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(CH_3)_2CH_2(CO_2CH_2CH_3)$, then W^2 is not the same as W^1 ;

- (iv) if G is CH_2 -phenyl- CH_2 , each occurrence of Z is CH_2 , each occurrence of m is 1, and W^1 is $-COCH_2C(CH_3)_2CH_2CO_2H$, then W^2 is not the same as W^1 ;

20

- (v) if G is $(CH_2)_x$, x is 4, each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(phenyl)_2CH_2CO_2H$, then W^2 is not the same as W^1 ;

25

- (vi) if G is $CH=CH$, each occurrence of Z is CH_2 , each occurrence of m is 1, and W^1 is $-C(CH_3)_2CH_2(CO_2H)$, then W^2 is not the same as W^1 ; and

- (vii) if G is phenyl, each occurrence of Z is CH_2 , each occurrence of m is 1, and W^1 is $-C(phenyl)_2CO_2H$, then W^2 is not the same as W^1 .

30

Preferred compounds of formula I are those wherein:

- (a) W^1 and W^2 are independently L, V, or $C(R^1)(R^2)-(CH_2)_c-V$, where c is 1 or 2; and

- (b) R^1 and R^2 are independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl.

Other preferred compounds of formula **I** are those wherein W^1 is L.

5 Other preferred compounds of formula **I** are those wherein W^1 is V.


Other preferred compounds of formula **I** are those wherein W^1 is $C(R^1)(R^2)-(CH_2)_c-C(R^3)(R^4)-(CH_2)_n-Y$.

Other preferred compounds of formula **I** are those wherein W^1 is $C(R^1)(R^2)-(CH_2)_c-V$.

10 Other preferred compounds of formula **I** are those wherein W^1 and W^2 are independent L groups.

Other preferred compounds of formula **I** are those wherein each occurrence of Y is independently OH, $COOR^5$, or COOH.

15 In another embodiment, the invention relates to a compound of the formula **Ia**:



Ia


20

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

- (a) each occurrence of Z is independently CH_2 or $CH=CH$, wherein each occurrence of m is independently an integer ranging from 1 to 9;
- (b) G is $(CH_2)_x$, $CH_2CH=CHCH_2$, or $CH=CH$, where x is 2, 3, or 4;
- (c) W^1 and W^2 are independently L, V, or $C(R^1)(R^2)-(CH_2)_c-V$, where c is 1 or 2;
- (d) each occurrence of R^1 and R^2 is independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl;
- (e) L is $C(R^1)(R^2)-(CH_2)_n-Y$, where n is an independent integer ranging from 0 to 4;


35

(f) V is



(g) each occurrence of Y is independently OH, COOH, CHO, $(\text{CH}_2)_n\text{COOR}^3$, SO_3H ,

5



where:

(i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,

(ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups; and

(iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;


provided that:

(i) if x is 4, each occurrence of Z is CH_2 , each occurrence of m is 4, and W^1 is $-CH(CH_3)CO_2H$, then W^2 is not the same as W^1 ; and

(ii) if x is 4, each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(phenyl)_2CH_2CO_2H$, then W^2 is not the same as W^1 .

Preferably, in formula **Ia** each occurrence of Y is independently OH, $COOR^3$, or COOH.

In yet another embodiment, the invention relates to a compound of the formula **Ib**:



or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

(a) each occurrence of m is independently an integer ranging from 1 to 9;





(b) x is 2, 3, or 4;

- (c) each occurrence of n is an independent integer ranging from 0 to 4;
- (d) each occurrence of R¹ and R² is independently (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl; and

5

- (e) each occurrence of Y is independently OH, COOH, CHO, COOR³, SO₃H,

10



15

where:


- (i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- (ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups; and
- (iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;

provided that:

- (i) if x is 4 each occurrence of m is 4, and W^1 is $-CH(CH_3)CO_2H$, then W^2 is not the same as W^1 ; and
- (ii) if x is 4 occurrence of m is 2, and W^1 is $-C(phenyl)_2CH_2CO_2H$, then W^2 is not the same as W^1 .


Preferably in formula **Ib**, each occurrence of Y is independently OH, $COOR^3$, or COOH.

In still another embodiment, the invention relates to a compound of the formula **Ic**:



or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

- (a) each occurrence of m is an independent integer ranging from 1 to 9;
- (b) x is 2, 3, or 4;
- (c) V is



provided that:


- (i) if x is 4 each occurrence of m is 4, and W^1 is $-\text{CH}(\text{CH}_3)\text{CO}_2\text{H}$, then W^2 is not the same as W^1 ; and

5

- (ii) if x is 4 each occurrence of m is 2, and W^1 is $-\text{C}(\text{phenyl})_2\text{CH}_2\text{CO}_2\text{H}$, then W^2 is not the same as W^1 .

In another embodiment, the invention relates to a compound of the formula II:

10



II


15 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:


- (a) R¹ and R² are independently (C₁–C₆)alkyl, (C₂–C₆)alkenyl, (C₂–C₆)alkynyl, phenyl, or benzyl; or R¹, R², and the carbon to which they are both attached are taken together to form a (C₃–C₇)cycloalkyl group;

20

- (b) n is an integer ranging from 1 to 5;

- (c) each occurrence of m is independently an integer ranging from 0 to 4;
- (d) each occurrence of W¹ and W² is independently CH₂OH, COOH, CHO, OC(O)R³, C(O)OR³, SO₃H,





where:

- (i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- (ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups;
- (iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl; and
- (iv) each occurrence of n is independently an integer ranging from 0 to 4.

Preferred compounds of formula **II** are those wherein each occurrence of W is independently OH, $COOR^3$, or COOH.

Other preferred compounds of formula **II** are those wherein R^1 and R^2 are independent (C_1-C_6) alkyl groups.

Other preferred compounds of formula **II** are those wherein m is 0.

Other preferred compounds of formula **II** are those wherein m is 1.

Other preferred compounds of formula **II** are those wherein R^1 and R^2 are each independently (C_1-C_6) alkyl.


Other preferred compounds of formula **II** are those wherein R¹ and R² are each methyl.

Other preferred compounds of formula **II** are those wherein W¹ and/or W² is COOH or CH₂OH.

5


In another embodiment, the invention relates to a compound of the formula **IIa**:

10

**IIa**

15 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

(a) R¹ and R² are OH, COOH, CHO, COOR⁷, SO₃H,



20

where:

(i) R⁷ is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C₁-C₆)alkoxy, or phenyl groups,

25

- (ii) each occurrence of R^8 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups, and
- 5 (iii) each occurrence of R^9 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;
- (b) R^3 and R^4 are (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl;
- 10 (c) R^5 and R^6 are hydrogen, halogen, (C_1-C_4) alkyl, (C_1-C_4) alkoxy, (C_6) aryloxy, CN, or NO_2 , $N(R^5)_2$ where R^5 is H, (C_1-C_4) alkyl, phenyl, or benzyl;
- (d) each occurrence of m is independently an integer ranging from 1 to 5;
- 15 (e) each occurrence of n is independently an integer ranging from 0 to 4; and
- (f) C^{*1} and C^{*2} represent independent chiral-carbon centers, wherein each center may independently be R or S.
- 20 Preferred compounds of formula **IIa** are those wherein each occurrence of R^1 and R^2 is independently OH, $COOR^7$, or COOH.
- Other preferred compounds of formula **IIa** are those wherein m is 0.
- Other preferred compounds of formula **IIa** are those wherein m is 1.
- Other preferred compounds of formula **IIa** are those wherein R^1 and/or R^2 is COOH
- 25 or CH_2OH .
- Other preferred compounds of formula **IIa** are those wherein R^3 and R^4 are each independently (C_1-C_6) alkyl.
- Other preferred compounds of formula **IIa** are those wherein R^3 and R^4 are each methyl.
- 30 Other preferred compounds of formula **IIa** are those wherein C^{*1} is of the stereochemical configuration R or substantially R.
- Other preferred compounds of formula **IIa** are those wherein C^{*1} is of the stereochemical configuration S or substantially S.
- Other preferred compounds of formula **IIa** are those wherein C^{*2} is of the
- 35 stereochemical configuration R or substantially R.

Other preferred compounds of formula **IIa** are those wherein C^{*2} is of the stereochemical configuration S or substantially S.


In a particular embodiment, compounds of formula **IIa** are those wherein C^{*1} C^{*2} are of the stereochemical configuration (S¹,S²) or substantially (S¹,S²).

5 In another particular embodiment, compounds of formula **IIa** are those wherein C^{*1} C^{*2} are of the stereochemical configuration (S¹,R²) or substantially (S¹,R²).

In another particular embodiment, compounds of formula **IIa** are those wherein C^{*1} C^{*2} are of the stereochemical configuration (R¹,R²) or substantially (R¹,R²).

10 In another particular embodiment, compounds of formula **IIa** are those wherein C^{*1} C^{*2} are of the stereochemical configuration (R¹,S²) or substantially (R¹,S²).


In still another embodiment, the invention relates to a compound of the formula **III**:



III


15 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

- (a) each occurrence of Z is independently CH₂, CH=CH, or phenyl, where each occurrence of m is independently an integer ranging from 1 to 5, but when Z is phenyl then its associated m is 1;
- 20 (b) G is (CH₂)_x, CH₂CH=CHCH₂, CH=CH, CH₂-phenyl-CH₂, or phenyl, where x is an integer ranging from 1 to 4;
- 25 (c) W¹ and W² are independently C(R¹)(R²)-(CH₂)_n-Y where n is an integer ranging from 0 to 4;





- (d) each occurrence of R¹ and R² is independently (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl, or where R¹ and R² are both hydrogen;
- 5 (e) each occurrence of R⁶ and R⁷ is independently H, (C₁-C₆)alkyl, or where R⁶ and R⁷ are taken together to form a carbonyl group;
- (f) each occurrence of Y is independently OH, COOH, CHO, COOR³, SO₃H,

10



15





where:

- 5 (i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- 10 (ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- (iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl; and
- 15 (g) each occurrence of p is independently 0 or 1, where the broken line represents an optional presence of one or more additional carbon-carbon bonds that when present complete one or more carbon-carbon double bonds.


Preferred compounds of formula **III** are those wherein each occurrence of Y is independently OH, $COOR^3$, or COOH.

20 Other preferred compounds of formula **III** are those wherein p is 2.

Other preferred compounds of formula **III** are those wherein p is 3.

25


In yet another embodiment, the invention relates to a compound of the formula **IIIa**:




IIIa

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric
5 isomer or mixtures thereof wherein:

- (a) each occurrence of m is independently an integer ranging from 1 to 5;
- (b) x is an integer ranging from 1 to 4;
- (c) W^1 and W^2 are independently $C(R^1)(R^2)-(CH_2)_n-Y$; where n is an integer ranging from 0 to 4,



- 15 (d) each occurrence of R¹ or R² is independently (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl;
- (e) each occurrence of Y is independently OH, COOH, CHO, COOR³, SO₃H,



where:

(i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,

(ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups,

(iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl; and

(f) each occurrence of p is independently 0 or 1.

5 Preferably in compound **IIIa**, W^1 and W^2 are independent $C(R^1)(R^2)-Y$ groups and each occurrence of Y is independently OH, $COOR^3$, or COOH.

The compounds of the invention are useful in medical applications for treating or preventing cardiovascular diseases, dyslipidemias, dyslipoproteinemias, disorders of glucose metabolism, Alzheimer's Disease, Syndrome X, PPAR-associated disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal diseases, cancer,
10 inflammation, and impotence. As used herein, the phrase "compounds of the invention" means, collectively, the compounds of formulas **I**, **II**, and **III** and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof. Compounds of formula **I** encompass subgroup formulas **Ia**, **Ib**, and **Ic**. Compounds of formula **II** encompass subgroup formula **IIa** and compounds
15 of formula **III** encompass subgroup of formula **IIIa**. Thus, "compound of the invention" collectively means compound of formulas **I**, **Ia**, **Ib**, **Ic**, **II**, **IIa**, **III**, and **IIIa** and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof. The compounds of the invention are identified herein by their chemical structure and/or chemical name. Where a compound is
20 referred to by both a chemical structure and a chemical name, and the chemical structure and chemical name conflict, the chemical structure is determinative of the compound's identity.

3.1. Brief Description of the Drawings

25 Various aspects of the invention can be understood with reference to the figures described below:

FIG. 1 illustrates the effect of one week of daily oral gavage treatment on lipoprotein total cholesterol in chow-fed male Sprague-Dawley rats;

FIG. 2 illustrates the effect of one week of daily oral gavage treatment on serum lipids in chow-fed male Sprague-Dawley rats;

30 FIG. 3 illustrates the effect of two weeks of daily oral gavage treatment on lipoprotein total cholesterol in chow-fed obese female Zucker rats;

FIG. 4 is a table illustrating the effect of two weeks of daily oral gavage treatment using a specific compound of the invention in chow-fed obese female Zucker rats; and

35 FIG. 5 is a table illustrating the effect of two weeks of daily oral gavage treatment using a specific compound of the invention on the synthesis of saponified and non-saponified

lipids in hepatocyte cells isolated from male Sprague-Dawley rats.

4. Detailed Description of the Invention

The present invention provides novel compounds useful for treating or preventing a cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, Alzheimer's Disease, Syndrome X, a PPAR-associated disorder, septicemia, a thrombotic disorder, obesity, pancreatitis, hypertension, a renal disease, cancer, inflammation, and impotence.

In this regard, the compounds of the invention are particularly useful when incorporated in a pharmaceutical composition having a carrier, excipient, diluent, or a mixture thereof. A composition of the invention need not contain additional ingredients, such as an excipient, other than a compound of the invention. Accordingly, in one embodiment, the compositions of the invention can omit pharmaceutically acceptable excipients and diluents and can be delivered in a gel cap or drug delivery device.


Accordingly, the present invention provides methods for treating or preventing cardiovascular diseases, dyslipidemias, dyslipoproteinemias, disorders of glucose metabolism, Alzheimer's Disease, Syndrome X, PPAR-associated disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal diseases, cancer, inflammation, or impotence, comprising administering to a patient in need thereof a therapeutically effective amount of a compound or composition of the invention.

In certain embodiments of the invention, a compound of the invention is administered in combination with another therapeutic agent. The other therapeutic agent provides additive or synergistic value relative to the administration of a compound of the invention alone. The therapeutic agent can be a lovastatin; a thiazolidinedione or fibrate; a bile-acid-binding-resin; a niacin; an anti-obesity drug; a hormone; a tyroprostatin; a sulfonylurea-based drug; a biguanide; an α -glucosidase inhibitor; an apolipoprotein A-I agonist; apolipoprotein E; a cardiovascular drug; an HDL-raising drug; an HDL enhancer; or a regulator of the apolipoprotein A-I, apolipoprotein A-IV and/or apolipoprotein genes.

Table 1 lists the compounds of the invention:

TABLE 1: Compounds of the Invention


5

**I-1**

10


5-Hydroxy-1-[4-(5-hydroxy-5-methyl-2-oxo-hexyl)-phenyl]-5-methyl-hexan-2-one

15

**I-2**

6-Hydroxy-1-[4-(6-hydroxy-5,5-dimethyl-2-oxo-hexyl)-phenyl]-5,5-dimethyl-hexan-2-one


20

**I-3**

25


6-[4-(5-Carboxy-5-methyl-2-oxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanoic acid

30

**I-4**

6-[4-(5,5-Dimethyl-2,6-dioxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanal

35




5

I-5

6-[4-(5-Methoxycarbonyl-5-methyl-2-oxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanoic acid methyl ester

10




15

I-6

2,2-Dimethyl-6-[4-(5-methyl-2-oxo-5-phenoxy-carbonyl-hexyl)-phenyl]-5-oxo-hexanoic acid phenyl ester

20




25

I-7

6-[4-(5-Benzyloxycarbonyl-5-methyl-2-oxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanoic acid benzyl ester

30




35

I-8

2-Methyl-6-[4-(5-methyl-2-oxo-5-sulfo-hexyl)-phenyl]-5-oxo-hexane-2-sulfonic acid


5

**I-9**

10

Phosphoric acid mono-{1,1-dimethyl-5-[4-(5-methyl-2-oxo-5-phosphonooxy-hexyl)-phenyl]-4-oxo-pentyl} ester


15

**I-10**

20

4-Hydroxy-1-[4-(4-hydroxy-4-methyl-pentanoyl)-phenyl]-4-methyl-pentan-1-one


25

**I-11**

30

5-Hydroxy-1-[4-(5-hydroxy-4,4-dimethyl-pentanoyl)-phenyl]-4,4-dimethyl-pentan-1-one


35



5

I-12


5-[4-(4-Carboxy-4-methyl-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanoic acid




10

I-13

5-[4-(4,4-Dimethyl-5-oxo-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanal




20

I-1425 5-[4-(4-Methoxycarbonyl-4-methyl-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanoic acid
methyl ester

30


I-1535 2,2-Dimethyl-6-[4-(5-methyl-2-oxo-5-phenoxy-carbonyl-hexyl)-phenyl]-5-oxo-hexanoic
acid phenyl ester

5

**I-16**


10 5-[4-(4-Benzyloxycarbonyl-4-methyl-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanoic
acid benzyl ester

15

**I-17**


20 2-Methyl-5-[4-(4-methyl-4-sulfo-pentanoyl)-phenyl]-5-oxo-pentane-2-sulfonic acid

25


**I-18**

30 Phosphoric acid mono-{1,1-dimethyl-4-[4-(4-methyl-4-phosphonooxy-pentanoyl)-phenyl]-
4-oxo-butyl} ester


35

**Ib-1**


2,12-Dihydroxy-2,12-dimethyl-tridecane-5,9-dione

**Ib-2**


1,13-Dihydroxy-2,2,12,12-tetramethyl-tridecane-5,9-dione

**Ib-3**


2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid

**Ib-4**

2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedial

**Ib-5**


2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid dimethyl ester



5

Ib-6


2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid diphenyl ester



10

Ib-7


2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid dibenzyl ester



15

Ib-8

2,12-Dimethyl-5,9-dioxo-tridecane-2,12-disulfonic acid




20

Ib-9

Phosphoric acid mono-(1,1,11-trimethyl-4,8-dioxo-11-phosphonooxy-dodecyl) ester

25




30

Ib-10

2,12-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,12-dimethyl-tridecane-5,9-dione

35




5

Ib-11


2,12-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,12-dimethyl-tridecane-5,9-dione

10

**Ib-12**


2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid dicyanimide

15

**Ib-13**


20 Phosphoramidic acid mono-[11-(amino-hydroxy-phosphoryloxy)-1,1,11-trimethyl-4,8-dioxo-dodecyl] ester

25

**Ib-14**


2,12-Dimethyl-2,12-bis-(amino-hydroxy-phosphoryloxy)-tridecane-5,9-dione

30


**Ib-15**

2,12-Dimethyl-2,12-bis-tetrazol-1-yl-tridecane-5,9-dione


35

**Ib-16**


2,12-Dimethyl-2,12-bis-(1H-tetrazol-5-yl)-tridecane-5,9-dione

**Ib-17**


2,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,12-dimethyl-tridecane-5,9-dione

**Ib-18**


2,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,12-dimethyl-tridecane-5,9-dione

**Ib-19**

2,12-Bis-(5-hydroxy-4-oxo-4H-pyran-3-yl)-2,12-dimethyl-tridecane-5,9-dione

**Ib-20**

2,12-Bis-(5-hydroxy-4-oxo-4H-pyran-2-yl)-2,12-dimethyl-tridecane-5,9-dione




5

Ib-21

1-Ethyl-3-[11-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-1,1,11-trimethyl-4,8-dioxo-dodecyl]-imidazolidine-2,4-dione


10

**Ib-22**

15


2,12-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,12-dimethyl-tridecane-5,9-dione

20

**Ib-23**

2,12-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,12-dimethyl-tridecane-5,9-dione


25

**Ib-24**


30

2,12-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,12-dimethyl-tridecane-5,9-dione


35

**Ib-25**


1,15-Dihydroxy-3,3,13,13-tetramethyl-pentadecane-6,10-dione

**Ib-26**


3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedioic acid

**Ib-27**


3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedial

**Ib-28**

3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedioic acid dimethyl ester

**Ib-29**


2,2,12,12-Tetramethyl-5,9-dioxo-tetradecanedioic acid diphenyl ester



Ib-30


3,3,13,13-Tetramethyl-6,10,14-trioxo-16-phenyl-hexadecanoic acid benzyl ester

5

**Ib-31**


2,2,12,12-Tetramethyl-5,9-dioxo-tridecane-1,13-disulfonic acid

10

**Ib-32**


15 Phosphoric acid mono-(2,2,12,12-tetramethyl-5,9-dioxo-13-phosphonooxy-tridecyl) ester

20

**Ib-33**


1,13-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione

25

**Ib-34**

30 1,13-Bis-(4,6-dithio-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione


35



Ib-35


3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedioic acid dicyanimide

5

**Ib-36**

Phosphoramidic acid mono-[13-(amino-hydroxy-phosphoryloxy)-2,2,12,12-tetramethyl-6,9-dioxo-tridecyl] ester

10




15

Ib-37

Phosphoramidic acid


mono-[11-(amino-hydroxy-phosphoryloxy)-1,1,11-trimethyl-4,8-dioxo-dodecyl] ester

20

**Ib-38**

25

2,2,12,12-Tetramethyl-1,13-bis-tetrazol-1-yl-tridecane-5,9-dione




30

Ib-39

1,13-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione


35



Ib-40


1,13-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione

5

**Ib-41**

1,13-Bis-(3-hydroxy-isoxazol-4-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione

10




15

Ib-42


1-(5-Hydroxy-4-oxo-4H-pyran-3-yl)-13-(5-hydroxy-4-oxo-4H-pyran-2-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione

20

**Ib-43**


1,13-Bis-(5-hydroxy-4-oxo-4H-pyran-2-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione

30

**Ib-44**

1,13-Bis-(5-hydroxy-4-oxo-4H-pyran-3-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione


35



5

Ib-45


1-Ethyl-3-[13-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-5,9-dioxo-tridecyl]-imidazolidine-2,4-dione



10

Ib-46


1,13-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione



15

Ib-47


1,13-Bis-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione



25

Ib-48

1,13-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione




30

Ib-49

35


1,13-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione

5

**Ib-50**


2,11-Dihydroxy-2,11-dimethyl-dodecane-5,8-dione

10

**Ib-51**

1,12-Dihydroxy-2,2,11,11-tetramethyl-dodecane-5,8-dione

15




20

Ib-52


2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid

25

**Ib-53**

2,11-Dimethyl-5,8-dioxo-dodecane-2,11-disulfonic acid

30




35

Ib-54


2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedial

5

**Ib-55**


2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dimethyl ester

10

**Ib-56**

2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid diphenyl ester

15




20

Ib-57


2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dibenzyl ester

25

**Ib-58**


Phosphoric acid mono-(1,1,10-trimethyl-4,7-dioxo-10-phosphonoxy-undecyl) ester

30


**Ib-59**

2,14-Dihydroxy-2,14-dimethyl-pentadecane-6,10-dione


35

**Ib-60**


1,15-Dihydroxy-2,2,14,14-tetramethyl-pentadecane-6,10-dione

**Ib-61**


2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedioic acid

**Ib-62**


2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedial

**Ib-63**

2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedioic acid dimethyl ester

**Ib-64**

2,2,14,14-Tetramethyl-6,10-dioxo-hexadecanedioic acid diphenyl ester




5

Ib-65


2,2,14,14-Tetramethyl-6,10-dioxo-hexadecanedioic acid dibenzyl ester

10

**Ib-66**


2,14-Dimethyl-6,10-dioxo-pentadecane-2,14-disulfonic acid

15

**Ib-67**

Phosphoric acid mono-(1,1,13-trimethyl-5,9-dioxo-13-phosphonooxy-tetradecyl) ester


20

**Ib-68**

25


2,14-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,14-dimethyl-pentadecane-6,10-dione

30

**Ib-69**


35

2,14-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,14-dimethyl-pentadecane-6,10-dione

**Ib-70**

5


2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedioic acid dicyanimide



10

Ib-71

Phosphoramidic acid mono-[13-(amino-hydroxy-phosphoryloxy)-1,1,13-trimethyl-5,9-dioxo-tetradecyl] ester




15

Ib-72

20


2,14-Dimethyl-2,14-bis-(amino-hydroxy-phosphoryloxy)-pentadecane-6,10-dione



25

Ib-73

2,14-Dimethyl-2,14-bis-tetrazol-1-yl-pentadecane-6,10-dione




30

Ib-74

2,14-Dimethyl-2,14-bis-(1H-tetrazol-5-yl)-pentadecane-6,10-dione

35




5

Ib-75


2,14-Bis-(3-hydroxy-isoxazol-5-yl)-2,14-dimethyl-pentadecane-6,10-dione

10

**Ib-76**

2,14-Bis-(3-hydroxy-isoxazol-4-yl)-2,14-dimethyl-pentadecane-6,10-dione

15




20

Ib-77

2,14-Bis-(5-hydroxy-4-oxo-4H-pyran-3-yl)-2,14-dimethyl-pentadecane-6,10-dione

25




30

Ib-78

2-(5-Hydroxy-4-oxo-4H-pyran-2-yl)-2,14-dimethyl-14-(5-methyl-4-oxo-4H-pyran-2-yl)-pentadecane-6,10-dione


35



5

Ib-79

2,14-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione




10

Ib-80

2,14-Bis-(3-ethyl-2,5-dithio-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione

15




20

Ib-81

2,14-Bis-(3-ethyl-5-oxo-2-thio-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione

25




30

Ib-82

2,14-Bis-(3-ethyl-2-oxo-5-thio-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione


35



5

Ib-83


1,14-Dihydroxy-3,3,12,12-tetramethyl-tetradecane-6,9-dione



10

Ib-84


3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid



15

Ib-85


3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedial



20

Ib-86

3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid dimethyl ester




25

Ib-87


3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid diphenyl ester

30


35

**Ib-88**


3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid dibenzyl ester

**Ib-89**


2,2,11,11-Tetramethyl-5,8-dioxo-dodecane-1,12-disulfonic acid

**Ib-90**


Phosphoric acid mono-(2,2,11,11-tetramethyl-5,8-dioxo-12-phosphonoxy-dodecyl) ester

**Ib-91**

1,12-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione

**Ib-92**


1,12-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dithione



5

Ib-93


3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid dicyanimide



10

Ib-94


Phosphoramidic acid mono-[12-(amino-hydroxy-phosphoryloxy)-2,2,11,11-tetramethyl-5,8-dioxo-dodecyl] ester



15

Ib-95


2,2,11,11-Tetramethyl-1,12-bis-(aminohydroxyphosphoryloxy)-dodecane-5,8-dione



20

Ib-96

2,2,11,11-Tetramethyl-1,12-bis-(1H-tetrazol-5-yl)-dodecane-5,8-dione




30

Ib-97

1,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione

35




5

Ib-98

1,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione


10

**Ib-99**

1-(5-Hydroxy-4-oxo-4H-pyran-3-yl)-12-(5-hydroxy-4-oxo-4H-pyran-2-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione


15

20

**Ib-100**

1,12-Bis-(5-hydroxy-4-oxo-4H-pyran-3-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione

25




30


Ib-101

1,12-Bis-(5-hydroxy-4-oxo-4H-pyran-3-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione


35

**Ib-102**


1-Ethyl-3-[12-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-5,8-dioxo-dodecyl]-imidazolidine-2,4-dione

**Ib-103**


1-Ethyl-3-[12-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-5,8-dioxo-dodecyl]-imidazolidine-2,4-dione

**Ib-104**


1,12-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione

**Ib-105**


1,12-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione

**Ib-106**


1,16-Dihydroxy-4,4,13,13-tetramethyl-hexadecane-7,10-dione

**Ib-107**


4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid

**Ib-108**

4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedial

**Ib-109**


4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid dimethyl ester



5

Ib-110


4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid diphenyl ester



10

Ib-111


4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid dibenzyl ester



15

Ib-112


3,3,12,12-Tetramethyl-6,9-dioxo-tetradecane-1,14-disulfonic acid



20

Ib-113

Phosphoric acid mono-(3,3,12,12-tetramethyl-6,9-dioxo-14-phosphonooxy-tetradecyl) ester




30

Ib-114

1,14-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione


35



5

Ib-115

1,14-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione




10

Ib-116

4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid dicyanimide


15



20

Ib-117


Phosphoramidic acid mono-[14-(amino-hydroxy-phosphoryloxy)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl] ester



25

Ib-118

3,3,12,12-Tetramethyl-1,14-bis-(amino-hydroxy-phosphoryloxy)-tetradecane-6,9-dione




30

Ib-119

1,12-Dihydroxy-2,2,11,11-tetramethyl-dodecane-5,8-dione


35



5

Ib-120


2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid



10

Ib-121


2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedial



15

Ib-122


2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dimethyl ester



20

Ib-123

2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid diphenyl ester




30


Ib-124

2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dibenzyl ester


35

**Ib-125**


2,11-Dimethyl-5,8-dioxo-dodecane-2,11-disulfonic acid

**Ib-126**


Phosphoric acid mono-(1,1,10-trimethyl-4,7-dioxo-10-phosphonoxy-undecyl) ester

**Ib-127**


2,11-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,11-dimethyl-dodecane-5,8-dione

**Ib-128**

2,11-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,11-dimethyl-dodecane-5,8-dione

**Ib-129**

2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dicyanimide




5

Ib-130


Phosphoramidic acid mono-[10-(amino-hydroxy-phosphoryloxy)-1,1,10-trimethyl-4,7-dioxo-undecyl] ester

10

**Ib-131**


2,2,11,11-Tetramethyl-1,12-(amino-hydroxy-phosphoryloxy)-dodecane-5,8-dione

15

**Ib-132**

20

3,3,12,12-Tetramethyl-1,14-bis-tetrazol-1-yl-tetradecane-6,9-dione




25

Ib-133

3,3,12,12-Tetramethyl-1,14-bis-(1H-tetrazol-5-yl)-tetradecane-6,9-dione


30



35

Ib-134

1,14-Bis-(3-hydroxy-isoxazol-5-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione




5

Ib-135

1,14-Bis-(3-hydroxy-isoxazol-4-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione


10

**Ib-136**

1-(5-Hydroxy-4-oxo-4H-pyran-2-yl)-14-(5-hydroxy-4-oxo-4H-pyran-3-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione


15

20

**Ib-137**

1,14-Bis-(5-hydroxy-4-oxo-4H-pyran-2-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione

25




30

Ib-138

1,14-Bis-(5-hydroxy-4-oxo-4H-pyran-3-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione

35




5

Ib-139

1-Ethyl-3-[14-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl]-imidazolidine-2,4-dione

10




15

Ib-140

1-Ethyl-3-[14-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl]-imidazolidine-2,4-dione

20




25

Ib-141

1-Ethyl-3-[14-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl]-imidazolidine-2,4-dithione

30




35

Ib-142

1,14-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione

5

**Ib-143**

10

1,14-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione


15

20


25

30


35

**Ib-144**


1,17-Dihydroxy-3,3,15,15-tetramethyl-heptadecane-7,11-dione

**Ib-145**


3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedial

**Ib-146**


3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid dimethyl ester

**Ib-147**


1,17-Dihydroxy-3,3,15,15-tetramethyl-heptadecane-7,11-dione

**Ib-148**

3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid diphenyl ester

**Ib-149**


3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid dibenzyl ester



5

Ib-150

2,11-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,11-dimethyldodecane-5,8-dione




10

Ib-151

2,11-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,11-dimethyldodecane-5,8-dione


15



20

Ib-152

2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dicyanamide




25

Ib-153

Phosphoramidic acid mono-[10-(amino-hydroxy-phosphoryloxy)-1,1,10-trimethyl-4,7-dioxo-undecyl] ester

30


35



5

Ib-154


2,11-Dimethyl-2,11-bis-(amino-hydroxy-phosphoryloxy)-dodecane-5,8-dione



10

Ib-155


2,11-Dimethyl-2,11-bis-tetrazol-1-yl-dodecane-5,8-dione



15

Ib-156


2,11-Dimethyl-2,11-bis-(1H-tetrazol-5-yl)-dodecane-5,8-dione



25

Ib-157


2,2,14,14-Tetramethyl-6,10-dioxo-pentadecane-1,15-disulfonic acid



30

Ib-158Phosphoric acid mono-(2,2,14,14-tetramethyl-6,10-dioxo-15-phosphonooxy-pentadecyl)
ester

35




5

Ib-159

1,15-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione

10




15

Ib-160


1,15-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione

20

**Ib-161**

3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid dicyanamide

25




30

Ib-162

Phosphoramidic acid mono-[16-(amino-hydroxy-phosphoryloxy)-4,4,15,15-tetramethyl-7,11-dioxo-hexadecyl] ester


35



5

Ib-163


2,2,14,14-Tetramethyl-1,15-bis-(amino-hydroxy-phosphoryloxy)-pentadecane-6,10-dione



10

Ib-164


2,2,14,14-Tetramethyl-1,15-bis-tetrazol-1-yl-pentadecane-6,10-dione



15

Ib-165


2,2,14,14-Tetramethyl-1,15-bis-(1H-tetrazol-5-yl)-pentadecane-6,10-dione



25

Ib-166

1,15-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione




30

Ib-167

1,15-Bis-(3-hydroxy-isoxazol-4-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione

35




5

Ib-168


1-(5-Hydroxy-4-oxo-4H-pyran-3-yl)-15-(5-hydroxy-4-oxo-4H-pyran-2-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione

10

**Ib-169**

1,15-Bis-(5-hydroxy-4-oxo-4H-pyran-2-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione

15




20

Ib-170


1,15-Bis-(5-hydroxy-4-oxo-4H-pyran-3-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione

25

**Ib-171**

1,15-Bis-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione

35




5

Ib-172

1-Ethyl-3-[15-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-6,10-dioxo-pentadecyl]-imidazolidine-2,4-dione

10




15

Ib-173

1,15-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione

20




25

Ib-174

1,15-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione


30



35


Ib-175

1,15-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione

**Ic-1**


1,9-Bis-(tetrahydro-pyran-2-yloxy)-nonane-3,7-dione

5

**Ic-2**


1,9-Bis-(4-oxo-oxetan-2-yl)-nonane-3,7-dione

10

**Ic-3**


1,9-Bis-(2-oxo-oxetan-3-yl)-nonane-3,7-dione

15

**Ic-4**

1,9-Bis-(5-oxo-tetrahydrofuran-2-yl)-nonane-3,7-dione

20


**Ic-5**

1,9-Bis-(5-oxo-tetrahydrofuran-3-yl)-nonane-3,7-dione

25

30

35




5

Ic-6

1,9-Bis-(2-oxo-tetrahydrofuran-3-yl)-nonane-3,7-dione

10




15

Ic-7


{2-[9-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-3,7-dioxo-nonyl]-4-hydroxy-6-oxo-tetrahydropyran-4-yl}-acetic acid

20

**Ic-8**

1,9-Bis-(6-oxo-tetrahydropyran-2-yl)-nonane-3,7-dione

25




30

Ic-9

1,9-Bis-(6-oxo-tetrahydropyran-3-yl)-nonane-3,7-dione


35



5

Ic-10


1,9-Bis-(2-oxo-tetrahydropyran-4-yl)-nonane-3,7-dione



10

Ic-11


1,9-Bis-(2-oxo-tetrahydropyran-3-yl)-nonane-3,7-dione



15

Ic-12


1,11-Bis-(tetrahydro-pyran-2-yloxy)-undecane-4,8-dione



20

Ic-13

1,11-Bis-(2-oxo-oxetan-3-yl)-undecane-4,8-dione




30

Ic-14

1,11-Bis-(2-oxo-oxetan-3-yl)-undecane-4,8-dione


35



5

Ic-15


1,11-Bis-(5-oxo-tetrahydrofuran-2-yl)-undecane-4,8-dione



10

Ic-16


1,11-Bis-(5-oxo-tetrahydrofuran-3-yl)-undecane-4,8-dione



15

Ic-17

1,11-Bis-(2-oxo-tetrahydrofuran-3-yl)-undecane-4,8-dione




20

Ic-18

{2-[11-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-4,8-dioxo-undecyl]-4-hydroxy-6-oxo-tetrahydropyran-4-yl}-acetic acid

25




30

Ic-19


1,11-Bis-(6-oxo-tetrahydropyran-2-yl)-undecane-4,8-dione

35

**Ic-20**

5


1,11-Bis-(6-oxo-tetrahydropyran-3-yl)-undecane-4,8-dione



10

Ic-21

1,11-Bis-(2-oxo-tetrahydropyran-4-yl)-undecane-4,8-dione



15

Ic-22

1,11-Bis-(2-oxo-tetrahydropyran-3-yl)-undecane-4,8-dione


20

25

30


35

5

**IC-23**


1,8-Bis-(tetrahydropyran-2-yloxy)-octane-3,6-dione

10

**IC-24**

1,8-Bis-(4-oxo-oxetan-2-yl)-octane-3,6-dione

15




20

IC-25

1,8-Bis-(2-oxo-oxetan-3-yl)-octane-3,6-dione

25




30

IC-26

1,8-Bis-(5-oxo-tetrahydro-furan-2-yl)-octane-3,6-dione


35



5

IC-27


1,8-Bis-(5-oxo-tetrahydro-furan-3-yl)-octane-3,6-dione



10

IC-28

1,8-Bis-(2-oxo-tetrahydro-furan-3-yl)-octane-3,6-dione




15

20

IC-29

{2-[8-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-3,6-dioxo-octyl]-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl}-acetic acid




25

30

IC-30

1,8-Bis-(6-oxo-tetrahydropyran-2-yl)-octane-3,6-dione


35



5

IC-31


1,8-Bis-(6-oxo-tetrahydropyran-3-yl)-octane-3,6-dione



10

IC-32

1,8-Bis-(2-oxo-tetrahydropyran-4-yl)-octane-3,6-dione



15

20


IC-33

1,8-Bis-(2-oxo-tetrahydropyran-3-yl)-octane-3,6-dione


25

30


35

**II-1**


1,13-Dihydroxy-2,2,12,12-tetramethyl-tridecan-7-one

**II-2**


12-Hydroxy-2,2,12-trimethyl-7-oxo-tridecanoic acid; compound with formaldehyde

**II-3**


11-Hydroperoxy-2,2,10,10-tetramethyl-6-oxo-undecanoic acid

**II-4**

1,11-Dihydroxy-2,2,10,10-tetramethyl-undecan-6-one


**II-5**

11-Hydroxy-2,2,10,10-tetramethyl-6-oxo-undecanoic acid

**II-6**


5

2,2,10,10-Tetramethyl-6-oxo-undecanedioic acid

**II-7**


10

1,15-Dihydroxy-2,2,14,14-tetramethyl-pentadecan-8-one

**II-8**


15

15-Hydroxy-2,2,14,14-tetramethyl-8-oxo-pentadecanoic acid

**II-9**

20

2,2,14,14-Tetramethyl-8-oxo-pentadecanedioic acid


**II-10**

25

2,2,12,12-Tetramethyl-7-oxo-tridecanedial

30


35



5

II-11


2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid dimethyl ester



10

II-12


2,2,12,12-Tetramethyl-1,13-diphenyl-tridecane-1,7,13-trione



15

II-13


3,3,13,13-Tetramethyl-1,15-diphenyl-pentadecane-2,8,14-trione



20

II-14

2,12-Dimethyl-7-oxo-tridecane-2,12-disulfonic acid




25

II-15


Phosphoric acid mono-(1,1,11-trimethyl-6-oxo-11-phosphonooxy-dodecyl) ester

35

**II-16**


2,2,14,14-Tetramethyl-8-oxo-pentadecanedial

5

**II-17**


2,2,14,14-Tetramethyl-8-oxo-pentadecanedioic acid dimethyl ester

10

**II-18**


2,2,14,14-Tetramethyl-1,15-diphenyl-pentadecane-1,8,15-trione

15

**II-19**

3,3,15,15-Tetramethyl-1,17-diphenyl-heptadecane-2,9,16-trione

20


**II-20**

2,14-Dimethyl-8-oxo-pentadecane-2,14-disulfonic acid

25

30


35



5

II-21


Phosphoric acid mono-(1,1,13-trimethyl-7-oxo-13-phosphonooxy-tetradecyl) ester



10

II-22


1,15-Dihydroxy-3,3,13,13-tetramethyl-pentadecan-8-one



15

II-23


15-Hydroxy-3,3,13,13-tetramethyl-8-oxo-pentadecanoic acid



20

II-24

3,3,13,13-Tetramethyl-8-oxo-pentadecanedioic acid




25

II-25

1,13-Dihydroxy-3,3,11,11-tetramethyl-tridecan-7-one


30

35

**II-26**

5


13-Hydroxy-3,3,11,11-tetramethyl-7-oxo-tridecanoic acid



10

II-27


3,3,11,11-Tetramethyl-7-oxo-tridecanedioic acid



15

II-28

1,17-Dihydroxy-3,3,15,15-tetramethyl-heptadecan-9-one




20

II-29

17-Hydroxy-3,3,15,15-tetramethyl-9-oxo-heptadecanoic acid

25




30

II-30

3,3,15,15-Tetramethyl-9-oxo-heptadecanedioic acid


35



5

II-31


1,17-Dihydroxy-4,4,14,14-tetramethyl-heptadecan-9-one



10

II-32


17-Hydroxy-4,4,14,14-tetramethyl-9-oxo-heptadecanoic acid



15

II-33


4,4,14,14-Tetramethyl-heptadecan-9-oxo-1,17-dicarboxylic acid



20

II-34

1,15-Dihydroxy-4,4,14,14-tetramethyl-pentadecan-8-one




30


II-35

15-Hydroxy-4,4,12,12-tetramethyl-8-oxo-pentadecanoic acid

35

**II-36**


5 . 4,4,12,12-Tetramethyl-8-oxo-pentadecanedioic acid



10

II-37


1,19-Dihydroxy-4,4,16,16-tetramethyl-nonadecan-10-one



15

II-38

19-Hydroxy-4,4,16,16-tetramethyl-10-oxo-nonadecanoic acid




20

II-39

4,4,16,16-Tetramethyl-10-oxo-nonadecanedioic acid

25




30

II-40

5-[9-(4-Mercapto-3-methyl-2,6-dioxo-3,6-dihydro-2H-pyridin-1-yl)-1,1,9-trimethyl-5-oxo-decyl]-3,3a-dihydro-2H-thieno[3,2-c]pyridine-4,6-dione

35




5

II-41


2,10-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,10-dimethyl-undecan-6-one

10

**II-42**

2,2,10,10-Tetramethyl-6-oxo-undecanedioic acid bis-cyanoamide

15




20

II-43

Phosphoramidic acid mono-[9-(amino-hydroxy-phosphoryloxy)-1,1,9-trimethyl-5-oxo-decyl] ester


25

**II-44**

Phosphoramidic acid mono-[9-(amino-hydroxy-phosphoryloxy)-1,1,9-trimethyl-5-oxo-decyl] ester

30


35



5

II-45


2,12-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,12-dimethyl-tridecan-7-one



10

II-46


2,12-Bis-(4,6-dithio-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,12-dimethyl-tridecan-7-one



20

II-47

2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid bis-cyanoamide




25

II-48

Phosphoramidic acid mono-[11-(amino-hydroxy-phosphoryloxy)-1,1,11-trimethyl-6-oxo-dodecyl] ester

30


35



5

II-49


Phosphoramidic acid mono-[11(amino-hydroxy-phosphoryloxy)-1,1,1-trimethyl-6-oxo-dodecyl] ester



10

II-50


2,12-Dimethyl-2,12-bis-tetrazol-1-yl-tridecan-7-one



15

II-51

2,12-Dimethyl-2,12-bis-(1H-tetrazol-5-yl)-tridecan-7-one



25


II-52

2,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,12-dimethyl-tridecan-7-one

30


35

5

**II-53**


2,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,12-dimethyl-tridecan-7-one

10

**II-54**


4-[11-(4-oxo-oxetan-2-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-oxetan-2-one

15

**II-55**

3-[11-(4-oxo-oxetan-2-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-oxetan-2-one

20




25

II-56

5-[11-(5-oxo-tetrahydro-furan-3-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-dihydro-furan-2-one


30

**II-57**

3-[11-(5-oxo-tetrahydro-furan-3-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-dihydro-furan-2-one


35

5

**II-58**


4-[11-(5-oxo-tetrahydro-furan-3-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-dihydro-furan-2-one

10

**II-59**

2,12-Dimethyl-2,12-bis-(tetrahydro-pyran-2-yloxy)-tridecan-7-one

15

**II-60**


20

{2-[11-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-1,1,11-trimethyl-6-oxo-dodecyl]-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl}-acetic acid


25

30


35

**IIa-1**


1,15-Dihydroxy-2,14-dimethyl-2,14-diphenyl-pentadecan-8-one

**IIa-2**


15-Hydroxy-2,14-dimethyl-8-oxo-2,14-diphenyl-pentadecanoic acid

**IIa-3**


2,14-Dimethyl-8-oxo-2,14-diphenyl-pentadecanedioic acid

**IIa-4**

1,13-Dihydroxy-2,12-dimethyl-2,12-diphenyl-tridecan-7-one

**IIa-5**


13-Hydroxy-2,12-dimethyl-7-oxo-2,12-diphenyl-tridecanoic acid



5

IIa-6

2,12-Dimethyl-7-oxo-2,12-diphenyl-tridecanedioic acid




10

IIa-7

1,11-Dihydroxy-2,10-dimethyl-2,10-diphenyl-undecan-6-one


15



20

IIa-8

11-Hydroxy-2,10-dimethyl-6-oxo-2,10-diphenyl-undecanoic acid




25

IIa-9

2,10-Dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid


30



35

IIa-10


2,14-Dimethyl-8-oxo-2,14-diphenyl-pentadecanedial



5

IIa-11


2,14-Dimethyl-8-oxo-2,14-diphenyl-pentadecanedioic acid dimethyl ester



10

IIa-12


2,14-Dimethyl-1,2,14,15-tetraphenyl-pentadecane-1,8,15-trione



20

IIa-13


3,15-Dimethyl-1,3,15,17-tetraphenyl-heptadecane-2,9,16-trione



25

IIa-14

8-Oxo-2,14-diphenyl-pentadecane-2,14-disulfonic acid




30

IIa-15

Phosphoric acid mono-(1-methyl-7-oxo-1,13-diphenyl-13-phosphonooxy-tetradecyl) ester


35



5

IIa-16


1,17-Dihydroxy-3,15-dimethyl-3,15-diphenyl-heptadecan-9-one



10

IIa-17


17-Hydroxy-3,15-dimethyl-9-oxo-3,15-diphenyl-heptadecanoic acid



15

IIa-18


3,15-Dimethyl-9-oxo-3,15-diphenyl-heptadecanedioic acid



25

IIa-19

1,15-Dihydroxy-3,13-dimethyl-3,13-diphenyl-pentadecan-8-one




30

IIa-20


15-Hydroxy-3,13-dimethyl-8-oxo-3,13-diphenyl-pentadecanoic acid

35

**IIa-21**

5


3,13-Dimethyl-8-oxo-3,13-diphenyl-pentadecanedioic acid



10

IIa-22

1,13-Dihydroxy-3,11-dimethyl-3,11-diphenyl-tridecan-7-one




15

IIa-23

13-Hydroxy-3,11-dimethyl-7-oxo-3,11-diphenyl-tridecanoic acid


20



25

IIa-24

3,11-Dimethyl-7-oxo-3,11-diphenyl-tridecanedioic acid




30

IIa-25

13-Hydroxy-3,11-dimethyl-7-oxo-3,11-diphenyl-tridecanoic acid


35



5

IIa-26


3,11-Dimethyl-7-oxo-3,11-diphenyl-tridecanedioic acid



10

IIa-27


1,19-Dihydroxy-4,16-dimethyl-4,16-diphenyl-nonadecan-10-one



15

IIa-28


19-Hydroxy-4,16-dimethyl-10-oxo-4,16-diphenyl-nonadecanoic acid



25

IIa-29

4,16-Dimethyl-10-oxo-4,16-diphenyl-nonadecanedioic acid




30

IIa-30

1,17-Dihydroxy-4,14-dimethyl-4,14-diphenyl-heptadecan-9-one


35



5

IIa-31


17-Hydroxy-4,14-dimethyl-9-oxo-4,14-diphenyl-heptadecanoic acid



10

IIa-32


4,14-Dimethyl-9-oxo-4,14-diphenyl-heptadecanedioic acid



15

IIa-33

1,15-Dihydroxy-4,12-dimethyl-4,12-diphenyl-pentadecan-8-one




25

IIa-34

15-Hydroxy-4,12-dimethyl-8-oxo-4,12-diphenyl-pentadecanoic acid

30

35




5

IIa-35

4,12-Dimethyl-8-oxo-4,12-diphenyl-pentadecanedioic acid


10

**IIa-36**

15

2,12-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,12-diphenyl-tridecan-7-one

20

**IIa-37**


25

2,12-Bis-(4,6-dithio-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,12-diphenyl-tridecan-7-one

30


35

5

**IIa-38**

2,12-Dimethyl-2,12-diphenyl-7-oxo-tridecanedioic acid bis-cyanoamide


10




15

IIa-39Phosphoramidic acid mono-[11-(amino-hydroxy-phosphoryloxy)-
1-methyl-6-oxo-1,11-diphenyl-dodecyl] ester

20

**IIa-40**25 Phosphoramidic acid mono-[11(amino-hydroxy-phosphoryloxy)-1,11-diphenyl-1-methyl-6-
oxo-dodecyl] ester


30

**IIa-41**

2,12-Diphenyl-2,12-bis-tetrazol-1-yl-tridecan-7-one


35

5

**IIa-42**

2,12-Diphenyl-2,12-bis-(1H-tetrazol-5-yl)-tridecan-7-one

10




15

IIa-43


2,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,12-diphenyl-tridecan-7-one

20

**IIa-44**

2,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,12-diphenyl-tridecan-7-one

25




30

IIa-45

2,12-Diphenyl-2,12-bis-(tetrahydro-pyran-2-yloxy)-tridecan-7-one

35




5

IIa-46

5-[11-(5-oxo-tetrahydro-furan-2-yl)-1,11-Diphenyl-1-methyl-6-oxo-dodecyl]-dihydro-furan-2-one

10




15

IIa-47

4-[11-(4-oxo-oxetan-2-yl)-1,11-diphenyl-1-methyl-6-oxo-dodecyl]-oxetan-2-one

20




25

IIa-48

4-[11-(5-oxo-tetrahydro-furan-2-yl)-1,11-Diphenyl-1-methyl-6-oxo-dodecyl]-dihydro-furan-2-one

30




35

IIa-49

3-[11-(5-oxo-tetrahydro-furan-2-yl)-1,11-Diphenyl-1-methyl-6-oxo-dodecyl]-dihydro-furan-2-one

5



10

IIa-50

{2-[11-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-1-methyl-6-oxo-1,11-diphenyl-dodecyl]-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl}-acetic acid


15

20

25

30

35




5

III-1

5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol


10

**III-2**

15


5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

20

**III-3**

5-(6-{3-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid


25

**III-4**


30

5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol


35

**III-5**


5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

**III-6**


5-(6-{3-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

**III-7**

6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol

**III-8**

6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid




5

III-9


6-(6-{3-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

10

**III-10**

15

6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol




20

III-11

6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid


25

**III-12**

30

6-(6-{3-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid


35



5

III-13

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol




10

III-14

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid


15



20

III-15

6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid




25

III-16

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol

30

35




5

III-17

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid


10

**III-18**

15


6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

20

**III-19**

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol

25




30


III-20

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

35

**III-21**

5 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid




10

III-22


5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol

15

**III-23**


20 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid

25

**III-24**

30 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid

35




5

III-25

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol


10

**III-26**

15

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid


20

**III-27**

25


5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

30


**III-28**

35

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol

**III-29**

5 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

**III-30**

10 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid


15

20

25

30

35




5

III-31

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol


10

**III-32**

15


6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

20

**III-33**

6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid


25

**III-34**

30

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol


35



5

III-35

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid




10

III-36

6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

15




20

III-37

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol

25




30

III-38

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

35




5

III-39


5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

10

**III-40**


5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol

20

**III-41**

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol


25

**III-42**

5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

30

35




5

III-43


6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol

10

**III-44**

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid

15




20

III-45

6-(6-{2-[6-(6-Carboxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid


25

**III-46**

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol

30

35




5

III-47

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

10




15

III-48

6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid


20

**III-49**

25


6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol

30

**III-50**

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

35




5

III-51


6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

10

**III-52**

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol


15

**III-53**

20

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid

25


**III-54**

5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid

30


35

5

**III-55**

5-(6-{2-[6-(5-Hydroxy-4-methyl-pentyl)-1,4-dioxo-cyclohex-2-yl]-phenyl}-1,4-dioxo-cyclohex-2-yl)-2,2-dimethyl-pentan-1-ol

10




15

III-56

5-(6-{2-[6-(5-Hydroxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

20




25

III-57


5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

30

**III-58**

35

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol




5


III-59

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid


10

**III-60**

15 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid


**III-61**

20 5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentan-1-ol

**III-62**

25


5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid

**III-63**


30

5-(5-{3-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid

35

**III-64**


5 6-(5-{3-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexan-1-ol



10

III-65

6-(5-{3-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid




15


III-66

6-(5-{3-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid

20


**III-67**

25 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexan-1-ol


**III-68**

30 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid

35


**III-69**

6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid

**III-70**


6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexan-1-ol

15

**III-71**


20 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid

25

**III-72**


30 6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid

35


**III-73**

5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentan-1-ol


35

**III-74**


5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid

**III-75**


5-(5-{2-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid

**III-76**


5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentan-1-ol

**III-77**


5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid

**III-78**


5-(5-{2-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid

**III-79**


5 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexan-1-ol

**III-80**

10 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid


**III-81**

15 6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid

**III-82**


20 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexan-1-ol

25

**III-83**

30 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid

35




5

III-84


6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid

10

**III-85**


5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-ethyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentan-1-ol

15

**III-86**

5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-ethyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid


25

**III-87**


5-(5-{2-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentadien-2-yl]-ethyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid

30


35

**IIIa-1**


5 5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol

**IIIa-2**


10 5-(6-{3-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid

**IIIa-3**

15 5-(6-{3-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid


**IIIa-4**

20 6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol


**IIIa-5**

30 6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid


35

**IIIa-6**


5 6-(6-{3-[6-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid

**IIIa-7**

10 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol


**IIIa-8**

15 20 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid

**IIIa-9**

25 30 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid


35



5

IIIa-10

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol




10

IIIa-11

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid


15



20

IIIa-12

5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid




25

IIIa-13

5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-propyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentan-1-ol


30



35

IIIa-14

5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-propyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid

**IIIa-15**

5-(5-{3-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentan-2-yl]-propyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid

5

10

15

20


25

30

35

4.1. Definitions and Abbreviations

- Apo(a): apolipoprotein(a)
 Apo A-I: apolipoprotein A-I
 5 Apo B: apolipoprotein B
 Apo E: apolipoprotein E
 FH: Familial hypercholesterolemia
 FCH: Familial combined hyperlipidemia
 GDM: Gestational diabetes mellitus
 10 HDL: High density lipoprotein
 IDL: Intermediate density lipoprotein
 IDDM: Insulin dependent diabetes mellitus
 LDH: Lactate dehydrogenase
 LDL: Low density lipoprotein
 15 Lp(a): Lipoprotein (a)
 MODY: Maturity onset diabetes of the young
 NIDDM: Non-insulin dependent diabetes mellitus
 PPAR: Peroxisome proliferator activated receptor
 RXR: Retinoid X receptor
 20 VLDL: Very low density lipoprotein
 The term "compound A" means the compound 1,13-dihydroxy-2,2,12,12-tetramethyl-tridecan-7-one having the structure:



Compound A

1,13-Dihydroxy-2,2,12,12-tetramethyl-tridecan-7-one

- 25 The compounds of the invention can contain one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as double-bond isomers (*i.e.*, geometric isomers), enantiomers, or diastereomers. According to the invention, the chemical structures depicted herein, and therefore the compounds of the invention, encompass all of the corresponding compound's enantiomers and stereoisomers, that is,

both the stereomerically pure form (*e.g.*, geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric and stereoisomeric mixtures.

A compound of the invention is considered optically active or enantiomerically pure (*i.e.*, substantially the R-form or substantially the S-form) with respect to a chiral center
5 when the compound is about 90% ee (enantiomeric excess) or greater, preferably, equal to or greater than 95% ee with respect to a particular chiral center. A compound of the invention is considered to be in enantiomerically-enriched form when the compound has an enantiomeric excess of greater than about 80% ee with respect to a particular chiral center. A compound of the invention is considered diastereomerically pure with respect to multiple
10 chiral centers when the compound is about 90% de (diastereomeric excess) or greater, preferably, equal to or greater than 95% de with respect to a particular chiral center. A compound of the invention is considered to be in diastereomerically-enriched form when the compound has an diastereomeric excess of greater than about 80% de with respect to a particular chiral center. As used herein, a racemic mixture means about 50% of one
15 enantiomer and about 50% of its corresponding enantiomer relative to all chiral centers in the molecule. Thus, the invention encompasses all enantiomerically-pure, enantiomerically-enriched, diastereomerically pure, diastereomerically enriched, and racemic mixtures of compounds of Formulas I through III.

Enantiomeric and diastereomeric mixtures can be resolved into their component
20 enantiomers or stereoisomers by well known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent. Enantiomers and diastereomers can also be obtained from diastereomerically- or enantiomerically-pure intermediates, reagents, and catalysts by well known asymmetric
25 synthetic methods.

The compounds of the invention are defined herein by their chemical structures and/or chemical names. Where a compound is referred to by both a chemical structure and a chemical name, and the chemical structure and chemical name conflict, the chemical structure is determinative of the compound's identity.

30 When administered to a patient, *e.g.*, to an animal for veterinary use or for improvement of livestock, or to a human for clinical use, the compounds of the invention are administered in isolated form or as the isolated form in a pharmaceutical composition. As used herein, "isolated" means that the compounds of the invention are separated from other components of either (a) a natural source, such as a plant or cell, preferably bacterial
35 culture, or (b) a synthetic organic chemical reaction mixture. Preferably, via conventional

techniques, the compounds of the invention are purified. As used herein, "purified" means that when isolated, the isolate contains at least 95%, preferably at least 98%, of a single ether compound of the invention by weight of the isolate.

The phrase "pharmaceutically acceptable salt(s)," as used herein includes, but are not limited to, salts of acidic or basic groups that may be present in the compounds of the invention. Compounds that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, *i.e.*, salts containing pharmacologically acceptable anions, including but not limited to sulfuric, citric, maleic, acetic, oxalic, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (*i.e.*, 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Compounds of the invention that include an amino moiety also can form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above. Compounds of the invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium lithium, zinc, potassium, and iron salts.

As used herein, the term "solvate" means a compound of the invention or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. Preferred solvents are volatile, non-toxic, and/or acceptable for administration to humans in trace amounts.

As used herein, the term "hydrate" means a compound of the invention or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.

As used herein, the term "clathrate" means a compound of the invention or a salt thereof in the form of a crystal lattice that contains spaces (*e.g.*, channels) that have a guest molecule (*e.g.*, a solvent or water) trapped within.

"Altering lipid metabolism" indicates an observable (measurable) change in at least one aspect of lipid metabolism, including but not limited to total blood lipid content, blood HDL cholesterol, blood LDL cholesterol, blood VLDL cholesterol, blood triglyceride, blood Lp(a), blood apo A-I, blood apo E and blood non-esterified fatty acids.

"Altering glucose metabolism" indicates an observable (measurable) change in at least one aspect of glucose metabolism, including but not limited to total blood glucose content, blood insulin, the blood insulin to blood glucose ratio, insulin sensitivity, and oxygen consumption.

5 As used herein, the term "alkyl group" means a saturated, monovalent unbranched or branched hydrocarbon chain. Examples of alkyl groups include, but are not limited to, (C₁–C₆)alkyl groups, such as methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, *t*-butyl, pentyl, isopentyl, neopentyl, and hexyl, and longer alkyl groups, such as heptyl, and octyl. An alkyl group can be unsubstituted or substituted with one or two suitable substituents.

15 An "alkenyl group" means a monovalent unbranched or branched hydrocarbon chain having one or more double bonds therein. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Suitable alkenyl groups include, but are not limited to (C₂–C₆)alkenyl groups, such as vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, 4-(2-methyl-3-butene)-pentenyl. An alkenyl group can be unsubstituted or substituted with one or two suitable substituents.

20 An "alkynyl group" means monovalent unbranched or branched hydrocarbon chain having one or more triple bonds therein. The triple bond of an alkynyl group can be unconjugated or conjugated to another unsaturated group. Suitable alkynyl groups include, but are not limited to, (C₂–C₆)alkynyl groups, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl-1-butynyl, 4-propyl-2-pentynyl, and 4-butyl-2-hexynyl. An alkynyl group can be unsubstituted or substituted with one or two suitable substituents.

25 An "aryl group" means a monocyclic or polycyclic-aromatic radical comprising carbon and hydrogen atoms. Examples of suitable aryl groups include, but are not limited to, phenyl, tolyl, anthacenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl. An aryl group can be unsubstituted or substituted with one or two suitable substituents. Preferably, the aryl group is a monocyclic ring, wherein the ring comprises 6 carbon atoms, referred to herein as "(C₆)aryl".

30 A "heteroaryl group" means a monocyclic- or polycyclic aromatic ring comprising carbon atoms, hydrogen atoms, and one or more heteroatoms, preferably 1 to 3 heteroatoms,

independently selected from nitrogen, oxygen, and sulfur. Illustrative examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrimidinyl, pyrazyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3)- and (1,2,4)-triazolyl, pyrazinyl, pyrimidinyl, tetrazolyl, furyl, thiophenyl, isoxazolyl, thiazolyl, furyl, phenyl, isoxazolyl, and oxazolyl. A heteroaryl group can be unsubstituted or substituted with one or two suitable substituents. Preferably, a heteroaryl group is a monocyclic ring, wherein the ring comprises 2 to 5 carbon atoms and 1 to 3 heteroatoms, referred to herein as “(C₂–C₅)heteroaryl”.

10 A “cycloalkyl group” means a monocyclic or polycyclic saturated ring comprising carbon and hydrogen atoms and having no carbon-carbon multiple bonds. Examples of cycloalkyl groups include, but are not limited to, (C₃–C₇)cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, and saturated cyclic and bicyclic terpenes. A cycloalkyl group can be unsubstituted or substituted by one or two suitable substituents. Preferably, the cycloalkyl group is a monocyclic ring or bicyclic ring.

15 A “heterocycloalkyl group” means a monocyclic or polycyclic ring comprising carbon and hydrogen atoms and at least one heteroatom, preferably, 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, and having no unsaturation. Examples of heterocycloalkyl groups include pyrrolidinyl, pyrrolidino, piperidinyl, piperidino, piperazinyl, piperazino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, and pyranyl. A heterocycloalkyl group can be unsubstituted or substituted with one or two suitable substituents. Preferably, the heterocycloalkyl group is a monocyclic or bicyclic ring, more preferably, a monocyclic ring, wherein the ring comprises from 3 to 6 carbon atoms and from 1 to 3 heteroatoms, referred to herein as (C₁–C₆)heterocycloalkyl.

25 As used herein a “heterocyclic radical” or “heterocyclic ring” means a heterocycloalkyl group or a heteroaryl group.

The term “alkoxy group” means an –O–alkyl group, wherein alkyl is as defined above. An alkoxy group can be unsubstituted or substituted with one or two suitable substituents. Preferably, the alkyl chain of an alkyloxy group is from 1 to 6 carbon atoms in length, referred to herein as “(C₁–C₆)alkoxy”.

30 The term “aryloxy group” means an –O–aryl group, wherein aryl is as defined above. An aryloxy group can be unsubstituted or substituted with one or two suitable substituents. Preferably, the aryl ring of an aryloxy group is a monocyclic ring, wherein the ring comprises 6 carbon atoms, referred to herein as “(C₆)aryloxy”.

The term “benzyl” means –CH₂–phenyl.

The term "phenyl" means C_6H_5 . A phenyl group can be unsubstituted or substituted with one or two suitable substituents.

5 A "hydrocarbyl" group means a monovalent group selected from $(\text{C}_1\text{--}\text{C}_8)$ alkyl, $(\text{C}_2\text{--}\text{C}_8)$ alkenyl, and $(\text{C}_2\text{--}\text{C}_8)$ alkynyl, optionally substituted with one or two suitable substituents. Preferably, the hydrocarbon chain of a hydrocarbyl group is from 1 to 6 carbon atoms in length, referred to herein as " $(\text{C}_1\text{--}\text{C}_6)$ hydrocarbyl".

A "carbonyl" group is a divalent group of the formula --C(O)-- .

10 An "alkoxycarbonyl" group means a monovalent group of the formula --C(O)--alkoxy . Preferably, the hydrocarbon chain of an alkoxycarbonyl group is from 1 to 8 carbon atoms in length, referred to herein as a "lower alkoxycarbonyl" group.

A "carbamoyl" group means the radical --C(O)N(R')_2 , wherein R' is chosen from the group consisting of hydrogen, alkyl, and aryl.

15 As used herein, "halogen" means fluorine, chlorine, bromine, or iodine. Correspondingly, the meaning of the terms "halo" and "Hal" encompass fluoro, chloro, bromo, and iodo.

As used herein, a "suitable substituent" means a group that does not nullify the synthetic or pharmaceutical utility of the compounds of the invention or the intermediates useful for preparing them. Examples of suitable substituents include, but are not limited to:

20 $(\text{C}_1\text{--}\text{C}_8)$ alkyl; $(\text{C}_1\text{--}\text{C}_8)$ alkenyl; $(\text{C}_1\text{--}\text{C}_8)$ alkynyl; (C_6) aryl; $(\text{C}_2\text{--}\text{C}_5)$ heteroaryl; $(\text{C}_3\text{--}\text{C}_7)$ cycloalkyl; $(\text{C}_1\text{--}\text{C}_8)$ alkoxy; (C_6) aryloxy; --CN ; --OH ; oxo; halo, $\text{--CO}_2\text{H}$; --NH_2 ; $\text{--NH}((\text{C}_1\text{--}\text{C}_8)\text{alkyl})$; $\text{--N}((\text{C}_1\text{--}\text{C}_8)\text{alkyl})_2$; $\text{--NH}((\text{C}_6)\text{aryl})$; $\text{--N}((\text{C}_6)\text{aryl})_2$; --CHO ; $\text{--CO}((\text{C}_1\text{--}\text{C}_8)\text{alkyl})$; $\text{--CO}((\text{C}_6)\text{aryl})$; $\text{--CO}_2((\text{C}_1\text{--}\text{C}_8)\text{alkyl})$; and $\text{--CO}_2((\text{C}_6)\text{aryl})$. One of skill in the art can readily choose a suitable substituent based on the stability and pharmacological and synthetic activity of the compound of the invention.

25

4.2. Synthesis of the Compounds of the Invention

The compounds of the invention can be obtained via the synthetic methodology illustrated in Schemes 1-13. Starting materials useful for preparing the compounds of the invention and intermediates thereof, are commercially available or can be prepared from

30 commercially available materials using known synthetic methods and reagents.

Scheme 1 illustrates the synthesis of mono-protected diols of the formula **X**, wherein n is an integer ranging from 0 to 4 and R^1 and R^2 are as defined above, and E is a leaving group as defined below. Scheme 1 first outlines the synthesis of mono-protected diols **X**, wherein n is 0, where esters **4** are successively reacted with a first $((\text{R}^1)_p\text{--M})$ then a second

35 $((\text{R}^2)_p\text{--M})$ organometallic reagent providing ketones **5** and alcohols **6**, respectively. M is a


metal group and p is the metal's valency value (*e.g.*, the valency of Li is 1 and that of Zn is 2). Suitable metals include, but are not limited to, Zn, Na, Li, and –Mg–Hal, wherein Hal is a halide selected from iodo, bromo, or chloro. Preferably, M is –Mg–Hal, in which case the organometallic reagents, $(R^1)_p\text{--Mg--Hal}$ and $(R^2)_p\text{--Mg--Hal}$, are known in the art as a

5 Grignard reagents. Esters 4 are available commercially (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or can be prepared by well-known synthetic methods, for example, *via* esterification of the appropriate 5-halovaleric acid (commercially available, *e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin). Both $(R^1)_p\text{--M}$ and $(R^2)_p\text{--M}$ are available

10 commercially (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or can be prepared by well-known methods (see *e.g.*, Kharasch *et al.*, *Grignard Reactions of Non-Metallic Substances*; Prentice-Hall, Englewood Cliffs, NJ, pp. 138-528 (1954) and Hartley; Patai, *The Chemistry of the Metal-Carbon Bond*, Vol. 4, Wiley: New York, pp. 159-306 and pp. 162-175 (1989), both citations are hereby expressly incorporated herein by reference).

15

Scheme 1: Synthesis of Compounds of Formula X



The reaction of a first $((\text{R}^1)_p-\text{M})$ then a second $((\text{R}^2)_p-\text{M})$ organometallic reagent with esters **4** can be performed using the general procedures referenced in March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 920-929 and Eicher, Patai, *The Chemistry of the Carbonyl Group*, pt. 1, pp. 621-693; Wiley: New York, (1966), hereby expressly incorporated herein by reference. For example, the

synthetic procedure described in Comins *et al.*, 1981, *Tetrahedron Lett.* 22:1085, hereby expressly incorporated herein by reference, can be used. As one example, the reaction can be performed by adding an organic solution of $(R^1)_p-M$ (about 0.5 to about 1 equivalents) to a stirred, cooled (about 0°C to about -80°C) solution comprising esters **4**, under an inert atmosphere (*e.g.*, nitrogen) to give a reaction mixture comprising ketones **5**. Preferably, $(R^1)_p-M$ is added at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. The progress of the reaction can be followed by using an appropriate analytical method, such as thin-layer chromatography or high-performance-liquid chromatography. Next, an organic solution of $(R^2)_p-M$ (about 0.5 to about 1 equivalent) is added to the reaction mixture comprising ketones **5** in the same manner used to add $(R^1)_p-M$. After the reaction providing alcohols **6** is substantially complete, the reaction mixture can be quenched and the product can be isolated by workup. Suitable solvents for obtaining alcohols **6** include, but are not limited to, dichloromethane, diethyl ether, tetrahydrofuran, benzene, toluene, xylene, hydrocarbon solvents (*e.g.*, pentane, hexane, and heptane), and mixtures thereof. Preferably, the organic solvent is diethyl ether or tetrahydrofuran. Next, alcohols **6** are converted to mono-protected diols **X**, wherein *n* is 0, using the well-known Williamson ether synthesis. This involves reacting alcohols **6** with ^-O-PG , wherein $-PG$ is a hydroxy-protecting group. For a general discussion of the Williamson ether synthesis, *See* March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 386-387, and for a list of procedures and reagents useful in the Williamson ether synthesis, *See, for example*, Larock *Comprehensive Organic Transformations*; VCH: New York, 1989, pp. 446-448, both of which references are incorporated herein by reference. As used herein, a "hydroxy-protecting group" means a group that is reversibly attached to a hydroxy moiety that renders the hydroxy moiety unreactive during a subsequent reaction(s) and that can be selectively cleaved to regenerate the hydroxy moiety once its protecting purpose has been served. Examples of hydroxy-protecting groups are found in Greene, T.W., *Protective Groups in Organic Synthesis*, 3rd edition 17-237 (1999), hereby expressly incorporated herein by reference. Preferably, the hydroxy-protecting group is stable in a basic reaction medium, but can be cleaved by acid. Examples of suitable base-stable acid-labile hydroxy-protecting groups suitable for use with the invention include, but are not limited to, ethers, such as methyl, methoxy methyl, methylthiomethyl, methoxyethoxymethyl, *bis*(2-chloroethoxy)methyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl, tetrahydrothiofuranyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, *t*-butyl, allyl, benzyl, *o*-nitrobenzyl, triphenylmethyl, α -naphthylldiphenylmethyl, *p*-methoxyphenyldiphenylmethyl,

9-(9-phenyl-10-oxo)anthranyl, trimethylsilyl, isopropyl dimethylsilyl, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl, tribenzylsilyl, and triisopropylsilyl; and esters, such as pivaloate, adamantate, and 2,4,6-trimethylbenzoate. Ethers are preferred, particularly straight chain ethers, such as methyl ether, methoxymethyl ether, methylthiomethyl ether, methoxyethoxymethyl ether, *bis*(2-chloroethoxy)methyl ether. Preferably -PG is methoxymethyl (CH₃OCH₂-). Reaction of alcohols 6 with -O-PG under the conditions of the Williamson ether synthesis involves adding a base to a stirred organic solution comprising HO-PG (*e.g.*, methoxymethanol), maintained at a constant temperature within the range of about 0°C to about 80°C, preferably at about room temperature. Preferably, the base is added at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. The base can be added as an organic solution or in undiluted form. Preferably, the base will have a base strength sufficient to deprotonate a proton, wherein the proton has a pK_a of greater than about 15, preferably greater than about 20. As is well known in the art, the pK_a is a measure of the acidity of an acid H-A, according to the equation $pK_a = -\log K_a$, wherein K_a is the equilibrium constant for the proton transfer. The acidity of an acid H-A is proportional to the stability of its conjugate base ⁻A. For tables listing pK_a values for various organic acids and a discussion on pK_a measurement, see March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 248-272, incorporated herein by reference. Suitable bases include, but are not limited to, alkylmetal bases such as methyllithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride. The preferred base is lithium diisopropylamide. Solvents suitable for reacting alcohols 6 with -OPG include, but are not limited, to dimethyl sulfoxide, dichloromethane, ethers, and mixtures thereof, preferably tetrahydrofuran. After addition of the base, the reaction mixture can be adjusted to within a temperature range of about 0°C to about room temperature and alcohols 6 can be added, preferably at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. Alcohols 6 can be diluted in an organic solvent or added in their undiluted form. The resulting reaction mixture is stirred until the reaction is substantially complete as determined by using an appropriate analytical method, preferably by gas chromatography, then the mono-protected diols X can be isolated by workup and purification.

Next, Scheme 1 outlines a method useful for synthesizing mono-protected diols X, wherein n is 1. First, compounds 7, wherein E is a suitable leaving group, are reacted with compounds 8, wherein R¹ and R² are as defined above and R⁸ is H, (C₁–C₆)alkyl or (C₆)aryl, providing compounds 9. Suitable leaving groups are well known in the art, for example, but not limited to halides, such as chloride, bromide, and iodide; aryl- or alkylsulfonyloxy, substituted arylsulfonyloxy (*e.g.*, tosyloxy or mesyloxy); substituted alkylsulfonyloxy (*e.g.*, haloalkylsulfonyloxy); (C₆)aryloxy or substituted (C₆)aryloxy; and acyloxy groups. Compounds 7 are available commercially (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or can be prepared by well-known methods such as halogenation or sulfonation of butanediol. Compounds 8 are also available commercially (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or by well-known methods, such as those listed in Larock *Comprehensive Organic Transformations*; Wiley-VCH: New York, 1999, pp. 1754-1755 and 1765. A review on alkylation of esters of type 8 is given by J. Mulzer in *Comprehensive Organic Functional Transformations*, Pergamon, Oxford 1995, pp. 148-151 and exemplary synthetic procedures for reacting compounds 7 with compounds 8 are described in United States Patent No. 5,648,387, column 6 and Ackerly, *et al.*, *J. Med. Chem.* **1995**, pp. 1608, all of which citations are hereby expressly incorporated herein by reference. The reaction requires the presence of a suitable base. Preferably, a suitable base will have a pK_a of greater than about 25, more preferably greater than about 30. Suitable bases include, but are not limited to, alkylmetal bases such as methyllithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium hexamethyldisilazide; hydride bases such as sodium hydride and potassium hydride. Metal amide bases, such as lithium diisopropylamide are preferred. Preferably, to react compounds 7 with compounds 8, a solution of about 1 to about 2 equivalents of a suitable base is added to a stirred solution comprising esters 8 and a suitable organic solvent, under an inert atmosphere, the solution maintained at a constant temperature within the range of about –95 °C to about room temperature, preferably at about –78 °C to about –20°C. Preferably, the base is diluted in a suitable organic solvent before addition. Preferably, the base is added at a rate of about 1.5 moles per hour. Organic solvents suitable for the reaction of compounds 7 with the compounds 8 include, but are not limited to, dichloromethane, diethyl ether, tetrahydrofuran, dimethylformamide, dimethyl sulfoxide, benzene, toluene, xylene, hydrocarbon solvents (*e.g.*, pentane, hexane, and heptane), and mixtures thereof. After

addition of the base, the reaction mixture is allowed to stir for about 1 to about 2 hours, and a compound 7, preferably dissolved in a suitable organic solvent, is added, preferably at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. After addition of compounds 7, the reaction-

5 mixture temperature can be adjusted to within a temperature range of about -20 °C to about room temperature, preferably to about room temperature, and the reaction mixture is allowed to stir until the reaction is substantially complete as determined by using an appropriated analytical method, preferably thin-layer chromatography or high-performance liquid chromatography. Then the reaction mixture is quenched and compounds 9, wherein n

10 is 1 can be isolated by workup. Compounds 10 are then synthesized by reacting compounds 9 with -O-PG according to the protocol described above for reacting alcohols 6 with -O-PG. Next, compounds 10 can be converted to mono-protected diols X, wherein n is 1, by reduction of the ester group of compounds 10 to an alcohol group with a suitable reducing agent. A wide variety of reagents are available for reduction of such esters to

15 alcohols, e.g., see M. Hudlicky, *Reductions in Organic Chemistry*, 2nd ed., 1996 pp. 212-217, hereby expressly incorporated herein by reference. Preferably, the reduction is effected with a hydride type reducing agent, for example, lithium aluminum hydride, lithium borohydride, lithium triethyl borohydride, diisobutylaluminum hydride, lithium trimethoxyaluminum hydride, or sodium bis(2-methoxy)aluminum hydride. For exemplary

20 procedures for reducing esters to alcohols, see Nystrom *et al.*, 1947, *J. Am. Chem. Soc.* 69:1197; and Moffet *et al.*, 1963, *Org. Synth., Collect.* 834(4), lithium aluminum hydride; Brown *et al.*, 1965, *J. Am. Chem. Soc.* 87:5614, lithium trimethoxyaluminum hydride; Cerny *et al.*, 1969, *Collect. Czech. Chem. Commun.* 34:1025, sodium bis(2-methoxy)aluminum hydride; Nystrom *et al.*, 1949, *J. Am. Chem.* 71:245, lithium borohydride; and Brown *et al.*,

25 1980, *J. Org. Chem.* 45:1, lithium triethyl borohydride, all of which citations are hereby expressly incorporated herein by reference. Preferably, the reduction is conducted by adding an organic solution of compounds 10 to a stirred mixture comprising a reducing agent, preferably lithium aluminum hydride, and an organic solvent. During the addition, the reaction mixture is maintained at a constant temperature within the range of about -20 °C to

30 about 80 °C, preferably at about room temperature. Organic solvents suitable for reacting 9 with -OPG include, but are not limited to, dichloromethane, diethyl ether, tetrahydrofuran or mixtures thereof, preferably tetrahydrofuran. After the addition, the reaction mixture is stirred at a constant temperature within the range of about room temperature to about 60°C, until the reaction is substantially complete as determined by using an appropriate analytical


35 method, preferably thin-layer chromatography or high-performance-liquid chromatography.

Then the reaction mixture can be quenched and mono-protected diols **X**, wherein *n* is 1, can be isolated by workup and purification.

Scheme 1 next illustrates a three step synthetic sequence for homologating mono-protected diols **X** comprising: (a) halogenation (converting $-\text{CH}_2\text{OH}$ to $-\text{CH}_2\text{-Hal}$);
5 (b) carbonylation (replacing $-\text{Hal}$ with $-\text{CHO}$); and (c) reduction (converting $-\text{CHO}$ to $-\text{CH}_2\text{OH}$), wherein a reaction sequence of (a), (b), and (c) increases the value of *n* by 1. In step (a) protected halo-alcohols **11**, wherein Hal is a halide selected from the group of chloro, bromo, or iodo, preferably iodo, can be prepared by halogenating mono-protected diols **X**, by using well-known methods (for a discussion of various methods for conversion
10 of alcohols to halides see March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 431-433, hereby expressly incorporated herein by reference). For example, protected iodo-alcohols **11** can be synthesized starting from mono-protected diols **X** by treatment with $\text{Ph}_3\text{I}_2/\text{imidazole}$ (Garegg *et al.*, 1980, *J.C.S Perkin I* 2866); 1,2-diphenylene phosphorochloridite/ I_2 (Corey *et al.*, 1967, *J. Org. Chem.* 82:4160); or preferably with $\text{Me}_3\text{SiCl}/\text{NaI}$ (Olah *et al.*, 1979, *J. Org. Chem.* 44:8, 1247), all
15 of which citations are hereby expressly incorporated herein by reference. Step (b); carbonylation of alkyl halides, such as protected halo-alcohols **11**, is reviewed in Olah *et al.*, 1987, *Chem Rev.* 87:4, 671; and March, J., *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 483-484, both of which are hereby expressly
20 incorporated herein by reference). Protected halo-alcohols **11** can be carbonylated with $\text{Li}(\text{BF}_3 \cdot \text{Et}_2\text{O})/\text{HCONMe}_2$ using the procedure described in Maddaford *et al.*, 1993, *J. Org. Chem.* 58:4132; Becker *et al.*, 1982, *J. Org. Chem.* 3297; or Myers *et al.*, 1992, *J. Am. Chem. Soc.* 114:9369 or, alternatively, with an organometallic/*N*-formylmorpholine using the procedure described in Olah *et al.*, 1984, *J. Org. Chem.* 49:3856 or Vogtle *et al.*, 1987, *J.*
25 *Org. Chem.* 52:5560, all of which citations are hereby expressly incorporated herein by reference. The method described in Olah *et al.*, 1984, *J. Org. Chem.* 49:3856 is preferred. Reduction step (c) useful for synthesizing mono-protected diols **X** from aldehydes **12**, can be accomplished by well-known methods in the art for reduction of aldehydes to the corresponding alcohols (for a discussion see M. Hudlicky, *Reductions in Organic*
30 *Chemistry*, 2nd ed., 1996 pp 137-139), for example, by catalytic hydrogenation (*see e.g.*, Carothers, 1949, *J. Am. Chem. Soc.* 46:1675) or, preferably by reacting aldehydes **12** with a hydride reducing agent, such as lithium aluminum hydride, lithium borohydride, sodium borohydride (*see e.g.*, the procedures described in Chaikin *et al.*, 1949, *J. Am. Chem. Soc.* 71:3245; Nystrom *et al.*, 1947, *J. Am. Chem. Soc.* 69:1197; and Nystrom *et al.*, 1949, *J. Am.*

Chem. 71:3245, all of which are hereby expressly incorporated herein by reference). Reduction with lithium aluminum hydride is preferred.

Scheme 2: Synthesis of Compounds of Formula 12a, which correspond to Compounds $W^{(1)(2)}-Z_m-OH$, Wherein $W^{(1)(2)}$ is $C(R^1)(R^2)-Y$




Scheme 2 outlines the method for the synthesis of protected alcohols **12a** wherein Y, R^1 , R^2 , Z, and m are defined as above. Protected alcohols **12a** correspond to compounds of the formula $W^{(1)(2)}-Z_m-OH$, wherein $W^{(1)(2)}$ is $C(R^1)(R^2)-Y$.

- Protected alcohols **16**, wherein Y comprises a $-COOH$ group, can be synthesized by oxidizing mono-protected diols X with an agent suitable for oxidizing a primary alcohol to a carboxylic acid (for a discussion see M. Hudlicky, *Oxidations in Organic Chemistry*, ACS Monograph 186, 1990, pp. 127-130, hereby expressly incorporated herein by reference). Suitable oxidizing agents include, but are not limited to, pyridinium dichromate (Corey *et al.*, 1979, *Tetrahedron Lett.* **399**); manganese dioxide (Ahrens *et al.*, 1967, *J. Heterocycl. Chem.* **4**:625); sodium permanganate monohydrate (Menger *et al.*, 1981, *Tetrahedron Lett.* **22**:1655); and potassium permanganate (Sam *et al.*, 1972, *J. Am. Chem. Soc.* **94**:4024), all of which citations are hereby expressly incorporated herein by reference. The preferred oxidizing reagent is pyridinium dichromate. In an alternative synthetic procedure, protected alcohols **16**, wherein Y comprises a $-COOH$ group, can be synthesized by treatment of protected halo-alcohols **14**, wherein X is iodo, with CO or CO_2 , as described in Bailey *et al.*, 1990, *J. Org. Chem.* **55**:5404 and Yanagisawa *et al.*, 1994, *J. Am. Chem. Soc.* **116**:6130,


- the two of which citations are hereby expressly incorporated herein by reference. Protected alcohols 16, wherein Y comprises $-C(O)OR^5$, wherein R^5 is as defined above, can be synthesized by oxidation of mono-protected diols X in the presence of R^5OH (see generally, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 1196). An exemplary procedure for such an oxidation is described in Stevens *et al.*, 1982, *Tetrahedron Lett.* 23:4647 (HOCl); Sundararaman *et al.*, 1978, *Tetrahedron Lett.* 1627 (O_3/KOH); Wilson *et al.*, 1982, *J. Org. Chem.* 47:1360 ($t-BuOOH/Et_3N$); and Williams *et al.*, 1988, *Tetrahedron Lett.* 29:5087 (Br_2), the four of which citations are hereby expressly incorporated herein by reference. Preferably, protected alcohols 16, wherein Y comprises a $-C(O)OR^5$ group are synthesized from the corresponding carboxylic acid (*i.e.*, 16, wherein Y comprises $-COOH$) by esterification with R^5OH (*e.g.*, see March, J., *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 393-394, hereby expressly incorporated herein by reference). In another alternative synthesis, protected alcohols 16, wherein Y comprises $-C(O)OR^5$, can be prepared from protected halo-alcohols 14 by carbonylation with transition metal complexes (*see e.g.*, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 484-486; Urata *et al.*, 1991, *Tetrahedron Lett.* 32:36, 4733); and Ogata *et al.*, 1969, *J. Org. Chem.* 3985, the three of which citations are hereby expressly incorporated herein by reference).
- Protected alcohols 16, wherein Y comprises $-OC(O)R^5$, wherein R^5 is as defined above, can be prepared by acylation of mono-protected diols X with a carboxylate equivalent such as an acyl halide (*i.e.*, $R^5C(O)-Hal$, wherein Hal is iodo, bromo, or chloro, *see e.g.*, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 392 and *Org. Synth. Coll.* Vol. III, Wiley, NY, pp. 142, 144, 167, and 187 (1955)) or an anhydride (*i.e.*, $R^5C(O)-O-(O)CR^5$, *see e.g.*, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 392-393 and *Org. Synth. Coll.* Vol. III, Wiley, NY, pp. 11, 127, 141, 169, 237, 281, 428, 432, 690, and 833 (1955), all of which citations are hereby expressly incorporated herein by reference). Preferably, the reaction is conducted by adding a base to a solution comprising mono-protected diols X, a carboxylate equivalent, and an organic solvent, which solution is preferably maintained at a constant temperature within the range of $0^\circ C$ to about room temperature. Solvents suitable for reacting mono-protected diols X with a carboxylate equivalent include, but are not limited to, dichloromethane, toluene, and ether, preferably dichloromethane. Suitable bases include, but are not limited to, hydroxide sources, such as sodium hydroxide, potassium hydroxide, sodium carbonate, or potassium carbonate; or an amine such as triethylamine, pyridine, or dimethylaminopyridine, amines are preferred. The progress of the reaction can

be followed by using an appropriate analytical technique, such as thin layer chromatography or high performance liquid chromatography and when substantially complete, the product can be isolated by workup and purified if desired.

- 5 Protected alcohols **16**, wherein Y comprises one of the following phosphate ester groups



- wherein R^6 is defined as above, can be prepared by phosphorylation of mono-protected diols **X** according to well-known methods (for a general reviews, see Corbridge *Phosphorus: An Outline of its Chemistry, Biochemistry, and Uses*, Studies in Inorganic Chemistry, 3rd ed., pp. 357-395 (1985); Ramirez *et al.*, 1978, *Acc. Chem. Res.* **11**:239; and Kalckare *Biological Phosphorylations*, Prentice-Hall, New York (1969); J. B. Sweeny in *Comprehensive Organic Functional Group Transformations*, A.R. Katritzky, O. Meth-Cohn and C.W. Rees, Eds. Pergamon: Oxford, 1995, vol 2, pp. 104-109, the four of which are hereby expressly incorporated herein by reference). Protected alcohols **16** wherein Y comprises a monophosphate group of the formula:
- 10
- 15



- wherein R^6 is defined as above, can be prepared by treatment of mono-protected diol **X** with phosphorous oxychloride in a suitable solvent, such as xylene or toluene, at a constant temperature within the range of about 100°C to about 150°C for about 2 hours to about 24 hours. After the reaction is deemed substantially complete, by using an appropriate analytical method, the reaction mixture is hydrolyzed with $\text{R}^6\text{-OH}$. Suitable procedures are referenced in Houben-Weyl, *Methoden der Organische Chemie*, Georg Thieme Verlag Stuttgart 1964, vol. XII/2, pp. 143-210 and 872-879, hereby expressly incorporated herein by reference. Alternatively, when both R^6 are hydrogen, can be synthesized by reacting mono-protected diols **X** with silyl polyphosphate (Okamoto *et al.*, 1985, *Bull Chem. Soc. Jpn.* **58**:3393, hereby expressly incorporated herein by reference) or by hydrogenolysis of their benzyl or phenyl esters (Chen *et al.*, 1998, *J. Org. Chem.* **63**:6511, hereby expressly
- 20
- 25

incorporated herein by reference). In another alternative procedure, when R⁶ is (C₁–C₆)alkyl, (C₂–C₆)alkenyl, or (C₂–C₆)alkynyl, the monophosphate esters can be prepared by reacting mono-protected diols X with appropriately substituted phosphoramidites followed by oxidation of the intermediate with *m*-chloroperbenzoic acid (Yu *et al.*, 1988, *Tetrahedron Lett.* 29:979, hereby expressly incorporated herein by reference) or by reacting


5 mono-protected diols X with dialkyl or diaryl substituted phosphorochloridates (Pop, *et al.*, 1997, *Org. Prep. and Proc. Int.* 29:341, hereby expressly incorporated herein by reference). The phosphoramidites are commercially available (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or readily prepared according to literature procedures (*see e.g.*,

10 Uhlmann *et al.* 1986, *Tetrahedron Lett.* 27:1023 and Tanaka *et al.*, 1988, *Tetrahedron Lett.* 29:199, both of which are hereby expressly incorporated herein by reference). The phosphorochloridates are also commercially available (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or prepared according to literature methods (*e.g.*, Gajda *et al.* 1995, *Synthesis* 25:4099. In still another alternative synthesis, protected alcohols 16, wherein Y

15 comprises a monophosphate group and R⁶ is alkyl or aryl, can be prepared by reacting IP⁺(OR⁶)₃ with mono-protected diols X according to the procedure described in Stowell *et al.*, 1995, *Tetrahedron Lett.* 36:11, 1825 or by alkylation of protected halo alcohols 14 with the appropriate dialkyl or diaryl phosphates (*see e.g.*, Okamoto, 1985, *Bull Chem. Soc. Jpn.* 58:3393, hereby expressly incorporated herein by reference).


20

Protected alcohols 16 wherein Y comprises a diphosphate group of the formula




wherein R⁶ is defined as above, can be synthesized by reacting the above-discussed


25 monophosphates of the formula:




with a phosphate of the formula




- (commercially available, *e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin), in the presence of carbodiimide such as dicyclohexylcarbodiimide, as described in Houben-Weyl, *Methoden der Organische Chemie*, Georg Thieme Verlag Stuttgart 1964, vol. XII/2, pp. 881-885. In the same fashion, protected alcohols **16**, wherein Y comprises a triphosphate group of the formula:



can be synthesized by reacting the above-discussed diphosphate protected alcohols, of the formula:




- with a phosphate of the formula:




- as described above. Alternatively, when R⁶ is H, protected alcohols **16** wherein Y comprises the triphosphate group, can be prepared by reacting mono-protected diols **X** with salicyl phosphorochloridite and then pyrophosphate and subsequent cleavage of the adduct thus obtained with iodine in pyridine as described in Ludwig *et al.*, 1989, *J. Org. Chem.* 54:631, hereby expressly incorporated herein by reference.

Protected alcohols **16**, wherein Y is -SO₃H or a heterocyclic group selected from the group consisting of:



can be prepared by halide displacement from protected halo-alcohols **14**. Thus, when Y is $-\text{SO}_3\text{H}$, protected alcohols **16** can be synthesized by reacting protected halo-alcohols **14** with sodium sulfite as described in Gilbert *Sulfonation and Related Reactions*; Wiley: New York, 1965, pp. 136-148 and pp. 161-163; *Org. Synth. Coll.* Vol. II, Wiley, NY, 558, 564
 5 (1943); and *Org. Synth. Coll.* Vol. IV, Wiley, NY, 529 (1963), all three of which are hereby expressly incorporated herein by reference. When Y is one of the above-mentioned heterocycles, protected alcohols **16** can be prepared by reacting protected halo-alcohols **14** with the corresponding heterocycle in the presence of a base. The heterocycles are available commercially (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or prepared by well-
 10 known synthetic methods (see the procedures described in Ware, 1950, *Chem. Rev.* **46**:403-470, hereby expressly incorporated herein by reference). Preferably, the reaction is conducted by stirring a mixture comprising **14**, the heterocycle, and a solvent at a constant temperature within the range of about room temperature to about 100°C , preferably within the range of about 50°C to about 70°C for about 10 to about 48 hours. Suitable bases
 15 include hydroxide bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, or potassium carbonate. Preferably, the solvent used in forming protected alcohols **16** is selected from dimethylformamide; formamide; dimethyl sulfoxide; alcohols, such as methanol or ethanol; and mixtures thereof. The progress of the reaction can be followed by using an appropriate analytical technique, such as thin layer chromatography or high
 20 performance liquid chromatography and when substantially complete, the product can be isolated by workup and purified if desired.

Protected alcohols **16**, wherein Y is a heteroaryl ring selected from



can be prepared by metallating the suitable heteroaryl ring then reacting the resulting metallated heteroaryl ring with protected halo-alcohols **14** (for a review, see Katritzky *Handbook of Heterocyclic Chemistry*, Pergamon Press: Oxford 1985). The heteroaryl rings

5 are available commercially or prepared by well-known synthetic methods (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995; De Sarlo *et al.*, 1971, *J. Chem. Soc. (C)* **86**; Oster *et al.*, 1983, *J. Org. Chem.* **48**:4307; Iwai *et al.*, 1966, *Chem. Pharm. Bull.* **14**:1277; and United States Patent No. 3,152,148, all of which citations are hereby expressly incorporated herein by reference). As used herein, the term “metallating” means the forming of a carbon-

10 metal bond, which bond may be substantially ionic in character. Metallation can be accomplished by adding about 2 equivalents of strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, to a mixture comprising a suitable organic solvent and the heterocycle. Two equivalents of base are required: one equivalent of the base deprotonates the $-OH$ group or the $-NH$ group, and the

15 second equivalent metallates the heteroaryl ring. Alternatively, the hydroxy group of the heteroaryl ring can be protected with a base-stable, acid-labile protecting group as described in Greene, T.W., *Protective Groups in Organic Synthesis*, 3rd edition 17-237 (1999), hereby expressly incorporated herein by reference. Where the hydroxy group is protected, only one equivalent of base is required. Examples of suitable base-stable, acid-labile hydroxyl-


20 protecting groups, include but are not limited to, ethers, such as methyl, methoxy methyl, methylthiomethyl, methoxyethoxymethyl, *bis*(2-chloroethoxy)methyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahyrofuranyl, tetrahydrothiofuranyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, *t*-butyl, allyl, benzyl, *o*-nitrobenzyl, triphenylmethyl, α -naphthyl, diphenylmethyl, *p*-methoxyphenyldiphenylmethyl, 9-(9-phenyl-10-oxo)anthranyl,

25 trimethylsilyl, isopropyldimethylsilyl, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl, tribenzylsilyl, triisopropylsilyl; and esters, such as pivaloate, adamantate, and 2,4,6-trimethylbenzoate. Ethers are preferred, particularly straight chain ethers, such as methyl ether, methoxymethyl ether, methylthiomethyl ether, methoxyethoxymethyl ether, *bis*(2-chloroethoxy)methyl ether. Preferably, the pK_a of the base is higher than the pK_a of the


proton of the heterocycle to be deprotonated. For a listing of pK_as for various heteroaryl rings, see Fraser *et al.*, 1985, *Can. J. Chem.* **63**:3505, hereby expressly incorporated herein by reference. Suitable bases include, but are not limited to, alkylmetal bases such as methyl lithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride. If desired, the organometallic base can be activated with a complexing agent, such as *N,N,N',N'*-tetramethylethylenediamine or hexamethylphosphoramide (1970, *J. Am. Chem. Soc.* **92**:4664, hereby expressly incorporated herein by reference). Solvents suitable for synthesizing protected alcohols **16**, wherein Y is a heteroaryl ring include, but are not limited to, diethyl ether; tetrahydrofuran; and hydrocarbons, such as pentane. Generally, metallation occurs alpha to the heteroatom due to the inductive effect of the heteroatom, however, modification of conditions, such as the identity of the base and solvents, order of reagent addition, reagent addition times, and reaction and addition temperatures can be modified by one of skill in the art to achieve the desired metallation position (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995, pp. 30-42, hereby expressly incorporated herein by reference). Alternatively, the position of metallation can be controlled by use of a halogenated heteroaryl group, wherein the halogen is located on the position of the heteroaryl ring where metallation is desired (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995, p. 33 and Saulnier *et al.*, 1982, *J. Org. Chem.* **47**:757, the two of which citations are hereby expressly incorporated herein by reference). Halogenated heteroaryl groups are available commercially (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or can be prepared by well-known synthetic methods (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995, pp. 78, 85, 122, 193, 234, 261, 280, 308, hereby expressly incorporated herein by reference). After metallation, the reaction mixture comprising the metallated heteroaryl ring is adjusted to within a temperature range of about 0°C to about room temperature and protected halo-alcohols **14** (diluted with a solvent or in undiluted form) are added, preferably at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. After addition of protected halo-alcohols **14**, the reaction mixture is stirred at a constant temperature within the range of about room temperature and about the solvent's boiling temperature and the reaction's progress can be monitored by the appropriate analytical technique, preferably thin-layer chromatography or high-performance liquid chromatography. After the reaction

is substantially complete, protected alcohols **16** can be isolated by workup and purification. It is to be understood that conditions, such as the identity of protected halo-alcohol **14**, the base, solvents, orders of reagent addition, times, and temperatures, can be modified by one of skill in the art to optimize the yield and selectivity. Exemplary procedures that can be used in such a transformation are described in Shirley *et al.*, 1995, *J. Org. Chem.* **20**:225; Chadwick *et al.*, 1979, *J. Chem. Soc., Perkin Trans. 1* **2845**; Rewcastle, 1993, *Adv. Het. Chem.* **56**:208; Katritzky *et al.*, 1993, *Adv. Het. Chem.* **56**:155; and Kessar *et al.*, 1997, *Chem. Rev.* **97**:721.


When Y is



protected alcohols **16** can be prepared from their corresponding carboxylic acid derivatives (**16**, wherein Y is $-\text{CO}_2\text{H}$) as described in Belletire *et al.*, 1988, *Synthetic Commun.* **18**:2063 or from the corresponding acylchlorides (**16**, wherein Y is $-\text{CO}-\text{halo}$) as described in Skinner *et al.*, 1995, *J. Am. Chem. Soc.* **77**:5440, both citations are hereby expressly incorporated herein by reference. The acylhalides can be prepared from the carboxylic acids by well known procedures such as those described in March, J., *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 437-438, hereby expressly incorporated herein by reference. When Y is



wherein R^7 is as defined above, protected alcohols **16** can be prepared by first reacting protected halo-alcohols **15** with a trialkyl phosphite according to the procedure described in Kosolapoff, 1951, *Org. React.* **6**:273 followed by reacting the derived phosphonic diester with ammonia according to the procedure described in Smith *et al.*, 1957, *J. Org. Chem.* **22**:265, hereby expressly incorporated herein by reference. When Y is




protected alcohols **16** can be prepared by reacting their sulphonic acid derivatives (*i.e.*, **16**, wherein Y is $-\text{SO}_3\text{H}$) with ammonia as described in Sianesi *et al.*, 1971, *Chem. Ber.*


104:1880 and Campagna *et al.*, 1994, *Farmaco, Ed. Sci.* 49:653, both of which citations are hereby expressly incorporated herein by reference).

- 5** As further illustrated in Scheme 2, protected alcohols **16** can be deprotected providing alcohols **20a**. The deprotection method depends on the identity of the alcohol-protecting group, *see e.g.*, the procedures listed in Greene, T.W., *Protective Groups in Organic Synthesis*, 3rd edition 17-237 (1999), particularly see pages 48-49, hereby expressly incorporated herein by reference. One of skill in the art will readily be able to choose the
- 10** appropriate deprotection procedure. When the alcohol is protected as an ether function (*e.g.*, methoxymethyl ether), the alcohol is preferably deprotected with aqueous or alcoholic acid. Suitable deprotection reagents include, but are not limited to, aqueous hydrochloric acid, *p*-toluenesulfonic acid in methanol, pyridinium-*p*-toluenesulfonate in ethanol, Amberlyst H-15 in methanol, boric acid in ethylene-glycol-monoethylether, acetic acid in a
- 15** water-tetrahydrofuran mixture, aqueous hydrochloric acid is preferred. Examples of such procedures are described, respectively, in Bernady *et al.*, 1979, *J. Org. Chem.* 44:1438; Miyashita *et al.*, 1977, *J. Org. Chem.* 42:3772; Johnston *et al.*, 1988, *Synthesis* 393; Bongini *et al.*, 1979, *Synthesis* 618; and Hoyer *et al.*, 1986, *Synthesis* 655; Gigg *et al.*, 1967, *J. Chem. Soc. C*, 431; and Corey *et al.*, 1978, *J. Am. Chem. Soc.* 100:1942, all of which are hereby
- 20** expressly incorporated herein by reference.

Scheme 3: Synthesis of Compounds of Formula 13a, which correspond to $\text{W}^{(1)(2)}-\text{Z}_m-\text{OH}$, Wherein $\text{W}^{(1)(2)}$ is a Lactone Group




Scheme 3 depicts the synthesis of protected lactone alcohols **20** and lactone alcohols **13a**. Compounds **20** and **13a** correspond to compounds of the formula $W^{(1)(2)}-Z_m-OPG$ and $W^{(1)(2)}-Z_m-OH$ respectively, wherein $W^{(1)(2)}$ is a lactone group selected from:




- 5 Protected lactone alcohols **20** can be prepared from compounds of the formula **17**, **18**, or **19** by using well-known condensation reactions and variations of the Michael reaction. Methods for the synthesis of lactones are disclosed in Miltzer in *Comprehensive Organic Functional Group Transformations*, A.R. Katritzky, O. Meth-Cohn and C.W. Rees, Eds. Pergamon: Oxford, 1995, vol 5, pp. 161-173, hereby expressly incorporated herein by
10 reference. Mono-protected diols **19**, electrophilic protected alcohols **18**, and aldehydes **19** are readily available either commercially (e.g., Aldrich Chemical Co., Milwaukee, WI) or by well known synthetic procedures.

When $W^{(1)(2)}$ is a beta-lactone group of the formula:




- protected lactone alcohols **20** can be prepared from aldehydes **19** and electrophilic protected
15 alcohols **18**, respectively, by a one-pot-addition-lactonization according to the procedure of
Masamune *et al.*, 1976, *J. Am. Chem. Soc.* 98:7874 and Danheiser *et al.*, 1991, *J. Org. Chem.*
56:1176, both of which are hereby expressly incorporated herein by reference. This one-
pot-addition-lactonization methodology has been reviewed by Multzer in *Comprehensive*

Organic Functional Group Transformations, A.R. Katritzky, O. Meth-Cohn and C.W. Rees, Eds. Pergamon: Oxford, 1995, vol 5, pp. 161, hereby expressly incorporated herein by reference When $W^{(1)(2)}$ is a gamma- or delta-lactone group of the formula:




protected lactone alcohols **20** can be prepared from aldehydes **19** according to well known synthetic methodology. For example, the methodology described in Masuyama *et al.*, 2000, *J. Org. Chem.* 65:494; Eisch *et al.*, 1978, *J. Organo. Met. Chem.* C8 160; Eaton *et al.*, 1947, *J. Org. Chem.* 37:1947; Yunker *et al.*, 1978, *Tetrahedron Lett.* 4651; Bhanot *et al.*, 1977, *J. Org. Chem.* 42:1623; Ehlinger *et al.*, 1980, *J. Am. Chem. Soc.* 102:5004; and Raunio *et al.*, 1957, *J. Org. Chem.* 22:570, all of which citations are hereby expressly incorporated herein by reference. For instance, as described in Masuyama *et al.*, 2000, *J. Org. Chem.* 65:494, aldehydes **19** can be treated with about 1 equivalent of a strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, in a suitable organic solvent to give a reaction mixture. Suitable bases include, but are not limited to, alkylmetal bases such as methyllithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride, preferably lithium tetramethylpiperidide. Suitable solvents include, but are not limited to, diethyl ether and tetrahydrofuran. The reaction-mixture temperature is adjusted to within the range of about 0°C to about 100°C, preferably about room temperature to about 50°C, and a halide of the formula:




wherein z is 1 or 2 (diluted with a solvent or in undiluted form) is added. The reaction mixture is stirred for a period of about 2 hours to about 48 hours, preferably about 5 to about 10 hours, during which time the reaction's progress can be followed by using an appropriate

analytical technique, such as thin layer chromatography or high performance liquid chromatography. When the reaction is deemed substantially complete, protected lactone alcohols **20** can be isolated by workup and purified if desired. When $W^{(1)(2)}$ is a gamma- or delta-lactone group of the formula:




- 5 protected lactone alcohols **20** can be synthesized by deprotonating the corresponding lactone with a strong base providing the lactone enolate and reacting the enolate with electrophilic protected alcohols **20** (for a detailed discussion of enolate formation of active methylene compounds such as lactones, see House *Modern Synthetic Reactions*; W. A. Benjamin, Inc. Philippines 1972 pp. 492-570, and for a discussion of reaction of lactone enolates with
- 10 electrophiles such as carbonyl compounds, see March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 944-945, both of which are hereby expressly incorporated herein by reference). Lactone-enolate formation can be accomplished by adding about 1 equivalent of a strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, to a mixture
- 15 comprising a suitable organic solvent and the lactone. Suitable bases include, but are not limited to, alkylmetal bases such as methyl lithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium
- 20 hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride, preferably lithium tetramethylpiperidide. Solvents suitable for lactone-enolate formation include, but are not limited to, diethyl ether and tetrahydrofuran. After enolate formation, the reaction-mixture temperature is adjusted to within the range of about -78°C to about room temperature, preferably about -50°C to about
- 25 0°C , and electrophilic protected alcohols **18** (diluted with a solvent or in undiluted form) are added, preferably at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. The reaction mixture is stirred for a period of about 15 minutes to about 5 hours, during which time the reaction's progress can be followed by using an appropriate analytical technique, such as thin layer

chromatography or high performance liquid chromatography. When the reaction is deemed substantially complete, protected lactone alcohols **20** can be isolated by workup and purified if desired. When $W^{(1)(2)}$ is a lactone group of the formula:




- 5 protected lactone alcohols **20** can be prepared from aldehydes **19** according to the procedure described in United States Patent No. 4,622,338, hereby expressly incorporated herein by reference.

When $W^{(1)(2)}$ is a gamma- or delta-lactone group of the formula:




- 10 protected lactone alcohols **20** can be prepared according to a three step sequence. The first step comprises base-mediated reaction of electrophilic protected alcohols **18** with succinic acid esters (*i.e.*, $R^9O_2CCH_2CH_2CO_2R^9$, wherein R^9 is alkyl) or glutaric acid esters (*i.e.*, $R^9O_2CCH_2CH_2CH_2CO_2R^9$, wherein R^9 is alkyl) providing a diester intermediate of the formula **21**:




21

- 15 wherein x is 1 or 2 depending on whether the gamma or delta lactone group is desired. The reaction can be performed by adding about 1 equivalent of a strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, to a mixture comprising a suitable organic solvent and the succinic or glutaric acid ester. Suitable bases include, but are not limited to, alkylmetal bases such as methyllithium,
- 20 *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium

amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride, preferably lithium tetramethylpiperidide. Suitable solvents include, but are not limited to, diethyl ether and tetrahydrofuran. After enolate formation, the reaction-mixture temperature is adjusted to within the range of about -78°C to about room temperature, preferably about -50°C to about 0°C , and electrophilic protected alcohols **18** (diluted with a solvent or in undiluted form) are added, preferably at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. The reaction mixture is stirred for a period of about 15 minutes to about 5 hours, during which time the reaction's progress can be followed by using an appropriate analytical technique, such as thin layer chromatography or high performance liquid chromatography. When the reaction is deemed substantially complete, the diester intermediate be isolated by workup and purified if desired. In the second step, the intermediate diester can be reduced, with a hydride reducing agent, to yield a diol of the formula **22**:


**22**

The reduction can be performed according to the procedures referenced in March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 1214, hereby expressly incorporated herein by reference). Suitable reducing agents include, but are not limited to, lithium aluminum hydride, diisobutylaluminum hydride, sodium borohydride, and lithium borohydride). In the third step, the diol can be oxidatively cyclized with $\text{RuH}_2(\text{PPh}_3)_4$ to the product protected lactone alcohols **20** according to the procedure of Yoshikawa *et al.*, 1986, *J. Org. Chem.* 51:2034 and Yoshikawa *et al.*, 1983, *Tetrahedron Lett.* 26:2677, both of which citations are hereby expressly incorporated herein by reference. When $\text{W}^{(1)(2)}$ is a lactone group of the formula:



- protected lactone alcohols **20** can be synthesized by reacting the Grignard salts of electrophilic protected alcohols **18**, where E is a halide, with 5,6-dihydro-2H-pyran-2-one, commercially available (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin), in the presence of catalytic amounts of a 1-dimethylaminoacetylpyrrolidine-2-yl)methyl-diarylphosphine-copper (I) iodide complex as described in Tomioka *et al.*, 1995, *Tetrahedron Lett.* **36**:4275, hereby expressly incorporated herein by reference.

Scheme 4: Synthesis of Compounds of Formula 14




Scheme 4 outlines methodology for the synthesis of protected alcohols **14**. Compounds **14**, wherein n is an integer ranging from 1 to 5, can be prepared from compounds **11** using general synthetic strategy depicted and adapting the synthetic protocols from those discussed for Scheme 1.

5 Next, Scheme 4 depicts the general strategy for the synthesis of compounds **14** wherein n is 0. First, Esters **27**, wherein R^8 is as defined above, are synthesized by oxidation of mono-protected diols **X** in the presence of R^8OH (see generally, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 1196). An exemplary procedure for such an oxidation is described in Stevens *et al.*, 1982, *Tetrahedron Lett.* 23:4647 (HOCl); Sundararaman *et al.*, 1978, *Tetrahedron Lett.* 1627 (O₃/KOH); Wilson *et al.*, 1982, *J. Org. Chem.* 47:1360 (*t*-BuOOH/Et₃N); and Williams *et al.*, 1988, *Tetrahedron Lett.* 29:5087 (Br₂), the four of which citations are hereby expressly incorporated herein by reference. Compounds **28** are converted to compounds **14** wherein n is 0 by adapting the synthetic procedures depicted in Scheme 1.

15

Scheme 5: Synthesis of Compounds of Formula 15a, which correspond to compounds $W^{(1)(2)}-Z_m-OH$, Where $W^{(1)(2)}$ is $C(R^1)(R^2)-(CH_2)_cC(R^3)(R^4)-Y$




20 Scheme 5 outlines methodology for the synthesis of protected alcohols **29** and alcohols **15a**, which correspond to $W^{(1)(2)}-Z_m-OPG$ and $W^{(1)(2)}-Z_m-OH$, respectively, wherein $W^{(1)(2)}$ is $C(R^1)(R^2)-(CH_2)_cC(R^3)(R^4)-Y$. The synthesis of starting materials **14**, **26**,

and 28 are depicted in Scheme 4 and the synthetic methods and procedures can be adapted from those described for Scheme 2.


5

10

Scheme 6: Synthesis of Compounds of Formula 16, which correspond to compounds $W^{(1)(2)}-Z_m-OH$, Wherein $W^{(1)(2)}$ is $C(R^1)(R^2)(CH_2)_c-V$ where V is a Lactone Group




Scheme 6 depicts the synthesis of protected lactone alcohols 30 and lactone alcohols 16a. Compounds 30 and 16a correspond to compounds of the formula, which correspond to compounds $W^{(1)(2)}-Z_m-OH$, Wherein $W^{(1)(2)}$ is $C(R^1)(R^2)(CH_2)_c-V$ and V is a Group selected from:



As shown in Scheme 6, protected lactone alcohols **30** and lactone alcohols **16a** can be synthesized from compounds of the formula **X**, **11**, or **12** by adaptation of the methods and procedures discussed above for Scheme 3.

5


Scheme 7: Conversion of Alcohols 18 to Halides 18e



Scheme 7 depicts the synthesis of halides 17. Halides 17 can be synthesized by a variety of methods. One method involves conversion of the alcohol to a leaving group such as a sulfonic ester, such as, for example, tosylate, brosylate, mesylate, or nosylate. This intermediate is then treated with a source of X⁻, wherein X⁻ is I⁻, Br⁻, or Cl⁻ in a solvent such as THF or ether. A general method for converting vinyl and phenyl alcohols to thiols involves initially converting the alcohol to a leaving group (*e.g.*, a tosylate) then treating with a halide nucleophile.

15


Scheme 8: Synthesis of Compounds of Formula I



Scheme 8 outlines the synthesis of compounds **I**. In the first step, compounds **I** are synthesized by reacting compounds **17** (compounds **X 11, 12, 13, 14, 15, and 16** are encompassed by **17**) with compounds **31** under the conditions suitable for the formation of compounds **I**. The conditions and methods discussed in Scheme 1 above for the synthesis of mono-protected diols **X** from alcohols **6** can be adapted for the synthesis of compounds **17**. Compounds **31**, wherein **Y** is a suitable leaving group as defined above, preferably an anhydride, an ester, or an amide group, are readily obtained commercially (*e.g.*, Aldrich Chemical Co. Milwaukee WI) or by well known synthetic methods. Compounds **I** are obtained by reacting compounds **31** with compounds **17** under the conditions suitable for alkyl-de-acyloxy substitution. (For a review, See Kharasch; Reinmuth, *Grignard Reactions of Nonmetallic Substances*; Prentice Hall: Englewood Cliffs, NJ, 1954, pp. 561-562 and 846-908. In a preferred procedure, the conversion of anhydrides, carboxylic esters, or amides to ketones with organometallic compounds. In a particular procedure, anhydrides and carboxylic esters give ketones when treated using inverse addition of Grignard reagents at low temperature with the solvent HMPA. See Newman, *J. Org. Chem.* **1948**, *13*, 592; Huet; Empotz; Jubier *Tetrahedron* **1973**, *29*, 479; and *Comprehensive Organic Transformations*; VCH: New York, **1989**, pp. 685-686, 693-700. Ketones can also be prepared by the treatment of thioamides with organolithium compounds (alkyl or aryl). See Tominaga; Kohra; Hosomi *Tetrahedron Lett.* **1987**, *28*, 1529. Moreover, alkyllithium compounds have been used to give ketones from carboxylic esters. See Petrov; Kaplan; Tsir *J. Gen. Chem. USSR* **1962**, *32*, 691. The reaction must be carried out in a high-boiling solvent such as toluene. Di-substituted amides also can be used to synthesize ketones. See Evans *J. Chem. Soc.* 1956, 4691; and Wakefield *Organolithium Methods*; Academic Press: New York, **1988**, pp. 82-88.

25

5


Scheme 9: Synthesis of Compounds of Formula II

- 10 Scheme 9 illustrates the alpha disubstitution of an ester containing a terminal protected hydroxyl moiety. Compounds that contain strong electron withdrawing groups are easily converted to the corresponding enolates. These enolate ions can readily attack an electrophile resulting in alpha substitution. *See Some Modern Methods of Organic Synthesis*, 3rd Ed.; Cambridge University Press: Cambridge, 1986, pp. 1-26, hereby
- 15 expressly incorporated herein by reference. The reaction is successful for primary and secondary alkyl, allylic, and benzylic. The use of polar aprotic solvents, e.g., dimethylformamide or dimethylsulfoxide, are preferred. Phase transfer catalysts can also be

used. See Tundo *et al. J. Chem. Soc., Perkin Trans. 1*, 1987, 2159, which is hereby expressly incorporated herein by reference.

The conversion to a carboxylic acid with an additional carbon is achieved by treating an acyl halide with diazomethane to generate an intermediate diazo ketone, which in the presence of water and silver oxide rearranges through a ketene intermediate to a carboxylic acid with an additional carbon aton 37. If the reaction is done in an alcohol instead of water an ester is recovered. See Meier *et al. Angew. Chem. Int. Ed. Eng.* 1975, 14, 32-43, which is hereby expressly incorporated herein by reference. Alternatively, the carboxylic acid can be esterified by known techniques. The reaction can be repeated to generate methylene groups adjacent to the carboxylic acid.

Scheme 10: Synthesis of Compounds of Formula 42a which correspond to Compounds $W^{(1)(2)}-(CH_2)_4-OH$, wherein $W^{(1)(2)}$ is $C(R^1)(R^2)(CH_2)_nY$



15

Scheme 10 outlines methodology for the synthesis of protected alcohols 42a wherein Y, R¹, R², Z, and m are defined as above. Protected alcohols 42a correspond to compounds of the formula $W^{(1)(2)}-Zm-OPG$, wherein $W^{(1)(2)}$ is $C(R^1)(R^2)-Y$.


Protected alcohols 42, wherein Y comprises a -COOH group, can be synthesized by oxidizing mono-protected diols 39 with an agent suitable for oxidizing a primary alcohol to a carboxylic acid (for a discussion see M. Hudlicky, *Oxidations in Organic Chemistry*, ACS Monograph 186, 1990, pp. 127-130, hereby expressly incorporated herein by reference).

Suitable oxidizing agents include, but are not limited to, pyridinium dichromate (Corey *et al.*, 1979, *Tetrahedron Lett.* 399); manganese dioxide (Ahrens *et al.*, 1967, *J. Heterocycl. Chem.* 4:625); sodium permanganate monohydrate (Menger *et al.*, 1981, *Tetrahedron Lett.* 22:1655); and potassium permanganate (Sam *et al.*, 1972, *J. Am. Chem. Soc.* 94:4024), all of which citations are hereby expressly incorporated herein by reference. The preferred oxidizing reagent is pyridinium dichromate. In an alternative synthetic procedure, protected alcohols **42**, wherein Y comprises a --COOH group, can be synthesized by treatment of protected halo-alcohols **40**, wherein X is iodo, with CO or CO_2 , as described in Bailey *et al.*, 1990, *J. Org. Chem.* 55:5404 and Yanagisawa *et al.*, 1994, *J. Am. Chem. Soc.* 116:6130, the two of which citations are hereby expressly incorporated herein by reference. Protected alcohols **42**, wherein Y comprises --C(O)OR^5 , wherein R^5 is as defined above, can be synthesized by oxidation of mono-protected diols **39** in the presence of R^5OH (see generally, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 1196). An exemplary procedure for such an oxidation is described in Stevens *et al.*, 1982, *Tetrahedron Lett.* 23:4647 (HOCl); Sundararaman *et al.*, 1978, *Tetrahedron Lett.* 1627 (O_3/KOH); Wilson *et al.*, 1982, *J. Org. Chem.* 47:1360 ($t\text{-BuOOH}/\text{Et}_3\text{N}$); and Williams *et al.*, 1988, *Tetrahedron Lett.* 29:5087 (Br_2), the four of which citations are hereby expressly incorporated herein by reference. Preferably, protected alcohols **42**, wherein Y comprises a --C(O)OR^5 group are synthesized from the corresponding carboxylic acid (*i.e.*, **42**, wherein Y comprises --COOH) by esterification with R^5OH (*e.g.*, see March, J., *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 393-394, hereby expressly incorporated herein by reference). In another alternative synthesis, protected alcohols **42**, wherein Y comprises --C(O)OR^5 , can be prepared from protected halo-alcohols **40** by carbonylation with transition metal complexes (*see e.g.*, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 484-486; Urata *et al.*, 1991, *Tetrahedron Lett.* 32:36, 4733); and Ogata *et al.*, 1969, *J. Org. Chem.* 3985, the three of which citations are hereby expressly incorporated herein by reference).


Protected alcohols **42**, wherein Y comprises --OC(O)R^5 , wherein R^5 is as defined above, can be prepared by acylation of mono-protected diols **39** with a carboxylate equivalent such as an acyl halide (*i.e.*, $\text{R}^5\text{C(O)--Hal}$, wherein Hal is iodo, bromo, or chloro, *see e.g.*, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 392 and *Org. Synth. Coll. Vol. III*, Wiley, NY, pp. 142, 144, 167, and 187 (1955)) or an anhydride (*i.e.*, $\text{R}^5\text{C(O)--O--(O)CR}^5$, *see e.g.*, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 392-393 and *Org. Synth. Coll. Vol. III*, Wiley, NY, pp. 11, 127, 141, 169, 237, 281, 428, 432, 690, and 833 (1955)),

all of which citations are incorporated herein by reference). Preferably, the reaction is conducted by adding a base to a solution comprising mono-protected diols **39**, a carboxylate equivalent, and an organic solvent, which solution is preferably maintained at a constant temperature within the range of 0°C to about room temperature. Solvents suitable for reacting mono-protected diols **39** with a carboxylate equivalent include, but are not limited to, dichloromethane, toluene, and ether, preferably dichloromethane. Suitable bases include, but are not limited to, hydroxide sources, such as sodium hydroxide, potassium hydroxide, sodium carbonate, or potassium carbonate; or an amine such as triethylamine, pyridine, or dimethylaminopyridine, amines are preferred. The progress of the reaction can be followed by using an appropriate analytical technique, such as thin layer chromatography or high performance liquid chromatography and when substantially complete, the product can be isolated by workup and purified if desired.

Protected alcohols **42**, wherein Y comprises one of the following phosphate ester groups



wherein R⁶ is defined as above, can be prepared by phosphorylation of mono-protected diols **X** according to well-known methods (for a general reviews, see Corbridge *Phosphorus: An Outline of its Chemistry, Biochemistry, and Uses*, Studies in Inorganic Chemistry, 3rd ed., pp. 357-395 (1985); Ramirez *et al.*, 1978, *Acc. Chem. Res.* **11**:239; and Kalckare *Biological Phosphorylations*, Prentice-Hall, New York (1969); J. B. Sweeny in *Comprehensive Organic Functional Group Transformations*, A.R. Katritzky, O. Meth-Cohn and C.W. Rees, Eds. Pergamon: Oxford, 1995, vol 2, pp. 104-109, the four of which are hereby expressly incorporated herein by reference). Protected alcohols **42** wherein Y comprises a monophosphate group of the formula:



wherein R⁶ is defined as above, can be prepared by treatment of mono-protected diol **39** with phosphorous oxychloride in a suitable solvent, such as xylene or toluene, at a constant

temperature within the range of about 100°C to about 150°C for about 2 hours to about 24 hours. After the reaction is deemed substantially complete, by using an appropriate analytical method, the reaction mixture is hydrolyzed with R⁶-OH. Suitable procedures are referenced in Houben-Weyl, Methoden der Organische Chemie, Georg Thieme Verlag


5 Stuttgart 1964, vol. XII/2, pp. 143-210 and 872-879, hereby expressly incorporated herein by reference. Alternatively, when both R⁶ are hydrogen, can be synthesized by reacting mono-protected diols X with silyl polyphosphate (Okamoto *et al.*, 1985, *Bull Chem. Soc. Jpn.* 58:3393, hereby expressly incorporated herein by reference) or by hydrogenolysis of their benzyl or phenyl esters (Chen *et al.*, 1998, *J. Org. Chem.* 63:6511, incorporated herein

10 by reference). In another alternative procedure, when R⁶ is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, or (C₂-C₆)alkynyl, the monophosphate esters can be prepared by reacting mono-protected diols 39 with appropriately substituted phosphoramidites followed by oxidation of the intermediate with *m*-chloroperbenzoic acid (Yu *et al.*, 1988, *Tetrahedron Lett.* 29:979, incorporated herein by reference) or by reacting mono-protected diols 39 with dialkyl or


15 diaryl substituted phosphorochloridates (Pop, *et al.*, 1997, *Org. Prep. and Proc. Int.* 29:341, incorporated herein by reference). The phosphoramidites are commercially available (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or readily prepared according to literature procedures (*see e.g.*, Uhlmann *et al.* 1986, *Tetrahedron Lett.* 27:1023 and Tanaka *et al.*, 1988, *Tetrahedron Lett.* 29:199, both of which are incorporated herein by reference). The

20 phosphorochloridates are also commercially available (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or prepared according to literature methods (*e.g.*, Gajda *et al.*, 1995, *Synthesis* 25:4099. In still another alternative synthesis, protected alcohols 42, wherein Y comprises a monophosphate group and R⁶ is alkyl or aryl, can be prepared by reacting IP⁺(OR⁶)₃ with mono-protected diols 39 according to the procedure described in Stowell *et al.*, 1995, *Tetrahedron Lett.* 36:11, 1825 or by alkylation of protected halo alcohols 40 with the appropriate dialkyl or diaryl phosphates (*see e.g.*, Okamoto, 1985, *Bull Chem. Soc. Jpn.* 58:3393, incorporated herein by reference).


Protected alcohols 42 wherein Y comprises a diphosphate group of the formula




30 wherein R⁶ is defined as above, can be synthesized by reacting the above-discussed monophosphates of the formula:




with a phosphate of the formula




(commercially available, *e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin), in the presence of carbodiimide such as dicyclohexylcarbodiimide, as described in Houben-Weyl, 5 *Methoden der Organische Chemie*, Georg Thieme Verlag Stuttgart 1964, vol. XII/2, pp. 881-885. In the same fashion, protected alcohols **42**, wherein Y comprises a triphosphate group of the formula:



- 10 can be synthesized by reacting the above-discussed diphosphate protected alcohols, of the formula:




with a phosphate of the formula:



- as described above. Alternatively, when R⁶ is H, protected alcohols **42** wherein Y 15 comprises the triphosphate group, can be prepared by reacting mono-protected diols **39** with salicyl phosphorochloridite and then pyrophosphate and subsequent cleavage of the adduct


thus obtained with iodine in pyridine as described in Ludwig *et al.*, 1989, *J. Org. Chem.* 54:631, incorporated herein by reference.

Protected alcohols **42**, wherein Y is $-\text{SO}_3\text{H}$ or a heterocyclic group selected from the group consisting of:



- 5 can be prepared by halide displacement from protected halo-alcohols **40**. Thus, when Y is $-\text{SO}_3\text{H}$, protected alcohols **42** can be synthesized by reacting protected halo-alcohols **40** with sodium sulfite as described in Gilbert *Sulfonation and Related Reactions*; Wiley: New York, 1965, pp. 136-148 and pp. 161-163; *Org. Synth. Coll.* Vol. II, Wiley, NY, 558, 564 (1943); and *Org. Synth. Coll.* Vol. IV, Wiley, NY, 529 (1963), all three of which are
- 10 incorporated herein by reference. When Y is one of the above-mentioned heterocycles, protected alcohols **42** can be prepared by reacting protected halo-alcohols **40** with the corresponding heterocycle in the presence of a base. The heterocycles are available commercially (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or prepared by well-
- 15 known synthetic methods (see the procedures described in Ware, 1950, *Chem. Rev.* 46:403-470, incorporated herein by reference). Preferably, the reaction is conducted by stirring a mixture comprising **40**, the heterocycle, and a solvent at a constant temperature within the range of about room temperature to about 100°C , preferably within the range of about 50°C to about 70°C for about 10 to about 48 hours. Suitable bases include hydroxide bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, or potassium carbonate.
- 20 Preferably, the solvent used in forming protected alcohols **42** is selected from dimethylformamide; formamide; dimethyl sulfoxide; alcohols, such as methanol or ethanol; and mixtures thereof. The progress of the reaction can be followed by using an appropriate analytical technique, such as thin layer chromatography or high performance liquid chromatography and when substantially complete, the product can be isolated by workup
- 25 and purified if desired.

Protected alcohols 42, wherein Y is a heteroaryl ring selected from



can be prepared by metallating the suitable heteroaryl ring then reacting the resulting metallated heteroaryl ring with protected halo-alcohols 40 (for a review, see Katritzky

5 *Handbook of Heterocyclic Chemistry*, Pergamon Press: Oxford 1985). The heteroaryl rings are available commercially or prepared by well-known synthetic methods (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995; De Sarlo *et al.*, 1971, *J. Chem. Soc. (C)* 86; Oster *et al.*, 1983, *J. Org. Chem.* 48:4307; Iwai *et al.*, 1966, *Chem. Pharm. Bull.* 14:1277; and United States Patent No. 3,152,148, all of which citations are incorporated herein by

10 reference). As used herein, the term “metallating” means the forming of a carbon-metal bond, which bond may be substantially ionic in character. Metallation can be accomplished by adding about 2 equivalents of strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, to a mixture comprising a suitable organic solvent and the heterocycle. Two equivalents of base are required: one

15 equivalent of the base deprotonates the $-OH$ group or the $-NH$ group, and the second equivalent metallates the heteroaryl ring. Alternatively, the hydroxy group of the heteroaryl ring can be protected with a base-stable, acid-labile protecting group as described in Greene, T.W., *Protective Groups in Organic Synthesis*, 3rd edition 17-237 (1999), hereby expressly incorporated herein by reference. Where the hydroxy group is protected, only one

20 equivalent of base is required. Examples of suitable base-stable, acid-labile hydroxyl-protecting groups, include but are not limited to, ethers, such as methyl, methoxy methyl, methylthiomethyl, methoxyethoxymethyl, *bis*(2-chloroethoxy)methyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahyrofuranyl, tetrahydrothiofuranyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, *t*-butyl, allyl, benzyl, *o*-nitrobenzyl, triphenylmethyl, α -


25 naphthyl, diphenylmethyl, *p*-methoxyphenyldiphenylmethyl, 9-(9-phenyl-10-oxo)anthranyl, trimethylsilyl, isopropyldimethylsilyl, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl, tribenzylsilyl, triisopropylsilyl; and esters, such as pivaloate, adamantate, and 2,4,6-trimethylbenzoate. Ethers are preferred, particularly straight chain ethers, such as methyl ether, methoxymethyl ether, methylthiomethyl ether, methoxyethoxymethyl ether, *bis*(2-chloroethoxy)methyl ether. Preferably, the pK_a of the base is higher than the pK_a of the

30


proton of the heterocycle to be deprotonated. For a listing of pK_a s for various heteroaryl rings, see Fraser *et al.*, 1985, *Can. J. Chem.* **63**:3505, incorporated herein by reference. Suitable bases include, but are not limited to, alkylmetal bases such as methyllithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride. If desired, the organometallic base can be activated with a complexing agent, such as *N,N,N',N'*-tetramethylethylenediamine or hexamethylphosphoramide (1970, *J. Am. Chem. Soc.* **92**:4664, hereby expressly incorporated herein by reference). Solvents suitable for synthesizing protected alcohols **42**, wherein Y is a heteroaryl ring include, but are not limited to, diethyl ether; tetrahydrofuran; and hydrocarbons, such as pentane. Generally, metallation occurs alpha to the heteroatom due to the inductive effect of the heteroatom, however, modification of conditions, such as the identity of the base and solvents, order of reagent addition, reagent addition times, and reaction and addition temperatures can be modified by one of skill in the art to achieve the desired metallation position (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995, pp. 30-42, hereby expressly incorporated herein by reference). Alternatively, the position of metallation can be controlled by use of a halogenated heteroaryl group, wherein the halogen is located on the position of the heteroaryl ring where metallation is desired (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995, p. 33 and Saulnier *et al.*, 1982, *J. Org. Chem.* **47**:757, the two of which citations are hereby expressly incorporated herein by reference). Halogenated heteroaryl groups are available commercially (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or can be prepared by well-known synthetic methods (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995, pp. 78, 85, 122, 193, 234, 261, 280, 308, hereby expressly incorporated herein by reference). After metallation, the reaction mixture comprising the metallated heteroaryl ring is adjusted to within a temperature range of about 0°C to about room temperature and protected halo-alcohols **40** (diluted with a solvent or in undiluted form) are added, preferably at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. After addition of protected halo-alcohols **40**, the reaction mixture is stirred at a constant temperature within the range of about room temperature and about the solvent's boiling temperature and the reaction's progress can be monitored by the appropriate analytical technique, preferably thin-layer chromatography or high-performance liquid chromatography. After the reaction

- is substantially complete, protected alcohols **42** can be isolated by workup and purification. It is to be understood that conditions, such as the identity of protected halo-alcohol **40**, the base, solvents, orders of reagent addition, times, and temperatures, can be modified by one of skill in the art to optimize the yield and selectivity. Exemplary procedures that can be used in such a transformation are described in Shirley *et al.*, 1995, *J. Org. Chem.* 20:225; Chadwick *et al.*, 1979, *J. Chem. Soc., Perkin Trans. 1* 2845; Rewcastle, 1993, *Adv. Het. Chem.* 56:208; Katritzky *et al.*, 1993, *Adv. Het. Chem.* 56:155; and Kessar *et al.*, 1997, *Chem. Rev.* 97:721.


When Y is



- protected alcohols **42** can be prepared from their corresponding carboxylic acid derivatives (**42**, wherein Y is $-\text{CO}_2\text{H}$) as described in Belletire *et al.*, 1988, *Synthetic Commun.* 18:2063 or from the corresponding acylchlorides (**42**, wherein Y is $-\text{CO}-\text{halo}$) as described in Skinner *et al.*, 1995, *J. Am. Chem. Soc.* 77:5440, both citations are incorporated herein by reference. The acylhalides can be prepared from the carboxylic acids by well known procedures such as those described in March, J., *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 437-438, hereby expressly incorporated herein by reference. When Y is




- wherein R^7 is as defined above, protected alcohols **42** can be prepared by first reacting protected halo-alcohols **40** with a trialkyl phosphite according to the procedure described in Kosolapoff, 1951, *Org. React.* 6:273 followed by reacting the derived phosphonic diester with ammonia according to the procedure described in Smith *et al.*, 1957, *J. Org. Chem.* 22:265, incorporated herein by reference. When Y is



protected alcohols **42** can be prepared by reacting their sulphonic acid derivatives (*i.e.*, **42**, wherein Y is $-\text{SO}_3\text{H}$) with ammonia as described in Sianesi *et al.*, 1971, *Chem. Ber.* 104:1880 and Campagna *et al.*, 1994, *Farmaco, Ed. Sci.* 49:653, both of which citations are incorporated herein by reference).

5


Scheme 11: Synthesis of Compounds of Formula 46 which correspond to Compounds $\text{W}^{(1)(2)}-(\text{CH}_2)_4-\text{OH}$, wherein $\text{W}^{(1)(2)}$ is $\text{C}(\text{R}^1)(\text{R}^2)(\text{CH}_2)_4$ -Lactone



- As further illustrated in Scheme 11, protected alcohols **42** can be deprotected providing alcohols **42a**. The deprotection method depends on the identity of the alcohol-protecting group, *see e.g.*, the procedures listed in Greene, T.W., *Protective Groups in Organic Synthesis*, 3rd edition 17-237 (1999), particularly see pages 48-49, incorporated herein by reference. One of skill in the art will readily be able to choose the appropriate deprotection procedure. When the alcohol is protected as an ether function (*e.g.*, methoxymethyl ether), the alcohol is preferably deprotected with aqueous or alcoholic acid. Suitable deprotection reagents include, but are not limited to, aqueous hydrochloric acid, *p*-toluenesulfonic acid in methanol, pyridinium-*p*-toluenesulfonate in ethanol, Amberlyst H-15 in methanol, boric acid in ethylene-glycol-monoethylether, acetic acid in a water-tetrahydrofuran mixture, aqueous hydrochloric acid is preferred. Examples of such procedures are described, respectively, in Bernady *et al.*, 1979, *J. Org. Chem.* 44:1438; Miyashita *et al.*, 1977, *J. Org. Chem.* 42:3772; Johnston *et al.*, 1988, *Synthesis* 393; Bongini *et al.*, 1979, *Synthesis* 618; and Hoyer *et al.*, 1986, *Synthesis* 655; Gigg *et al.*, 1967, *J. Chem.*

Soc. C, 431; and Corey *et al.*, 1978, *J. Am. Chem. Soc.* 100:1942, all of which are incorporated herein by reference.


Scheme 11 depicts the synthesis of protected lactone alcohols **46** and lactone. Compound **46** corresponds to compounds of the formula $W^{(1)(2)}\text{-Zin-OPG}$ and , wherein
 5 $W^{(1)(2)}$ is a lactone group selected from:



Protected lactone alcohols **46** can be prepared from compounds of the formula **46**, **45**, or **44** by using well-known condensation reactions and variations of the Michael reaction.


Methods for the synthesis of lactones are disclosed in Miltzer in *Comprehensive Organic*
 10 *Functional Group Transformations*, A.R. Katritzky, O. Meth-Cohn and C.W. Rees, Eds. Pergamon: Oxford, 1995, vol 5, pp. 161-173, incorporated herein by reference. Mono-protected diols **43**, electrophilic protected alcohols **44**, and aldehydes **45** are readily available either commercially (*e.g.*, Aldrich Chemical Co., Milwaukee, WI) or by well known synthetic procedures.

15 When $W^{(1)(2)}$ is a beta-lactone group of the formula:




protected lactone alcohols **46** can be prepared from aldehydes **45** and electrophilic protected alcohols **44**, respectively, by a one-pot-addition-lactonization according to the procedure of Masamune *et al.*, 1976, *J. Am. Chem. Soc.* 98:7874 and Danheiser *et al.*, 1991, *J. Org. Chem.*

56:1176, both of which are incorporated herein by reference. This one-pot-addition-lactonization methodology has been reviewed by Multzer in *Comprehensive Organic Functional Group Transformations*, A.R. Katritzky, O. Meth-Cohn and C.W. Rees, Eds. Pergamon: Oxford, 1995, vol 5, pp. 161, incorporated herein by reference When W⁽¹⁾⁽²⁾ is a
 5 gamma- or delta-lactone group of the formula:




protected lactone alcohols **46** can be prepared from aldehydes **45** according to well known synthetic methodology. For example, the methodology described in Masuyama *et al.*, 2000, *J. Org. Chem.* **65**:494; Eisch *et al.*, 1978, *J. Organo. Met. Chem.* **C8** **160**; Eaton *et al.*, 1947, *J. Org. Chem.* **37**:1947; Yunker *et al.*, 1978, *Tetrahedron Lett.* **4651**; Bhanot *et al.*, 1977, *J.*
 10 *Org. Chem.* **42**:1623; Ehlinger *et al.*, 1980, *J. Am. Chem. Soc.* **102**:5004; and Raunio *et al.*, 1957, *J. Org. Chem.* **22**:570, all of which citations are incorporated herein by reference. For instance, as described in Masuyama *et al.*, 2000, *J. Org. Chem.* **65**:494, aldehydes **45** can be treated with about 1 equivalent of a strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, in a suitable organic
 15 solvent to give a reaction mixture. Suitable bases include, but are not limited to, alkylmetal bases such as methyl lithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium
 20 hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride, preferably lithium tetramethylpiperidide. Suitable solvents include, but are not limited to, diethyl ether and tetrahydrofuran. The reaction-mixture temperature is adjusted to within the range of about 0°C to about 100°C, preferably about room temperature to about 50°C, and a halide of the formula:




25

wherein z is 1 or 2 (diluted with a solvent or in undiluted form) is added. The reaction mixture is stirred for a period of about 2 hours to about 48 hours, preferably about 5 to about 10 hours, during which time the reaction's progress can be followed by using an appropriate analytical technique, such as thin layer chromatography or high performance liquid chromatography. When the reaction is deemed substantially complete, protected lactone alcohols **46** can be isolated by workup and purified if desired. When $W^{(1)(2)}$ is a gamma- or delta-lactone group of the formula:




protected lactone alcohols **46** can be synthesized by deprotonating the corresponding lactone with a strong base providing the lactone enolate and reacting the enolate with electrophilic protected alcohols **44** (for a detailed discussion of enolate formation of active methylene compounds such as lactones, see House *Modern Synthetic Reactions*; W. A. Benjamin, Inc. Philippines 1972 pp. 492-570, and for a discussion of reaction of lactone enolates with electrophiles such as carbonyl compounds, see March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 944-945, both of which are incorporated herein by reference). Lactone-enolate formation can be accomplished by adding about 1 equivalent of a strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, to a mixture comprising a suitable organic solvent and the lactone. Suitable bases include, but are not limited to, alkylmetal bases such as methyllithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride, preferably lithium tetramethylpiperidide. Solvents suitable for lactone-enolate formation include, but are not limited to, diethyl ether and tetrahydrofuran. After enolate formation, the reaction-mixture temperature is adjusted to within the range of about -78°C to about room temperature, preferably about -50°C to about 0°C , and electrophilic protected alcohols **44** (diluted with a solvent or in undiluted form) are added, preferably at a rate such that the reaction-mixture temperature remains within about


- one to two degrees of the initial reaction-mixture temperature. The reaction mixture is stirred for a period of about 15 minutes to about 5 hours, during which time the reaction's progress can be followed by using an appropriate analytical technique, such as thin layer chromatography or high performance liquid chromatography. When the reaction is deemed substantially complete, protected lactone alcohols **46** can be isolated by workup and purified if desired. When $W^{(1)(2)}$ is a lactone group of the formula:



- protected lactone alcohols **46** can be prepared from aldehydes **45** according to the procedure described in United States Patent No. 4,622,338, hereby expressly incorporated herein by reference.
- When $W^{(1)(2)}$ is a gamma- or delta-lactone group of the formula:




- protected lactone alcohols **46** can be prepared according to a three step sequence. The first step comprises base-mediated reaction of electrophilic protected alcohols **44** with succinic acid esters (*i.e.*, $R^9O_2CCH_2CH_2CO_2R^9$, wherein R^9 is alkyl) or glutaric acid esters (*i.e.*, $R^9O_2CCH_2CH_2CH_2CO_2R^9$, wherein R^9 is alkyl) providing a diester intermediate of the formula **44i**:

**44i**

- wherein x is 1 or 2 depending on whether the gamma or delta lactone group is desired. The reaction can be performed by adding about 1 equivalent of a strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, to a mixture comprising a suitable organic solvent and the succinic or glutaric acid ester.


Suitable bases include, but are not limited to, alkylmetal bases such as methyllithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride, preferably lithium tetramethylpiperidide. Suitable solvents include, but are not limited to, diethyl ether and tetrahydrofuran. After enolate formation, the reaction-mixture temperature is adjusted to within the range of about -78°C to about room temperature, preferably about -50°C to about 0°C , and electrophilic protected alcohols **44** (diluted with a solvent or in undiluted form) are added, preferably at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. The reaction mixture is stirred for a period of about 15 minutes to about 5 hours, during which time the reaction's progress can be followed by using an appropriate analytical technique, such as thin layer chromatography or high performance liquid chromatography. When the reaction is deemed substantially complete, the diester intermediate be isolated by workup and purified if desired. In the second step, the intermediate diester can be reduced, with a hydride reducing agent, to yield a diol:



20


The reduction can be performed according to the procedures referenced in March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 1214, incorporated herein by reference). Suitable reducing agents include, but are not limited to, lithium aluminum hydride, diisobutylaluminum hydride, sodium borohydride, and lithium borohydride). In the third step, the diol can be oxidatively cyclized with $\text{RuH}_2(\text{PPh}_3)_4$ to the product protected lactone alcohols **46** according to the procedure of Yoshikawa *et al.*, 1986, *J. Org. Chem.* **51**:2034 and Yoshikawa *et al.*, 1983, *Tetrahedron Lett.* **26**:2677, both of which citations are incorporated herein by reference. When $\text{W}^{(1)(2)}$ is a lactone group of the formula:

30



- protected lactone alcohols **46** can be synthesized by reacting the Grignard salts of electrophilic protected alcohols **44**, where E is a halide, with 5,6-dihydro-2H-pyran-2-one, commercially available (e.g., Aldrich Chemical Co., Milwaukee, Wisconsin), in the presence of catalytic amounts of a 1-dimethylaminoacetylpyrrolidine-2-yl)methyl-diarylphosphine-copper (I) iodide complex as described in Tomioka *et al.*, 1995, *Tetrahedron Lett.* **36**:4275, incorporated herein by reference.

Scheme 12: Synthesis of Compounds of Formula II




- Scheme 12 illustrates the synthesis of ketone **II**. The alcohol **47** is initially converted to a halogen **48**. See Larock, *Comprehensive Organic Transformations*, VCH: New York, 1989, pp. 360-362; all references disclosed therein are incorporated herein by reference. The halide **48** is then converted to a carboxylic acid **49** with subsequent conversion to an acyl halide **50**. See Larock, *Comprehensive Organic Transformations*, VCH: New York, 1989, pp. 850-851, 855-856, 859-860, 977, 980, and 985; all references disclosed therein are incorporated herein by reference. The acyl halide **50** is then coupled with the halide to afford compound **II**. See Rappoport, *The Chemistry of the Functional Groups*, Supp. D, pt. 2; Wiley: New York, 1983; House, *Modern Synthetic Reactions*, 2nd

Ed. Benjamin: New York, 1972, pp. 691-694, 734-765, which are incorporated herein by reference.

Scheme 13 depicts the synthesis of compounds **IIIa**, that is, compounds **III** where a double bond is not present in the ring. In the first step, compounds **53**, prepared as
5 discussed in Schemes 1 to 6 above, can be converted to compounds **54** by standard oxidation of the primary alcohol to an aldehyde group. Such oxidations are described in M. Hudlicky, *Oxidations in Organic Chemistry*, ACS Monograph 186, 1990, pp. 114-127, hereby expressly incorporated herein by reference. In the next step Grignard reaction of **54** with **55** followed by standard OH protection gives **57**. Compounds **55** are commercially
10 available (*e.g.*, from Aldrich Chemical Co. Milwaukee, WI) or readily prepared by standard synthetic methodology. For exemplary procedures for Grignard reaction see March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 920-929, incorporated herein by reference. Similarly, in the next step, the Grignard salt of **57** is condensed with **58** to provide **59**. Next **59** is oxidized and then cyclized to **60**.
15 When p is one, exemplary cyclization procedures are found in Friedrichsen, W. in *Comprehensive Heterocyclic Chemistry II*; Katritzky, A. R.; Rees, W. C.; Scriven, E. F. V. Eds.; Pergamon Press: Oxford, 1996; Vol.2, p 351, and *Comprehensive Heterocyclic Chemistry*; Katritzky, A. R.; Rees, W. C. Eds.; Pergamon Press: Oxford, 1986; Vol.3. When p is 0, cyclization procedures are found in Hepworth, J. D. in *Comprehensive*
20 *Heterocyclic Chemistry II*; Katritzky, A. R.; Rees, W. C.; Scriven, E. F. V. Eds.; Pergamon Press: Oxford, 1996; Vol.5, p 351 and *Comprehensive Heterocyclic Chemistry*; Katritzky, A. R.; Rees, W. C. Eds.; Pergamon Press: Oxford, 1986; Vol.3, all of which citations are hereby expressly incorporated herein by reference.

25

Scheme 13: Synthesis of Compounds III



- The hydroxy ketone is subjected to cyclization, as described in the above Hepworth, J. D. in *Comprehensive Heterocyclic Chemistry II*; Katritzky, A. R.; Rees, W. C.; Scriven, E. F. V. Eds.; Pergamon Press: Oxford, 1996; Vol.5, p 386. For compounds **III** where $W^{(1)(2)}$ is $HO(CH_2)_n-R^1R^2$: The hydroxy group is first deprotected as described in Greene, T.W., *Protective Groups in Organic Synthesis*, 3rd edition(1999). For other structures, where Y is a group such as an acid, aldehydes, *etc.*, protection is needed (acids as esters, preferably pivaloyl, aldehydes as silyl derivatives such as TIPS, stable in both basic and acidic conditions). When $W^{(1)(2)}$ is a Lactone it can be introduced as discussed in Scheme 3 above. The compounds are then coupled to afford compound of the formula **IIIa**.

The reactions are performed under similar conditions for substituted cyclic compounds. After the formation of the mono-cyclic compounds, they are *in situ* reacted with electrophiles (*e.g.*, MeI) at temperatures between $-40\text{ }^{\circ}\text{C}$ to $+60\text{ }^{\circ}\text{C}$, for a reaction time of 1 hr to 5 days. In addition, ing double bonds can be selectively added or reduced or

otherwise manipulated by well known synthetic methods to give compounds **III** having one or two selectively-placed double bonds (*i.e.*, the double bond(s) can be positioned in the desired location within the ring), for example, the methods disclosed in March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 771-780, incorporated herein by reference.

4.3. Therapeutic Uses of Compounds or Compositions of the Invention

In accordance with the invention, a compound of the invention or a composition of the invention, comprising a compound of the invention and a pharmaceutically acceptable vehicle, is administered to a patient, preferably a human, with or at risk of cardiovascular disease, a dyslipidemia, a dyslipoproteinemia, a disorder of glucose metabolism, Alzheimer's Disease, Syndrome X, a PPAR-associated disorder, septicemia, a thrombotic disorder, obesity, pancreatitis, hypertension, a renal disease, cancer, inflammation, or impotence. In one embodiment, "treatment" or "treating" refers to an amelioration of a disease or disorder, or at least one discernible symptom thereof. In another embodiment, "treatment" or "treating" refers to inhibiting the progression of a disease or disorder, either physically, *e.g.*, stabilization of a discernible symptom, physiologically, *e.g.*, stabilization of a physical parameter, or both.

In certain embodiments, the compounds of the invention or the compositions of the invention are administered to a patient, preferably a human, as a preventative measure against such diseases. As used herein, "prevention" or "preventing" refers to a reduction of the risk of acquiring a given disease or disorder. In a preferred mode of the embodiment, the compositions of the present invention are administered as a preventative measure to a patient, preferably a human having a genetic predisposition to a cardiovascular disease, a dyslipidemia, a dyslipoproteinemia, a disorder of glucose metabolism, Alzheimer's Disease, Syndrome X, a PPAR-associated disorder, septicemia, a thrombotic disorder, obesity, pancreatitis, hypertension, a renal disease, cancer, inflammation, or impotence. Examples of such genetic predispositions include but are not limited to the $\epsilon 4$ allele of apolipoprotein E, which increases the likelihood of Alzheimer's Disease; a loss of function or null mutation in the lipoprotein lipase gene coding region or promoter (*e.g.*, mutations in the coding regions resulting in the substitutions D9N and N291S; for a review of genetic mutations in the lipoprotein lipase gene that increase the risk of cardiovascular diseases, dyslipidemias and dyslipoproteinemias, see Hayden and Ma, 1992, *Mol. Cell Biochem.* **113**:171-176); and familial combined hyperlipidemia and familial hypercholesterolemia.

In another preferred mode of the embodiment, the compounds of the invention or compositions of the invention are administered as a preventative measure to a patient having a non-genetic predisposition to a cardiovascular disease, a dyslipidemia, a dyslipoproteinemia, a disorder of glucose metabolism, Alzheimer's Disease, Syndrome X, a PPAR-associated disorder, septicemia, a thrombotic disorder, obesity, pancreatitis, hypertension, a renal disease, cancer, inflammation, or impotence. Examples of such non-genetic predispositions include but are not limited to cardiac bypass surgery and percutaneous transluminal coronary angioplasty, which often lead to restenosis, an accelerated form of atherosclerosis; diabetes in women, which often leads to polycystic ovarian disease; and cardiovascular disease, which often leads to impotence. Accordingly, the compositions of the invention may be used for the prevention of one disease or disorder and concurrently treating another (*e.g.*, prevention of polycystic ovarian disease while treating diabetes; prevention of impotence while treating a cardiovascular disease).

4.3.1. Cardiovascular Diseases for Treatment or Prevention

The present invention provides methods for the treatment or prevention of a cardiovascular disease, comprising administering to a patient a therapeutically effective amount of a compound or a composition comprising a compound of the invention and a pharmaceutically acceptable vehicle. As used herein, the term "cardiovascular diseases" refers to diseases of the heart and circulatory system. These diseases are often associated with dyslipoproteinemias and/or dyslipidemias. Cardiovascular diseases which the compositions of the present invention are useful for preventing or treating include but are not limited to arteriosclerosis; atherosclerosis; stroke; ischemia; endothelium dysfunctions, in particular those dysfunctions affecting blood vessel elasticity; peripheral vascular disease; coronary heart disease; myocardial infarction; cerebral infarction and restenosis.

4.3.2. Dyslipidemias for Treatment or Prevention

The present invention provides methods for the treatment or prevention of a dyslipidemia comprising administering to a patient a therapeutically effective amount of a compound or a composition comprising a compound of the invention and a pharmaceutically acceptable vehicle.

As used herein, the term "dyslipidemias" refers to disorders that lead to or are manifested by aberrant levels of circulating lipids. To the extent that levels of lipids in the blood are too high, the compositions of the invention are administered to a patient to restore

normal levels. Normal levels of lipids are reported in medical treatises known to those of skill in the art. For example, recommended blood levels of LDL, HDL, free triglycerides and others parameters relating to lipid metabolism can be found at the web site of the American Heart Association and that of the National Cholesterol Education Program of the National Heart, Lung and Blood Institute (http://www.americanheart.org/cholesterol/about_level.html and http://www.nhlbi.nih.gov/health/public/heart/cho/hbc_what.html, respectively). At the present time, the recommended level of HDL cholesterol in the blood is above 35 mg/dL; the recommended level of LDL cholesterol in the blood is below 130 mg/dL; the recommended LDL:HDL cholesterol ratio in the blood is below 5:1, ideally 3.5:1; and the recommended level of free triglycerides in the blood is less than 200 mg/dL.

Dyslipidemias which the compositions of the present invention are useful for preventing or treating include but are not limited to hyperlipidemia and low blood levels of high density lipoprotein (HDL) cholesterol. In certain embodiments, the hyperlipidemia for prevention or treatment by the compounds of the present invention is familial hypercholesterolemia; familial combined hyperlipidemia; reduced or deficient lipoprotein lipase levels or activity, including reductions or deficiencies resulting from lipoprotein lipase mutations; hypertriglyceridemia; hypercholesterolemia; high blood levels of ketone bodies (*e.g.* β -OH butyric acid); high blood levels of Lp(a) cholesterol; high blood levels of low density lipoprotein (LDL) cholesterol; high blood levels of very low density lipoprotein (VLDL) cholesterol and high blood levels of non-esterified fatty acids.

The present invention further provides methods for altering lipid metabolism in a patient, *e.g.*, reducing LDL in the blood of a patient, reducing free triglycerides in the blood of a patient, increasing the ratio of HDL to LDL in the blood of a patient, and inhibiting saponified and/or non-saponified fatty acid synthesis, said methods comprising administering to the patient a compound or a composition comprising a compound of the invention in an amount effective alter lipid metabolism.

4.3.3. Dyslipoproteinemias for Treatment or Prevention

The present invention provides methods for the treatment or prevention of a dyslipoproteinemia comprising administering to a patient a therapeutically effective amount of a compound or a composition comprising a compound of the invention and a pharmaceutically acceptable vehicle.

As used herein, the term "dyslipoproteinemias" refers to disorders that lead to or are manifested by aberrant levels of circulating lipoproteins. To the extent that levels of

lipoproteins in the blood are too high, the compositions of the invention are administered to a patient to restore normal levels. Conversely, to the extent that levels of lipoproteins in the blood are too low, the compositions of the invention are administered to a patient to restore normal levels. Normal levels of lipoproteins are reported in medical treatises known to those of skill in the art.

Dyslipoproteinemias which the compositions of the present invention are useful for preventing or treating include but are not limited to high blood levels of LDL; high blood levels of apolipoprotein B (apo B); high blood levels of Lp(a); high blood levels of apo(a); high blood levels of VLDL; low blood levels of HDL; reduced or deficient lipoprotein lipase levels or activity, including reductions or deficiencies resulting from lipoprotein lipase mutations; hypoalphalipoproteinemia; lipoprotein abnormalities associated with diabetes; lipoprotein abnormalities associated with obesity; lipoprotein abnormalities associated with Alzheimer's Disease; and familial combined hyperlipidemia.

The present invention further provides methods for reducing apo C-II levels in the blood of a patient; reducing apo C-III levels in the blood of a patient; elevating the levels of HDL associated proteins, including but not limited to apo A-I, apo A-II, apo A-IV and apo E in the blood of a patient; elevating the levels of apo E in the blood of a patient, and promoting clearance of triglycerides from the blood of a patient, said methods comprising administering to the patient a compound or a composition comprising a compound of the invention in an amount effective to bring about said reduction, elevation or promotion, respectively.

4.3.4. Glucose Metabolism Disorders for Treatment or Prevention

The present invention provides methods for the treatment or prevention of a glucose metabolism disorder, comprising administering to a patient a therapeutically effective amount of a compound or a composition comprising a compound of the invention and a pharmaceutically acceptable vehicle. As used herein, the term "glucose metabolism disorders" refers to disorders that lead to or are manifested by aberrant glucose storage and/or utilization. To the extent that indicia of glucose metabolism (*i.e.*, blood insulin, blood glucose) are too high, the compositions of the invention are administered to a patient to restore normal levels. Conversely, to the extent that indicia of glucose metabolism are too low, the compositions of the invention are administered to a patient to restore normal levels. Normal indicia of glucose metabolism are reported in medical treatises known to those of skill in the art.

Glucose metabolism disorders which the compositions of the present invention are useful for preventing or treating include but are not limited to impaired glucose tolerance; insulin resistance; insulin resistance related breast, colon or prostate cancer; diabetes, including but not limited to non-insulin dependent diabetes mellitus (NIDDM), insulin
5 dependent diabetes mellitus (IDDM), gestational diabetes mellitus (GDM), and maturity onset diabetes of the young (MODY); pancreatitis; hypertension; polycystic ovarian disease; and high levels of blood insulin and/or glucose.

The present invention further provides methods for altering glucose metabolism in a patient, for example to increase insulin sensitivity and/or oxygen consumption of a patient,
10 said methods comprising administering to the patient a compound or a composition comprising a compound of the invention in an amount effective to alter glucose metabolism.

4.3.5. PPAR Associated Disorders for Treatment or Prevention

The present invention provides methods for the treatment or prevention of a PPAR-associated disorder, comprising administering to a patient a therapeutically effective amount
15 of a compound or a composition comprising a compound of the invention and a pharmaceutically acceptable vehicle. As used herein, "treatment or prevention of PPAR associated disorders" encompasses treatment or prevention of rheumatoid arthritis; multiple sclerosis; psoriasis; inflammatory bowel diseases; breast; colon or prostate cancer; low
20 levels of blood HDL; low levels of blood, lymph and/or cerebrospinal fluid apo E; low blood, lymph and/or cerebrospinal fluid levels of apo A-I; high levels of blood VLDL; high levels of blood LDL; high levels of blood triglyceride; high levels of blood apo B; high levels of blood apo C-III and reduced ratio of post-heparin hepatic lipase to lipoprotein
lipase activity. HDL may be elevated in lymph and/or cerebral fluid.

25

4.3.6. Renal Diseases for Treatment or Prevention

The present invention provides methods for the treatment or prevention of a renal disease, comprising administering to a patient a therapeutically effective amount of a
compound or a composition comprising a compound of the invention and a
30 pharmaceutically acceptable vehicle. Renal diseases that can be treated by the compounds of the present invention include glomerular diseases (including but not limited to acute and chronic glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis, glomerular lesions associated with systemic disease, such as systemic lupus erythematosus, Goodpasture's syndrome, multiple myeloma,
35 diabetes, neoplasia, sickle cell disease, and chronic inflammatory diseases), tubular diseases

(including but not limited to acute tubular necrosis and acute renal failure, polycystic renal diseasemedullary sponge kidney, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis), tubulointerstitial diseases (including but not limited to pyelonephritis, drug and toxin induced tubulointerstitial nephritis, hypercalcemic nephropathy, and
 5 hypokalemic nephropathy) acute and rapidly progressive renal failure, chronic renal failure, nephrolithiasis, or tumors (including but not limited to renal cell carcinoma and nephroblastoma). In a most preferred embodiment, renal diseases that are treated by the compounds of the present invention are vascular diseases, including but not limited to hypertension, nephrosclerosis, microangiopathic hemolytic anemia, atheroembolic renal
 10 disease, diffuse cortical necrosis, and renal infarcts.

4.3.7. Cancers for Treatment or Prevention

The present invention provides methods for the treatment or prevention of cancer, comprising administering to a patient a therapeutically effective amount of a compound or a
 15 composition comprising a compound of the invention and a pharmaceutically acceptable vehicle. Cancers that can be treated or prevented by administering the compounds or the compositions of the invention include, but are not limited to, human sarcomas and carcinomas, *e.g.*, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma,
 20 lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma,
 25 renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma,
 30 retinoblastoma; leukemias, *e.g.*, acute lymphocytic leukemia and acute myelocytic leukemia (myeloblastic, promyelocytic, myelomonocytic, monocytic and erythroleukemia); chronic leukemia (chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia); and polycythemia vera, lymphoma (Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenström's macroglobulinemia, and heavy chain disease. In a most preferred
 35 embodiment, cancers that are treated or prevented by administering the compounds of the

present invention are insulin resistance or Syndrome X related cancers, including but not limited to breast, prostate and colon cancer.

4.3.8. Other Diseases for Treatment or Prevention

5 The present invention provides methods for the treatment or prevention of Alzheimer's Disease, Syndrome X, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, inflammation, and impotence, comprising administering to a patient a therapeutically effective amount of a compound or a composition comprising a compound of the invention and a pharmaceutically acceptable vehicle.

10 As used herein, "treatment or prevention of Alzheimer's Disease" encompasses treatment or prevention of lipoprotein abnormalities associated with Alzheimer's Disease.

 As used herein, "treatment or prevention of Syndrome X or Metabolic Syndrome" encompasses treatment or prevention of a symptom thereof, including but not limited to impaired glucose tolerance, hypertension and dyslipidemia/dyslipoproteinemia.

15 As used herein, "treatment or prevention of septicemia" encompasses treatment or prevention of septic shock.

 As used herein, "treatment or prevention of thrombotic disorders" encompasses treatment or prevention of high blood levels of fibrinogen and promotion of fibrinolysis.

20 In addition to treating or preventing obesity, the compositions of the invention can be administered to an individual to promote weight reduction of the individual.

4.4. Surgical Uses

Cardiovascular diseases such as atherosclerosis often require surgical procedures such as angioplasty. Angioplasty is often accompanied by the placement of a reinforcing a
25 metallic tube-shaped structure known as a "stent" into a damaged coronary artery. For more serious conditions, open heart surgery such as coronary bypass surgery may be required. These surgical procedures entail using invasive surgical devices and/or implants, and are associated with a high risk of restenosis and thrombosis. Accordingly, the compounds and compositions of the invention may be used as coatings on surgical devices (*e.g.*, catheters)
30 and implants (*e.g.*, stents) to reduce the risk of restenosis and thrombosis associated with invasive procedures used in the treatment of cardiovascular diseases.

35

4.5. Veterinary and Livestock Uses

A composition of the invention can be administered to a non-human animal for a veterinary use for treating or preventing a disease or disorder disclosed herein.

In a specific embodiment, the non-human animal is a household pet. In another specific embodiment, the non-human animal is a livestock animal. In a preferred

5 embodiment, the non-human animal is a mammal, most preferably a cow, horse, sheep, pig, cat, dog, mouse, rat, rabbit, or guinea pig. In another preferred embodiment, the non-human animal is a fowl species, most preferably a chicken, turkey, duck, goose, or quail.

In addition to veterinary uses, the compounds and compositions of the invention can be used to reduce the fat content of livestock to produce leaner meats. Alternatively, the
10 compounds and compositions of the invention can be used to reduce the cholesterol content of eggs by administering the compounds to a chicken, quail, or duck hen. For non-human animal uses, the compounds and compositions of the invention can be administered via the animals' feed or orally as a drench composition.

15 **4.6. Therapeutic/Prophylactic Administration and Compositions**

Due to the activity of the compounds and compositions of the invention, they are useful in veterinary and human medicine. As described above, the compounds and compositions of the invention are useful for the treatment or prevention of cardiovascular diseases, dyslipidemias, dyslipoproteinemias, glucose metabolism disorders, Alzheimer's
20 Disease, Syndrome X, PPAR-associated disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence.

The invention provides methods of treatment and prophylaxis by administration to a patient of a therapeutically effective amount of a compound or a composition comprising a compound of the invention. The patient is an animal, including, but not limited, to an
25 animal such a cow, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit, guinea pig, *etc.*, and is more preferably a mammal, and most preferably a human.

The compounds and compositions of the invention, are preferably administered orally. The compounds and compositions of the invention may also be administered by any other convenient route, for example, by intravenous infusion or bolus injection, by
30 absorption through epithelial or mucocutaneous linings (*e.g.*, oral mucosa, rectal and intestinal mucosa, *etc.*) and may be administered together with another biologically active agent. Administration can be systemic or local. Various delivery systems are known, *e.g.*, encapsulation in liposomes, microparticles, microcapsules, capsules, *etc.*, and can be used to administer a compound of the invention. In certain embodiments, more than one compound
35 of the invention is administered to a patient. Methods of administration include but are not

limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intranasal, intracerebral, intravaginal, transdermal, rectally, by inhalation, or topically, particularly to the ears, nose, eyes, or skin. The preferred mode of administration is left to the discretion of the practitioner, and will depend in-part upon the site of the medical condition. In most instances, administration will result in the release of the compounds of the invention into the bloodstream.

In specific embodiments, it may be desirable to administer one or more compounds of the invention locally to the area in need of treatment. This may be achieved, for example, and not by way of limitation, by local infusion during surgery, topical application, *e.g.*, in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) of an atherosclerotic plaque tissue.

In certain embodiments, for example, for the treatment of Alzheimer's Disease, it may be desirable to introduce one or more compounds of the invention into the central nervous system by any suitable route, including intraventricular, intrathecal and epidural injection. Intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.

Pulmonary administration can also be employed, *e.g.*, by use of an inhaler or nebulizer, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon or synthetic pulmonary surfactant. In certain embodiments, the compounds of the invention can be formulated as a suppository, with traditional binders and vehicles such as triglycerides.

In another embodiment, the compounds and compositions of the invention can be delivered in a vesicle, in particular a liposome (*see* Langer, 1990, *Science* 249:1527-1533; Treat *et al.*, in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; *see generally ibid.*).

In yet another embodiment, the compounds and compositions of the invention can be delivered in a controlled release system. In one embodiment, a pump may be used (*see* Langer, *supra*; Sefton, 1987, *CRC Crit. Ref. Biomed. Eng.* 14:201; Buchwald *et al.*, 1980, *Surgery* 88:507 Saudek *et al.*, 1989, *N. Engl. J. Med.* 321:574). In another embodiment, polymeric materials can be used (*see* Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability,

Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61; *see also* Levy *et al.*, 1985, *Science* 228:190; During *et al.*, 1989, *Ann. Neurol.* 25:351; Howard *et al.*, 1989, *J. Neurosurg.* 71:105). In yet another embodiment, a controlled-release system can be
5 placed in proximity of the target area to be treated, *e.g.*, the liver, thus requiring only a fraction of the systemic dose (*see, e.g.*, Goodson, in Medical Applications of Controlled Release, *supra*, vol. 2, pp. 115-138 (1984)). Other controlled-release systems discussed in the review by Langer, 1990, *Science* 249:1527-1533) may be used.

The present compositions will contain a therapeutically effective amount of a
10 compound of the invention, optionally more than one compound of the invention, preferably in purified form, together with a suitable amount of a pharmaceutically acceptable vehicle so as to provide the form for proper administration to the patient.

In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S.
15 Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "vehicle" refers to a diluent, adjuvant, excipient, or carrier with which a compound of the invention is administered. Such pharmaceutical vehicles can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The
20 pharmaceutical vehicles can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents may be used. When administered to a patient, the compounds and compositions of the invention and pharmaceutically acceptable vehicles are preferably sterile. Water is a preferred vehicle when the compound of the invention is administered
25 intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid vehicles, particularly for injectable solutions. Suitable pharmaceutical vehicles also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present
30 compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.

The present compositions can take the form of solutions, suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form
35 suitable for use. In one embodiment, the pharmaceutically acceptable vehicle is a capsule

(see *e.g.*, U.S. Patent No. 5,698,155). Other examples of suitable pharmaceutical vehicles are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.

In a preferred embodiment, the compounds and compositions of the invention are formulated in accordance with routine procedures as a pharmaceutical composition adapted
5 for intravenous administration to human beings. Typically, compounds and compositions of the invention for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the compositions may also include a solubilizing agent. Compositions for intravenous administration may optionally include a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately
10 or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the compound of the invention is to be administered by intravenous infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the compound of the invention is
15 administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

Compounds and compositions of the invention for oral delivery may be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs. Compounds and compositions of the invention for oral delivery
20 can also be formulated in foods and food mixes. Orally administered compositions may contain one or more optionally agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the compositions may be coated to delay
25 disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active driving compound are also suitable for orally administered compounds and compositions of the invention. In these later platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the
30 agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time delay material such as glycerol monostearate or glycerol stearate may also be used. Oral compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, *etc.* Such
35 vehicles are preferably of pharmaceutical grade.

The amount of a compound of the invention that will be effective in the treatment of a particular disorder or condition disclosed herein will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, *in vitro* or *in vivo* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the compositions will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for oral administration are generally about 0.001 milligram to 200 milligrams of a compound of the invention per kilogram body weight. In specific preferred embodiments of the invention, the oral dose is 0.01 milligram to 70 milligrams per kilogram body weight, more preferably 0.1 milligram to 50 milligrams per kilogram body weight, more preferably 0.5 milligram to 20 milligrams per kilogram body weight, and yet more preferably 1 milligram to 10 milligrams per kilogram body weight. In a most preferred embodiment, the oral dose is 5 milligrams of a compound of the invention per kilogram body weight. The dosage amounts described herein refer to total amounts administered; that is, if more than one compound of the invention is administered, the preferred dosages correspond to the total amount of the compounds of the invention administered. Oral compositions preferably contain 10% to 95% active ingredient by weight.

Suitable dosage ranges for intravenous (i.v.) administration are 0.01 milligram to 100 milligrams per kilogram body weight, 0.1 milligram to 35 milligrams per kilogram body weight, and 1 milligram to 10 milligrams per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Suppositories generally contain 0.01 milligram to 50 milligrams of a compound of the invention per kilogram body weight and comprise active ingredient in the range of 0.5% to 10% by weight. Recommended dosages for intradermal, intramuscular, intraperitoneal, subcutaneous, epidural, sublingual, intracerebral, intravaginal, transdermal administration or administration by inhalation are in the range of 0.001 milligram to 200 milligrams per kilogram of body weight. Suitable doses of the compounds of the invention for topical administration are in the range of 0.001 milligram to 1 milligram, depending on the area to which the compound is administered. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems. Such animal models and systems are well known in the art.

The invention also provides pharmaceutical packs or kits comprising one or more containers filled with one or more compounds of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency

regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In a certain embodiment, the kit contains more than one compound of the invention. In another embodiment, the kit comprises a compound of the invention and another lipid-

5 mediating compound, including but not limited to a statin, a thiazolidinedione, or a fibrate.

The compounds of the invention are preferably assayed *in vitro* and *in vivo*, for the desired therapeutic or prophylactic activity, prior to use in humans. For example, *in vitro* assays can be used to determine whether administration of a specific compound of the invention or a combination of compounds of the invention is preferred for lowering fatty

10 acid synthesis. The compounds and compositions of the invention may also be demonstrated to be effective and safe using animal model systems.

Other methods will be known to the skilled artisan and are within the scope of the invention.

15 4.7. Combination Therapy

In certain embodiments of the present invention, the compounds and compositions of the invention can be used in combination therapy with at least one other therapeutic agent. The compound of the invention and the therapeutic agent can act additively or, more preferably, synergistically. In a preferred embodiment, a compound or a composition

20 comprising a compound of the invention is administered concurrently with the administration of another therapeutic agent, which can be part of the same composition as the compound of the invention or a different composition. In another embodiment, a compound or a composition comprising a compound of the invention is administered prior or subsequent to administration of another therapeutic agent. As many of the disorders for

25 which the compounds and compositions of the invention are useful in treating are chronic disorders, in one embodiment combination therapy involves alternating between administering a compound or a composition comprising a compound of the invention and a composition comprising another therapeutic agent, *e.g.*, to minimize the toxicity associated with a particular drug. The duration of administration of each drug or therapeutic agent can

30 be, *e.g.*, one month, three months, six months, or a year. In certain embodiments, when a composition of the invention is administered concurrently with another therapeutic agent that potentially produces adverse side effects including but not limited to toxicity, the therapeutic agent can advantageously be administered at a dose that falls below the threshold at which the adverse side is elicited.

The present compositions can be administered together with a statin. Statins for use in combination with the compounds and compositions of the invention include but are not limited to atorvastatin, pravastatin, fluvastatin, lovastatin, simvastatin, and cerivastatin.

The present compositions can also be administered together with a PPAR agonist, for example a thiazolidinedione or a fibrate. Thiazolidinediones for use in combination with the compounds and compositions of the invention include but are not limited to 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione, troglitazone, pioglitazone, ciglitazone, WAY-120,744, englitazone, AD 5075, darglitazone, and rosiglitazone. Fibrates for use in combination with the compounds and compositions of the invention include but are not limited to gemfibrozil, fenofibrate, clofibrate, or ciprofibrate. As mentioned previously, a therapeutically effective amount of a fibrate or thiazolidinedione often has toxic side effects. Accordingly, in a preferred embodiment of the present invention, when a composition of the invention is administered in combination with a PPAR agonist, the dosage of the PPAR agonist is below that which is accompanied by toxic side effects.

The present compositions can also be administered together with a bile-acid-binding resin. Bile-acid-binding resins for use in combination with the compounds and compositions of the invention include but are not limited to cholestyramine and colestipol hydrochloride. The present compositions can also be administered together with niacin or nicotinic acid. The present compositions can also be administered together with a RXR agonist. RXR agonists for use in combination with the compounds of the invention include but are not limited to LG 100268, LGD 1069, 9-cis retinoic acid, 2-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-cyclopropyl)-pyridine-5-carboxylic acid, or 4-((3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)2-carbonyl)-benzoic acid. The present compositions can also be administered together with an anti-obesity drug. Anti-obesity drugs for use in combination with the compounds of the invention include but are not limited to β -adrenergic receptor agonists, preferably β -3 receptor agonists, fenfluramine, dexfenfluramine, sibutramine, bupropion, fluoxetine, and phentermine. The present compositions can also be administered together with a hormone. Hormones for use in combination with the compounds of the invention include but are not limited to thyroid hormone, estrogen and insulin. Preferred insulins include but are not limited to injectable insulin, transdermal insulin, inhaled insulin, or any combination thereof. As an alternative to insulin, an insulin derivative, secretagogue, sensitizer or mimetic may be used. Insulin secretagogues for use in combination with the compounds of

the invention include but are not limited to forskolin, dibutryl cAMP or isobutylmethylxanthine (IBMX).

5 The present compositions can also be administered together with a tyrophostine or an analog thereof. Tyrophostines for use in combination with the compounds of the invention include but are not limited to tryophostine 51.

10 The present compositions can also be administered together with sulfonylurea-based drugs. Sulfonylurea-based drugs for use in combination with the compounds of the invention include, but are not limited to, glisoxepid, glyburide, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbutamide, and tolcyclamide. The present compositions can also be administered together with a biguanide. Biguanides for use in combination with the compounds of the invention include but are not limited to metformin, phenformin and buformin.

15 The present compositions can also be administered together with an α -glucosidase inhibitor. α -glucosidase inhibitors for use in combination with the compounds of the invention include but are not limited to acarbose and miglitol.

20 The present compositions can also be administered together with an apo A-I agonist. In one embodiment, the apo A-I agonist is the Milano form of apo A-I (apo A-IM). In a preferred mode of the embodiment, the apo A-IM for administration in conjunction with the compounds of the invention is produced by the method of U.S. Patent No. 5,721,114 to Abrahamsen. In a more preferred embodiment, the apo A-I agonist is a peptide agonist. In a preferred mode of the embodiment, the apo A-I peptide agonist for administration in conjunction with the compounds of the invention is a peptide of U.S. Patent No. 6,004,925 or 6,037,323 to Dasseux.

25 The present compositions can also be administered together with apolipoprotein E (apo E). In a preferred mode of the embodiment, the apoE for administration in conjunction with the compounds of the invention is produced by the method of U.S. Patent No. 5,834,596 to Ageland.

30 In yet other embodiments, the present compositions can be administered together with an HDL-raising drug; an HDL enhancer; or a regulator of the apolipoprotein A-I, apolipoprotein A-IV and/or apolipoprotein genes.

4.8. Combination Therapy with Cardiovascular Drugs

35 The present compositions can be administered together with a known cardiovascular drug. Cardiovascular drugs for use in combination with the compounds of the invention to

prevent or treat cardiovascular diseases include but are not limited to peripheral antiadrenergic drugs, centrally acting antihypertensive drugs (*e.g.*, methyldopa, methyldopa HCl), antihypertensive direct vasodilators (*e.g.*, diazoxide, hydralazine HCl), drugs affecting renin-angiotensin system, peripheral vasodilators, phentolamine, antianginal drugs, cardiac glycosides, inodilators (*e.g.*, amrinone, milrinone, enoximone, fenoximone, imazodan, sulmazole), antidysrhythmic drugs, calcium entry blockers, ranitine, bosentan, and rezulin.

4.9. Combination Therapy for Cancer Treatment

The present compositions can be administered together with treatment with irradiation or one or more chemotherapeutic agents. For irradiation treatment, the irradiation can be gamma rays or X-rays. For a general overview of radiation therapy, see Hellman, Chapter 12: Principles of Radiation Therapy Cancer, in: Principles and Practice of Oncology, DeVita *et al.*, eds., 2nd. Ed., J.B. Lippencott Company, Philadelphia. Useful chemotherapeutic agents include methotrexate, taxol, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbazine, etoposides, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, asparaginase, vinblastine, vincristine, vinorelbine, paclitaxel, and docetaxel. In a specific embodiment, a composition of the invention further comprises one or more chemotherapeutic agents and/or is administered concurrently with radiation therapy. In another specific embodiment, chemotherapy or radiation therapy is administered prior or subsequent to administration of a present composition, preferably at least an hour, five hours, 12 hours, a day, a week, a month, more preferably several months (*e.g.*, up to three months), subsequent to administration of a composition of the invention.


5

10

5. EXAMPLES

15

5.1.a. Synthesis of 1,13-Dihydroxy-2,2,12,12-tetramethyl-tridecan-7-one also known as Compound A



1,13-Dihydroxy-2,2,12,12-tetramethyl-tridecan-7-one

20


To a solution of 2-(6-bromo-2,2-dimethyl-hexyloxy)-tetrahydro-pyran (13.0 g, 44.33 mmol) and p-toluenesulphonylmethyl isocyanide (4.33 g, 22.17 mmol) in anhydrous DMSO (50 ml) and anhydrous diethyl ether (50 ml) was added sodium hydride (60% dispersion in mineral oil, 2.13 g, 53.20 mmol) at rt under N₂ atmosphere. After solidification of the

reaction mixture, additional anhydrous DMSO (50 ml) was added. After stirring for 5.5 h at room temperature, tetrabutylammonium iodide (1.64 g, 4.43 mmol) was added and the mixture stirred for additional 22.5 h at rt. The reaction mixture was carefully hydrolyzed with water (10 ml), diluted with water (200 ml), and extracted with diethyl ether (200 ml).

- 5 The organic layer was washed with saturated NaCl solution (100 ml), dried over MgSO_4 , and concentrated *in vacuo* to give crude 2-[7-isocyano-2,2,12,12-tetramethyl-13-(tetrahydro-pyran-2-yloxy)-7-(toluene-4-sulfonyl)-tridecyloxy]-tetrahydro-pyran (15.5 g) as an oil.

- 10 The crude material (14.8 g) was dissolved in methanol (180 ml), concentrated HCl (20 ml), and water (40 ml) and heated to reflux for 2 h. The reaction mixture was poured into CH_2Cl_2 (200 ml) and saturated NaCl solution (200 ml). The layers were separated and the aqueous layer was extracted with CH_2Cl_2 (200 ml). The combined organic layers were washed with saturated NaHCO_3 solution (2 x 100 ml) and brine (100 ml), dried over anhydrous MgSO_4 , and concentrated *in vacuo*. The resulting crude oil was purified by flash
15 chromatography (silica; hexanes/ethyl acetate = 1/1) to give the pure product (4.3 g, 71 % over two steps) as a colorless oil. ^1H NMR (CDCl_3 , 300 MHz) δ = 3.28 (s, 4 H); 2.80 (m, 2 H); 2.42 (t, 4 H, J = 7.3); 1.54 (m, 4 H); 1.25 (m, 8 H); 0.84 (s, 12 H). ^{13}C NMR (CDCl_3 , 75 MHz) 212.06, 71.24, 42.47, 38.11, 34.76, 24.45, 23.72, 23.25.

20 **5.1.b. Synthesis of 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid diethyl ester also referred to herein as Compound B diethyl ester**




2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid diethyl ester

- Under N₂ atmosphere, to a solution of ethyl-(5-bromo-2,2-dimethyl-pentanoate (11.1 g, 44.2 mol) in DMSO (150 ml, dried over 4 Å molecular sieves) was added
- 5 *p*-toluenesulphonylmethyl isocyanide (4.31 g, 22.1 mmol), sodium hydride (60 % w/w in mineral oil, 2.12 g, 53.02 mmol), and tetra-*n*-butyl ammonium iodide at rt. The reaction mixture was stirred for 18 h at rt, then cooled to 0 °C, carefully hydrolyzed with water (10 ml), and then diluted with additional water (250 ml). The solution was extracted with diethyl ether (3 x 150 ml). The combined organic layers were washed with saturated NaCl solution (2 x 100 ml), dried over anhydrous MgSO₄, concentrated *in vacuo*, and dried in
- 10 high *vacuo* to give the *p*-toluenesulphonyl intermediate (11.1 g, 93 %) as an oil. ¹H NMR (CDCl₃, 300 MHz): δ = 7.85 (d, 2 H, J = 8.3); 7.43 (d, 2 H, J = 8.3); 4.12 (q, 4 H, J = 7.0); 2.49 (s, 3 H); 1.94 (m, 4 H); 1.60 - 1.34 (m, 8 H); 1.30 - 1.15 (m, 4 H); 1.25 (t, 6 H, J = 7.0); 1.15 (s, 12 H). ¹³C NMR (CDCl₃, 75 MHz): δ = 177.77, 164.08, 146.43, 131.20, 130.34, 129.96, 81.78, 60.37, 42.12, 40.27, 33.21, 25.25, 25.19, 24.97, 24.26, 21.86, 14.34.
- 15 To a solution intermediate (11.0 g, 20.53 mmol) in CH₂Cl₂ (250 ml) was added concentrated HCl (50 ml) and the reaction mixture was stirred for 30 min at rt. The solution was diluted with water (200 ml) and the layers were separated. The aqueous layer was extracted with CH₂Cl₂ (200 ml). The combined organic layers were washed with saturated NaHCO₃ solution (2 x 100 ml), half-saturated NaCl solution (100 ml), and saturated NaCl
- 20 solution. The organic phases were dried over MgSO₄, concentrated *in vacuo*, and dried in high *vacuo* to furnish crude compound B ethyl ester (8.2 g, 108 %) as an oil. ¹H NMR (CDCl₃, 300 MHz): δ = 4.03 (q, 4 H, J = 7.1); 2.31 (t, 4 H, J = 7.5); 1.45 (m, 8 H); 1.20 - 1.08 (m, 4 H); 1.16 (t, 6 H, J = 7.1); 1.07 (s, 12 H). ¹³C NMR (CDCl₃, 75 MHz): δ = 211.14, 178.05, 60.34, 42.69, 42.20, 40.52, 25.24, 24.71, 24.30, 14.35.

25

5.1.c. Synthesis of 1,11-Dihydroxy-2,2,10,10-tetramethyl-undecan-6-one



5-Bromo-2,2-dimethylpentan-1-ol

- In a 1-L 3-neck round-bottomed flask fitted with condenser, dropping funnel pressure equalizer and magnetic stirrer were placed dichloromethane (300 mL) and lithium borohydride (12.97 g, 0.595 moles). The mixture was heated to 28-30 °C, then the heating was discontinued and methanol (19.04 g, 0.595 moles) was added, at a rate that maintained the temperature below 30 °C. To this solution, ethyl 5-bromo-2,2-dimethylpentanoate (94 g, 0.397 mol) in dichloromethane (100 mL) was added under argon atmosphere, allowing a gentle reflux during the addition. After the completion of the addition, the mixture was heated to 36-40 °C until no more starting material was detected by GC. The reaction mixture was cooled to 0 °C and was treated with crushed ice (130 g) under vigorous stirring until the effervescence ceased. The reaction mixture was treated with saturated aqueous NH_4Cl (120 mL), stirred for 25 min, and warmed to above 15 °C. The organic layer was separated and the aqueous layer was extracted with dichloromethane (2 × 100 mL). The combined organic phases were washed with saturated aqueous NH_4Cl (2 × 100 mL). The organic phase was dried (MgSO_4) and the solvent was evaporated under reduced pressure to give 5-bromo-2,2-dimethylpentan-1-ol (78 g, 88.1 % yield). ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm) 5.02 (s, 1 H), 3.39-3.34 (t, $J = 14$, 2 H), 3.33 (s, 2 H), 1.85-1.75 (m, 2 H), 1.38-1.31 (m, 2 H), 0.88 (s, 6 H). ^{13}C NMR (75 MHz, $\text{CDCl}_3 = 77.0$ ppm /TMS): δ (ppm) 71.5, 37.1, 34.8, 34.6, 27.6, 23.8.

5-Bromo-1-(tetrahydropyranyloxy)-2,2-dimethylpentane

To a solution of 5-bromo-2,2-dimethyl-1-pentanol (78 g, 0.35 mol) and *p*-toluenesulfonic acid (0.42 g) in dichloromethane (0.5 L) was added 3,4-dihydro-2H-pyran (45 mL) slowly at 0 °C. The reaction mixture was stirred at rt overnight, or until no more starting material was evidenced by TLC. The mixture was filtered through aluminum oxide
5 and was washed with dichloromethane (300 mL). The filtrate was evaporated under vacuum to produce 5-bromo-1-(tetrahydropyranyloxy)-2,2-dimethylpentane (101 g, 94.7 % yield) as a pale-yellow oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 4.48 - 4.52 (m, 1 H), 3.90 - 3.75 (m, 1 H), 3.50 - 3.35 (m, 4 H), 2.95 (d, *J* = 12 Hz, 1 H), 1.90 - 1.20 (m, 10 H), 0.90 (s, 6 H). ¹³C NMR (75 MHz, CDCl₃ = 77.0 ppm/TMS): δ (ppm) 99.2, 76.3, 62.0, 38.0,
10 34.9, 34.2, 30.7, 28.0, 25.7, 24.8, 24.7, 19.3.

1,11-Dihydroxy-2,2,10,10-tetramethyl-undecan-6-one

Under N₂ atmosphere, to a solution of 5-bromo-1-(tetrahydropyranyloxy)-2,2-dimethylpentane (40.0 g, 0.143 mol) and *p*-toluenesulphonylmethyl isocyanide (TosMIC;
15 13.99 g, 0.072 mol) in anhydrous DMSO (400 mL) was added sodium hydride (60% dispersion in mineral oil, 6.86 g, 0.173 mol) under cooling in a water-bath. Tetra-*n*-butylammonium iodide (5.28 g, 0.0143 mol) was then added while cooling in a water-bath. The mixture was stirred for 6 h at rt., then carefully hydrolyzed by drop-wise addition of
20 water (100 mL) under cooling in a water-bath. The reaction mixture was diluted with dichloromethane (100 mL), additional water (100 mL), and dichloromethane (100 mL). The layers were separated and the aqueous layer was extracted with dichloromethane (3 × 100 mL). The combined organic layers were washed with water (2 × 200 mL) and saturated NaCl solution (100 mL), dried over MgSO₄, concentrated *in vacuo*, and dried in high *vacuo*
25 to give crude 2-[6-isocyano-2,2,10,10-tetramethyl-11-(tetrahydropyran-2-yloxy)-6-(toluene-4-sulfonyl)-undecyloxy]-tetrahydropyran (47.9 g) as a brownish, viscous oil. This crude oil (47.0 g) was dissolved in methanol (200 mL) and water (40 mL). Concentrated sulfuric acid (20 mL) was added drop-wise over 10 min whereupon the solution warmed up to ca. 30 °C. The reaction mixture was stirred at rt for ca. 150 min and then diluted with water (200 mL).
30 The mixture was extracted with CH₂Cl₂ (2 × 200 mL, 1 × 100 mL) and the combined organic layers were washed with water (200 mL), 10 % potassium hydroxide solution (3 × 200 mL), water (200 mL), and brine (160 mL). The organic extracts were dried over MgSO₄, concentrated *in vacuo*, and dried in high *vacuo* to furnish crude 1,11-dihydroxy-2,2,10,10-tetramethyl-undecan-6-one (26.0 g) as a brown oil. The crude product was
35 purified by chromatography (silica, 330 g, hexanes/ethyl acetate = 90/10, 70/30, 50/50) to


obtain three fractions: A: 1.1 g, 93.5 % purity by HPLC, 5.6 % yield; B: 3.0 g, ca. 96.7 % purity by HPLC, 16 % yield, and C: 4.0 g, ≥ 90 % purity by NMR, 19.5 %. Fraction C was again purified by chromatography (silica, 150 g, hexanes/ethyl acetate = 60/40) to give clean product (1.5 g, purity by HPLC: 96.3 %). Overall yield: 5.6 g, 30.3 % over two steps. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm) 3.25 (s, 4 H), 2.60 (br., 2 H), 2.32 (t, 4 H, $J = 7.2$), 1.45 (m, 4 H), 1.12 (m, 4 H), 0.79 (s, 12 H). ^{13}C NMR (75 MHz, $\text{CDCl}_3 = 77.0$ ppm/TMS): δ (ppm) 212.25, 70.99, 43.15, 37.69, 34.94, 23.89, 17.91. HRMS (LSIMS, gly): Calcd for $\text{C}_{15}\text{H}_{29}\text{O}_2$ ($\text{MH}^+ - \text{H}_2\text{O}$): 241.2168, found: 241.2169.

10

15

20

5.1.d. Synthesis of 2,12-Dimethyl-7-oxo-2,12-di-*p*-tolyl-tridecanedioic acid



2-*p*-Tolyl-propionic acid ethyl ester

Under N₂ atmosphere, a solution of ethyl *p*-tolyl-acetate (2.72 g, 15.2 mmol) in anhydrous THF (70 mL) was cooled to -40 °C and a solution of LDA (7.6 mL, 15.25 mmol) was added drop-wise over 30 minutes. The reaction mixture was stirred for 1 h, and methyl iodide (3.03 g, 21.30 mmol) was added drop-wise, followed by the addition of DMPU (1 mL). The reaction mixture was allowed to warm to rt, after 1 h and stirred overnight. The reaction mixture was poured into water (30 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with saturated NH₄Cl solution (10 mL), 1 M HCl (10 mL), saturated NaHCO₃ solution (10 mL), and brine (10 mL), then dried over MgSO₄, and concentrated *in vacuo*. The residue was distilled in high *vacuo* (bp. 59 - 63 °C/0.2 mmHg) to furnish 2-*p*-tolyl-propionic acid ethyl ester (2.5 g, 86.0%) as an oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.18 (d, 2 H, *J* = 8.1), 7.10 (d, 2 H, *J* = 8.1), 4.09 (m, 2 H), 3.67 (q, 1 H, *J* = 7.2), 2.29 (s, 3 H), 1.47 (d, *J* = 7.2 Hz, 3 H), 1.20 (t, *J* = 5.7 Hz, 3 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 174.71, 137.80, 136.63, 129.33, 129.14, 127.36, 60.66, 45.18, 21.05, 18.70, 14.15. [Lit. ref.: Ghosh, S.; Pardo, S. N.; Salomon, R. G. *J. Org. Chem.* **1982**, *47*, 4692 - 4702.].

6-Bromo-2-methyl-2-*p*-tolyl-hexanoic acid ethyl ester

Under N₂ atmosphere, LDA (54.5 mL, 110 mmol) was added drop-wise to a stirred solution of 2-*p*-tolyl-propionic acid ethyl ester (21 g, 110 mmol) in anhydrous THF (190 mL) at -78 °C. After 1 h, the reaction mixture was added to a solution of 1,4-dibromobutane (38 g, 176 mmol) in THF (50 mL) at -78 °C, followed by addition of DMPU (20 mL). The reaction mixture was stirred for 2 h, then warmed to rt overnight. The resulting mixture was poured into saturated NH₄Cl solution (1000 mL), and extracted with ethyl acetate (4 × 250 mL). The combined organic layers were washed with brine (300 mL), 1 M HCl (200 mL), saturated NaHCO₃ solution (300 mL), and brine (200 mL). The organic layer was dried over MgSO₄ and concentrated *in vacuo*. The residue was distilled in high *vacuo* (bp. 128 - 130 °C/0.2 mmHg) to furnish 6-bromo-2-methyl-2-*p*-tolyl-hexanoic acid ethyl ester (22 g, 89.5 %) as an oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.19 (d, 2 H, *J* = 8.2 Hz), 7.12 (d, 2 H, *J* = 8.2 Hz), 4.13 (q, 2 H, *J* = 7.2 Hz), 3.37 (t, *J* = 6.6 Hz, 2 H), 2.32 (s, 3 H), 2.10 - 1.80 (m, 4 H), 1.54 (s, 3 H), 1.36 (m, 2 H), 1.19 (t, *J* = 7.2 Hz, 3 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 176.26, 140.92, 136.35, 129.21, 125.89, 60.88, 49.82, 38.53, 33.61, 33.33, 23.59, 22.78, 21.07, 14.25. HRMS (LSIMS, nba): Calcd. for (C₁₆H₂₃BrO₂) 327.0959, found 327.0975.

2,12-Dimethyl-7-oxo-2,12-di-*p*-tolyl-tridecanedioic acid diethyl ester


To a solution of 6-bromo-2-methyl-2-*p*-tolyl-hexanoic acid ethyl ester (21 g, 64.22 mmol), tetra-*n*-butylammonium iodide (2.37 g, 6.42 mmol), and *p*-toluene-sulphonylmethyl isocyanide (TosMIC, 6.26g, 32.11 mmol) in anhydrous DMSO (320 mL) and anhydrous diethyl ether (110 mL) was added sodium hydride (60% dispersion in mineral oil, 3.24 g, 80.92 mmol) at rt under N₂ atmosphere. The reaction mixture was stirred for 24 h at rt, then carefully hydrolyzed with ice-water (600 mL) and extracted with diethyl ether (2 × 300 mL). The combined organic layers were washed with brine (2 × 300 mL), dried over MgSO₄, and concentrated to furnish a crude 2,12-dimethyl-7-isocyano-2,12-di-*p*-tolyl-7-(toluene-4-sulfonyl)-tridecanedioic acid diethyl ester. A solution of this crude intermediate in CH₂Cl₂ (500 mL) and concd HCl (140 mL) was stirred for 2 h at rt. The reaction mixture was diluted with water (500 mL) and the layers were separated. The aqueous layer was extracted with CH₂Cl₂ (2 × 200 mL). The combined organic layers were washed with saturated NaHCO₃ solution (150 mL), and brine (150 mL), dried over MgSO₄, and concentrated in *vacuo*. The resulting crude oil was purified by flash chromatography (silica gel, ethyl acetate/hexanes = 1/20, 1/10) to furnish 2,12-dimethyl-7-oxo-2,12-di-*p*-tolyl-tridecanedioic acid diethyl ester (9.0 g, 67.12%) as a light yellowish oil. ¹H NMR (300 MHz,

CDCl₃/TMS): δ (ppm) 7.10 (d, 4 H, $J = 7.9$ Hz), 7.02 (d, 4 H, $J = 7.9$ Hz), 4.05 (q, 4 H, $J = 7.0$ Hz), 2.25 (t, $J = 9$ Hz, 4 H), 2.20 (s, 6 H), 1.95 - 1.70 (m, 4 H), 1.42 (s, 6 H), 1.50 - 1.05 (m, 8 H), 1.08 (t, 6 H, $J = 7.0$ Hz). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 211.10, 176.00, 141.00, 135.80, 128.50, 124.51, 60.50, 49.50, 42.01, 39.50, 24.05, 22.10, 20.50, 13.00. HRMS (LSIMS, nba): Calcd. for C₃₃H₄₇O₅ (MH⁺): 523.3424, found: 523.3405.

2,12-Dimethyl-7-oxo-2,12-di-*p*-tolyl-tridecanedioic acid

2,12-Dimethyl-7-oxo-2,12-di-*p*-tolyl-tridecanedioic acid diethyl ester (9.0 g, 17.24 mmol) was added to a homogenous solution of KOH (85%, 4.0 g, 60.34 mmol) in water (10 mL) and ethanol (30 mL). The reaction mixture was heated to reflux for 6 h. The ethanol was removed under reduced pressure. The residue was diluted with water (30 mL) and the solution was acidified with concd. HCl (12 mL) to pH 1, then extracted with CH₂Cl₂ (3 \times 80 mL). The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, concentrated, and purified by flash chromatography (silica gel, ethyl acetate/hexanes = 1/20, 1/10, 1/2) to furnish 2,12-dimethyl-7-oxo-2,12-di-*p*-tolyl-tridecanedioic acid (3.1 g, 38.8%) as a white solid. Mp.: 48 - 50 °C. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 9.69 (br, 2 H), 7.22 (d, 4 H, $J = 8.1$), 7.12 (d, 4 H, $J = 8.1$), 2.36 (t, $J = 7.5$ Hz, 4 H), 2.31 (s, 6 H), 1.98 - 1.80 (m, 4 H), 1.56 - 1.44 (m, 4 H), 1.51 (s, 6 H), 1.24 - 1.15 (m, 4 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 211.63, 183.07, 140.40, 137.00, 129.58, 126.43, 50.02, 42.82, 39.10, 24.74, 24.50, 22.82, 21.39. HRMS (LSIMS, nba): Calcd. for C₂₉H₃₉O₅ (MH⁺): 467.2797, found: 467.2785.

5.1.e. Synthesis of 1,13-Dihydroxy-2,12-dimethyl-2,12-di-*p*-tolyl-tridecan-7-one



6-Bromo-2-methyl-2-*p*-tolyl-hexan-1-ol

- 5 Methanol (3.14 g, 98.22 mmol) was added drop-wise to a stirred suspension of LiBH₄ (2.19 g, 101 mmol) in anhydrous CH₂Cl₂ (50 mL) under N₂ atmosphere. After the addition of ethyl 6-bromo-2-methyl-2-*p*-tolyl-hexanoate (22 g, 67.28 mmol), the reaction mixture was heated to reflux overnight. The reaction mixture was cooled to 5 °C and hydrolyzed with ice (ca. 40 g) and saturated NH₄Cl solution (150 mL) for 1 h. The layers
- 10 were separated and the aqueous layer was extracted with CH₂Cl₂ (3 × 200 mL). The combined organic layers were washed with saturated NH₄Cl solution (3 × 150 mL), dried over anhydrous MgSO₄ and concentrated *in vacuo* to furnish 6-bromo-2-methyl-2-*p*-tolyl-hexan-1-ol (18.44 g, 96.2 %) as an oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.25 - 7.00 (m, 4 H), 3.68 - 3.50 (m, 1 H), 3.49 - 3.35 (m, 1 H), 3.34 - 3.21 (t, *J* = 6.9 Hz, 2 H),
- 15 2.31 (s, 3 H), 1.88 - 1.51 (m, 4 H), 1.51 - 1.40 (m, 2 H), 1.31 (s, 3 H), 1.20 - 1.00 (m, 1 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 141.49, 135.74, 129.47, 126.63, 72.54, 43.03, 37.53, 33.69, 33.51, 22.66, 21.58, 20.98. HRMS (LSIMS, nba): Calcd. for C₁₄H₂₀Br (MH⁺ - H₂O): 267.0748, found: 267.0750.

2-(6-Bromo-2-methyl-2-*p*-tolyl-hexyloxy)-tetrahydropyran


- 20 Under N₂ atmosphere, 3,4-dihydro-2*H*-pyran (6.39 g, 76.09 mmol) was added drop-wise to a stirred solution of 6-bromo-2-methyl-2-*p*-tolyl-hexan-1-ol (18.20 g, 63.86 mmol) and *p*-toluenesulfonic acid hydrate (0.43 g, 2.26 mmol) in dichloromethane (300 mL) at - 5 °C. The reaction mixture was allowed to warm to rt and stirred for 3 h. The solution was
- 25 filtered through aluminum oxide (160 g), which was washed with CH₂Cl₂ (500 mL). The filtrate was concentrated *in vacuo* to furnish 2-(6-bromo-2-methyl-2-*p*-tolyl-hexyloxy)-tetrahydropyran (22 g, 93.4 %) as an oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.25 - 7.05 (m, 4 H), 4.60 - 4.48 (m, 1 H), 3.82 (m, 2 H), 3.48 - 3.37 (m, 2 H), 3.35 - 3.26 (m, 2 H), 2.30 (s, 3 H), 1.90 - 1.40 (m, 11 H), 1.40 - 1.33 (s, 3 H), 1.40 - 1.08 (m, 1 H). ¹³C NMR
- 30 (75 MHz, CDCl₃/TMS): δ (ppm) 142.78, 135.22, 128.81, 126.39, 99.09, 61.99, 41.67, 38.12, 37.87, 33.68, 30.99, 25.96, 23.08, 22.89, 21.12, 20.97, 19.41. HRMS (LSIMS, nba): Calcd. for C₁₉H₃₀O₂Br (MH⁺): 369.1429, found: 369.1451.

1,13-Dihydroxy-2,12-dimethyl-2,12-di-*p*-tolyl-tridecan-7-one

To a solution of 2-(6-bromo-2-methyl-2-*p*-tolyl-hexyloxy)-tetrahydropyran (21.5 g, 58.27 mmol), tetra-*n*-butylammonium iodide (2.36 g, 6.41 mmol), and *p*-toluenesulphonyl-methyl isocyanide (TosMIC, 5.68 g, 29.14 mmol) in anhydrous DMSO (300 mL) and anhydrous diethyl ether (100 mL) was added sodium hydride (60% dispersion in mineral oil, 2.94 g, 73.42 mmol) at rt under N₂ atmosphere. The mixture was stirred for 24 h at rt. The reaction mixture was carefully hydrolyzed with ice-water (500 mL) and extracted with diethyl ether (2 × 300 mL). The organic layer was washed with brine (2 × 300 mL), dried over anhydrous MgSO₄, and concentrated in vacuo to furnish crude 2-[7-isocyano-2,12-dimethyl-2,12-di-*p*-tolyl-13-(tetrahydropyran-2-yloxy)-7-(toluene-4-sulfonyl)-tridecanyloxy]-tetrahydropyran (18.44 g) as a brown oil. A solution of this crude intermediate (18 g) in methanol (300 mL), concd. HCl (36 mL), and water (70 mL) was heated to reflux for 3 h. The reaction mixture was poured into CH₂Cl₂ (250 mL) and ice-water (250 mL). The layers were separated and the aqueous layer was extracted with CH₂Cl₂ (3 × 100 mL). The combined organic layers were washed with saturated NaHCO₃ solution (3 × 100 mL) and brine (150 mL), dried over anhydrous MgSO₄ and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography (silica gel, ethyl acetate/hexanes = 20/1, 15/1, 10/1, 5/1, and 1/1) to furnish 1,13-dihydroxy-2,12-dimethyl-2,12-di-*p*-tolyl-tridecan-7-one (2.72 g, 26.2 % over two steps) as a colorless oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.18 (d, 4 H, *J* = 8.1 Hz), 7.12 (d, 4 H, *J* = 8.1 Hz), 3.63 (d, *J* = 11.0 Hz, 2 H), 3.49 (d, *J* = 11.0 Hz, 2 H), 2.31 (s, 6 H), 2.26 (t, *J* = 7.8 Hz, 4 H), 1.78-1.40 (m, 10 H), 1.28 (s, 6 H), 1.24 - 0.82 (m, 4 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 211.51, 141.75, 135.64, 129.23, 126.64, 72.54, 43.06, 42.65, 38.28, 24.53, 23.59, 21.66, 20.98. HRMS (LSIMS, nba): Calcd. for C₂₉H₄₃O₃ (MH⁺): 439.3212, found: 439.3222.

5

5.1.f. Synthesis of 2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-oxo-tridecanedioic acid



10

6-Bromo-2-(4-isobutyl-phenyl)-2-methyl-hexanoic acid ethyl ester

Ethyl (4-isobutyl-phenyl)-acetate (10.5 g, 44.8 mmol) was dissolved in freshly distilled tetrahydrofuran (150 mL) and cooled to -78°C . Lithium diisopropylamide (2 N, 28 mL, 56 mmol) was added and the solution stirred for 1 hour at -78°C under a nitrogen atmosphere. 1,4-Dibromobutane (25 mL, 37.5 g, 175 mmol) was then added drop-wise over 30 minutes. The solution was allowed to warm to room temperature over five hours. After stirring at room temperature for an additional 16 hours, the reaction was quenched with water (100 mL) and extracted with diethyl ether (2×100 mL). The ether was washed with 10% hydrochloric acid (2×100 mL), saturated sodium bicarbonate (100 mL) and water

(100 mL). After drying with sodium sulfate (5 g), filtration and concentration, the product was purified by flash chromatography on silica gel (200 g), eluting with 5% ethyl acetate/hexanes. The product was then heated to 150 °C under vacuum (0.5 mm Hg) for 30 minutes to remove excess 1,4-dibromobutane. The reaction yielded 6-bromo-2-(4-isobutyl-phenyl)-2-methyl-hexanoic acid ethyl ester (14.49 g, 87.5% yield) as a clear, viscous oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm): 7.19 (d, 2H, *J* = 8.0 Hz), 7.08 (d, 2H, *J* = 8.0 Hz), 4.11 (q, 2H, *J* = 7.0 Hz), 3.35 (t, 2H, *J* = 6.8 Hz), 2.43 (d, 2H, *J* = 7.3 Hz), 2.10 - 1.92 (m, 1H), 1.92 - 1.78 (m, 4H), 1.53 (s, 3H), 1.40 - 1.28 (m, 2H), 1.17 (t, 3H, *J* = 7.0 Hz), 0.88 (d, 6H, *J* = 6.8). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 176.17, 141.12, 140.04, 129.14, 125.64, 60.77, 49.80, 44.99, 38.52, 33.51, 33.26, 30.22, 23.55, 22.69, 22.50, 14.19. HRMS (LSIMS, nba): Calcd. for C₁₉H₃₀O₂Br (MH⁺): 369.1429, found: 369.1445.

2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-oxo-tridecanedioic acid diethyl ester

6-Bromo-2-(4-isobutyl-phenyl)-2-methyl-hexanoic acid ethyl ester (14.13 g, 38.2 mmol) was dissolved in freshly distilled methylsulfoxide (200 mL) and TosMIC (3.73 g, 19.1 mmol), tetra-*n*-butylammonium iodide (1.30 g, 3.5 mmol), and sodium hydride (2.0 g 60%, 19.1 mmol) were added at room temperature under a nitrogen atmosphere. After stirring for 18 hours at room temperature, the reaction was quenched by the slow addition of water (200 mL). Dichloromethane (100 mL) was added and the layers were separated. The aqueous fraction was then extracted with additional dichloromethane (2 × 50 mL). The dichloromethane fractions were combined and washed with water (100 mL) and brine (100 mL) before drying with sodium sulfate. After filtration, concentration and drying under high vacuum, the crude intermediate was dissolved in dichloromethane (100 mL) and concentrated hydrochloric acid (50 mL). After stirring for one hour at room temperature, cold water (200 mL) was added and the layers were separated. The aqueous portion was extracted with additional dichloromethane (100 mL). The dichloromethane fractions were combined, dried with sodium sulfate, filtered and concentrated. The product was purified by flash chromatography on silica gel (300 g), eluting with 10% ethyl acetate/hexanes (2 L) followed by 20 % ethyl acetate/hexanes (1 L). The reaction yielded 2,12-bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-oxo-tridecanedioic acid diethyl ester (9.49 g, 82% yield) as a colorless oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.18 (d, 4H, *J* = 8.0 Hz), 7.07 (d, 4H, *J* = 8.0 Hz), 4.10 (q, 4H, *J* = 7.0 Hz), 2.43 (d, 4H, *J* = 7.0 Hz), 2.34 (t, 4H, *J* = 7.6 Hz), 2.10-1.92 (m, 2H), 1.92-1.78 (m, 4H), 1.60-1.50 (m, 4H), 1.50 (s, 6H), 1.19-1.11 (m, 5H), 1.17 (t, 3H, *J* = 7.0 Hz), 0.88 (d, 12H, *J* = 6.6 Hz). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 211.06, 176.39, 141.36, 140.04, 129.16, 125.71, 60.77, 49.90, 45.06, 42.66, 39.18,


30.27, 24.59, 24.35, 22.86, 22.56, 14.23. HRMS (LSIMS, nba): Calcd. for $C_{39}H_{59}O_5$ (MH^+): 607.4362, found: 607.4337.

2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-oxo-tridecanedioic acid

- 5 2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-oxo-tridecanedioic acid diethyl ester (3.0 g, 4.95 mmol) was dissolved in ethanol (40 mL) and water (10 mL) with potassium hydroxide (4.4 g 85%). The solution was heated to reflux for six hours, cooled and concentrated. After the ethanol was removed, water (200 mL) was added and the solution was extracted with diethyl ether (100 mL). The aqueous fraction was acidified with
- 10 concentrated hydrochloric acid (10 mL, to pH = 1). The product was then extracted with diethyl ether (2×100 mL). The ether fractions were combined and dried with sodium sulfate (5 g). After filtration, concentration and drying under high vacuum, the reaction yielded 2,12-bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-oxo-tridecanedioic acid (2.35 g, 82% yield) as a light yellow foam. 1H NMR (300 MHz, $CDCl_3$ /TMS): δ (ppm) 10.02 (bs, 2H),
- 15 7.24 (d, 4H, $J = 8.0$ Hz), 7.09 (d, 4H, $J = 8.0$ Hz), 2.43 (d, 4H, $J = 7.0$ Hz), 2.33 (t, 4H, $J = 7.3$ Hz), 2.05-1.88 (m, 2H), 1.96-1.77 (m, 4H), 1.55-1.42 (m, 10H), 1.22-1.08 (m, 4H), 0.88 (d, 12H, $J = 6.6$). ^{13}C NMR (75 MHz, $CDCl_3$ /TMS): δ (ppm): 211.48, 182.94, 140.43, 140.24, 129.27, 125.94, 49.71, 45.06, 42.58, 42.58, 38.91, 30.25, 24.45, 24.24, 22.58, 22.40. HRMS (LSIMS, nba): Calcd. for $C_{35}H_{50}O_5Na$ (MNa^+): 573.3555, found: 573.3459.

20

5.1.g. Synthesis of 1,13-Dihydroxy-2,12-bis-(4-isobutyl-phenyl)-2,12-dimethyl-tridecan-7-one



2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-([1,3]dithianyl)-tridecanedioic acid diethyl ester

- 5 2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-oxo-tridecanedioic acid diethyl ester (5.50 g, 9.0 mmol) was dissolved in freshly distilled dichloromethane (60 mL) with borontrifluoride etherate (0.45 mL) and 1,3-propanedithiol (1.0 mL, 0.98 g, 9.0 mmol). The solution was stirred for three hours at room temperature under a nitrogen atmosphere. After three hours, an additional volume of dichloromethane (100 mL) was added and the solution
- 10 was extracted with 5% sodium hydroxide solution (2 × 50 mL) and water (100 mL). After drying with sodium sulfate, filtration, and concentration, the product was purified by flash chromatography on silica gel (130 g), eluting with 10% ethyl acetate/hexanes. The reaction yielded 2,12-bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-([1,3]dithianyl)-tridecanedioic acid diethyl ester (6.16 g, 98% yield) as a colorless oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ
- 15 (ppm) 7.20 (d, 4H, *J* = 8.0 Hz), 7.07 (d, 4H, *J* = 8.0 Hz), 4.10 (q, 4H, *J* = 7.0 Hz), 2.76 (t, 4H, *J* = 5.3 Hz), 2.43 (d, 4H, *J* = 7.0 Hz), 2.09-1.95 (m, 2H), 1.94-1.78 (m, 10H), 1.51 (s, 6H), 1.46-1.36 (m, 4H), 1.25-1.12 (m, 4 H), 1.18 (t, 6 H, *J* = 7.0 Hz), 0.88 (d, 12H, *J* = 6.5 Hz). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 176.42, 141.43, 140.00, 129.14, 125.74, 60.74, 53.30, 49.97, 45.05, 39.22, 38.29, 30.26, 26.10, 25.64, 25.17, 24.76, 22.99, 22.56, 14.26.
- 20 HRMS (LSIMS, nba): Calcd. for C₄₂H₆₅O₄S₂ (MH⁺): 696.4246, found: 696.4234.

2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-([1,3]dithianyl)-tridecane-1,13-diol

- 25 2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-([1,3]dithianyl)-tridecanedioic acid diethyl ester (5.81 g, 8.33 mmol) was dissolved in freshly distilled tetrahydrofuran (THF, 50 mL) and added to lithium aluminum hydride (1.0 g, 26.3 mmol) in THF (50 mL) at -78 °C under a nitrogen atmosphere. The solution was warmed to room temperature over four
- 30 hours. The reaction was then cooled back to -78 °C and quenched with ethyl acetate (5.0 mL). After warming to room temperature, water (100 mL) was added and the product was extracted with diethyl ether (2 × 100 mL). The ether extracts were combined, dried with sodium sulfate, filtered, and concentrated. After drying under high vacuum for four hours, the reaction yielded 2,12-bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-([1,3]dithianyl)-tridecane-
- 35 1,13-diol (4.80 g, 94% yield) as a colorless oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.20 (d, 4H, *J* = 8.0 Hz), 7.09 (d, 4H, *J* = 8.0 Hz), 3.64 (d, 2H, *J* = 10.7 Hz), 3.48 (d, 2H, *J* = 10.7 Hz), 2.71 (t, 4H, *J* = 5.1 Hz), 2.50 - 2.35 (m br., 2 H), 2.43 (d, 4H, *J* = 7.0 Hz), 1.90-1.80

(m, 4H), 1.80-1.68 (m, 6H), 1.58-1.42 (m, 2H), 1.38-1.25 (m, 4H), 1.30 (s, 6H), 1.26-1.10 (m, 2H), 1.10-0.95 (m, 2H), 0.89 (d, 12H, $J = 6.6$ Hz). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm) 141.94, 139.39, 129.20, 126.44, 72.48, 53.30, 44.97, 43.09, 38.45, 38.18, 30.21, 26.01, 25.64, 24.84, 24.09, 22.55, 21.64. HRMS (LSIMS, nba): Calcd. for $\text{C}_{38}\text{H}_{61}\text{O}_2\text{S}_2$ (MH^+): 613.4113, found: 613.4075.


10

1,13-Dihydroxy-2,12-bis-(4-isobutyl-phenyl)-2,12-dimethyl-tridecan-7-one

2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-([1,3]dithianyl)-tridecane-1,13-diol (4.50 g, 7.35 mmol) was dissolved in dimethoxyethane (DME, 50 mL) with concentrated hydrochloric acid (10 mL). Methylsulfoxide (DMSO, 5.0 mL) was added drop-wise over five minutes and the solution was stirred for thirty minutes at room temperature. The reaction was then slowly poured into saturated sodium bicarbonate solution (100 mL) and extracted with diethyl ether (2×100 mL). The ether fractions were combined, dried with sodium sulfate, filtered, and concentrated. The product was purified by flash chromatography on silica gel (100 g), eluting with 30 % ethyl acetate/hexanes. The reaction yielded 1,13-dihydroxy-2,12-bis-(4-isobutyl-phenyl)-2,12-dimethyl-tridecan-7-one (3.2 g, 83.5 %) as a colorless oil. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm): 7.19 (d, 4H, $J = 8.0$ Hz), 7.09 (d, 4H, $J = 8.0$ Hz), 3.63 (d, 2H, $J = 11.0$ Hz), 3.49 (d, 2H, $J = 11.0$ Hz), 2.43 (d, 4H, $J = 7.0$ Hz), 2.26 (t, 4H, $J = 7.3$ Hz), 1.88-1.66 (m, 4H), 1.52-1.41 (m, 8H), 1.29 (s, 6H), 1.15-1.10 (m, 2H), 0.98-0.88 (m, 2H), 0.89 (d, 12H, $J = 6.6$ Hz). ^{13}C NMR (75 MHz, CDCl_3/TMS): $\delta = 211.47, 141.97, 139.51, 129.28, 126.45, 72.53, 45.02, 43.11, 42.69, 38.36, 30.26, 24.57, 23.63, 22.58, 21.72$. HRMS (LSIMS, nba): Calcd. for $\text{C}_{35}\text{H}_{55}\text{O}_3$ (MH^+): 523.4151, found: 523.4144.

30

5.1.h. Synthesis of 2,10-Dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid




2,10-Dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid diethyl ester

- To a solution of ethyl 5-bromo-2-methyl-2-phenylpentanoate (25 g, 75.25 mmol), tetra-*n*-butylammonium iodide (2.78 g, 7.53 mmol), and *p*-toluenesulfonylmethyl isocyanide (TosMIC, 7.34 g, 37.63 mmol) in anhydrous DMSO (400 mL) and anhydrous diethyl ether (150 mL) was added sodium hydride (60% dispersion in mineral oil, 3.80 g, 95 mmol) at rt under N₂ atmosphere. The reaction mixture was stirred for 24 h at rt, then carefully hydrolized with ice-water (600 mL), and extracted with diethyl ether (2 × 300 mL). The organic layer was washed with brine (2 × 300 mL) dried over anhydrous MgSO₄, concentrated in vacuo to furnish crude 2,10-dimethyl-6-isocyano-6-(4-tolyl-sulfonyl)-2,10-diphenyl-undecanedioic acid diethyl ester (28 g) as a brown oil. A solution of this crude intermediate (25 g) was dissolved in CH₂Cl₂ (500 mL) and concd. HCl (140 mL) and stirred for 2 h at rt. The reaction mixture was diluted with water (500 mL) and the layers were separated. The aqueous layer was extracted with CH₂Cl₂ (2 × 200 mL). The combined layers were washed with saturated NaHCO₃ solution (150 mL), and brine (150 mL), dried over MgSO₄, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography (silica gel, ethyl acetate/hexanes = 1/20, 1/10) to furnish 2,10-dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid diethyl ester (9.5 g, 50.3 %) as a light yellowish oil.
- ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.40 - 7.10 (m, 10 H), 4.20 - 4.05 (m, 4 H), 2.38 (m, 4 H), 2.05 - 1.80 (m, 4 H), 1.60 (s, 6 H), 1.50 - 1.20 (m, 4 H), 1.22 (m, 6 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 210.24, 176.06, 143.71, 128.42, 126.72, 125.97, 60.83, 50.13, 42.97, 38.91, 22.73, 22.47, 19.09, 14.13. HRMS (LSIMS, nba): Calcd. for C₂₉H₃₉O₅ (MH⁺): 467.2797, found: 467.2772.

2,10-Dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid

To a homogenous solution of KOH (85%, 7.17 g, 108.90 mmol) in water (15 mL) and ethanol (45 mL) was added 2,10-dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid diethyl ester (14.5 g, 31.12 mmol). The reaction solution was heated to reflux for 6 h. The ethanol was removed in reduced pressure and the residue was diluted with water (300 mL). The solution was acidified with concd. HCl (18 mL) to pH 1 and extracted with CH₂Cl₂ (3 × 100 mL). The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄ and purified by flash chromatography (silica gel, ethyl acetate/hexanes = 1/20, 1/10, 1/2) to furnish 2,10-dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid (4 g, 31.4 %) as a white solid. Mp.: 44 - 46 °C. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 10.25 (br, 2 H), 7.35 - 7.22 (m, 10 H), 2.32 (m, 4 H), 1.94 - 1.86 (m, 4 H), 1.57 (s, 6 H), 1.51 - 1.22 (m, 4 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 210.64, 182.66, 142.69, 128.66, 127.18, 126.29, 50.07, 42.97, 38.62, 22.20, 19.11. HRMS (LSIMS, nba): Calcd. for C₂₅H₃₁O₅ (MH⁺): 411.2171, found: 411.2144.

5.1.i. Synthesis of 1,11-Dihydroxy-2,10-dimethyl-2,10-diphenyl-undecan-6-one



5-Bromo-2-methyl-2-phenyl-pentan-1-ol

Methanol (5.24 g, 164 mmol) was added drop-wise to a stirred suspension of LiBH₄ (3.45 g, 150 mmol) in anhydrous CH₂Cl₂ (150 mL) under N₂ atmosphere. After the addition of ethyl 5-bromo-2-methyl-2-phenyl-pentanoate (23.70 g, 106 mmol), the reaction mixture was heated to reflux overnight. The reaction mixture was cooled to 5 °C and hydrolyzed

with ice (ca. 30 g) and NH_4Cl solution (150 mL) for 1 h. The layers were separated and the aqueous layer was extracted with CH_2Cl_2 (3×150 mL). The combined organic layers were washed with NH_4Cl solution (3×100 mL), dried over MgSO_4 and concentrated in vacuo to furnish 5-bromo-2-methyl-2-phenyl-pentan-1-ol (20 g, 96.8 %) as an oil. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm) 7.34 - 7.14 (m, 5 H), 3.60 (m, 1 H), 3.48 (m, 1 H), 3.29 (t, $J = 6.0$ Hz, 2 H), 1.96 - 1.44 (m, 5 H), 1.32 (s, 3 H). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm) 144.25, 128.59, 126.71, 126.41, 72.44, 43.15, 37.06, 34.64, 27.58, 21.61. HRMS (LSIMS, nba): Calcd. for $\text{C}_{12}\text{H}_{16}\text{Br}$ ($\text{MH}^+ - \text{H}_2\text{O}$): 239.0435, found: 239.0444.

10 2-(5-Bromo-2-methyl-2-phenyl-pentyloxy)-tetrahydropyran

Under N_2 atmosphere, 3,4-dihydro-2H-pyran (8.19 g, 98 mmol) was added dropwise to a stirred solution of 5-bromo-2-methyl-2-phenyl-pentan-1-ol (20 g, 78 mmol) at -5°C . The reaction mixture was allowed to warm to rt and stirred for 5 h. The solution was filtered through aluminum oxide (100 g), which was washed with CH_2Cl_2 (500 mL). The filtrate was concentrated in vacuo to furnish 2-(5-bromo-2-methyl-2-phenyl-pentyloxy)-tetrahydropyran (25.23 g, 96.2 %) as an oil. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm) 7.26 - 7.08 (m, 5 H), 4.45 (m, 1 H), 3.72 (m, 1 H), 3.58 (m, 1 H), 3.35 - 3.05 (m, 2 H), 3.28 (t, $J = 6.6$, 2 H), 1.95 - 1.39 (m, 10 H), 1.25 (s, 3 H). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm) 145.37, 128.14, 126.51, 126.03, 99.06, 98.92, 61.91, 61.80, 41.82, 41.74, 37.58, 37.43, 34.65, 30.61, 27.88, 25.58, 23.03, 22.89, 19.39, 19.32. HRMS (HR, LSIMS, nba): Calcd. for $\text{C}_{17}\text{H}_{26}\text{O}_2\text{Br}$ (MH^+): 341.1116, found: 341.1127.

1,11-Dihydroxy-2,10-dimethyl-2,10-diphenyl-undecan-6-one

To a solution of 2-(5-bromo-2-methyl-2-phenyl-pentyloxy)-tetrahydropyran (25 g, 74.18 mmol), tetra-*n*-butylammonium iodide (3.0 g, 8.16 mmol), and *p*-toluenesulfonyl-methyl isocyanide (TosMIC, 7.23 g, 37.09 mmol) in anhydrous DMSO (350 mL) and anhydrous diethyl ether (100 mL) was added sodium hydride (60% dispersion in mineral oil, 3.73 g, 1.26 mmol) at rt under N_2 atmosphere. The reaction mixture was allowed to stir for 24 h at this temperature, then was carefully hydrolyzed with ice and water (600 mL) and extracted with diethyl ether (2×300 mL). The combined organic layers were washed with brine (2×300 mL), dried over MgSO_4 , and concentrated in vacuo to furnish 6-isocyano-6-(4-tolyl-sulfonyl)-2,10-dimethyl-2,10-diphenyl-11-(tetrahydropyran-2-yloxy)-undecanyloxy-tetrahydropyran (28 g) as a brown oil. A solution of this crude intermediate (28 g, 41.12 mmol) was dissolved in methanol (500 mL), concd. HCl (60 mL), and water (120 mL) and heated to reflux for 3 h. The reaction mixture was poured into CH_2Cl_2 (300 mL) and ice and


water (300 g). The layers were separated and the aqueous layer was extracted with CH_2Cl_2 (3×150 mL). The combined organic layers were washed with saturated NaHCO_3 solution (3×150 mL) and brine (150 mL), dried over MgSO_4 , and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography (silica gel; hexanes, then ethyl acetate/hexanes = 1/20, 1/10, 1/2, 1/1) to furnish 1,11-dihydroxy-2,10-dimethyl-2,10-diphenyl-undecan-6-one (5.3 g, 34 %) as a light yellowish oil. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm) 7.38 - 7.30 (m, 8 H), 7.26 - 7.18 (m, 2 H), 3.62 (d, $J = 10.5$ Hz, 2 H), 3.48 (d, $J = 10.5$ Hz, 2 H), 2.25 (m, 6 H) 1.76 - 1.64 (m, 2 H), 1.58 - 1.16 (m, 6 H), 1.32 (s, 6 H). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm) 211.43, 144.84, 128.32, 126.58, 126.03, 71.79, 43.11, 42.89, 37.61, 21.68, 18.12. HRMS (LSIMS, nba): Calcd. for $\text{C}_{25}\text{H}_{33}\text{O}_2$ ($\text{MH}^+ - \text{H}_2\text{O}$): 365.2481, found: 365.2482.

15

20

25

5.1.j. Synthesis of 9-Hydroxy-3-(6-hydroxy-5,5-dimethyl-hexyl)-8,8-dimethyl-nonan-2-one



30

2,2-Bis-[5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl]-malonic acid diethyl ester

Under nitrogen atmosphere, to a solution of 2-(6-bromo-2,2-dimethyl-hexyloxy)-tetrahydropyran (17.6 g, 60 mmol) and diethyl malonate (4.8 g, 30 mmol) in anhydrous DMSO (145 mL) was added sodium hydride (60 % dispersion in mineral oil, 2.88 g, 72 mmol) under cooling with a water-bath. Tetra-*n*-butylammonium iodide (2.1 g, 3.6 mmol) was then added. The mixture was stirred for 16 h at room temperature. Water (140 mL) was added carefully to the reaction mixture under cooling with water-bath. The product was extracted with diethyl ether (3 × 60 mL) and the combined organic layers were washed with water (4 × 50 mL) and brine (50 mL). The solution was dried over sodium sulfate and concentrated in vacuo to give 2,2-*bis*-[5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl]-malonic acid diethyl ester (17.3 g, 82.3 %) as an oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 4.41 (t, *J* = 3.1 Hz, 2H), 4.01 (q, *J* = 7.0 Hz, 4 H), 3.82 - 3.70 (m, 2 H), 3.50 - 3.30 (m, 4 H), 2.87 (d, *J* = 9.1 Hz, 2 H), 1.80 - 1.35 (m, 16 H), 1.30 - 0.95 (m, 18 H), 0.88 - 0.74 (m, 12 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 172.0, 99.1, 76.6, 61.9, 60.9, 57.6, 39.2, 34.3, 32.3, 30.7, 25.7, 25.0, 24.6, 24.6, 24.3, 19.5, 14.2.

15

2,2-Bis(6-hydroxy-5,5-dimethyl-hexyl)-malonic acid diethyl ester

A solution of 2,2-*bis*-[5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl]-malonic acid diethyl ester (2.92 g, 5mmol) in concentrated HCl (2.4 mL) and water (1.6 mL) was refluxed for 1 h. Ethanol (8.2 mL) was added and the reaction mixture was heated to reflux for 3 h. The reaction mixture was diluted with water (20 mL) and extracted with diethyl ether (3 × 20 mL). The combined organic layers were washed with water (20 mL), brine (20 mL), and dried over Na₂SO₄. The solution was concentrated to furnish 2,2-*bis*(6-hydroxy-5,5-dimethyl-hexyl)-malonic acid diethyl ester (1.74 g, 84 %). ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 4.13 (q, *J* = 7.2 Hz, 4 H), 3.25 (s, 4 H), 2.42 (s, 2 H), 1.90 - 1.75 (m, 4 H), 1.30 - 1.12 (m, 18 H), 0.84 (s, 12 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 172.0, 71.7, 60.9, 57.4, 38.2, 34.9, 32.1, 24.8, 24.0, 23.7, 14.0.

25

2,2-Bis-(6-hydroxy-5,5-dimethyl-hexyl)-malonic acid

To a stirred solution of KOH (4.83 g, 75 mmol) in water (4.2 mL) and ethanol (15 mL) was added 2,2-*bis*(6-hydroxy-5,5-dimethyl-hexyl)-malonic acid diethyl ester (15 g). The reaction mixture was heated to reflux for 14 h, then concentrated *in vacuo*, and extracted with chloroform. The aqueous layer was acidified with HCl until pH 1 and extracted with diethyl ether (3 × 50 mL). The ethereal solution was dried over anhydrous MgSO₄ and concentrated *in vacuo* to afford 2,2-*bis*-(6-hydroxy-5,5-dimethyl-hexyl)-malonic acid (7.8 g, 82.3 %) as a yellow solid. ¹H NMR (300 MHz, CD₃OD/TMS): δ (ppm)

35

4.86 (s, 4 H), 3.22 (s, 4 H), 1.9 - 1.8 (m, 4 H), 1.36 - 1.10 (m, 12 H), 0.84 (s, 12 H). ¹³C NMR (75 MHz, CD₃OD/TMS): δ (ppm) 176.0, 72.0, 58.7, 39.8, 36.0, 34.1, 26.5, 25.5, 24.5. Mp.: 178 - 180 °C.


5 **8-Hydroxy-2-(6-hydroxy-5,5-dimethyl-hexyl)-7,7-dimethyl-octanoic acid**

2,2-Bis-(6-hydroxy-5,5-dimethyl-hexyl)-malonic acid was heated to 200 °C using an oil-bath. This temperature was kept for 30 minutes until the effervescence ceased. 8-Hydroxy-2-(6-hydroxy-5,5-dimethyl-hexyl)-7,7-dimethyl-octanoic acid was obtained as an oil (4.04 g, 98 %). ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 4.88 (s, 3 H), 3.22 (s, 4 H), 2.29 (m, 1 H), 1.70 - 1.40 (m, 4 H), 1.4 - 1.1 (m, 12 H), 0.84 (s, 12 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 180.5, 72.1, 47.1, 39.9, 36.0, 33.8, 29.7, 25.0, 24.6.

9-Hydroxy-3-(6-hydroxy-5,5-dimethyl-hexyl)-8,8-dimethyl-nonan-2-one

8-Hydroxy-2-(6-hydroxy-5,5-dimethyl-hexyl)-7,7-dimethyl-octanoic acid (1.0 g, 3.16 mmol) was dissolved in THF (40 mL) and cooled in an ice-water bath. Methyl lithium (27 mL) was then added at once. The reaction was continued for 2 h at 0 °C. The reaction mixture was poured into dilute hydrochloric acid (5 mL concentrated hydrochloric acid in 60 mL water). The organic layer was separated and the aqueous layer was extracted with diethyl ether (2 × 50 mL). The combined organic layers were dried over sodium sulfate and concentrated in vacuo to give the crude product (1.0 g). The crude product was purified by column chromatography (hexanes : ethyl acetate = 4 : 1, then 1 : 1) to give 9-hydroxy-3-(6-hydroxy-5,5-dimethyl-hexyl)-8,8-dimethyl-nonan-2-one (0.41 g, yield 41 %) and 7-(1-hydroxy-1-methylethyl)-2,2,12,12-tetramethyltridecan-1,13-diol (0.4 g, 38 %, not shown) as a by-product. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 3.46 (s, 4 H), 2.65 - 2.50 (m, 1 H), 2.28 (s, 3 H), 2.60 (br., 2 H), 1.82 - 1.50 (m, 4 H), 1.50 - 1.25 (m, 12 H), 1.02 (s, 12 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 213.4, 71.7, 53.2, 38.3, 34.9, 31.6, 28.7, 28.3, 23.8. HRMS (LSIMS, nba): Calcd. for C₁₉H₃₉O₃ (MH⁺): 315.2899, found: 315.2866.

5.1.k. Synthesis of Bis[3-(3-hydroxy-2,2-dimethylpropyl)phenyl]methanone



3-{3-[3-(2-Ethoxycarbonyl-2-methyl-propyl)-benzoyl]-phenyl}-2,2-dimethyl-propionic acid ethyl ester

5

A solution of lithium diisopropylamide (LDA, 2.0 M in heptane/THF, ethyl benzene, 42.2 mL, 84.4 mmol) was added drop-wise to a solution of ethyl isobutyrate (9.78 g, 84.3 mmol) in anhydrous THF (30 mL) at -78°C . The mixture was allowed to stir at -78°C for 1 h, before 3,3'-bis(bromomethyl)benzophenone ((prepared according to Shultz, D.A.; Fox, M. A. *J. Am. Chem. Soc.* **1989**, *16*, 6311, from 3-bromobenzyl methyl ether (Friedman, L.; Shechter, H. *J. Org. Chem.* **1961**, *26*, 2522), 10.34 g, 28.1 mmol) was added, followed by addition of DMPU (2.7 g, 17 mmol). The mixture was stirred for 30 min at -78°C , allowed to warm to rt, and stirred for 30 min. The THF was removed under reduced pressure and the residue was diluted with saturated NH_4Cl (280 mL). The aqueous layer was extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with brine (200 mL), 5 % HCl (100 mL), and saturated NaHCO_3 solution (50 mL), then dried over anhydrous Na_2SO_4 and concentrated *in vacuo* to furnish 3-{3-[3-(2-ethoxycarbonyl-2-methyl-propyl)-benzoyl]-phenyl}-2,2-dimethyl-propionic acid ethyl ester (11.0 g, 90%) as an oil. ^1H NMR (300 MHz, CDCl_3): δ (ppm): 7.8 - 7.2 (m, 8 H), 3.98 (q, J

= 6.9 Hz, 4 H), 2.83 (s, 4 H), 1.2 - 0.8 (m, 18 H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm): 196.5, 176.8, 138.1, 137.2, 134.0, 131.4, 128.1, 127.7, 60.3, 45.7, 43.3, 24.8, 13.9.

5 **3-(3-{2-[3-(2-Ethoxycarbonyl-2-methyl-propyl)-phenyl]-[1,3]dithian-2-yl}-phenyl)-2,2-dimethyl-propanoic acid ethyl ester**

To a solution of 3-{3-[3-(2-ethoxycarbonyl-2-methyl-propyl)-benzoyl]-phenyl}-2,2-dimethyl-propionic acid ethyl ester (6.2 g, 14 mmol) in dichloromethane (100 mL) was added 1,3-propanedithiol (1.9 g, 17.5 mmol) and borontrifluoride etherate (0.52 mL). The solution was stirred at room temperature overnight and 5 % sodium hydroxide solution (17.5 mL) was added. The organic layer was separated, washed with water (50 mL), dried over sodium sulfate, and evaporated to afford 3-(3-{2-[3-(2-ethoxycarbonyl-2-methyl-propyl)-phenyl]-[1,3]dithian-2-yl}-phenyl)-2,2-dimethyl-propanoic acid ethyl ester (6.5 g, 86 %) as an oil. ¹H NMR (300 MHz, CDCl₃): δ (ppm): 7.58 - 6.96 (m, 8 H), 4.10 (q, *J* = 7.2 Hz, 4 H), 2.85 (s, 4 H), 2.76 (t, *J* = 5.6 Hz, 4 H), 1.98 (m, 2 H), 1.25 - 1.14 (m, 18 H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm): 177.2, 142.2, 138.1, 131.1, 129.3, 127.8, 127.3, 60.4, 46.2, 43.5, 29.4, 24.9, 24.5, 14.1.

20 **3-(3-{2-[3-(3-Hydroxy-2,2-dimethyl-propyl)-phenyl]-[1,3]dithian-2-yl}-phenyl)-2,2-dimethyl-propan-1-ol**


To a suspension of LiBH₄ (0.78 g, 33 mmol) in dichloromethane (55 mL) was added methanol (1.04 g, 33 mmol) at rt. After the addition of 3-(3-{2-[3-(2-ethoxycarbonyl-2-methyl-propyl)-phenyl]-[1,3]dithian-2-yl}-phenyl)-2,2-dimethyl-propanoic acid ethyl ester (6.5 g, 12.2 mmol), the reaction mixture was heated to reflux for 6 h. After cooling to rt, saturated ammonium chloride solution (20 mL) and dichloromethane (15 mL) were added. The layers were separated and the aqueous layer was extracted with dichloromethane (2 × 10 mL). The combined organic phases were dried over sodium sulfate and concentrated in vacuo to afford crude 3-(3-{2-[3-(3-hydroxy-2,2-dimethyl-propyl)-phenyl]-[1,3]dithian-2-yl}-phenyl)-2,2-dimethyl-propan-1-ol (4.66 g, 85 %) as an oil. ¹H NMR (300 MHz, CDCl₃): δ (ppm): 7.6 - 6.8 (m, 8 H), 3.63 (s, 4 H), 3.16 (s, 4 H), 2.95 - 2.60 (m, 4 H), 2.0 - 1.8 (m, 2 H), 1.61 (s, 2 H), 0.75 (s, 12 H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm): 142.4, 139.2, 131.7, 128.9, 128.1, 127.0, 71.1, 44.9, 43.7, 36.7, 29.6, 27.3, 24.2.

35

Bis-[3-(3-hydroxy-2,2-dimethylpropyl)-phenyl]-methanone

A three-necked flask fitted with a magnetic stirring bar, a condenser, and a pressure-equalizing dropping funnel was charged with copper(II)oxide (0.96 g, 12 mmol), anhydrous copper(II)chloride (3.2 g, 24 mmol) and acetone (80 mL). The resulting suspension was brought to reflux with vigorous stirring, and a solution of 3-(3-{2-[3-(3-hydroxy-2,2-dimethyl-propyl)-phenyl]-[1,3]dithian-2-yl}-phenyl)-2,2-dimethyl-propan-1-ol (4.44 g, 10 mmol) in acetone (20 mL) and DMF (1.2 mL) was added over five min. Reflux temperature was maintained for 90 min. The reaction mixture was cooled and filtered. The insoluble materials were washed with dichloromethane (3 × 20 mL) and the combined organic solutions were washed with aqueous 2 N sodium carbonate solution (50 mL), dried over sodium sulfate, and filtered. Concentration in vacuo gave crude *bis*-[3-(3-hydroxy-2,2-dimethylpropyl)-phenyl]-methanone, which was purified by chromatography on silica (hexanes : acetone = 4:1) to yield an oil (2.5 g, 70.6 %). ¹H NMR (300 MHz, CDCl₃): δ (ppm): 7.68 - 7.30 (m, 8 H), 3.31 (s, 4 H), 3.03 (s, 2 H), 2.65 (s, 4 H), 0.88 (s, 12 H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm): 197.4, 139.1, 137.0, 134.6, 131.9, 127.8, 127.6, 70.4, 44.1, 36.3, 23.8. HRMS (LSIMS, gly): Calcd. for C₂₃H₃₁O₃ (MH⁺): 355.2273, found: 355.2273.

5.1.1. Synthesis of 3-{3-[3-(2-Carboxy-2-methylpropyl)-benzoyl]-phenyl}-2,2-dimethyl-propanoic acid




3-{3-[3-(2-Carboxy-2-methylpropyl)benzoyl]-phenyl}-2,2-dimethyl-propanoic acid

To a solution of potassium hydroxide (1.57 g, 28 mmol) in water (1.5 mL) and absolute ethanol (5 mL) was added 3-{3-[3-(2-ethoxycarbonyl-2-methyl-propyl)-benzoyl]-phenyl}-2,2-dimethyl-propionic acid ethyl ester (4.38 g, 10 mmol) in portions. The mixture was heated to reflux for 3 h and the ethanol was distilled off under reduced pressure on a water-bath. The residual aqueous solution was extracted with chloroform (2 × 50 mL), then cooled with an ice-bath, and acidified with hydrochloric acid to pH 1. The mixture was extracted with diethyl ether (3 × 50 mL). The ethereal extracts were dried over sodium

sulfate and concentrated in vacuo to give 3-{3-[3-(2-carboxy-2-methylpropyl)benzoyl]-phenyl}-2,2-dimethyl-propanoic acid (3.88 g, 100 %) as a solid. Mp.: 46 - 48 °C. ¹H NMR (300 MHz, CDCl₃): δ (ppm): 7.8 - 7.2 (m, 8 H), 2.83 (s, 4 H), 1.25 (s 12 H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm): 198.02, 184.0, 139.2, 137.3, 134.5, 129.5, 128.4, 128.3, 127.6, 43.8, 24.7. HRMS (LSIMS, gly): Calcd. for C₂₃H₂₇O₅ (MH⁺): 383.1858, found: 383.1858.

5.1.m. Synthesis of 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid *bis*-methylamide



10

6-[2-(5-Ethoxycarbonyl-5-methyl-hexyl)-[1,3]dithian-2-yl]-2,2-dimethyl-hexanoic acid ethyl ester

15

Under N₂ atmosphere, to a solution of 2,2,12,12-tetramethyl-7-oxo-tridecanedioic acid diethyl ester (1.0 g, 2.70 mmol) and 1,3-propanedithiol (361 mg, 361 μL, 3.24 mmol) in dichloromethane (20 mL; dried with Aluminum oxide, activated, neutral, Brockmann I) was added boron trifluoride diethyl etherate (100 μL) at rt. The reaction mixture was stirred for 3 h, diluted with dichloromethane (100 mL), and extracted with 5 % NaOH solution (100 mL) and water (75 mL). The organic phase was dried over MgSO₄, concentrated in vacuo, and dried in high vacuo to furnish 6-[2-(5-ethoxycarbonyl-5-methyl-hexyl)-[1,3]dithian-2-yl]-2,2-dimethyl-hexanoic acid ethyl ester (1.0 g, 80 %) as a yellowish oil. ¹H

NMR (300 MHz, CDCl_3/TMS): δ (ppm): 4.11 (q, 4 H, $J = 7.1$), 2.79 (t, 4 H, $J = 5.6$), 1.94 (m, 2 H), 1.84 (m, 4 H), 1.54 (m, 4 H), 1.39 (m, 4 H), 1.24 (t, 6 H, $J = 7.1$), 1.30 – 1.20 (m, 4 H), 1.16 (s, 12 H). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm): 178.08, 60.33, 53.32, 42.27, 40.69, 38.28, 26.14, 25.67, 25.28, 24.71, 14.41. HRMS (LSIMS, nba): Calcd. for $\text{C}_{24}\text{H}_{45}\text{S}_2\text{O}_4$ (MH^+): 461.2759, found 461.2774.

6-[2-(5-Carboxy-5-methyl-hexyl)-[1,3]dithian-2-yl]-2,2-dimethyl-hexanoic acid

A solution of 6-[2-(5-ethoxycarbonyl-5-methyl-hexyl)-[1,3]dithian-2-yl]-2,2-dimethyl-hexanoic acid ethyl ester (870 mg, 1.89 mmol) and potassium hydroxide (85 %, 750 mg, 11.33 mmol) in ethanol (16 mL) and water (4 mL) was heated under reflux for 3 h. The reaction mixture was diluted with water (100 mL) and acidified to pH 4 with 1 N HCl (8 mL). The emulsion was extracted with dichloromethane (3×75 mL). The combined organic phases were washed with water (50 mL), dried over MgSO_4 , concentrated in vacuo, and dried in high vacuo to furnish 6-[2-(5-carboxy-5-methyl-hexyl)-[1,3]dithian-2-yl]-2,2-dimethyl-hexanoic acid (730 mg, 95 %) as a viscous, yellowish oil. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm): 2.80 (m, 4 H), 1.94 (m, 2 H), 1.85 (m, 4 H), 1.56 (m, 4 H), 1.41 (m, 4 H), 1.30 (m, 4 H), 1.19 (s, 12 H). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm): 185.08, 53.36, 42.28, 40.52, 38.27, 26.18, 25.69, 25.23, 25.11, 24.73. HRMS (LSIMS, nba): Calcd. for $\text{C}_{20}\text{H}_{37}\text{O}_4\text{S}_2$ (MH^+): 405.2133, found: 405.2115.

2,2-Dimethyl-6-[2-(5-methyl-5-methylcarbamoyl-hexyl)-[1,3]dithian-2-yl]-hexanoic acid methylamide


Under N_2 atmosphere, to a solution of 6-[2-(5-carboxy-5-methyl-hexyl)-[1,3]dithian-2-yl]-2,2-dimethyl-hexanoic acid (280 mg, 0.67 mmol) and *N*-hydroxysuccinimide (170 mg, 1.47 mmol) in dichloromethane (5 mL; dried with Aluminum oxide, neutral, Brockmann I) was added dicyclohexyl carbodiimide (305 mg, 1.47 mmol). The reaction mixture was stirred and rt for 2 h, the urea was removed by filtration and washed with dichloromethane (2 mL). The filtrate was concentrated in vacuo and dried in high vacuo to give crude 6-[2-[5-(2,5-dioxo-pyrrolidin-1-yloxy-carbonyl)-5-methyl-hexyl]-[1,3]dithian-2-yl]-2,2-dimethyl-hexanoic acid 2,5-dioxo-pyrrolidin-1-yl ester (500 mg, 125 %) as a foamy, yellow oil. Under N_2 atmosphere, to a solution of this crude intermediate (370 mg, 0.62 mmol) in anhydrous THF (10 mL) was added a solution of methylamine in anhydrous THF (5 mL, 10 mmol, 2.0 M in THF), resulting in the immediate formation of a white precipitate. The reaction mixture was stirred at rt for 1.5 h, then diluted with dichloromethane (100 mL), and

extracted with saturated NaHCO_3 solution (2×50 mL), water (50 mL), 1 N HCl (50 mL), and saturated NaCl solution. The organic phase was concentrated in vacuo and the residue purified by flash chromatography (silica, hexanes/ethyl acetate = 50/50, then 25/75, then 0/100) to furnish 2,2-dimethyl-6-[2-(5-methyl-5-methylcarbamoyl-hexyl)-[1,3]dithian-2-yl]-hexanoic acid methylamide (100 mg, 37 %) as a colorless oil. Mp.: 104 - 106 °C. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm): 5.92 (m br, 2 H), 2.81 (d, 6 H, $J = 4.6$), 2.78 (m, 4 H), 1.94 (m, 2 H), 1.82 (m, 4 H), 1.52 (m, 4 H), 1.37 (m, 4 H), 1.30 - 1.14 (m, 4 H), 1.17 (s, 12 H). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm): 178.46, 53.23, 42.10, 41.32, 38.18, 26.56, 26.08, 25.62, 25.56, 25.16, 24.64. HRMS (LSIMS, nba): Calcd. for $\text{C}_{22}\text{H}_{43}\text{N}_2\text{S}_2\text{O}_2$ (MH^+): 431.2766, found: 431.2762.

2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid bis-methylamide

A suspension of 2,2-dimethyl-6-[2-(5-methyl-5-methylcarbamoyl-hexyl)-[1,3]dithian-2-yl]-hexanoic acid methylamide (3.30 g, 7.66 mmol), paraformaldehyde (6.9 g), and Amberlyst 15 (3.85 g) in acetone (100 mL) and water (10 mL) was heated to reflux for 16 h. The acetone was removed under reduced pressure, the reaction mixture was filtered, and the resin was washed with ethyl acetate (3×75 mL). The combined layers were extracted with saturated NaHCO_3 solution (30 mL) and saturated NaCl solution (30 mL), dried over MgSO_4 , and concentrated *in vacuo*. The residue was purified by flash chromatography (silica; ethyl acetate, then ethyl acetate/ethanol = 50/50) to furnish 2,2,12,12-tetramethyl-7-oxo-tridecanedioic acid bis-methylamide (2.45 g, 94 %) as a colorless, viscous oil that solidified on standing. Mp.: 91.5 - 93.5 °C. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm): 6.05 (d br., 2 H, $J = 4.6$), 2.78 (d, 6 H, $J = 4.6$), 2.36 (t, 4 H, $J = 7.3$), 1.58 - 1.45 (m, 8 H), 1.27 - 1.12 (m, 4 H), 1.15 (s, 12 H). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm): 211.50, 178.43, 42.56, 41.99, 41.03, 26.52, 25.48, 24.48, 24.20. HRMS (LSIMS, nba): Calcd. for $\text{C}_{19}\text{H}_{37}\text{N}_2\text{O}_3$ (MH^+): 341.2804, found: 341.2804.

5.1.n. Synthesis of 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid bis-phenylamide




2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid bis-phenylamide

- Under N₂ atmosphere, to a stirred solution of 2,2,12,12-tetramethyl-7-oxo-tridecanedioic acid (3.40 g, 10.9 mmol) in acetonitrile (50 ml) was added *N*-methyl-
- 5 morpholine (2.42 g, 2.63 ml, 23.9 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (4.20 g, 23.9 mmol) at rt. After 20 h, aniline (5.08 g, 5.0 ml, 54.5 mmol) was added and the reaction mixture was stirred for 26 h. The reaction mixture was diluted with ethyl acetate (100 mL) and extracted with ice-cold 1 N HCl (2 × 100 mL), saturated NaCl solution (100 mL), saturated NaHCO₃ solution (2 × 100 mL), and saturated NaCl solution (100 mL). The
- 10 organic layer was dried over MgSO₄, concentrated in vacuo, and dried in high vacuo to give a viscous, crude oil (4.50 g). 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid *bis*-phenylamide and 2,2,12-trimethyl-7-oxo-12-phenylcarbamoyl-tridecanoic acid were isolated from this crude product mixture by flash chromatography (silica; chloroform, then chloroform/acetone = 98/2, then chloroform/acetone = 95/5). Additional purification of
- 15 2,2,12,12-tetramethyl-7-oxo-tridecanedioic acid *bis*-phenylamide by crystallization (1.0 g oil in ca. 7.5 ml hexanes/chloroform/ethanol = 10/4/1) was necessary to give the clean *bis*-amide (290 mg, 6 %) as a white solid. Mp.: 113 – 114 °C. ¹H NMR (300 MHz, CDCl₃): δ (ppm): 7.52 (d, 2 H, *J* = 7.5), 7.50 (s, 2 H), 7.27 (t, 4 H, *J* = 7.5), 7.07 (t, 2 H, *J* = 7.5), 2.34 (t, 4 H, *J* = 7.3), 1.64 – 1.44 (m, 8 H), 1.34 – 1.14 (m, 4 H), 1.24 (s, 12 H). ¹³C NMR (75
- 20 MHz, CDCl₃): δ (ppm): 211.31, 176.08, 138.09, 128.93, 124.28, 120.36, 42.96, 42.84, 41.13, 25.58, 24.53, 24.20. HRMS (LSIMS, nba): Calcd. for C₂₉H₄₀N₂O₃ (MH⁺): 465.3118, found: 465.3129.

2,2,12-Trimethyl-7-oxo-12-phenylcarbamoyl-tridecanoic acid

- 25 Viscous oil (1.15 g, 25 %). ¹H NMR (300 MHz, CDCl₃): δ (ppm): 8.90 (m br., 1 H), 7.57 (s br, 1 H), 7.51 (d, 2 H, *J* = 7.9), 7.28 (m, 2 H), 7.08 (t, 1 H, *J* = 7.3), 2.38 (t, 2 H, *J* = 7.2), 2.36 (t, 2 H, *J* = 7.2 H), 1.53 (m, 8 H), 1.34 – 1.20 (m, 4 H), 1.26 (s, 6 H), 1.16 (s, 6 H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm): 211.54, 183.74, 176.28, 138.02, 128.92, 124.35, 120.46, 42.97, 42.55, 42.53, 42.06, 41.12, 40.21, 25.56, 25.05, 24.55, 24.52, 24.21, 24.17.
- 30 HRMS (LSIMS, nba): Calcd. for C₂₃H₃₆NO₄ (MH⁺): 390.2644, found: 390.2650.

5.1.o. Synthesis of 7-Oxo-2,12-dimethyl-2,12-diphenyl-tridecanedioic acid

5

7-Oxo-2,12-dimethyl-2,12-diphenyl-tridecanedioic acid diethyl ester

Under N₂-atmosphere, to a solution of ethyl 6-bromo-2-methyl-2-phenylhexanoate (9.59 g, 30 mmol) in DMSO (50 mL, dried over 4 Å molecular sieves) was added *p*-toluenesulphonylmethyl isocyanide (TosMIC, 3.02 g, 15 mmol), sodium hydride (60 % w/w in mineral oil, 1.44 g, 36 mmol), and tetra-*n*-butyl ammonium iodide (1.10 g, 3.0 mmol) under cooling with an ice-bath. After the addition, the reaction mixture was stirred for 96 h at rt, then cooled to 0 °C, and carefully hydrolyzed with water (100 mL). The product was extracted with dichloromethane (2 × 100 mL, 50 mL). The combined organic layers were washed with water (50 mL), dried over MgSO₄ and concentrated in *vacuo* to give an oil (30.0 g). To a solution of this oil (30.0 g) in CH₂Cl₂ (300 mL) was added concd. HCl (40 mL) and the reaction mixture was stirred for 2 h at rt. The solution was diluted with water (150 mL) and the layers were separated. The aqueous layer was extracted with CH₂Cl₂ (3 × 50 mL). The combined organic layers were washed with saturated NaHCO₃ solution (30 mL) and saturated NaCl solution (30 mL). The organic phases were dried over MgSO₄, concentrated in *vacuo* to give an oil (11.2 g). The product was purified by flash chromatography (silica; hexanes/ethyl acetate = 91/9) to furnish 7-oxo-2,12-dimethyl-2,12-diphenyl-tridecanedioic acid diethyl ester (5.0 g, 67 %) as a clear oil and 1.17 g (16%) of less pure fraction. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.40 - 7.10 (m, 10 H), 4.11 (q, *J* = 7.0 Hz, 4 H), 2.34 (t, *J* = 7.1 Hz, 4 H), 2.10 - 1.70 (m, 4 H), 1.6 - 1.4 (m, 10 H), 1.30 - 1.00 (m, 10 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm): 210.7, 176.0, 143.8, 128.2,

126.5, 125.8, 60.6, 50.0, 42.4, 38.9, 24.3, 24.1, 22.6, 14.0. HRMS (LSIMS, nba): Calcd. for $C_{31}H_{42}O_5$ (MH^+): 495.3110, found 495.3106.

5

7-Oxo-2,12-dimethyl-2,12-diphenyl-tridecanedioic acid

To a solution of 7-oxo-2,12-dimethyl-2,12-diphenyl-tridecanedioic acid diethyl ester (3.93 g, 7.55 mmol) in ethanol (60 mL) was added a solution of KOH (4.0 g, 85%, 60 mmol) in water (10 mL). The reaction mixture was heated under reflux for 3 h and then kept overnight at rt. The solution was concentrated under reduced pressure. The residue was dissolved in water (100 mL) and washed with ether (2×75 mL). The aqueous layer was acidified with concd. HCl (ca. 12 mL) until pH 1. The product was extracted with diethyl ether (3×75 mL). The combined organic extracts were dried over $MgSO_4$, filtered, and concentrated in *vacuo* to give 7-oxo-2,12-dimethyl-2,12-diphenyl-tridecanedioic acid as an oil (3.0 g, 90 %). 1H NMR (300 MHz, $CDCl_3/TMS$): δ (ppm): 7.40 - 7.10 (m, 10 H), 2.32 (t, $J = 7.2$ Hz, 4 H), 2.10 - 1.80 (m, 4 H), 1.6 - 1.45 (m, 10 H), 1.25 - 1.10 (m, 4 H). ^{13}C NMR (75 MHz, $CDCl_3/TMS$): δ (ppm): 211.1, 182.5, 142.8, 128.4, 126.9, 126.0, 49.9, 42.3, 38.7, 24.2, 24.0, 22.3. HRMS (LSIMS, nba): Calcd. for $C_{27}H_{35}O_5$ (MH^+): 439.2484, found 439.2497.

20

5.2. LDL-Cholesterol, HDL-Cholesterol and Triglyceride Levels in Male Sprague-Dawley Rats

Illustrative compounds of the invention are administered daily at a dose of 100 mg/kg to chow fed male Sprague-Dawley rats for seven days in the morning by oral gavage in 1.5% carboxymethylcellulose/0.2% Tween-20 (dosing vehicle). Animals are weighed daily. Animals are allowed free access to rodent chow and water throughout the study. After the seventh dose, animals are sacrificed in the evening and blood serum is assayed for lipoprotein cholesterol profiles, serum triglycerides, total cholesterol VLDL, LDL, and HDL cholesterol, and the ratio of HDL cholesterol to that of VLDL plus LDL cholesterol, apolipoproteins A-I, C-II, C-III, and E by immunoelectrophoresis, and percent weight gain.

35

5.3. LDL-Cholesterol, HDL-Cholesterol and Triglyceride Levels in Obese Female Zucker Rats

5.3.a. Experiment A

Dosing vehicle, Compound A (86 mg/kg of body weight) or troglitazone (120 mg/kg of body weight) is administered to eight week old female obese Zucker rats daily for seven days in the morning by oral gavage in 1.5% carboxymethylcellulose/0.2% Tween-20.

5 Troglitazone is obtained commercially. Finely crushed tablets are suspended in vehicle for dosing. Orbital blood samples are obtained following a six-hour fast prior to the initial dose and also following the seventh dose.

10 Blood serum is assayed for total cholesterol and triglycerides, lipoprotein cholesterol profiles, VLDL plus LDL cholesterol combined (also referred to as apo B containing lipoprotein cholesterol or non-HDL cholesterol), HDL cholesterol, and the ratio of HDL cholesterol to that of VLDL plus LDL cholesterol, serum glucose, and non-esterified fatty acids, and percent weight gain.

5.3.b. Experiments B, C, D, & E

15 In a number of different experiments, illustrative compounds of the invention and troglitazone are administered daily at various doses to 10 week old chow fed obese female Zucker rats for 14 days in the morning by oral gavage in 1.5% carboxymethylcellulose/0.2% Tween-20 (dosing vehicle). Animals are weighed daily. Animals are allowed free access to rodent chow and water throughout the study. Blood glucose is determined after a 6-hour fast in the afternoon without anesthesia from a tail vein. Serum is also prepared from
20 a blood sample subsequently obtained from the orbital venous plexus (with O₂/CO₂ anesthesia) prior to and after one week treatment and used lipid and insulin determinations.

At two weeks, blood glucose is again determined after a 6-hour fast without anesthesia from a tail vein. Soon thereafter, animals are sacrificed by CO₂ inhalation in the evening and cardiac blood serum is collected and assessed for various lipids and insulin.
25 Body weight is determined daily prior to dosing and at the time of euthanasia. Blood glucose and serum insulin levels are determined from fasted rats just prior to and following one and two weeks of treatment. Percent liver to body weight is determined after two weeks of treatment at the time of sacrifice.

30 5.4. Lipoprotein Cholesterol Profile in LDL Receptor-Deficient Mice

Homozygous familial hypercholesterolemia is a rare human disease (~1/1,000,000) characterized by absent or defective LDL receptors, markedly elevated serum LDL cholesterol levels and very early and severe onset of atherosclerosis. The more common
35 form of this disease in humans, heterozygous familial hypercholesterolemia, occurs in

about one in every 500 humans. Patients with the heterozygous form of this disease also present with elevated LDL levels and early onset of atherosclerosis.

The effect on LDL levels in a murine model of homozygous familial hypercholesterolemia can be studied according to the methods described in Ishibashi *et al.*, 1993, *J. Clin. Invest.* 92:883-893; Ishibashi *et al.*, 1994, *J. Clin. Invest.* 93:1885-1893, hereby expressly incorporated herein by reference. LDL receptor-deficient mice have elevated LDL cholesterol relative to wild type mice when fed a chow diet. When fed cholesterol-enriched diets, these mice develop atherosclerosis.

10 **5.5. Synthesis of Non-Saponified and Saponified** **Lipids in Hepatocytes Isolated from a Male Sprague-Dawley Rat**

Washout buffer containing; 149 mM sodium chloride, 9.2 mM sodium *N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid, 1.7 mM fructose, 0.5 mM EGTA, 10 U/ mL heparin at pH 7.5 and digestion buffer containing; 6.7 mM potassium chloride, 143 mM sodium chloride, 9.2 mM sodium *N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid, 5 mM calcium chloride-dihydrate, 1.7 mM fructose, 0.2% bovine serum albumin, 100 U/ mL collagenase Type 1, 93 U/ mL Hyaluronidase, 160 BAEE/ mL trypsin inhibitor at pH 7.5 were prepared. Solutions were oxygenate prior to perfusion. Wash buffer containing Dulbecco's Modified Eagle Medium (DMEM) containing 4.5 gm/L D-glucose, 2 mM GlutMax-1, 0.2% BSA, 5% fetal bovine serum (FBS), 12 nM insulin, 1.2 µM hydrocortisone and DMEM+HS solution containing DMEM, 2 mM GlutMax-1, 20 nM delta-aminolevulinic acid, 17.4 mM MEM non-essential amino acids, 20% EBS, 12 nM insulin and 1.2 µM hydrocortisone was prepared. DMEM- solution containing DMEM, 2 mM GlutMax-1, 20 nM delta-aminolevulinic acid and 17.4 mM MEM non-essential amino acids were prepared. Male Sprague-Dawley rats weighing 125-250 gms were maintained on a standard rodent chow diet and freely given water. On the evening prior to cell isolation, selected healthy animals were fed restricted. The rat was anesthetized with a 50 mg/kg intraperitoneal administration of sodium pentobarbital. Clotting was minimized with intraperitoneal administer of heparin at 1000 IU/kg body weight. The abdominal cavity was opened and the portal vein was surgical isolated. The angiocatheter was inserted into the portal vein at the general location of the lineal branch and connected to a perfusion pump, The in situ perfusion was performed at (~30 mL/min) with washout buffer, equilibrated with annosphere gases at a temperature of 37°C. The internal iliac artery was cut to allow pressure equilibration. The caustal area of the diaphragm was excised to provide access to the caudal vena cava and the aorta, using curved forceps both vessels were occluded. About

200 mL of buffer was needed to clear the liver. Digestion buffer was circulated at the same flow rate for about 7 minutes after the initial entry of digestion buffer into the liver. When the liver had significantly increased in size, and consistency, and started to leak perfusate the perfusion was discontinued. The liver was rinsed in situ with sterile saline and surgical removed from the animal to a sterile beaker. Additional digestion solution was dispensed into the beaker and cap with foil. The liver tissue was gently shaken using sterile forceps to free hepatocyte cells. Cells were filtered through presterilized stainless steels mesh sieves of pore sizes 250, 106 and 75 μm . Cells were diluted in with ice-cold wash buffer, pipetted successively to assist the disassociation of the cells and transferred to a 50 mL tube. The cells are centrifuged for about 4 minutes at 50 x g to form a loosely packed pellet. The supernatant is discarded and the pelleted cells were resuspend in ice-cold wash buffer. The washing procedure was repeated twice for a total of three washes. The final pellet was suspended in 50 mL of wash buffer and held on wet-ice. The viability and cell number was checked by diluting duplicate 100 μL aliquots of cell suspension with 400 μL of wash buffer and 500 μL of 0.4% trypan blue in isotonic buffer. The cell concentration was determined in several fields on the hemocytometer. The cell viability (those that exclude die) was 85% or greater. Cells were diluted in DMEM+HS to a final concentration to ensure plating at a density of 150,000 cells/ cm^2 on collagen coated 6- or 12-well plates. Four hours after plating change the media was changed with DMEM- and culture overnight. Solutions of lovastatin, and illustrative compounds were prepared at 30 mM with DMSO. To obtain a compound solution mixtures were vortexed and sonicated.

To evaluate the effect of reference and illustrative compounds on saponified and non-saponified lipid synthesis, the monolayer cultures were exposed to compounds formulated in DMEM- containing ^{14}C -acetate. All cells were exposed to 1% DMSO.

Metabolic labeling with ^{14}C -acetate continued for 4 hr at 37°C. After labeling, cells were washed twice with 1 mL of PBS followed by lysing in 1 mL deionized water. Cells were scraped from the dishes and transferred to glass tubes at which point they were sonicated. 2.5 mL of 2:1 chloroform/methanol mixture was added followed by 1.5 mL of Phosphate Buffered Saline (PBS). To correct for extraction efficiency in the upcoming extractions, 3000 dpm of ^3H -cholesterol was added to each tube. Tubes were shaken for 30 min. to extract lipids into the organic phase followed by centrifugation for 10 minutes at 1000 x g to separate the organic and aqueous phases. The lower organic phase containing total lipids was removed and placed in a new tube. The organic solution was evaporated under N_2 . Resuspend the dry lipid extract in 1 ml. of 93% ethanol containing 1 M KOH and placed at 70°C for 2.5 hours. After the reaction and cooling, 2 mL of hexane and 2.5 mL of water was

added to each tube followed by rigorous shaking for 10 min. Tubes were centrifuged for 10 mm at 1000 x g and the organic (top) layer containing the non-saponified lipids was transferred to a new tube followed by evaporation of the organic solvent under N₂. The aqueous phase containing the saponified lipids was also transferred to a new tube. The non-saponified lipid extract, after drying, was suspended in toluene and an aliquot added to scintillation cocktail followed by radioactive counting. ¹⁴C counts representing the incorporation of ¹⁴C acetate into non-saponified lipids was corrected by the ³H counts, which represented the extraction efficiency of the procedure as, noted above by the addition of ³H cholesterol. To isolate saponified lipids, 1.5 mL of aqueous phase solution was mixed with 400ul of 1M HCl and then lipids extracted by the addition of 2.5 mL of 2:1 chloroform:methanol, 1.5 ml. of PBS, and 1 mL of water followed by rigorous shaking and isolation of the organic phase. Resuspend the N₂ dried organic phase extraction in toluene, and measure radioactivity using liquid scintillant method. The rate of ¹⁴C-acetate incorporation into saponified and non-saponified lipids is reported.

Figure 5 shows the rates of saponified, non-saponified lipid synthesis following treatment with lovastatin and illustrative compounds of the invention. Data are represented as a percent of no compound treatment (Vehicle control). Data are represented as the mean of three measurements +/- one standard deviation. The data indicate that the illustrative compounds of the invention are useful for inhibition of lipid synthesis. In particular, compound A at 30 µM reduced the rates of both saponifiable and non-saponifiable lipid synthesis by at least 97% in the rat hepatocyte cells. Compound B also reduced the rates of both saponified and non-saponified lipids by at least 65% in the rat hepatocyte cells. Accordingly, Compounds A and B, or a pharmaceutically acceptable salt thereof, is useful for inhibiting the synthesis of saponified lipids.

25

5.6. Cytotoxicity

To evaluate cytotoxicity, monolayer hepatocyte cultures are exposed to increasing concentrations of up to 250 µM Compound A in DMEM for 24 hours. Control cells are exposed to the same media lacking a test compound. All cells are exposed to 0.1% DMSO. The measure of cytotoxicity, release of lactate dehydrogenase (LDH) from the cytosolic compartment of hepatocyte monolayer cultures, reflects damage to the plasma membrane. The assay, is based on the method of Wroblewski and LaDue, 1955, *Proc. Soc. Exp. Biol. Med.* 90:210-213; see also Ulrich *et al.*, 1995, *Toxicol. Lett.* 82/83:107-115, describing the use of hepatocytes as models for hepatic toxicity), and measures the LDH activity in tissue culture medium and a cell homogenate. Briefly, all the media are removed from plates and

35

transferred to a separate plate. Following removal of media, attached cells are lysed with a hypotonic Tris/Glycerol/EDTA buffer (0.1 M Tris, 20% glycerol, 1 mM EDTA pH 7.3). Activity of LDH in medium and cells is measured spectrophotometrically by monitoring the rate of pyruvate reduction to lactate, coupled with oxidation of NADH; the rate of absorbance change is measured at 340 nm. Cytotoxicity is expressed as a ratio using the following equation: $(\text{LDH in medium} / (\text{LDH in medium} + \text{LDH in solubilized hepatocytes})) = R$.

10

5.7. Insulin Sensitization Effects

Effects of Compound A on rate of differentiation of 3T3-L1 cells from a “committed pre-adipocyte” to an “adipocyte” phenotype in the absence or presence of insulin can be tested. The differentiation of 3T3-L1 cells to an adipocyte-like phenotype is highly dependent upon insulin. This insulin-dependent changes in cellular morphology and metabolism, including: expression of adipocyte-specific genes, greatly increased levels of glucose uptake and metabolism, induction of GLUT4 (and increased expression of GLUT1) glucose transporters, greatly increased lipid synthesis and deposition of intracellular lipid droplets. In this assay the degree of differentiation is a reflection of the rate of lipid synthesis, as measured through incorporation of ^{14}C -acetate over 2 hours. Thus the ability of a compound to stimulate a submaximal insulin response would suggest an insulin-sensitizing activity (Kletzein *et al.*, 1991, *Molecular Pharm.* 41:393-398).

3T3-L1 stem cells are induced to differentiate with dexamethasone, isobutylmethylxanthine and insulin (Green and Kehinde, 1975, *Cell* 5:19-27). Cells are plated in Dulbecco’s modified Eagle medium containing 10% calf serum and grown to confluence. Cells are then refreshed with 10% fetal calf serum, and treated with 0.5 mM isobutylmethylxanthine and 250 nM dexamethasone, but no additional insulin, for 48 hours. This treatment induces the differentiation of 3T3-L1 cells into pre-adipocytes. Conversion of preadipocytes to adipocyte phenotype requires the removal of dexamethasone and the presence of insulin, which stimulates differentiation of preadipocytes into adipocytes in a concentration- and time-dependent manner. A maximal insulin effect occurs at about 100 nM insulin, and leads to nearly complete (95-100%) conversion to adipocytes within 4 days.

The preadipocytes are then treated for 4 days with various concentrations of a test compound in 5% fetal calf serum in Dulbecco's modified Eagles medium, with or without a submaximal concentration of insulin (30 nM). Following this four-day treatment, the predipocytes are pulsed with 0.1 mCi ^{14}C -acetate per well for 2 hours. Cell are then washed
5 with phosphate buffered saline, lysed with 0.1 N NaOH, and ^{14}C -acetate incorporation into lipids is determined using phase separation and liquid scintillation counting.

5.8. *In Vivo* Test Results

Compound A was administered daily at a dose of 100 mg/kg to chow-fed male
10 Sprague-Dawley rats for 7 days in the morning by oral gavage in 1.5 percent carboxy-methylcellulose/0.2 percent tween-20 (dosing vehicle). Animals were weighed daily. Animals were allowed free access to rodent chow and water throughout the study period. After the seventh dose, animals were sacrificed in the evening and blood serum was assayed for lipoprotein cholesterol profiles (Figure 2), serum total cholesterol and serum
15 triglycerides (Figure 3). Values for VLDL, LDL and HDL cholesterol, and the ratio of HDL cholesterol to that of VLDL plus LDL cholesterol (Figure 3) were derived from the lipoprotein cholesterol profile (*i.e.*, Figure 2) and the independently determined total cholesterol value (Figure 3). Lipoprotein cholesterol profiles (Figure 2) shows treatment with Compound A results in a 72 percent reduction in VLDL cholesterol ($p < 0.0005$), an 88
20 percent reduction of LDL cholesterol ($p < 0.0001$), and a non-significant 3 percent increase of HDL cholesterol when compared to animals treated with the dosing vehicle alone. Compound A treatment also reduces total serum cholesterol by 30 percent ($p < 0.0005$) and serum triglycerides by 64 percent ($p < 0.0005$) (Figure 2). The change in total cholesterol as reflected by the reduction in VLDL plus LDL cholesterol and the slight elevation in HDL
25 cholesterol resulted in a HDL to VLDL plus LDL cholesterol ratio from 1.7 ± 0.1 (control) to 17.0 ± 6.9 (Compound A treated); a 9.9 fold improvement in the ratio (Figure 2). Compared to pretreatment body weights, Compound A caused a reduction in body weight gain (30.4 ± 0.6 percent weight gain) compared to the control group (34.3 ± 0.7 percent weight gain) after seven days.

30 Dosing vehicle or Compound A (93 mg/kg) was administered to 9-10 week old female obese Zucker rats (*i.e.* the *fa/fa* or leptin receptor deficient rat) daily for 14 days in the morning by oral gavage in 1.5 percent carboxymethylcellulose/0.2 percent tween-20. Tail vein blood for glucose determinations (without anesthesia) and orbital blood samples for serum (with anesthehesia for all other determinations) were obtained following a 6 hour
35 fast prior to the initial dose and after one and two weeks of dosing.

Blood serum were assayed for insulin, non-esterified fatty acids, β -hydroxy butyrate, total cholesterol, and triglycerides (Figure 5). Glucose was determined in whole blood (Figure 5). Blood serum was also used to produce lipoprotein cholesterol profiles (Figure 4), and used to determine VLDL plus LDL cholesterol combined (also referred to as apoB containing lipoprotein cholesterol or non-HDL cholesterol), HDL cholesterol, and the ratio of HDL cholesterol to that of VLDL plus LDL cholesterol (Figure 5). In addition, the effect of Compound A on weight gain after 14 days and the liver to body weight ratio at sacrifice are shown in Figure 5.

In the Zucker rat. Compound A increased total serum cholesterol by 33, and 79 percent after one and two weeks of treatment, respectively. Vehicle treatment resulted in only a -10 and 10 change of total serum cholesterol after one and two weeks of treatment, respectively (Figure 5). Serum triglycerides were reduced by 60 and 62 percent with ESP31015 treatment after one and two weeks of treatment (Figure 5).

Lipoprotein cholesterol profiles shows treatment with Compound A resulted in a marked alteration in the distribution of cholesterol among lipoproteins (Figure 4). In particular, Compound A caused a marked elevation in HDL cholesterol after one week of treatment, which was further elevated after two weeks of treatment. Using the serum total cholesterol values (Figure 5) and the lipoprotein cholesterol distribution (Figure 4), the amount of cholesterol associated with non-HDL (i.e. VLDL plus LDL cholesterol) and HDL cholesterol were determined (Figure 5). Compound A decreased non-HDL cholesterol by 58 and 27 percent, and markedly increased HDL cholesterol 2.3-fold and 3.2-fold after one and two weeks treatment, respectively. When these data are expressed as a ratio of HDL/non-HDL cholesterol, it can be clearly seen Compound A markedly improves the ratio from 0.83 (pretreatment) to 2.97 and 3.45 after one-week and two-weeks of treatment, respectively.

Impaired glucose tolerance is the metabolic symptom beginning at about 8-12 weeks of age in obese female Zucker rats and therefore the animals are able to maintain normal glucose levels at the expense of elevated insulin levels. As shown in Figure 5, pretreatment and posttreatment blood glucose levels were similar after one and two weeks of Compound A treatment. An indication of an improved diabetic state is the reduction of non-esterified fatty acids from 2.51 to 0.77 mmol/L after two weeks of Compound A coupled to an elevation in β -hydroxy butyrate. These data may reflect an enhanced hepatic β -oxidation of excess fatty acids resulting from the reduction of serum non-esterified fatty acids and triglycerides (Figure 5). Compound A treatment did not induce a hypoglycemic state.

The present invention is not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the invention and any embodiments which are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the appended claims.

10


15

THE CLAIMS

What is claimed is:

20

1. A compound of a formula **I**:




I

25 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:


(a) each occurrence of Z is independently CH₂, CH=CH, or phenyl, where each occurrence of m is independently an integer ranging from 1 to 9, but when Z is phenyl then its associated m is 1;

30

- (b) G is $(\text{CH}_2)_x$, $\text{CH}_2\text{CH}=\text{CHCH}_2$, $\text{CH}=\text{CH}$, CH_2 -phenyl- CH_2 , or phenyl, where x is 2, 3, or 4;
- (c) W^1 and W^2 are independently L, V, $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_c-\text{C}(\text{R}^3)(\text{R}^4)-(\text{CH}_2)_n-\text{Y}$, or $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_c-\text{V}$ where c is 1 or 2 and n is an independent integer ranging from 0 to 4;
- (d) each occurrence of R^1 or R^2 is independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl or when one or both of W^1 and W^2 is $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_c-\text{C}(\text{R}^3)(\text{R}^4)-(\text{CH}_2)_n-\text{Y}$, then R^1 and R^2 can both be H to form a methylene group;
- (e) R^3 is H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_1-C_6) alkoxy, phenyl, benzyl, Cl, Br, CN, NO_2 , or CF_3 ;
- (f) R^4 is OH, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_1-C_6) alkoxy, phenyl, benzyl, Cl, Br, CN, NO_2 , or CF_3 ;
- (g) L is $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_n-\text{Y}$ where n is an independent integer ranging from 0 to 4;
- (h) V is



- (i) each occurrence of Y is independently OH, COOH, CHO, COOR⁵, SO₃H,



5

where

- (i) R⁵ is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C₁-C₆)alkoxy, or phenyl groups,

10

(ii) each occurrence of R^6 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, (C_1-C_6) alkoxy, or phenyl groups, and

5 (iii) each occurrence of R^7 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;

provided that:

- 10 (i) if G is $(CH_2)_x$, x is 4, each occurrence of Z is CH_2 , each occurrence of m is 4, and W^1 is $-CH(CH_3)CO_2H$, then W^2 is not the same as W^1 ;
- (ii) if G is CH_2 -phenyl- CH_2 , each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(CH_3)_2CH(CO_2CH_2CH_3)_2$, then W^2 is not the same as W^1 ;
- 15 (iii) if G is CH_2 -phenyl- CH_2 , each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(CH_3)_2CH_2(CO_2CH_2CH_3)$, then W^2 is not the same as W^1 ;
- (iv) if G is CH_2 -phenyl- CH_2 , each occurrence of Z is CH_2 , each occurrence of m is 1, and W^1 is $-COCH_2C(CH_3)_2CH_2CO_2H$, then W^2 is not the same as W^1 ;
- 20 (v) if G is $(CH_2)_x$, x is 4, each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(phenyl)_2CH_2CO_2H$, then W^2 is not the same as W^1 ;
- (vi) if G is $CH=CH$, each occurrence of Z is CH_2 , each occurrence of m is 1, and W^1 is $-C(CH_3)_2CH_2(CO_2H)$, then W^2 is not the same as W^1 ; and
- 25 (vii) if G is phenyl, each occurrence of Z is CH_2 , each occurrence of m is 1, and W^1 is $-C(phenyl)_2CO_2H$, then W^2 is not the same as W^1 .

30


2. The compound of claim 1, wherein:

- (a) W^1 and W^2 are independently L, V, or $C(R^1)(R^2)-(CH_2)_c-V$ where c is 1 or 2; and
- (b) R^1 or R^2 are independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl.
- 35

3. The compound of claim 1, wherein W^1 is L.
4. The compound of claim 1, wherein W^1 is V.
5. The compound of claim 1, wherein W^1 is $C(R^1)(R^2)-(CH_2)_c-C(R^3)(R^4)-(CH_2)_n-Y$.
6. The compound of claim 1, wherein W^1 is $C(R^1)(R^2)-(CH_2)_c-V$.
7. The compound of claim 1, wherein W^1 and W^2 are independent L groups.
8. The compound of claim 7, wherein each occurrence of Y is independently OH, $COOR^5$, or COOH.

15

9. A compound of the formula **Ia**:

**Ia**

20

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:


- (a) each occurrence of Z is independently CH_2 or $CH=CH$, where each occurrence of m is independently an integer ranging from 1 to 9;
- (b) G is $(CH_2)_x$, $CH_2CH=CHCH_2$, or $CH=CH$, where x is 2, 3, or 4;
- (c) W^1 and W^2 are independently L, V, or $C(R^1)(R^2)-(CH_2)_c-V$ where c is 1 or 2;

30

where:

5

(i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,



10

(ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, (C_1-C_6) alkoxy, or phenyl groups, and

(iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;

provided that:

15

(i) if x is 4, each occurrence of Z is CH_2 , each occurrence of m is 4, and W^1 is $-CH(CH_3)CO_2H$, then W^2 is not the same as W^1 ; and

(ii) if x is 4, each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(phenyl)_2CH_2CO_2H$, then W^2 is not the same as W^1 .

20

10. The compound of claim 9, wherein W^1 is L.

11. The compound of claim 9, wherein W^1 is V.


12. The compound of claim 9, wherein W^1 is $C(R^1)(R^2)-(CH_2)_c-V$.

13. The compound of claim 9, wherein W^1 and W^2 are independent L groups.

5 14. The compound of claim 13, wherein each occurrence of Y is independently OH, $COOR^3$, or COOH.

15. A compound of the formula **Ib**

10



Ib

15 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:


(a) each occurrence of m is independently an integer ranging from 1 to 9;


20 (b) x is 2, 3, or 4;

(c) each occurrence of n is independently an integer ranging from 0 to 4;

25 (d) each occurrence of R^1 or R^2 is independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl; and

(e) each occurrence of Y is independently OH, COOH, CHO, $COOR^3$, SO_3H ,





where:

- 5 (i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- 10 (ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups; and
- (iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;

15 provided that:


- (i) if x is 4 each occurrence of m is 4, and W^1 is $-\text{CH}(\text{CH}_3)\text{CO}_2\text{H}$, then W^2 is not the same as W^1 ; and
- (ii) if x is 4 occurrence of m is 2, and W^1 is $-\text{C}(\text{phenyl})_2\text{CH}_2\text{CO}_2\text{H}$, then W^2 is not the same as W^1 .

5

16. The compound of claim 15, wherein each occurrence of Y is independently OH, COOR^3 , or COOH.


10 17. The compound of claim 16, wherein each R^1 or R^2 is the same or different (C_1-C_6) alkyl group.

18. A compound of the formula **Ic**



15 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

- (a) each occurrence of m is an independent integer ranging from 1 to 9;
- 20 (b) x is 2, 3, or 4;
- 25 (c) V is



provided that:

- (i) if x is 4 each occurrence of m is 4, and W^1 is $-\text{CH}(\text{CH}_3)\text{CO}_2\text{H}$, then W^2 is not the same as W^1 ; and

5


- (ii) if x is 4 each occurrence of m is 2, and W^1 is $-C(\text{phenyl}), CH_2, CO, H$, then W^2 is not the same as W^1 .

19. A compound according to claim 1, having the formula

5-[2-(5-hydroxy-4,4-dimethyl-pentyloxy)-ethoxy]-2,2-dimethyl-pentan-1-ol or

10 4-[3-(3,3-Dimethyl-4-oxo-butoxy)-propoxy]-2,2-dimethyl-butyric acid.

20. A compound of the formula **II**:




II

15

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:


- (a) R^1 and R^2 are independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl; or R^1 , R^2 , and the carbon to which they are both attached are taken together to form a (C_3-C_7) cycloalkyl group;
- 5 (b) n is an integer ranging from 1 to 5;
- (c) each occurrence of m is independently an integer ranging from 0 to 4;
- (d) each occurrence of W^1 and W^2 is independently CH_2OH , $COOH$, CHO , $OC(O)R^3$,
 10 $C(O)OR^3$, SO_3H ,



where:

(i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,

(ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted




with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups,

(iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl; and

(iv) each occurrence of n is independently an integer ranging from 0 to 4.


21. A compound of the formula **IIa**:



IIa

5 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

(a) R^1 and R^2 are OH, COOH, CHO, COOR⁷, SO₃H,



10

where:

(i) R^7 is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C₁-C₆)alkoxy, or phenyl groups,

15

(ii) each occurrence of R^8 is independently H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, or (C₂-C₆)alkynyl and is unsubstituted or substituted with one or two halo, OH, C₁-C₆ alkoxy, or phenyl groups,

(iii) each occurrence of R^9 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;

- 5 (b) R^3 and R^4 are (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl;
- (c) R^5 and R^6 are hydrogen, halogen, (C_1-C_4) alkyl, (C_1-C_4) alkoxy, (C_6) aryloxy, CN, or NO_2 , $N(R^5)_2$ where R^5 is H, (C_1-C_4) alkyl, phenyl, or benzyl;
- 10 (d) each occurrence of m is independently an integer ranging from 1 to 5;
- (e) each occurrence of n is independently an integer ranging from 0 to 4; and
- (f) C^{*1} and C^{*2} each represent independent chiral-carbon centers, wherein each center may independently be R or S.

15


22. The compound of claim 21 wherein C^{*1} is a chiral-carbon center of the stereochemical configuration R or substantially R.

20 23. The compound of claim 21 wherein C^{*1} is a chiral-center of the stereochemical configuration S or substantially S.

24. The compound of claim 21 wherein C^{*2} is a chiral-carbon center of the stereochemical configuration R or substantially R.


25 25. The compound of claim 21 wherein C^{*2} is a chiral-center of the stereochemical configuration S or substantially S.

26. A compound of the formula **III**:





**III**

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

- 5 (a) each occurrence of Z is independently CH₂, CH=CH, or phenyl, where each occurrence of m is independently an integer ranging from 1 to 5, but when Z is phenyl then its associated m is 1;
- 10 (b) G is (CH₂)_x, CH₂CH=CHCH₂, CH=CH, CH₂-phenyl-CH₂, or phenyl, where x is an integer ranging from 1 to 4;
- (c) W¹ and W² are independently C(R¹)(R²)-(CH₂)_n-Y where n is an independent integer ranging from 0 to 4;



- 15 (d) each occurrence of R¹ or R² is independently (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl, or where R¹ and R² are both hydrogen;
- (e) each occurrence of R⁶ and R⁷ are independently H, (C₁-C₆)alkyl, or where R⁶ and R⁷ are taken together to form a carbonyl group;
- 20 (f) each occurrence of Y is independently OH, COOH, CHO, COOR³, SO₃H,



where:

5

(i) R³ is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C₁-C₆)alkoxy, or phenyl groups,

10

(ii) each occurrence of R⁴ is independently H, (C₁–C₆)alkyl, (C₂–C₆)alkenyl, or (C₂–C₆)alkynyl and is unsubstituted or substituted with one or two halo, OH, C₁–C₆alkoxy, or phenyl groups,

(iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl, and

- 5 (g) each occurrence of p is independently 0 or 1 where the broken line represents an optional presence of one or more additional carbon-carbon bonds that when present complete one or more carbon-carbon double bonds.

10 27. The compound of claim 26, wherein W^1 and W^2 are independent $C(R^1)(R^2)-(CH_2)_n-Y$ groups, where n is an independent integer ranging from 0 to 4, and each occurrence of Y is independently OH, $COOR^4$, or COOH.


28. The compound of claim 26, wherein p is 0.

29. The compound of claim 26, wherein p is 1.

15

30. The compound of claim 26 wherein each occurrence of R_6 and R_7 is hydrogen;

31. A compound of the formula **IIIa**:



IIIa

20


or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

25


(a) each occurrence of m is independently an integer ranging from 1 to 5;


(b) x is an integer ranging from 1 to 4;

(c) W^1 and W^2 are independently $C(R^1)(R^2)-(CH_2)_n-Y$ where n is an integer from 0 to 4,



- (d) each occurrence of R¹ or R² is independently (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl;
- 5 (e) each occurrence of Y is independently OH, COOH, CHO, COOR³, SO₃H,





where

(i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,

(ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups,

(iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl, and

(f) each occurrence of p is independently 0 or 1.

32. The compound of claim 31, wherein W^1 and W^2 are independent $C(R^1)(R^2)-(CH_2)_n-Y$ groups, and each occurrence of Y is independently $-(CH_2)_nOH$, $-(CH_2)_nCOOR^3$, or $-(CH_2)_nCOOH$.

33. The compound of claim 31, wherein p is 0.

34. The compound of claim 31, wherein p is 1.

35. A compound having the formula:

- I-1** 5-Hydroxy-1-[4-(5-hydroxy-5-methyl-2-oxo-hexyl)-phenyl]-5-methyl-hexan-2-one;
- 5 I-2** 6-Hydroxy-1-[4-(6-hydroxy-5,5-dimethyl-2-oxo-hexyl)-phenyl]-5,5-dimethyl-hexan-2-one;
- I-3** 6-[4-(5-Carboxy-5-methyl-2-oxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanoic acid;
- 10 I-4** 6-[4-(5,5-Dimethyl-2,6-dioxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanal;
- I-5** 6-[4-(5-Methoxycarbonyl-5-methyl-2-oxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanoic acid methyl ester;
- 15 I-6** 2,2-Dimethyl-6-[4-(5-methyl-2-oxo-5-phenoxy-carbonyl-hexyl)-phenyl]-5-oxo-hexanoic acid phenyl ester;
- I-7** 6-[4-(5-Benzoyloxycarbonyl-5-methyl-2-oxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanoic acid benzyl ester;
- 20 I-8** 2-Methyl-6-[4-(5-methyl-2-oxo-5-sulfo-hexyl)-phenyl]-5-oxo-hexane-2-sulfonic acid;
- I-9** Phosphoric acid mono-{1,1-dimethyl-5-[4-(5-methyl-2-oxo-5-phosphonooxy-hexyl)-phenyl]-4-oxo-pentyl} ester;
- 25 I-10** 4-Hydroxy-1-[4-(4-hydroxy-4-methyl-pentanoyl)-phenyl]-4-methyl-pentan-1-one;
- I-11** 5-Hydroxy-1-[4-(5-hydroxy-4,4-dimethyl-pentanoyl)-phenyl]-4,4-dimethyl-pentan-1-one;
- 30 I-12** 5-[4-(4-Carboxy-4-methyl-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanoic acid;
- I-13** 5-[4-(4,4-Dimethyl-5-oxo-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanal;
- 35 I-14** 5-[4-(4-Methoxycarbonyl-4-methyl-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanoic acid methyl ester;
- I-15** 2,2-Dimethyl-6-[4-(5-methyl-2-oxo-5-phenoxy-carbonyl-hexyl)-phenyl]-5-oxo-hexanoic acid phenyl ester;
- 40 I-16** 5-[4-(4-Benzoyloxycarbonyl-4-methyl-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanoic acid benzyl ester;
- 45 I-17** 2-Methyl-5-[4-(4-methyl-4-sulfo-pentanoyl)-phenyl]-5-oxo-pentane-2-sulfonic acid;
- I-18** Phosphoric acid mono-{1,1-dimethyl-4-[4-(4-methyl-4-phosphonooxy-pentanoyl)-phenyl]-4-oxo-butyl} ester;
- 50 Ib-1** 2,12-Dihydroxy-2,12-dimethyl-tridecane-5,9-dione;

- Ib-2** 1,13-Dihydroxy-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-3** 2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid;
- 5 **Ib-4** 2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedial;
- Ib-5** 2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid dimethyl ester;
- 10 **Ib-6** 2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid diphenyl ester;
- Ib-7** 2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid dibenzyl ester;
- Ib-8** 2,12-Dimethyl-5,9-dioxo-tridecane-2,12-disulfonic acid;
- 15 **Ib-9** Phosphoric acid mono-(1,1,11-trimethyl-4,8-dioxo-11-phosphonooxy-dodecyl) ester;
- Ib-10** 2,12-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,12-dimethyl-tridecane-5,9-dione;
- 20 **Ib-11** 2,12-Bis-(4,6-dithio-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,12-dimethyl-tridecane-5,9-dione;
- Ib-12** 2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid dicyanamide
- 25 **Ib-13** Phosphoramidic acid mono-[11-(amino-hydroxy-phosphoryloxy)-1,1,11-trimethyl-4,8-dioxo-dodecyl] ester;
- Ib-14** 2,12-Dimethyl-2,12-bis-(amino-hydroxy-phosphoryloxy)-tridecane-5,9-dione;
- 30 **Ib-15** 2,12-Dimethyl-2,12-bis-tetrazol-1-yl-tridecane-5,9-dione;
- Ib-16** 2,12-Dimethyl-2,12-bis-(1*H*-tetrazol-5-yl)-tridecane-5,9-dione;
- Ib-17** 2,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,12-dimethyl-tridecane-5,9-dione;
- 35 **Ib-18** 2,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,12-dimethyl-tridecane-5,9-dione;
- Ib-19** 2,12-Bis-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-2,12-dimethyl-tridecane-5,9-dione;
- 40 **Ib-20** 2,12-Bis-(5-hydroxy-4-oxo-4*H*-pyran-2-yl)-2,12-dimethyl-tridecane-5,9-dione;
- Ib-21** 1-Ethyl-3-[11-(3-ethyl-2,5-dithio-2-oxo-imidazolidin-1-yl)-1,1,11-trimethyl-4,8-dioxo-dodecyl]-imidazolidine-2,4-dione;
- 45 **Ib-22** 2,12-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,12-dimethyl-tridecane-5,9-dione;
- Ib-23** 2,12-Bis-(3-ethyl-5-oxo-2-thio-2-oxo-imidazolidin-1-yl)-2,12-dimethyl-tridecane-5,9-dione;
- 50 **Ib-24** 2,12-Bis-(3-ethyl-2-oxo-5-thio-2-oxo-imidazolidin-1-yl)-2,12-dimethyl-tridecane-5,9-dione;

- Ib-25** 1,15-Dihydroxy-3,3,13,13-tetramethyl-pentadecane-6,10-dione;
- Ib-26** 3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedioic acid;
- 5 **Ib-27** 3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedial;
- Ib-28** 3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedioic acid dimethyl ester;
- 10 **Ib-29** 2,2,12,12-Tetramethyl-5,9-dioxo-tetradecanedioic acid diphenyl ester;
- Ib-30** 3,3,13,13-Tetramethyl-6,10,14-trioxo-16-phenyl-hexadecanoic acid benzyl ester;
- Ib-31** 2,2,12,12-Tetramethyl-5,9-dioxo-tridecane-1,13-disulfonic acid;
- 15 **Ib-32** Phosphoric acid mono-(2,2,12,12-tetramethyl-5,9-dioxo-13-phosphonoxy-tridecyl) ester;
- Ib-33** 1,13-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- 20 **Ib-34** 1,13-Bis-(4,6-dithio-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-35** 3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedioic acid dicyanimide
- 25 **Ib-36** Phosphoramidic acid mono-[13-(amino-hydroxy-phosphoryloxy)-2,2,12,12-tetramethyl-6,9-dioxo-tridecyl] ester;
- Ib-37** Phosphoramidic acid mono-[11-(amino-hydroxy-phosphoryloxy)-1,1,11-trimethyl-4,8-dioxo-dodecyl] ester;
- 30 **Ib-38** 2,2,12,12-Tetramethyl-1,13-bis-tetrazol-1-yl-tridecane-5,9-dione;
- Ib-39** 1,13-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- 35 **Ib-40** 1,13-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-41** 1,13-Bis-(3-hydroxy-isoxazol-4-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- 40 **Ib-42** 1-(5-Hydroxy-4-oxo-4*H*-pyran-3-yl)-13-(5-hydroxy-4-oxo-4*H*-pyran-2-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-43** 1,13-Bis-(5-hydroxy-4-oxo-4*H*-pyran-2-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- 45 **Ib-44** 1,13-Bis-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-45** 1-Ethyl-3-[13-(3-ethyl-2,5-dithio-2-imidazolidin-1-yl)-2,2,12,12-tetramethyl-5,9-dioxo-tridecyl]-imidazolidine-2,4-dione;
- 50

- Ib-46** 1,13-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- 5 **Ib-47** 1,13-Bis-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-48** 1,13-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- 10 **Ib-49** 1,13-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-50** 2,11-Dihydroxy-2,11-dimethyl-dodecane-5,8-dione;
- 15 **Ib-51** 1,12-Dihydroxy-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- Ib-52** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid;
- Ib-53** 2,11-Dimethyl-5,8-dioxo-dodecane-2,11-disulfonic acid;
- 20 **Ib-54** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedial;
- Ib-55** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dimethyl ester;
- 25 **Ib-56** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid diphenyl ester;
- Ib-57** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dibenzyl ester;
- Ib-58** Phosphoric acid mono-(1,1,10-trimethyl-4,7-dioxo-10-phosphonooxy-undecyl) ester;
- 30 **Ib-59** 2,14-Dihydroxy-2,14-dimethyl-pentadecane-6,10-dione;
- Ib-60** 1,15-Dihydroxy-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- 35 **Ib-61** 2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedioic acid;
- Ib-62** 2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedial;
- Ib-63** 2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedioic acid dimethyl ester;
- 40 **Ib-64** 2,2,14,14-Tetramethyl-6,10-dioxo-hexadecanedioic acid diphenyl ester;
- Ib-65** 2,2,14,14-Tetramethyl-6,10-dioxo-hexadecanedioic acid dibenzyl ester;
- 45 **Ib-66** 2,14-Dimethyl-6,10-dioxo-pentadecane-2,14-disulfonic acid;
- Ib-67** Phosphoric acid mono-(1,1,13-trimethyl-5,9-dioxo-13-phosphonooxy-tetradecyl) ester;
- 50 **Ib-68** 2,14-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,14-dimethyl-pentadecane-6,10-dione;

- Ib-69** 2,14-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- 5 **Ib-70** 2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedioic acid dicyanimide
- Ib-71** Phosphoramidic acid mono-[13-(amino-hydroxy-phosphoryloxy)-1,1,13-trimethyl-5,9-dioxo-tetradecyl] ester;
- 10 **Ib-72** 2,14-Dimethyl-2,14-bis-(amino-hydroxy-phosphoryloxy)-pentadecane-6,10-dione;
- Ib-73** 2,14-Dimethyl-2,14-bis-tetrazol-1-yl-pentadecane-6,10-dione;
- Ib-74** 2,14-Dimethyl-2,14-bis-(1*H*-tetrazol-5-yl)-pentadecane-6,10-dione;
- 15 **Ib-75** 2,14-Bis-(3-hydroxy-isoxazol-5-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- Ib-76** 2,14-Bis-(3-hydroxy-isoxazol-4-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- 20 **Ib-77** 2,14-Bis-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- Ib-78** 2-(5-Hydroxy-4-oxo-4*H*-pyran-2-yl)-2,14-dimethyl-14-(5-methyl-4-oxo-4*H*-pyran-2-yl)-pentadecane-6,10-dione;
- 25 **Ib-79** 2,14-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- Ib-80** 2,14-Bis-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- 30 **Ib-81** 2,14-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- Ib-82** 2,14-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- 35 **Ib-83** 1,14-Dihydroxy-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- Ib-84** 3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid;
- Ib-85** 3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedial;
- 40 **Ib-86** 3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid dimethyl ester;
- Ib-87** 3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid diphenyl ester;
- 45 **Ib-88** 3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid dibenzyl ester;
- Ib-89** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecane-1,12-disulfonic acid;
- 50 **Ib-90** Phosphoric acid mono-(2,2,11,11-tetramethyl-5,8-dioxo-12-phosphonooxy-dodecyl) ester;

- Ib-91** 1,12-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- 5 **Ib-92** 1,12-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dithione;
- Ib-93** 3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid dicyanimide
- 10 **Ib-94** Phosphoramidic acid mono-[12-(amino-hydroxy-phosphoryloxy)-2,2,11,11-tetramethyl-5,8-dioxo-dodecyl] ester;
- Ib-95** 2,2,11,11-Tetramethyl-1,12-bis-(aminohydroxyphosphoryloxy)-dodecane-5,8-dione;
- 15 **Ib-96** 2,2,11,11-Tetramethyl-1,12-bis-(1*H*-tetrazol-5-yl)-dodecane-5,8-dione;
- Ib-97** 1,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- Ib-98** 1,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- 20 **Ib-99** 1-(5-Hydroxy-4-oxo-4*H*-pyran-3-yl)-12-(5-hydroxy-4-oxo-4*H*-pyran-2-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- Ib-100** 1,12-Bis-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- 25 **Ib-101** 1,12-Bis-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- Ib-102** 1-Ethyl-3-[12-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-5,8-dioxo-dodecyl]-imidazolidine-2,4-dione;
- 30 **Ib-103** 1-Ethyl-3-[12-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-5,8-dioxo-dodecyl]-imidazolidine-2,4-dione;
- 35 **Ib-104** 1,12-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- Ib-105** 1,12-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- 40 **Ib-106** 1,16-Dihydroxy-4,4,13,13-tetramethyl-hexadecane-7,10-dione;
- Ib-107** 4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid;
- 45 **Ib-108** 4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedial;
- Ib-109** 4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid dimethyl ester;
- Ib-110** 4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid diphenyl ester;
- 50 **Ib-111** 4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid dibenzyl ester;

- Ib-112** 3,3,12,12-Tetramethyl-6,9-dioxo-tetradecane-1,14-disulfonic acid;
- Ib-113** Phosphoric acid mono-(3,3,12,12-tetramethyl-6,9-dioxo-14-phosphonooxy-tetradecyl) ester;
- 5 **Ib-114** 1,14-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- 10 **Ib-115** 1,14-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- Ib-116** 4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid dicyanamide
- 15 **Ib-117** Phosphoramidic acid mono-[14-(amino-hydroxy-phosphoryloxy)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl] ester;
- Ib-118** 3,3,12,12-Tetramethyl-1,14-bis-(amino-hydroxy-phosphoryloxy)-tetradecane-6,9-dione;
- 20 **Ib-119** 1,12-Dihydroxy-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- Ib-120** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid;
- Ib-121** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedial;
- 25 **Ib-122** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dimethyl ester;
- Ib-123** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid diphenyl ester;
- 30 **Ib-124** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dibenzyl ester;
- Ib-125** 2,11-Dimethyl-5,8-dioxo-dodecane-2,11-disulfonic acid;
- 35 **Ib-126** Phosphoric acid mono-(1,1,10-trimethyl-4,7-dioxo-10-phosphonooxy-undecyl) ester;
- Ib-127** 2,11-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,11-dimethyl-dodecane-5,8-dione;
- 40 **Ib-128** 2,11-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,11-dimethyl-dodecane-5,8-dione;
- Ib-129** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dicyanamide
- 45 **Ib-130** Phosphoramidic acid mono-[10-(amino-hydroxy-phosphoryloxy)-1,1,10-trimethyl-4,7-dioxo-undecyl] ester;
- Ib-131** 2,2,11,11-Tetramethyl-1,12-(amino-hydroxy-phosphoryloxy)-dodecane-5,8-dione;
- 50 **Ib-132** 3,3,12,12-Tetramethyl-1,14-bis-tetrazol-1-yl-tetradecane-6,9-dione;
- Ib-133** 3,3,12,12-Tetramethyl-1,14-bis-(1*H*-tetrazol-5-yl)-tetradecane-6,9-dione;

- Ib-134** 1,14-Bis-(3-hydroxy-isoxazol-5-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- Ib-135** 1,14-Bis-(3-hydroxy-isoxazol-4-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- 5 **Ib-136** 1-(5-Hydroxy-4-oxo-4*H*-pyran-2-yl)-14-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- Ib-137** 1,14-Bis-(5-hydroxy-4-oxo-4*H*-pyran-2-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- 10 **Ib-138** 1,14-Bis-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- 15 **Ib-139** 1-Ethyl-3-[14-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl]-imidazolidine-2,4-dione;
- Ib-140** 1-Ethyl-3-[14-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl]-imidazolidine-2,4-dione;
- 20 **Ib-141** 1-Ethyl-3-[14-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl]-imidazolidine-2,4-dithione;
- Ib-142** 1,14-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- 25 **Ib-143** 1,14-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- 30 **Ib-144** 1,17-Dihydroxy-3,3,15,15-tetramethyl-heptadecane-7,11-dione;
- Ib-145** 3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedial;
- Ib-146** 3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid dimethyl ester;
- 35 **Ib-147** 1,17-Dihydroxy-3,3,15,15-tetramethyl-heptadecane-7,11-dione;
- Ib-148** 3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid diphenyl ester;
- 40 **Ib-149** 3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid dibenzyl ester;
- Ib-150** 2,11-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,11-dimethyl-dodecane-5,8-dione;
- 45 **Ib-151** 2,11-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,11-dimethyl-dodecane-5,8-dione;
- Ib-152** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dicyanamide;
- 50 **Ib-153** Phosphoramidic acid mono-[10-(amino-hydroxy-phosphoryloxy)-1,1,10-trimethyl-4,7-dioxo-undecyl] ester;

- Ib-154** 2,11-Dimethyl-2,11-bis-(amino-hydroxy-phosphoryloxy)-dodecane-5,8-dione;
- Ib-155** 2,11-Dimethyl-2,11-bis-tetrazol-1-yl-dodecane-5,8-dione;
- 5 **Ib-156** 2,11-Dimethyl-2,11-bis-(1*H*-tetrazol-5-yl)-dodecane-5,8-dione;
- Ib-157** 2,2,14,14-Tetramethyl-6,10-dioxo-pentadecane-1,15-disulfonic acid;
- 10 **Ib-158** Phosphoric acid mono-(2,2,14,14-tetramethyl-6,10-dioxo-15-phosphonooxy-pentadecyl) ester;
- Ib-159** 1,15-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- 15 **Ib-160** 1,15-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- Ib-161** 3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid dicyanamide;
- 20 **Ib-162** Phosphoramidic acid mono-[16-(amino-hydroxy-phosphoryloxy)-4,4,15,15-tetramethyl-7,11-dioxo-hexadecyl] ester;
- Ib-163** 2,2,14,14-Tetramethyl-1,15-bis-(amino-hydroxy-phosphoryloxy)-pentadecane-6,10-dione;
- 25 **Ib-164** 2,2,14,14-Tetramethyl-1,15-bis-tetrazol-1-yl-pentadecane-6,10-dione;
- Ib-165** 2,2,14,14-Tetramethyl-1,15-bis-(1*H*-tetrazol-5-yl)-pentadecane-6,10-dione;
- 30 **Ib-166** 1,15-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- Ib-167** 1,15-Bis-(3-hydroxy-isoxazol-4-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- 35 **Ib-168** 1-(5-Hydroxy-4-oxo-4*H*-pyran-3-yl)-15-(5-hydroxy-4-oxo-4*H*-pyran-2-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- Ib-169** 1,15-Bis-(5-hydroxy-4-oxo-4*H*-pyran-2-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- 40 **Ib-170** 1,15-Bis-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- Ib-171** 1,15-Bis-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- 45 **Ib-172** 1-Ethyl-3-[15-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-6,10-dioxo-pentadecyl]-imidazolidine-2,4-dione;
- 50 **Ib-173** 1,15-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;

- Ib-174** 1,15-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- Ib-175** 1,15-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- Ic-1** 1,9-Bis-(tetrahydro-pyran-2-yloxy)-nonane-3,7-dione;
- Ic-2** 1,9-Bis-(4-oxo-oxetan-2-yl)-nonane-3,7-dione;
- Ic-3** 1,9-Bis-(2-oxo-oxetan-3-yl)-nonane-3,7-dione;
- Ic-4** 1,9-Bis-(5-oxo-tetrahydrofuran-2-yl)-nonane-3,7-dione;
- Ic-5** 1,9-Bis-(5-oxo-tetrahydrofuran-3-yl)-nonane-3,7-dione;
- Ic-6** 1,9-Bis-(2-oxo-tetrahydrofuran-3-yl)-nonane-3,7-dione;
- Ic-7** {2-[9-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-3,7-dioxo-nonyl]-4-hydroxy-6-oxo-tetrahydropyran-4-yl}-acetic acid;
- Ic-8** 1,9-Bis-(6-oxo-tetrahydropyran-2-yl)-nonane-3,7-dione;
- Ic-9** 1,9-Bis-(6-oxo-tetrahydropyran-3-yl)-nonane-3,7-dione;
- Ic-10** 1,9-Bis-(2-oxo-tetrahydropyran-4-yl)-nonane-3,7-dione;
- Ic-11** 1,9-Bis-(2-oxo-tetrahydropyran-3-yl)-nonane-3,7-dione;
- Ic-12** 1,11-Bis-(tetrahydro-pyran-2-yloxy)-undecane-4,8-dione;
- Ic-13** 1,11-Bis-(2-oxo-oxetan-3-yl)-undecane-4,8-dione;
- Ic-14** 1,11-Bis-(2-oxo-oxetan-3-yl)-undecane-4,8-dione;
- Ic-15** 1,11-Bis-(5-oxo-tetrahydrofuran-2-yl)-undecane-4,8-dione;
- Ic-16** 1,11-Bis-(5-oxo-tetrahydrofuran-3-yl)-undecane-4,8-dione;
- Ic-17** 1,11-Bis-(2-oxo-tetrahydrofuran-3-yl)-undecane-4,8-dione;
- Ic-18** {2-[11-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-4,8-dioxo-undecyl]-4-hydroxy-6-oxo-tetrahydropyran-4-yl}-acetic acid;
- Ic-19** 1,11-Bis-(6-oxo-tetrahydropyran-2-yl)-undecane-4,8-dione;
- Ic-20** 1,11-Bis-(6-oxo-tetrahydropyran-3-yl)-undecane-4,8-dione;
- Ic-21** 1,11-Bis-(2-oxo-tetrahydropyran-4-yl)-undecane-4,8-dione;
- Ic-22** 1,11-Bis-(2-oxo-tetrahydropyran-3-yl)-undecane-4,8-dione;

- Ic-23** 1,8-Bis-(tetrahydropyran-2-yloxy)-octane-3,6-dione;
- Ic-24** 1,8-Bis-(4-oxo-oxetan-2-yl)-octane-3,6-dione;
- 5 **Ic-25** 1,8-Bis-(2-oxo-oxetan-3-yl)-octane-3,6-dione;
- Ic-26** 1,8-Bis-(5-oxo-tetrahydro-furan-2-yl)-octane-3,6-dione;
- Ic-27** 1,8-Bis-(5-oxo-tetrahydro-furan-3-yl)-octane-3,6-dione;
- 10 **Ic-28** 1,8-Bis-(2-oxo-tetrahydro-furan-3-yl)-octane-3,6-dione;
- Ic-29** {2-[8-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-3,6-dioxo-octyl]-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl}-acetic acid;
- 15 **Ic-30** 1,8-Bis-(6-oxo-tetrahydropyran-2-yl)-octane-3,6-dione;
- Ic-31** 1,8-Bis-(6-oxo-tetrahydropyran-3-yl)-octane-3,6-dione;
- 20 **Ic-32** 1,8-Bis-(2-oxo-tetrahydropyran-4-yl)-octane-3,6-dione;
- Ic-33** 1,8-Bis-(2-oxo-tetrahydropyran-3-yl)-octane-3,6-dione;
- 25 **II-1** 1,13-Dihydroxy-2,2,12,12-tetramethyl-tridecan-7-one;
- II-2** 13-Hydroxy-2,2,12,12-tetramethyl-7-oxo-tridecanoic acid;
- II-3** 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid;
- 30 **II-4** 1,11-Dihydroxy-2,2,10,10-tetramethyl-undecan-6-one;
- II-5** 11-Hydroxy-2,2,10,10-tetramethyl-6-oxo-undecanoic acid;
- II-6** 2,2,10,10-Tetramethyl-6-oxo-undecanedioic acid;
- 35 **II-7** 1,15-Dihydroxy-2,2,14,14-tetramethyl-pentadecan-8-one;
- II-8** 15-Hydroxy-2,2,14,14-tetramethyl-8-oxo-pentadecanoic acid;
- 40 **II-9** 2,2,14,14-Tetramethyl-8-oxo-pentadecanedioic acid;
- II-10** 2,2,12,12-Tetramethyl-7-oxo-tridecanedial;
- II-11** 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid dimethyl ester;
- 45 **II-12** 2,2,12,12-Tetramethyl-1,13-diphenyl-tridecane-1,7,13-trione;
- II-13** 3,3,13,13-Tetramethyl-1,15-diphenyl-pentadecane-2,8,14-trione;
- 50 **II-14** 2,12-Dimethyl-7-oxo-tridecane-2,12-disulfonic acid;
- II-15** Phosphoric acid mono-(1,1,11-trimethyl-6-oxo-11-phosphonoxy-dodecyl) ester;

- II-16 2,2,14,14-Tetramethyl-8-oxo-pentadecanedial;
- II-17 2,2,14,14-Tetramethyl-8-oxo-pentadecanedioic acid dimethyl ester;
- 5 II-18 2,2,14,14-Tetramethyl-1,15-diphenyl-pentadecane-1,8,15-trione;
- II-19 3,3,15,15-Tetramethyl-1,17-diphenyl-heptadecane-2,9,16-trione;
- 10 II-20 2,14-Dimethyl-8-oxo-pentadecane-2,14-disulfonic acid;
- II-21 Phosphoric acid mono-(1,1,13-trimethyl-7-oxo-13-phosphonooxy-tetradecyl) ester;
- 15 II-22 1,15-Dihydroxy-3,3,13,13-tetramethyl-pentadecan-8-one;
- II-23 15-Hydroxy-3,3,13,13-tetramethyl-8-oxo-pentadecanoic acid;
- II-24 1,13-Dihydroxy-3,3,11,11-tetramethyl-tridecan-7-one;
- 20 II-25 1,13-Dihydroxy-3,3,11,11-tetramethyl-tridecan-7-one;
- II-26 13-Hydroxy-3,3,11,11-tetramethyl-7-oxo-tridecanoic acid;
- 25 II-27 3,3,11,11-Tetramethyl-7-oxo-tridecanedioic acid;
- II-28 1,17-Dihydroxy-3,3,15,15-tetramethyl-heptadecan-9-one;
- II-29 17-Hydroxy-3,3,15,15-tetramethyl-9-oxo-heptadecanoic acid;
- 30 II-30 3,3,15,15-Tetramethyl-9-oxo-heptadecanedioic acid;
- II-31 1,17-Dihydroxy-4,4,14,14-tetramethyl-heptadecan-9-one;
- 35 II-32 17-Hydroxy-4,4,14,14-tetramethyl-9-oxo-heptadecanoic acid;
- II-33 4,4,14,14-Tetramethyl-heptadecan-9-oxo-1,17-dicarboxylic acid;
- II-34 1,15-Dihydroxy-4,4,14,14-tetramethyl-pentadecan-8-one;
- 40 II-35 15-Hydroxy-4,4,12,12-tetramethyl-8-oxo-pentadecanoic acid;
- II-36 4,4,12,12-Tetramethyl-8-oxo-pentadecanedioic acid;
- 45 II-37 1,19-Dihydroxy-4,4,16,16-tetramethyl-nonadecan-10-one;
- II-38 19-Hydroxy-4,4,16,16-tetramethyl-10-oxo-nonadecanoic acid;
- II-39 4,4,16,16-Tetramethyl-10-oxo-nonadecanedioic acid;
- 50 II-40 2,10-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,10-dimethyl-undecan-6-one;

- II-41 2,10-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,10-dimethyl-undecan-6-one;
- 5 II-42 2,2,10,10-Tetramethyl-6-oxo-undecanedioic acid bis-cyanamide;
- II-43 Phosphoramidic acid mono-[9-(amino-hydroxy-phosphoryloxy)-1,1,9-trimethyl-5-oxo-decyl] ester;
- 10 II-44 Phosphoramidic acid mono-[9-(amino-hydroxy-phosphoryloxy)-1,1,9-trimethyl-5-oxo-decyl] ester;
- II-45 2,12-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,12-dimethyl-tridecan-7-one;
- 15 II-46 2,12-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,12-dimethyl-tridecan-7-one;
- II-47 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid bis-cyanamide;
- 20 II-48 Phosphoramidic acid mono-[11-(amino-hydroxy-phosphoryloxy)-1,1,11-trimethyl-6-oxo-dodecyl] ester;
- II-49 Phosphoramidic acid mono-[11-(amino-hydroxy-phosphoryloxy)-1,1,11-trimethyl-6-oxo-dodecyl] ester;
- 25 II-50 2,12-Dimethyl-2,12-bis-tetrazol-1-yl-tridecan-7-one;
- II-51 2,12-Dimethyl-2,12-bis-(1*H*-tetrazol-5-yl)-tridecan-7-one;
- 30 II-52 2,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,12-dimethyl-tridecan-7-one;
- II-53 2,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,12-dimethyl-tridecan-7-one;
- 35 II-54 4-[11-(4-oxo-oxetan-2-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-oxetan-2-one;
- II-55 3-[11-(4-oxo-oxetan-2-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-oxetan-2-one;
- II-56 5-[11-(5-oxo-tetrahydro-furan-3-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-dihydro-furan-2-one;
- 40 II-57 3-[11-(5-oxo-tetrahydro-furan-3-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-dihydro-furan-2-one;
- 45 II-58 4-[11-(5-oxo-tetrahydro-furan-3-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-dihydro-furan-2-one;
- II-59 2,12-Dimethyl-2,12-bis-(tetrahydro-pyran-2-yloxy)-tridecan-7-one;
- 50 II-60 {2-[9-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-1,1,9-trimethyl-5-oxo-decyl]-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl}-acetic acid;
- IIa-1 1,15-Dihydroxy-2,14-dimethyl-2,14-diphenyl-pentadecan-8-one;

	IIa-2	15-Hydroxy-2,14-dimethyl-8-oxo-2,14-diphenyl-pentadecanoic acid;
	IIa-3	2,14-Dimethyl-8-oxo-2,14-diphenyl-pentadecanedioic acid;
5	IIa-4	1,13-Dihydroxy-2,12-dimethyl-2,12-diphenyl-tridecan-7-one;
	IIa-5	13-Hydroxy-2,12-dimethyl-7-oxo-2,12-diphenyl-tridecanoic acid;
10	IIa-6	2,12-Dimethyl-7-oxo-2,12-diphenyl-tridecanedioic acid;
	IIa-7	1,11-Dihydroxy-2,10-dimethyl-2,10-diphenyl-undecan-6-one;
	IIa-8	11-Hydroxy-2,10-dimethyl-6-oxo-2,10-diphenyl-undecanoic acid;
15	IIa-9	2,10-Dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid;
	IIa-10	2,14-Dimethyl-8-oxo-2,14-diphenyl-pentadecanedial;
20	IIa-11	2,14-Dimethyl-8-oxo-2,14-diphenyl-pentadecanedioic acid dimethyl ester;
	IIa-12	2,14-Dimethyl-1,2,14,15-tetraphenyl-pentadecane-1,8,15-trione;
	IIa-13	3,15-Dimethyl-1,3,15,17-tetraphenyl-heptadecane-2,9,16-trione;
25	IIa-14	8-Oxo-2,14-diphenyl-pentadecane-2,14-disulfonic acid;
	IIa-15	Phosphoric acid mono-(1-methyl-7-oxo-1,13-diphenyl-13-phosphonooxy-tetradecyl) ester;
30	IIa-16	1,17-Dihydroxy-3,15-dimethyl-3,15-diphenyl-heptadecan-9-one;
	IIa-17	17-Hydroxy-3,15-dimethyl-9-oxo-3,15-diphenyl-heptadecanoic acid;
	IIa-18	3,15-Dimethyl-9-oxo-3,15-diphenyl-heptadecanedioic acid;
35	IIa-19	1,15-Dihydroxy-3,13-dimethyl-3,13-diphenyl-pentadecan-8-one;
	IIa-20	15-Hydroxy-3,13-dimethyl-8-oxo-3,13-diphenyl-pentadecanoic acid;
40	IIa-21	3,13-Dimethyl-8-oxo-3,13-diphenyl-pentadecanedioic acid;
	IIa-22	1,13-Dihydroxy-3,11-dimethyl-3,11-diphenyl-tridecan-7-one;
	IIa-23	13-Hydroxy-3,11-dimethyl-7-oxo-3,11-diphenyl-tridecanoic acid;
45	IIa-24	3,11-Dimethyl-7-oxo-3,11-diphenyl-tridecanedioic acid;
	IIa-25	13-Hydroxy-3,11-dimethyl-7-oxo-3,11-diphenyl-tridecanoic acid;
50	IIa-26	3,11-Dimethyl-7-oxo-3,11-diphenyl-tridecanedioic acid;
	IIa-27	1,19-Dihydroxy-4,16-dimethyl-4,16-diphenyl-nonadecan-10-one;

- IIa-28** 19-Hydroxy-4,16-dimethyl-10-oxo-4,16-diphenyl-nonadecanoic acid;
- IIa-29** 4,16-Dimethyl-10-oxo-4,16-diphenyl-nonadecanedioic acid;
- 5 **IIa-30** 1,17-Dihydroxy-4,14-dimethyl-4,14-diphenyl-heptadecan-9-one;
- IIa-31** 17-Hydroxy-4,14-dimethyl-9-oxo-4,14-diphenyl-heptadecanoic acid;
- 10 **IIa-32** 4,14-Dimethyl-9-oxo-4,14-diphenyl-heptadecanedioic acid;
- IIa-33** 1,15-Dihydroxy-4,12-dimethyl-4,12-diphenyl-pentadecan-8-one;
- IIa-34** 15-Hydroxy-4,12-dimethyl-8-oxo-4,12-diphenyl-pentadecanoic acid;
- 15 **IIa-35** 4,12-Dimethyl-8-oxo-4,12-diphenyl-pentadecanedioic acid;
- IIa-36** 2,12-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,12-diphenyl-tridecan-7-one;
- 20 **IIa-37** 2,12-Bis-(4,6-dithio-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,12-diphenyl-tridecan-7-one;
- IIa-38** 2,12-Dimethyl-2,12-diphenyl-7-oxo-tridecanedioic acid bis-cyanamide;
- 25 **IIa-39** Phosphoramidic acid mono-(amino-hydroxy-phosphoryloxy)-1-methyl-6-oxo-1,11-diphenyl-dodecyl] ester;
- IIa-40** Phosphoramidic acid mono-[11(amino-hydroxy-phosphoryloxy)-1,11-diphenyl-1-methyl-6-oxo-dodecyl] ester;
- 30 **IIa-41** 2,12-Diphenyl-2,12-bis-tetrazol-1-yl-tridecan-7-one;
- IIa-42** 2,12-Diphenyl-2,12-bis-(1*H*-tetrazol-5-yl)-tridecan-7-one;
- 35 **IIa-43** 2,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,12-diphenyl-tridecan-7-one;
- IIa-44** 2,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,12-diphenyl-tridecan-7-one;
- 40 **IIa-45** 2,12-Diphenyl-2,12-bis-(tetrahydro-pyran-2-yl)-tridecan-7-one;
- IIa-46** 5-[11-(5-oxo-tetrahydro-furan-2-yl)-1,11-Diphenyl-1-methyl-6-oxo-dodecyl]-dihydro-furan-2-one;
- 45 **IIa-47** 4-[11-(4-oxo-oxetan-2-yl)-1,11-diphenyl-1-methyl-6-oxo-dodecyl]-oxetan-2-one;
- IIa-48** 4-[11-(5-oxo-tetrahydro-furan-2-yl)-1,11-Diphenyl-1-methyl-6-oxo-dodecyl]-dihydro-furan-2-one;
- 50 **IIa-49** 3-[11-(5-oxo-tetrahydro-furan-2-yl)-1,11-Diphenyl-1-methyl-6-oxo-dodecyl]-dihydro-furan-2-one;

- IIa-50** {2-[11-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-1-methyl-6-oxo-1,11-diphenyl-dodecyl]-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl}-acetic acid;
- 5 **III-1** 5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-2** 5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 10 **III-3** 5-(6-{3-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-4** 5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- 15 **III-5** 5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-6** 5-(6-{3-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 20 **III-7** 6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- III-8** 6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 25 **III-9** 6-(6-{3-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 30 **III-10** 6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- III-11** 6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 35 **III-12** 6-(6-{3-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-13** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol;
- 40 **III-14** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- 45 **III-15** 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- III-16** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- 50

- III-17 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 5 III-18 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-19 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- 10 III-20 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-21 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 15 III-22 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-23 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- 20 III-24 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- III-25 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- 25 III-26 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 30 III-27 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-28 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- 35 III-29 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 40 III-30 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-31 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- 45 III-32 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-33 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 50

- III-34** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- 5 **III-35** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-36** 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 10 **III-37** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-38** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 15 **III-39** 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-40** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- 20 **III-41** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-42** 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 25 **III-43** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol;
- 30 **III-44** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- III-45** 6-(6-{2-[6-(6-Carboxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- 35 **III-46** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol;
- 40 **III-47** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-48** 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 45 **III-49** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- 50 **III-50** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;

- III-51 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 5 III-52 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-53 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- 10 III-54 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- III-55 5-(6-{2-[6-(5-Hydroxy-4-methyl-pentyl)-1,4-dioxo-cyclohex-2-yl]-phenyl}-1,4-dioxo-cyclohex-2-yl)-2,2-dimethyl-pentan-1-ol;
- 15 III-56 5-(6-{2-[6-(5-Hydroxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-57 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 20 III-58 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- 25 III-59 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-60 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 30 III-61 5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-62 5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 35 III-63 5-(5-{3-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 40 III-64 6-(5-{3-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- III-65 6-(5-{3-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 45 III-66 6-(5-{3-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-67 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexan-1-ol;
- 50

- III-68** 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid;
- 5 **III-69** 6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid;
- III-70** 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- 10 **III-71** 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-72** 6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 15 **III-73** 5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-74** 5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid;
- 20 **III-75** 5-(5-{2-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid;
- III-76** 5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- 25 **III-77** 5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 30 **III-78** 5-(5-{2-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-79** 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexan-1-ol;
- 35 **III-80** 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid;
- 40 **III-81** 6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid;
- III-82** 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- 45 **III-83** 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 50 **III-84** 6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid;

- III-85** 5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-ethyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- 5 **III-86** 5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-ethyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-87** 5-(5-{2-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentadien-2-yl]-ethyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 10 **IIIa-1** 5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol;
- IIIa-2** 5-(6-{3-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- 15 **IIIa-3** 5-(6-{3-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- IIIa-4** 6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol;
- 20 **IIIa-5** 6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- IIIa-6** 6-(6-{3-[6-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- 25 **IIIa-7** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol;
- 30 **IIIa-8** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- IIIa-9** 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- 35 **IIIa-10** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol;
- 40 **IIIa-11** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- IIIa-12** 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- 45 **IIIa-13** 5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-propyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentan-1-ol;
- 50 **IIIa-14** 5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-propyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid; or

IIIa-15 5-(5-{3-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentan-2-yl]-propyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid.

5 36. A pharmaceutical composition comprising a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35 and a pharmaceutically acceptable vehicle, excipient, or diluent.

 37. A pharmaceutical composition comprising the following compound:
6-(5,5-Dimethyl-6-hydroxy-hexane-1-sulfinyl)-2,2-dimethyl-hexan-1-ol or pharmaceutically
10 acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof and a pharmaceutically acceptable vehicle, excipient, or diluent.

 38. A method for treating or preventing a cardiovascular disease in a patient,
15 comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

 39. A method for treating or preventing a dyslipidemia in a patient, comprising
administering to a patient in need of such treatment or prevention a therapeutically effective
20 amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

 40. A method for treating or preventing a dyslipoproteinemia in a patient,
comprising administering to a patient in need of such treatment or prevention a
therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35
25 .

 41. A method for treating or preventing a disorder of glucose metabolism in a
patient, comprising administering to a patient in need of such treatment or prevention a
therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.
30

 42. A method for treating or preventing Alzheimer's Disease in a patient,
comprising administering to a patient in need of such treatment or prevention a
therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

43. A method for treating or preventing Syndrome X or Metabolic Syndrome in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

5 44. A method for treating or preventing septicemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

10 45. A method for treating or preventing a thrombotic disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

15 46. A method for treating or preventing a peroxisome proliferator activated receptor associated disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

20 47. A method for treating or preventing obesity in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

25 48. A method for treating or preventing pancreatitis in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

 49. A method for treating or preventing hypertension in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

30 50. A method for treating or preventing renal disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

51. A method for treating or preventing cancer in a patient, comprising administering to a patient in claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

5 52. A method for treating or preventing inflammation in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

10 53. A method for treating or preventing impotence in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

15 54. A method for reducing the fat content of meat in livestock comprising administering to livestock in need of such reduction a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

55. A method for reducing the cholesterol content of fowl eggs comprising administering to a fowl a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

20

Figure 1

Effect of One Week of Daily Oral Gavage Treatment with Compound B on Lipoprotein
Total Cholesterol in Chow-Fed Male Sprague-Dawley Rats




Figure 2

Effect of One Week of Daily Oral Gavage Treatment with Compound B on Serum Lipids in Chow-Fed Male Sprague-Dawley Rats




Figure 3

Effect of Two Weeks of Daily Oral Gavage Treatment with Compound B on Lipoprotein
Total Cholesterol in Chow Fed Obese Female Zucker Rats





Figure 4

Effect of Two Weeks of Daily Oral Gavage Treatment with Compound B
in Chow-Fed Obese Female Zucker Rats

Variable	Units	Control n=3			Compound B n=4 97/mg/kg/day		
		Pre	1 Week	2 Week	Pre	1 Week	2 Week
14 Day Percent Weight Gain	Percent	0		13.6	0		14.6
Liver/Body Weight	Percent			4.09			5.70
Blood Glucose	mg/dL	122	98	130	108	116	120
Insulin	ng/mL	12.2	8.7	6.2	10.0	8.7	8.7
Non-Esterified Fatty Acids	mmol/L	1.95	1.27	1.21	2.13	0.60	0.57
β -hydroxy butyrate	mg/dL	2.29	1.62	2.90	1.44	2.56	3.97
Total Cholesterol	mg/dL	62	56	68	59	93	112
Percent HDL Cholesterol (Gain/Loss)	Percent	0	-10	10	0	58	90
VLDL plus LDL Cholesterol	mg/dL	21	26	27	21	17	19
HDL Cholesterol	mg/dL	42	30	41	38	76	93
Percent HDL Cholesterol (Gain/Loss)	Percent	0	-28	0	0	99	143
HDL / (VLDL plus LDL)	Ratio	2.32	1.30	1.77	1.97	4.85	5.47
Triglycerides	mg/dL	999	984	887	861	299	324
Triglycerides (Gain/Loss)	Percent	0	-2	-11	0	-65	.82

Figure 5



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number
WO 02/030860 A3

(51) International Patent Classification⁷: **C07C 49/17**,
49/245, 49/258, 49/185, A61K 31/12, 31/122, 31/185,
31/21, 31/275, 31/095, 31/33, 31/66, A61P 9/00, C07C
49/82, 49/86, 49/782, 49/215, 49/723, 49/743, 49/747,
49/507, 50/30, 261/04, C07F 9/09, 9/24, 9/44, C07C
69/716, 69/738, 309/24, 309/07, 59/84, 59/347, 59/90,
59/50, 59/86, 59/82, C07D 309/30, 495/04, 257/04,
261/12, 309/40, 233/72, 233/84, 233/86, 309/12, 305/12,
307/33

(21) International Application Number: PCT/US01/31872

(22) International Filing Date: 11 October 2001 (11.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/239,232 11 October 2000 (11.10.2000) US

(71) Applicant: **ESPERION THERAPEUTICS, INC.**
[US/US]; 3621 S. State Street, 695 KMS Place, Ann
Arbor, MI 48108 (US).

(72) Inventors: **DASSEUX, Jean-Louis, H.**; 7898 Huron
Oak Drive, Brighton, MI 48116 (US). **ONICIU, Carmen,
Daniela**; 3920 N.W. 23rd Street, Gainesville, FL 32605
(US).

(74) Agent: **INSOGNA, Anthony, M.**; Pennie & Edmonds
LLP, 1155 Avenue of the Americas, New York, NY 10036
(US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— with international search report

(88) Date of publication of the international search report:
15 August 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES

(57) Abstract: The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.



WO 02/030860 A3

INTERNATIONAL SEARCH REPORT

national Application No
PCT/US 01/31872

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C49/17 C07C49/245 C07C49/258 C07C49/185 A61K31/12
A61K31/122 A61K31/185 A61K31/21 A61K31/275 A61K31/095
A61K31/33 A61K31/66 A61P9/00 C07C49/82 C07C49/86

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D C07F A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NAN F ET AL: "Dual function glutamate-related ligands: discovery of a novel, potent inhibitor of glutamate carboxypeptidase II possessing mGluR3 agonist activity" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, no. 5, 9 March 2000 (2000-03-09), pages 772-774, XP002144187 ISSN: 0022-2623 the whole document	1-55
A	US 3 441 605 A (STEPHEN BLAKE) 29 April 1969 (1969-04-29) the whole document	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

17 May 2002

Date of mailing of the international search report

29/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Beslier, L

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/31872

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C07C49/782	C07C49/215	C07C49/723	C07C49/743	C07C49/747
	C07C49/507	C07C50/30	C07C261/04	C07F9/09	C07F9/24
	C07F9/44	C07C69/716	C07C69/738	C07C309/24	C07C309/07

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	WO 00 64911 A (GEORGETOWN UNIVERSITY) 2 November 2000 (2000-11-02) the whole document	1-55
P, A	WO 01 46110 A (THE UNIVERSITY OF GEORGIA) 28 June 2001 (2001-06-28) the whole document	1-55

☐

Further documents are listed in the continuation of box C.

☒

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

17 May 2002

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Beslier, L

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/31872

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C07C59/84	C07C59/347	C07C59/90	C07C59/50	C07C59/86
	C07C59/82	C07D309/30	C07D495/04	C07D257/04	C07D261/12
	C07D309/40	C07D233/72	C07D233/84	C07D233/86	C07D309/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

17 May 2002

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Beslier, L

International Application No
PCT/US 01/31872

According to International Patent Classification (IPC) or to both national classification and IPC

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

<div style="border: 1px solid black; width: 30px; height: 30px; display: flex; align-items: center; justify-content: center; margin-bottom: 5px;"> X </div> <p>Further documents are listed in the continuation of box C.</p>	<div style="border: 1px solid black; width: 30px; height: 30px; display: flex; align-items: center; justify-content: center; margin-bottom: 5px;"> X </div> <p>Patent family members are listed in annex.</p>
<p>° Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>
<p>Date of the actual completion of the international search</p> <p style="text-align: center; font-size: 1.2em;">17 May 2002</p>	<p>Date of mailing of the international search report</p>
<p>Name and mailing address of the ISA</p> <p>European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016</p>	<p>Authorized officer</p> <p style="text-align: center; font-size: 1.2em;">Beslier, L</p>

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-18, 20-34 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the examples.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/31872

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 3441605	A	29-04-1969	BE 676592 A	16-08-1966
			DE 1543984 A1	05-02-1970
			FR 1471295 A	03-03-1967
			NL 6602087 A	18-08-1966
WO 0064911	A	02-11-2000	AU 4668200 A	10-11-2000
			EP 1177200 A1	06-02-2002
			WO 0064911 A1	02-11-2000
WO 0146110	A	28-06-2001	AU 2291001 A	03-07-2001
			WO 0146110 A2	28-06-2001
			US 2002040029 A1	04-04-2002

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number
WO 02/030860 A3

(51) International Patent Classification⁷: **C07C 49/17**,
49/245, 49/258, 49/185, A61K 31/12, 31/122, 31/185,
31/21, 31/275, 31/095, 31/33, 31/66, A61P 9/00, C07C
49/82, 49/86, 49/782, 49/215, 49/723, 49/743, 49/747,
49/507, 50/30, 261/04, C07F 9/09, 9/24, 9/44, C07C
69/716, 69/738, 309/24, 309/07, 59/84, 59/347, 59/90,
59/50, 59/86, 59/82, C07D 309/30, 495/04, 257/04,
261/12, 309/40, 233/72, 233/84, 233/86, 309/12, 305/12,
307/33

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZW.

(21) International Application Number: PCT/US01/31872

(22) International Filing Date: 11 October 2001 (11.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/239,232 11 October 2000 (11.10.2000) US

(71) Applicant: **ESPERION THERAPEUTICS, INC.**
[US/US]; 3621 S. State Street, 695 KMS Place, Ann
Arbor, MI 48108 (US).

(72) Inventors: **DASSEUX, Jean-Louis, H.**; 7898 Huron
Oak Drive, Brighton, MI 48116 (US). **ONICIU, Carmen,
Daniela**; 3920 N.W. 23rd Street, Gainesville, FL 32605
(US).

(74) Agent: **INSOGNA, Anthony, M.**; Pennie & Edmonds
LLP, 1155 Avenue of the Americas, New York, NY 10036
(US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:
— with international search report

(88) Date of publication of the international search report:
15 August 2002

(48) Date of publication of this corrected version:
20 February 2003

(15) Information about Correction:
see PCT Gazette No. 08/2003 of 20 February 2003, Sec-
tion II

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES

(57) Abstract: The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and meth-
ods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders
comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the inven-
tion are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related
disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence.
In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other
therapeutics, such as hypocholesterolemic and hypoglycemic agents.



WO 02/030860 A3

**KETONE COMPOUNDS AND COMPOSITIONS
FOR CHOLESTEROL MANAGEMENT AND RELATED USES**

5

1. Field of The Invention

The present invention relates to ketone compounds; compositions comprising the ketone compounds; and methods for treating or preventing a disease or disorder, such as cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, Alzheimer's Disease, Syndrome X, a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. The ketone compounds and compositions of the invention may also be used to reduce the fat content of meat in livestock and reduce the cholesterol content of eggs.

15

2. Background of The Invention

Obesity, hyperlipidemia, and diabetes have been shown to play a causal role in atherosclerotic cardiovascular diseases, which currently account for a considerable proportion of morbidity in Western society. Further, one human disease, termed "Syndrome X" or "Metabolic Syndrome", is manifested by defective glucose metabolism (insulin resistance), elevated blood pressure (hypertension), and a blood lipid imbalance (dyslipidemia). *See e.g. Reaven, 1993, Annu. Rev. Med. 44:121-131.*

The evidence linking elevated serum cholesterol to coronary heart disease is overwhelming. Circulating cholesterol is carried by plasma lipoproteins, which are particles of complex lipid and protein composition that transport lipids in the blood. Low density lipoprotein (LDL) and high density lipoprotein (HDL) are the major cholesterol-carrier proteins. LDL is believed to be responsible for the delivery of cholesterol from the liver, where it is synthesized or obtained from dietary sources, to extrahepatic tissues in the body. The term "reverse cholesterol transport" describes the transport of cholesterol from extrahepatic tissues to the liver, where it is catabolized and eliminated. It is believed that plasma HDL particles play a major role in the reverse transport process, acting as scavengers of tissue cholesterol. HDL is also responsible for the removal of non-cholesterol lipid, oxidized cholesterol and other oxidized products from the bloodstream.

Atherosclerosis, for example, is a slowly progressive disease characterized by the accumulation of cholesterol within the arterial wall. Compelling evidence supports the

belief that lipids deposited in atherosclerotic lesions are derived primarily from plasma apolipoprotein B (apo B)-containing lipoproteins, which include chylomicrons, CLDL, IDL and LDL. The apo B-containing lipoprotein, and in particular LDL, has popularly become known as the "bad" cholesterol. In contrast, HDL serum levels correlate inversely with coronary heart disease. Indeed, high serum levels of HDL are regarded as a negative risk factor. It is hypothesized that high levels of plasma HDL are not only protective against coronary artery disease, but may actually induce regression of atherosclerotic plaque (e.g., see Badimon *et al.*, 1992, *Circulation* 86:(Suppl. III)86-94; Dansky and Fisher, 1999, *Circulation* 100:1762-3.). Thus, HDL has popularly become known as the "good" cholesterol.

2.1. Cholesterol Transport

The fat-transport system can be divided into two pathways: an exogenous one for cholesterol and triglycerides absorbed from the intestine and an endogenous one for cholesterol and triglycerides entering the bloodstream from the liver and other non-hepatic tissue.

In the exogenous pathway, dietary fats are packaged into lipoprotein particles called chylomicrons, which enter the bloodstream and deliver their triglycerides to adipose tissue for storage and to muscle for oxidation to supply energy. The remnant of the chylomicron, which contains cholesteryl esters, is removed from the circulation by a specific receptor found only on liver cells. This cholesterol then becomes available again for cellular metabolism or for recycling to extrahepatic tissues as plasma lipoproteins.

In the endogenous pathway, the liver secretes a large, very-low-density lipoprotein particle (VLDL) into the bloodstream. The core of VLDL consists mostly of triglycerides synthesized in the liver, with a smaller amount of cholesteryl esters either synthesized in the liver or recycled from chylomicrons. Two predominant proteins are displayed on the surface of VLDL, apolipoprotein B-100 (apo B-100) and apolipoprotein E (apo E), although other apolipoproteins are present, such as apolipoprotein CIII (apo CIII) and apolipoprotein CII (apo CII). When a VLDL reaches the capillaries of adipose tissue or of muscle, its triglyceride is extracted. This results in the formation of a new kind of particle called intermediate-density lipoprotein (IDL) or VLDL remnant, decreased in size and enriched in cholesteryl esters relative to a VLDL, but retaining its two apoproteins.

In human beings, about half of the IDL particles are removed from the circulation quickly, generally within two to six hours of their formation. This is because IDL particles bind tightly to liver cells, which extract IDL cholesterol to make new VLDL and bile acids.

The IDL not taken up by the liver is catabolized by the hepatic lipase, an enzyme bound to the proteoglycan on liver cells. Apo E dissociates from IDL as it is transformed to LDL. Apo B-100 is the sole protein of LDL.

Primarily, the liver takes up and degrades circulating cholesterol to bile acids, which
5 are the end products of cholesterol metabolism. The uptake of cholesterol-containing particles is mediated by LDL receptors, which are present in high concentrations on hepatocytes. The LDL receptor binds both apo E and apo B-100 and is responsible for binding and removing both IDL and LDL from the circulation. In addition, remnant receptors are responsible for clearing chylomicrons and VLDL remnants (*i.e.*, IDL).
10 However, the affinity of apo E for the LDL receptor is greater than that of apo B-100. As a result, the LDL particles have a much longer circulating life span than IDL particles; LDL circulates for an average of two and a half days before binding to the LDL receptors in the liver and other tissues. High serum levels of LDL, the "bad" cholesterol, are positively associated with coronary heart disease. For example, in atherosclerosis, cholesterol derived
15 from circulating LDL accumulates in the walls of arteries. This accumulation forms bulky plaques that inhibit the flow of blood until a clot eventually forms, obstructing an artery and causing a heart attack or stroke.

Ultimately, the amount of intracellular cholesterol liberated from the LDL controls cellular cholesterol metabolism. The accumulation of cellular cholesterol derived from
20 VLDL and LDL controls three processes. First, it reduces the cell's ability to make its own cholesterol by turning off the synthesis of HMGCoA reductase, a key enzyme in the cholesterol biosynthetic pathway. Second, the incoming LDL-derived cholesterol promotes storage of cholesterol by the action of cholesterol acyltransferase ("ACAT"), the cellular enzyme that converts cholesterol into cholesteryl esters that are deposited in storage
25 droplets. Third, the accumulation of cholesterol within the cell drives a feedback mechanism that inhibits cellular synthesis of new LDL receptors. Cells, therefore, adjust their complement of LDL receptors so that enough cholesterol is brought in to meet their metabolic needs, without overloading (for a review, see Brown & Goldstein, In, The Pharmacological Basis Of Therapeutics, 8th Ed., Goodman & Gilman, Pergamon Press,
30 New York, 1990, Ch. 36, pp. 874-896).

High levels of apo B-containing lipoproteins can be trapped in the subendothelial space of an artery and undergo oxidation. The oxidized lipoprotein is recognized by scavenger receptors on macrophages. Binding of oxidized lipoprotein to the scavenger receptors can enrich the macrophages with cholesterol and cholesteryl esters independently
35 of the LDL receptor. Macrophages can also produce cholesteryl esters by the action of

ACAT. LDL can also be complexed to a high molecular weight glycoprotein called apolipoprotein(a), also known as apo(a), through a disulfide bridge. The LDL-apo(a) complex is known as Lipoprotein(a) or Lp(a). Elevated levels of Lp(a) are detrimental, having been associated with atherosclerosis, coronary heart disease, myocardial infarction, stroke, cerebral infarction, and restenosis following angioplasty.

2.2. Reverse Cholesterol Transport

Peripheral (non-hepatic) cells predominantly obtain their cholesterol from a combination of local synthesis and uptake of preformed sterol from VLDL and LDL. Cells expressing scavenger receptors, such as macrophages and smooth muscle cells, can also obtain cholesterol from oxidized apo B-containing lipoproteins. In contrast, reverse cholesterol transport (RCT) is the pathway by which peripheral cell cholesterol can be returned to the liver for recycling to extrahepatic tissues, hepatic storage, or excretion into the intestine in bile. The RCT pathway represents the only means of eliminating cholesterol from most extrahepatic tissues and is crucial to maintenance of the structure and function of most cells in the body.

The enzyme in blood involved in the RCT pathway, lecithin:cholesterol acyltransferase (LCAT), converts cell-derived cholesterol to cholesteryl esters, which are sequestered in HDL destined for removal. LCAT is produced mainly in the liver and circulates in plasma associated with the HDL fraction. Cholesterol ester transfer protein (CETP) and another lipid transfer protein, phospholipid transfer protein (PLTP), contribute to further remodeling the circulating HDL population (see for example Bruce *et al.*, 1998, *Annu. Rev. Nutr.* 18:297-330). PLTP supplies lecithin to HDL, and CETP can move cholesteryl ester made by LCAT to other lipoproteins, particularly apoB-containing lipoproteins, such as VLDL. HDL triglyceride can be catabolized by the extracellular hepatic triglyceride lipase, and lipoprotein cholesterol is removed by the liver via several mechanisms.

Each HDL particle contains at least one molecule, and usually two to four molecules, of apolipoprotein (apo A-I). Apo A-I is synthesized by the liver and small intestine as preproapolipoprotein which is secreted as a proprotein that is rapidly cleaved to generate a mature polypeptide having 243 amino acid residues. Apo A-I consists mainly of a 22 amino acid repeating segment, spaced with helix-breaking proline residues. Apo A-I forms three types of stable structures with lipids: small, lipid-poor complexes referred to as pre-beta-1 HDL; flattened discoidal particles, referred to as pre-beta-2 HDL, which contain only polar lipids (*e.g.*, phospholipid and cholesterol); and spherical particles containing both

polar and nonpolar lipids, referred to as spherical or mature HDL (HDL₃ and HDL₂). Most HDL in the circulating population contains both apo A-I and apo A-II, a second major HDL protein. This apo A-I- and apo A-II-containing fraction is referred to herein as the AI/AII-HDL fraction of HDL. But the fraction of HDL containing only apo A-I, referred to herein
5 as the AI-HDL fraction, appears to be more effective in RCT. Certain epidemiologic studies support the hypothesis that the AI-HDL fraction is antiatherogenic (Parra *et al.*, 1992, *Arterioscler. Thromb.* 12:701-707; Decossin *et al.*, 1997, *Eur. J. Clin. Invest.* 27:299-307).

Although the mechanism for cholesterol transfer from the cell surface is unknown, it
10 is believed that the lipid-poor complex, pre-beta-1 HDL, is the preferred acceptor for cholesterol transferred from peripheral tissue involved in RCT. Cholesterol newly transferred to pre-beta-1 HDL from the cell surface rapidly appears in the discoidal pre-beta-2 HDL. PLTP may increase the rate of disc formation (Lagrost *et al.*, 1996, *J. Biol. Chem.* 271:19058-19065), but data indicating a role for PLTP in RCT is lacking. LCAT
15 reacts preferentially with discoidal and spherical HDL, transferring the 2-acyl group of lecithin or phosphatidylethanolamine to the free hydroxyl residue of fatty alcohols, particularly cholesterol, to generate cholesteryl esters (retained in the HDL) and lysolecithin. The LCAT reaction requires an apolipoprotein such as apo A-I or apo A-IV as an activator. ApoA-I is one of the natural cofactors for LCAT. The conversion of cholesterol to its HDL-
20 sequestered ester prevents re-entry of cholesterol into the cell, resulting in the ultimate removal of cellular cholesterol. Cholesteryl esters in the mature HDL particles of the AI-HDL fraction are removed by the liver and processed into bile more effectively than those derived from the AI/AII-HDL fraction. This may be due, in part, to the more effective binding of AI-HDL to the hepatocyte membrane. Several HDL receptors have been
25 identified, the most well characterized of which is the scavenger receptor class B, type I (SR-BI) (Acton *et al.*, 1996, *Science* 271:518-520). The SR-BI is expressed most abundantly in steroidogenic tissues (*e.g.*, the adrenals), and in the liver (Landshulz *et al.*, 1996, *J. Clin. Invest.* 98:984-995; Rigotti *et al.*, 1996, *J. Biol. Chem.* 271:33545-33549). Other proposed HDL receptors include HB1 and HB2 (Hidaka and Fidge, 1992, *Biochem J.*
30 15:161-7; Kurata *et al.*, 1998, *J. Atherosclerosis and Thrombosis* 4:112-7).

While there is a consensus that CETP is involved in the metabolism of VLDL- and LDL-derived lipids, its role in RCT remains controversial. However, changes in CETP activity or its acceptors, VLDL and LDL, play a role in "remodeling" the HDL population. For example, in the absence of CETP, the HDL becomes enlarged particles that are poorly
35 removed from the circulation (for reviews on RCT and HDL, See Fielding & Fielding,

1995, *J. Lipid Res.* **36**:211-228; Barrans *et al.*, 1996, *Biochem. Biophys. Acta.* **1300**:73-85; Hirano *et al.*, 1997, *Arterioscler. Thromb. Vasc. Biol.* **17**:1053-1059).

5 2.3. Reverse Transport of Other Lipids

HDL is not only involved in the reverse transport of cholesterol, but also plays a role in the reverse transport of other lipids, *i.e.*, the transport of lipids from cells, organs, and tissues to the liver for catabolism and excretion. Such lipids include sphingomyelin, oxidized lipids, and lysophosphatidylcholine. For example, Robins and Fasulo (1997, *J. Clin. Invest.* 99:380-384) have shown that HDL stimulates the transport of plant sterol by the liver into bile secretions.

2.4. Peroxisome Proliferator Activated Receptor Pathway

Peroxisome proliferation are a structurally diverse group of compounds that, when administered to rodents, elicit dramatic increases in the size and number of hepatic and renal peroxisomes, as well as concomitant increases in the capacity of peroxisomes to metabolize fatty acids via increased expression of the enzymes required for the β -oxidation cycle (Lazarow and Fujiki, 1985, *Ann. Rev. Cell Biol.* 1:489-530; Vamecq and Draye, 1989, *Essays Biochem.* 24:1115-225; and Nelali *et al.*, 1988, *Cancer Res.* 48:5316-5324). Chemicals included in this group are the fibrate class of hypolipidemic drugs, herbicides, and phthalate plasticizers (Reddy and Lalwani, 1983, *Crit. Rev. Toxicol.* 12:1-58). Peroxisome proliferation can also be elicited by dietary or physiological factors, such as a high-fat diet and cold acclimatization.

Insight into the mechanism whereby peroxisome proliferators exert their pleiotropic effects was provided by the identification of a member of the nuclear hormone receptor superfamily activated by these chemicals (Isseman and Green, 1990, *Nature* 347:645-650). This receptor, termed peroxisome proliferator activated receptor α (PPAR $_{\alpha}$), was subsequently shown to be activated by a variety of medium and long-chain fatty acids. PPAR $_{\alpha}$ activates transcription by binding to DNA sequence elements, termed peroxisome proliferator response elements (PPRE), in the form of a heterodimer with the retinoid X receptor (RXR). RXR is activated by 9-cis retinoic acid (*see* Kliewer *et al.*, 1992, *Nature* 358:771-774; Gearing *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 90:1440-1444, Keller *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 90:2160-2164; Heyman *et al.*, 1992, *Cell* 68:397-406, and Levin *et al.*, 1992, *Nature* 355:359-361). Since the discovery of PPAR $_{\alpha}$, additional

isoforms of PPAR have been identified, *e.g.*, PPAR_β, PPAR_γ and PPAR_δ, which have similar functions and are similarly regulated.

PPREs have been identified in the enhancers of a number of gene-encoding proteins that regulate lipid metabolism. These proteins include the three enzymes required for peroxisomal β-oxidation of fatty acids; apolipoprotein A-I; medium-chain acyl-CoA dehydrogenase, a key enzyme in mitochondrial β-oxidation; and aP2, a lipid binding protein expressed exclusively in adipocytes (reviewed in Keller and Whali, 1993, *TEM*, 4:291-296; *see also* Staels and Auwerx, 1998, *Atherosclerosis* 137 Suppl:S19-23). The nature of the PPAR target genes coupled with the activation of PPARs by fatty acids and hypolipidemic drugs suggests a physiological role for the PPARs in lipid homeostasis.


2.5. Current Cholesterol Management Therapies

None of the commercially available cholesterol management drugs has a general utility in regulating lipid, lipoprotein, insulin and glucose levels in the blood. Thus, compounds that have one or more of these utilities are clearly needed. Further, there is a clear need to develop safer drugs that are efficacious at lowering serum cholesterol, increasing HDL serum levels, preventing coronary heart disease, and/or treating existing disease such as atherosclerosis, obesity, diabetes, and other diseases that are affected by lipid metabolism and/or lipid levels. There is also a clear need to develop drugs that may be used with other lipid-altering treatment regimens in a synergistic manner. There is still a further need to provide useful therapeutic agents whose solubility and Hydrophile/Lipophile Balance (HLB) can be readily varied.

Citation or identification of any reference in Section 2 of this application is not an admission that such reference is available as prior art to the present invention.

3. Summary of The Invention

In one embodiment, the invention relates to a compound of formula I:



I


or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, stereoisomer, diastereomer, racemate, geometric isomer or mixtures thereof wherein:

- (a) each occurrence of Z is independently CH_2 , $\text{CH}=\text{CH}$, or phenyl, wherein each occurrence of m is independently an integer ranging from 1 to 9, but when Z is phenyl then its associated m is 1;
- 5 (b) G is $(\text{CH}_2)_x$, $\text{CH}_2\text{CH}=\text{CHCH}_2$, $\text{CH}=\text{CH}$, CH_2 -phenyl- CH_2 , or phenyl, wherein x is 2, 3, or 4;
- (c) W^1 and W^2 are independently L, V, $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_c-\text{C}(\text{R}^3)(\text{R}^4)-(\text{CH}_2)_n-\text{Y}$, or $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_c-\text{V}$, wherein c is 1 or 2 and n is an independent integer ranging
- 10 from 0 to 4;
- (d) each occurrence of R^1 and R^2 is independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl or when W^1 or W^2 is $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_c-\text{C}(\text{R}^3)(\text{R}^4)-\text{Y}$, then R^1 and R^2 can both be H;
- 15 (e) R^3 is H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_1-C_6) alkoxy, phenyl, benzyl, Cl, Br, CN, NO_2 , or CF_3 ;
- (f) R^4 is OH, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_1-C_6) alkoxy, phenyl, benzyl, Cl, Br, CN, NO_2 , or CF_3 ;
- 20 (g) L is $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_n-\text{Y}$; where n is an independent integer ranging from 0 to 4;
- (h) V is


25

30

35



- (i) each occurrence of Y is independently OH, COOH, CHO, COOR⁵, SO₃H,



where:

5

- (i) R⁵ is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C₁-C₆)alkoxy, or phenyl groups,
- (ii) each occurrence of R⁶ is independently H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, or (C₂-C₆)alkynyl and is unsubstituted or substituted with one or two halo, OH, C₁-C₆ alkoxy, or phenyl groups; and

10

- (iii) each occurrence of R^7 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;

5

provided that:

10

- (i) if G is $(CH_2)_x$, x is 4, each occurrence of Z is CH_2 , each occurrence of m is 4, and W^1 is $-CH(CH_3)CO_2H$, then W^2 is not the same as W^1 ;

15

- (ii) if G is CH_2 -phenyl- CH_2 , each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(CH_3)_2CH(CO_2CH_2CH_3)_2$, then W^2 is not the same as W^1 ;

- (iii) if G is CH_2 -phenyl- CH_2 , each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(CH_3)_2CH_2(CO_2CH_2CH_3)_2$, then W^2 is not the same as W^1 ;

- (iv) if G is CH_2 -phenyl- CH_2 , each occurrence of Z is CH_2 , each occurrence of m is 1, and W^1 is $-COCH_2C(CH_3)_2CH_2CO_2H$, then W^2 is not the same as W^1 ;

20

- (v) if G is $(CH_2)_x$, x is 4, each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(phenyl)_2CH_2CO_2H$, then W^2 is not the same as W^1 ;

25

- (vi) if G is $CH=CH$, each occurrence of Z is CH_2 , each occurrence of m is 1, and W^1 is $-C(CH_3)_2CH_2(CO_2H)$, then W^2 is not the same as W^1 ; and

- (vii) if G is phenyl, each occurrence of Z is CH_2 , each occurrence of m is 1, and W^1 is $-C(phenyl)_2CO_2H$, then W^2 is not the same as W^1 .

30

Preferred compounds of formula **I** are those wherein:

- (a) W^1 and W^2 are independently L, V, or $C(R^1)(R^2)-(CH_2)_c-V$, where c is 1 or 2; and

- (b) R^1 and R^2 are independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl.

Other preferred compounds of formula **I** are those wherein W^1 is L.

5 Other preferred compounds of formula **I** are those wherein W^1 is V.


Other preferred compounds of formula **I** are those wherein W^1 is $C(R^1)(R^2)-(CH_2)_c-C(R^3)(R^4)-(CH_2)_n-Y$.

Other preferred compounds of formula **I** are those wherein W^1 is $C(R^1)(R^2)-(CH_2)_c-V$.

10 Other preferred compounds of formula **I** are those wherein W^1 and W^2 are independent L groups.

Other preferred compounds of formula **I** are those wherein each occurrence of Y is independently OH, $COOR^5$, or COOH.

15 In another embodiment, the invention relates to a compound of the formula **Ia**:




20 **Ia**

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

- (a) each occurrence of Z is independently CH_2 or $CH=CH$, wherein each occurrence of m is independently an integer ranging from 1 to 9;
- 25 (b) G is $(CH_2)_x$, $CH_2CH=CHCH_2$, or $CH=CH$, where x is 2, 3, or 4;
- (c) W^1 and W^2 are independently L, V, or $C(R^1)(R^2)-(CH_2)_c-V$, where c is 1 or 2;
- 30 (d) each occurrence of R^1 and R^2 is independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl;
- (e) L is $C(R^1)(R^2)-(CH_2)_n-Y$, where n is an independent integer ranging from 0 to 4;


35

(f) V is



(g) each occurrence of Y is independently OH, COOH, CHO, $(\text{CH}_2)_n\text{COOR}^3$, SO_3H ,

5



where:

(i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,

5

(ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups; and

10

(iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;

provided that:

15

(i) if x is 4, each occurrence of Z is CH_2 , each occurrence of m is 4, and W^1 is $-CH(CH_3)CO_2H$, then W^2 is not the same as W^1 ; and


20

(ii) if x is 4, each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(phenyl)_2CH_2CO_2H$, then W^2 is not the same as W^1 .

Preferably, in formula **Ia** each occurrence of Y is independently OH, $COOR^3$, or COOH.

In yet another embodiment, the invention relates to a compound of the formula **Ib**:

25



30

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:





(a) each occurrence of m is independently an integer ranging from 1 to 9;

35

(b) x is 2, 3, or 4;

- (c) each occurrence of n is an independent integer ranging from 0 to 4;
- (d) each occurrence of R¹ and R² is independently (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl; and
- 5 (e) each occurrence of Y is independently OH, COOH, CHO, COOR³, SO₃H,

10



15

where:

(i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,

(ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups; and

(iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;


provided that:

(i) if x is 4 each occurrence of m is 4, and W^1 is $-\text{CH}(\text{CH}_3)\text{CO}_2\text{H}$, then W^2 is not the same as W^1 ; and

(ii) if x is 4 occurrence of m is 2, and W^1 is $-\text{C}(\text{phenyl})_2\text{CH}_2\text{CO}_2\text{H}$, then W^2 is not the same as W^1 .

Preferably in formula **Ib**, each occurrence of Y is independently OH, COOR^3 , or COOH.

In still another embodiment, the invention relates to a compound of the formula **Ic**:




Ic

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

(a) each occurrence of m is an independent integer ranging from 1 to 9;

(b) x is 2, 3, or 4;

(c) V is



provided that:


(i) if x is 4 each occurrence of m is 4, and W^1 is $-\text{CH}(\text{CH}_3)\text{CO}_2\text{H}$, then W^2 is not the same as W^1 ; and

5

(ii) if x is 4 each occurrence of m is 2, and W^1 is $-\text{C}(\text{phenyl})_2\text{CH}_2\text{CO}_2\text{H}$, then W^2 is not the same as W^1 .

In another embodiment, the invention relates to a compound of the formula **II**:

10



II


15 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:


(a) R^1 and R^2 are independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl; or R^1 , R^2 , and the carbon to which they are both attached are taken together to form a (C_3-C_7) cycloalkyl group;

20

(b) n is an integer ranging from 1 to 5;

- (c) each occurrence of m is independently an integer ranging from 0 to 4;
- (d) each occurrence of W^1 and W^2 is independently CH_2OH , $COOH$, CHO , $OC(O)R^3$, $C(O)OR^3$, SO_3H ,





where:

- (i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- (ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups;
- (iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl; and
- (iv) each occurrence of n is independently an integer ranging from 0 to 4.

Preferred compounds of formula **II** are those wherein each occurrence of W is independently OH, $COOR^3$, or COOH.

Other preferred compounds of formula **II** are those wherein R^1 and R^2 are independent (C_1-C_6) alkyl groups.

Other preferred compounds of formula **II** are those wherein m is 0.

Other preferred compounds of formula **II** are those wherein m is 1.

Other preferred compounds of formula **II** are those wherein R^1 and R^2 are each independently (C_1-C_6) alkyl.


Other preferred compounds of formula **II** are those wherein R^1 and R^2 are each methyl.

Other preferred compounds of formula **II** are those wherein W^1 and/or W^2 is COOH or CH_2OH .

5


In another embodiment, the invention relates to a compound of the formula **IIa**:

10

**IIa**

15 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

(a) R^1 and R^2 are OH, COOH, CHO, COOR⁷, SO₃H,



20

where:

(i) R^7 is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C₁-C₆)alkoxy, or phenyl groups,

25

- (ii) each occurrence of R^8 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups, and
- 5 (iii) each occurrence of R^9 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;
- (b) R^3 and R^4 are (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl;
- 10 (c) R^5 and R^6 are hydrogen, halogen, (C_1-C_4) alkyl, (C_1-C_4) alkoxy, (C_6) aryloxy, CN, or NO_2 , $N(R^5)_2$ where R^5 is H, (C_1-C_4) alkyl, phenyl, or benzyl;
- (d) each occurrence of m is independently an integer ranging from 1 to 5;
- 15 (e) each occurrence of n is independently an integer ranging from 0 to 4; and
- (f) C^{*1} and C^{*2} represent independent chiral-carbon centers, wherein each center may independently be R or S.
- 20 Preferred compounds of formula **IIa** are those wherein each occurrence of R^1 and R^2 is independently OH, $COOR^7$, or COOH.
- Other preferred compounds of formula **IIa** are those wherein m is 0.
- Other preferred compounds of formula **IIa** are those wherein m is 1.
- Other preferred compounds of formula **IIa** are those wherein R^1 and/or R^2 is COOH
- 25 or CH_2OH .
- Other preferred compounds of formula **IIa** are those wherein R^3 and R^4 are each independently (C_1-C_6) alkyl.
- Other preferred compounds of formula **IIa** are those wherein R^3 and R^4 are each methyl.
- 30 Other preferred compounds of formula **IIa** are those wherein C^{*1} is of the stereochemical configuration R or substantially R.
- Other preferred compounds of formula **IIa** are those wherein C^{*1} is of the stereochemical configuration S or substantially S.
- Other preferred compounds of formula **IIa** are those wherein C^{*2} is of the
- 35 stereochemical configuration R or substantially R.

Other preferred compounds of formula **IIa** are those wherein C*² is of the stereochemical configuration S or substantially S.


In a particular embodiment, compounds of formula **IIa** are those wherein C*¹ C*² are of the stereochemical configuration (S¹,S²) or substantially (S¹,S²).

5 In another particular embodiment, compounds of formula **IIa** are those wherein C*¹ C*² are of the stereochemical configuration (S¹,R²) or substantially (S¹,R²).

In another particular embodiment, compounds of formula **IIa** are those wherein C*¹ C*² are of the stereochemical configuration (R¹,R²) or substantially (R¹,R²).

10 In another particular embodiment, compounds of formula **IIa** are those wherein C*¹ C*² are of the stereochemical configuration (R¹,S²) or substantially (R¹,S²).


In still another embodiment, the invention relates to a compound of the formula **III**:



III


15 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

- (a) each occurrence of Z is independently CH₂, CH=CH, or phenyl, where each occurrence of m is independently an integer ranging from 1 to 5, but when Z is phenyl then its associated m is 1;
- 20 (b) G is (CH₂)_x, CH₂CH=CHCH₂, CH=CH, CH₂-phenyl-CH₂, or phenyl, where x is an integer ranging from 1 to 4;
- 25 (c) W¹ and W² are independently C(R¹)(R²)-(CH₂)_n-Y where n is an integer ranging from 0 to 4;





- (d) each occurrence of R^1 and R^2 is independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl, or where R^1 and R^2 are both hydrogen;
- 5 (e) each occurrence of R^6 and R^7 is independently H, (C_1-C_6) alkyl, or where R^6 and R^7 are taken together to form a carbonyl group;
- (f) each occurrence of Y is independently OH, COOH, CHO, COOR³, SO₃H,

10



15





where:

- 5 (i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- 10 (ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- (iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl; and
- 15 (g) each occurrence of p is independently 0 or 1, where the broken line represents an optional presence of one or more additional carbon-carbon bonds that when present complete one or more carbon-carbon double bonds.


Preferred compounds of formula **III** are those wherein each occurrence of Y is independently OH, $COOR^3$, or COOH.

20 Other preferred compounds of formula **III** are those wherein p is 2.

Other preferred compounds of formula **III** are those wherein p is 3.

25


In yet another embodiment, the invention relates to a compound of the formula **IIIa**:




IIIa

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

- (a) each occurrence of m is independently an integer ranging from 1 to 5;
- (b) x is an integer ranging from 1 to 4;
- (c) W^1 and W^2 are independently $C(R^1)(R^2)-(CH_2)_n-Y$; where n is an integer ranging from 0 to 4,



- (d) each occurrence of R^1 or R^2 is independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl;
- (e) each occurrence of Y is independently OH, COOH, CHO, COOR³, SO₃H,



where:

(i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,

(ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups,

(iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl; and

(f) each occurrence of p is independently 0 or 1.

Preferably in compound **IIIa**, W^1 and W^2 are independent $C(R^1)(R^2)-Y$ groups and each occurrence of Y is independently OH, $COOR^3$, or COOH.

The compounds of the invention are useful in medical applications for treating or preventing cardiovascular diseases, dyslipidemias, dyslipoproteinemias, disorders of glucose metabolism, Alzheimer's Disease, Syndrome X, PPAR-associated disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal diseases, cancer, inflammation, and impotence. As used herein, the phrase "compounds of the invention" means, collectively, the compounds of formulas **I**, **II**, and **III** and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof. Compounds of formula **I** encompass subgroup formulas **Ia**, **Ib**, and **Ic**. Compounds of formula **II** encompass subgroup formula **IIa** and compounds of formula **III** encompass subgroup of formula **IIIa**. Thus, "compound of the invention" collectively means compound of formulas **I**, **Ia**, **Ib**, **Ic**, **II**, **IIa**, **III**, and **IIIa** and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof. The compounds of the invention are identified herein by their chemical structure and/or chemical name. Where a compound is referred to by both a chemical structure and a chemical name, and the chemical structure and chemical name conflict, the chemical structure is determinative of the compound's identity.

3.1. Brief Description of the Drawings

Various aspects of the invention can be understood with reference to the figures described below:

FIG. 1 illustrates the effect of one week of daily oral gavage treatment on lipoprotein total cholesterol in chow-fed male Sprague-Dawley rats;

FIG. 2 illustrates the effect of one week of daily oral gavage treatment on serum lipids in chow-fed male Sprague-Dawley rats;

FIG. 3 illustrates the effect of two weeks of daily oral gavage treatment on lipoprotein total cholesterol in chow-fed obese female Zucker rats;

FIG. 4 is a table illustrating the effect of two weeks of daily oral gavage treatment using a specific compound of the invention in chow-fed obese female Zucker rats; and

FIG. 5 is a table illustrating the effect of two weeks of daily oral gavage treatment using a specific compound of the invention on the synthesis of saponified and non-saponified

lipids in hepatocyte cells isolated from male Sprague-Dawley rats.

4. Detailed Description of the Invention

The present invention provides novel compounds useful for treating or preventing a cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, Alzheimer's Disease, Syndrome X, a PPAR-associated disorder, septicemia, a thrombotic disorder, obesity, pancreatitis, hypertension, a renal disease, cancer, inflammation, and impotence.

In this regard, the compounds of the invention are particularly useful when incorporated in a pharmaceutical composition having a carrier, excipient, diluent, or a mixture thereof. A composition of the invention need not contain additional ingredients, such as an excipient, other than a compound of the invention. Accordingly, in one embodiment, the compositions of the invention can omit pharmaceutically acceptable excipients and diluents and can be delivered in a gel cap or drug delivery device.


Accordingly, the present invention provides methods for treating or preventing cardiovascular diseases, dyslipidemias, dyslipoproteinemias, disorders of glucose metabolism, Alzheimer's Disease, Syndrome X, PPAR-associated disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal diseases, cancer, inflammation, or impotence, comprising administering to a patient in need thereof a therapeutically effective amount of a compound or composition of the invention.

In certain embodiments of the invention, a compound of the invention is administered in combination with another therapeutic agent. The other therapeutic agent provides additive or synergistic value relative to the administration of a compound of the invention alone. The therapeutic agent can be a lovastatin; a thiazolidinedione or fibrate; a bile-acid-binding-resin; a niacin; an anti-obesity drug; a hormone; a tyroprostatine; a sulfonylurea-based drug; a biguanide; an α -glucosidase inhibitor; an apolipoprotein A-I agonist; apolipoprotein E; a cardiovascular drug; an HDL-raising drug; an HDL enhancer; or a regulator of the apolipoprotein A-I, apolipoprotein A-IV and/or apolipoprotein genes.

Table 1 lists the compounds of the invention:

TABLE 1: Compounds of the Invention


5

**I-1**

10


5-Hydroxy-1-[4-(5-hydroxy-5-methyl-2-oxo-hexyl)-phenyl]-5-methyl-hexan-2-one

15

**I-2**

6-Hydroxy-1-[4-(6-hydroxy-5,5-dimethyl-2-oxo-hexyl)-phenyl]-5,5-dimethyl-hexan-2-one


20

**I-3**

25


6-[4-(5-Carboxy-5-methyl-2-oxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanoic acid

30

**I-4**

6-[4-(5,5-Dimethyl-2,6-dioxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanal

35




5

I-5

6-[4-(5-Methoxycarbonyl-5-methyl-2-oxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanoic
acid methyl ester

10




15

I-6

2,2-Dimethyl-6-[4-(5-methyl-2-oxo-5-phenoxy-carbonyl-hexyl)-phenyl]-5-oxo-hexanoic
acid phenyl ester

20




25

I-7

6-[4-(5-Benzyloxycarbonyl-5-methyl-2-oxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanoic
acid benzyl ester


30

**I-8**

2-Methyl-6-[4-(5-methyl-2-oxo-5-sulfo-hexyl)-phenyl]-5-oxo-hexane-2-sulfonic acid


35

5

**I-9**

Phosphoric acid mono-{1,1-dimethyl-5-[4-(5-methyl-2-oxo-5-phosphonooxy-hexyl)-phenyl]-4-oxo-pentyl} ester

10




15

I-10

4-Hydroxy-1-[4-(4-hydroxy-4-methyl-pentanoyl)-phenyl]-4-methyl-pentan-1-one

20




25

I-11

5-Hydroxy-1-[4-(5-hydroxy-4,4-dimethyl-pentanoyl)-phenyl]-4,4-dimethyl-pentan-1-one

30


35



5

I-12


5-[4-(4-Carboxy-4-methyl-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanoic acid



10

I-13


5-[4-(4,4-Dimethyl-5-oxo-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanal



20

I-14


25 5-[4-(4-Methoxycarbonyl-4-methyl-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanoic acid
methyl ester



30

I-15


35 2,2-Dimethyl-6-[4-(5-methyl-2-oxo-5-phenoxy-carbonyl-hexyl)-phenyl]-5-oxo-hexanoic
acid phenyl ester



5

I-16


10 5-[4-(4-Benzyloxycarbonyl-4-methyl-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanoic
acid benzyl ester



15

I-17

20 2-Methyl-5-[4-(4-methyl-4-sulfo-pentanoyl)-phenyl]-5-oxo-pentane-2-sulfonic acid




25


I-18

30 Phosphoric acid mono-{1,1-dimethyl-4-[4-(4-methyl-4-phosphonooxy-pentanoyl)-phenyl]-
4-oxo-butyl} ester


35

**Ib-1**


2,12-Dihydroxy-2,12-dimethyl-tridecane-5,9-dione

**Ib-2**


1,13-Dihydroxy-2,2,12,12-tetramethyl-tridecane-5,9-dione

**Ib-3**


2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid

**Ib-4**


2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedial

**Ib-5**


2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid dimethyl ester

**Ib-6**


2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid diphenyl ester

**Ib-7**


2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid dibenzyl ester

**Ib-8**


2,12-Dimethyl-5,9-dioxo-tridecane-2,12-disulfonic acid

**Ib-9**

Phosphoric acid mono-(1,1,11-trimethyl-4,8-dioxo-11-phosphonooxy-dodecyl) ester

**Ib-10**


2,12-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,12-dimethyl-tridecane-5,9-dione



5

Ib-11


2,12-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,12-dimethyl-tridecane-5,9-dione



10

Ib-12


2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid dicyanimide



15

Ib-13


Phosphoramidic acid mono-[11-(amino-hydroxy-phosphoryloxy)-1,1,11-trimethyl-4,8-dioxo-dodecyl] ester



25

Ib-14

2,12-Dimethyl-2,12-bis-(amino-hydroxy-phosphoryloxy)-tridecane-5,9-dione




30


Ib-15

2,12-Dimethyl-2,12-bis-tetrazol-1-yl-tridecane-5,9-dione


35

**Ib-16**


2,12-Dimethyl-2,12-bis-(1H-tetrazol-5-yl)-tridecane-5,9-dione

**Ib-17**


2,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,12-dimethyl-tridecane-5,9-dione

**Ib-18**


2,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,12-dimethyl-tridecane-5,9-dione

**Ib-19**

2,12-Bis-(5-hydroxy-4-oxo-4H-pyran-3-yl)-2,12-dimethyl-tridecane-5,9-dione

**Ib-20**


2,12-Bis-(5-hydroxy-4-oxo-4H-pyran-2-yl)-2,12-dimethyl-tridecane-5,9-dione



5

Ib-21


1-Ethyl-3-[11-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-1,1,11-trimethyl-4,8-dioxo-dodecyl]-imidazolidine-2,4-dione



10

Ib-22


2,12-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,12-dimethyl-tridecane-5,9-dione



20

Ib-23

2,12-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,12-dimethyl-tridecane-5,9-dione




25


Ib-24

2,12-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,12-dimethyl-tridecane-5,9-dione


35

**Ib-25**


1,15-Dihydroxy-3,3,13,13-tetramethyl-pentadecane-6,10-dione

**Ib-26**


3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedioic acid

**Ib-27**


3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedial

**Ib-28**

3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedioic acid dimethyl ester

**Ib-29**


2,2,12,12-Tetramethyl-5,9-dioxo-tetradecanedioic acid diphenyl ester



Ib-30


3,3,13,13-Tetramethyl-6,10,14-trioxo-16-phenyl-hexadecanoic acid benzyl ester

5

**Ib-31**


2,2,12,12-Tetramethyl-5,9-dioxo-tridecane-1,13-disulfonic acid

10

**Ib-32**


15 Phosphoric acid mono-(2,2,12,12-tetramethyl-5,9-dioxo-13-phosphonooxy-tridecyl) ester

20

**Ib-33**


1,13-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione

25

**Ib-34**

30 1,13-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione


35



Ib-35


3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedioic acid dicyanimide

5

**Ib-36**

Phosphoramidic acid mono-[13-(amino-hydroxy-phosphoryloxy)-2,2,12,12-tetramethyl-6,9-dioxo-tridecyl] ester

10




15

Ib-37

Phosphoramidic acid


mono-[11-(amino-hydroxy-phosphoryloxy)-1,1,11-trimethyl-4,8-dioxo-dodecyl] ester

20

**Ib-38**

25

2,2,12,12-Tetramethyl-1,13-bis-tetrazol-1-yl-tridecane-5,9-dione




30

Ib-39


1,13-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione

35




Ib-40

1,13-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione

**Ib-41**

1,13-Bis-(3-hydroxy-isoxazol-4-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione

10




15

Ib-42


1-(5-Hydroxy-4-oxo-4H-pyran-3-yl)-13-(5-hydroxy-4-oxo-4H-pyran-2-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione

20


**Ib-43**

1,13-Bis-(5-hydroxy-4-oxo-4H-pyran-2-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione

30

**Ib-44**


1,13-Bis-(5-hydroxy-4-oxo-4H-pyran-3-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione



5

Ib-45

1-Ethyl-3-[13-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-5,9-dioxo-tridecyl]-imidazolidine-2,4-dione




10

Ib-46

1,13-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione


15



20

Ib-47

1,13-Bis-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione




25

Ib-48

1,13-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione

30




35

Ib-49


1,13-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione

5

**Ib-50**


2,11-Dihydroxy-2,11-dimethyl-dodecane-5,8-dione

10

**Ib-51**

1,12-Dihydroxy-2,2,11,11-tetramethyl-dodecane-5,8-dione

15




20

Ib-52


2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid

25

**Ib-53**

2,11-Dimethyl-5,8-dioxo-dodecane-2,11-disulfonic acid


30



35

Ib-54


2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedial



5

Ib-55


2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dimethyl ester



10

Ib-56

2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid diphenyl ester




15

20

Ib-57


2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dibenzyl ester



25

Ib-58

Phosphoric acid mono-(1,1,10-trimethyl-4,7-dioxo-10-phosphonooxy-undecyl) ester




30


Ib-59

2,14-Dihydroxy-2,14-dimethyl-pentadecane-6,10-dione


35

**Ib-60**


1,15-Dihydroxy-2,2,14,14-tetramethyl-pentadecane-6,10-dione

**Ib-61**


2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedioic acid

**Ib-62**


2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedial

**Ib-63**

2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedioic acid dimethyl ester

**Ib-64**

2,2,14,14-Tetramethyl-6,10-dioxo-hexadecanedioic acid diphenyl ester




5

Ib-65


2,2,14,14-Tetramethyl-6,10-dioxo-hexadecanedioic acid dibenzyl ester

10

**Ib-66**


2,14-Dimethyl-6,10-dioxo-pentadecane-2,14-disulfonic acid

15

**Ib-67**

Phosphoric acid mono-(1,1,13-trimethyl-5,9-dioxo-13-phosphonoxy-tetradecyl) ester


20

**Ib-68**

2,14-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,14-dimethyl-pentadecane-6,10-dione


25

30


**Ib-69**

2,14-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,14-dimethyl-pentadecane-6,10-dione


35

**Ib-70**


2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedioic acid dicyanimide

**Ib-71**


Phosphoramidic acid mono-[13-(amino-hydroxy-phosphoryloxy)-1,1,13-trimethyl-5,9-dioxo-tetradecyl] ester

**Ib-72**


2,14-Dimethyl-2,14-bis-(amino-hydroxy-phosphoryloxy)-pentadecane-6,10-dione

**Ib-73**

2,14-Dimethyl-2,14-bis-tetrazol-1-yl-pentadecane-6,10-dione

**Ib-74**

2,14-Dimethyl-2,14-bis-(1H-tetrazol-5-yl)-pentadecane-6,10-dione




5

Ib-75


2,14-Bis-(3-hydroxy-isoxazol-5-yl)-2,14-dimethyl-pentadecane-6,10-dione

10

**Ib-76**

2,14-Bis-(3-hydroxy-isoxazol-4-yl)-2,14-dimethyl-pentadecane-6,10-dione

15




20

Ib-77

2,14-Bis-(5-hydroxy-4-oxo-4H-pyran-3-yl)-2,14-dimethyl-pentadecane-6,10-dione


25



30

Ib-782-(5-Hydroxy-4-oxo-4H-pyran-2-yl)-2,14-dimethyl-14-(5-methyl-4-oxo-4H-pyran-2-yl)-
pentadecane-6,10-dione


35



5

Ib-79


2,14-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione



10

Ib-80


2,14-Bis-(3-ethyl-2,5-dithio-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione



15

Ib-81

2,14-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione



20


25

Ib-82

2,14-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione

30


35



5

Ib-83


1,14-Dihydroxy-3,3,12,12-tetramethyl-tetradecane-6,9-dione



10

Ib-84


3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid



15

Ib-85


3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedial



20

Ib-86

3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid dimethyl ester




25

Ib-87


3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid diphenyl ester

30


35

**Ib-88**


3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid dibenzyl ester

**Ib-89**


2,2,11,11-Tetramethyl-5,8-dioxo-dodecane-1,12-disulfonic acid

**Ib-90**


Phosphoric acid mono-(2,2,11,11-tetramethyl-5,8-dioxo-12-phosphonooxy-dodecyl) ester

**Ib-91**

1,12-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione

**Ib-92**


1,12-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dithione



5

Ib-93


3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid dicyanimide



10

Ib-94


Phosphoramidic acid mono-[12-(amino-hydroxy-phosphoryloxy)-2,2,11,11-tetramethyl-5,8-dioxo-dodecyl] ester



15

Ib-95


2,2,11,11-Tetramethyl-1,12-bis-(aminohydroxyphosphoryloxy)-dodecane-5,8-dione



20

Ib-96

2,2,11,11-Tetramethyl-1,12-bis-(1H-tetrazol-5-yl)-dodecane-5,8-dione




30

Ib-97

1,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione

35




5

Ib-98

1,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione


10

**Ib-99**

1-(5-Hydroxy-4-oxo-4H-pyran-3-yl)-12-(5-hydroxy-4-oxo-4H-pyran-2-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione


15

20

**Ib-100**

1,12-Bis-(5-hydroxy-4-oxo-4H-pyran-3-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione

25




30


Ib-101

1,12-Bis-(5-hydroxy-4-oxo-4H-pyran-3-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione


35

**Ib-102**


1-Ethyl-3-[12-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-5,8-dioxo-dodecyl]-imidazolidine-2,4-dione

**Ib-103**


1-Ethyl-3-[12-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-5,8-dioxo-dodecyl]-imidazolidine-2,4-dione

**Ib-104**


1,12-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione

**Ib-105**


1,12-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione

**Ib-106**


1,16-Dihydroxy-4,4,13,13-tetramethyl-hexadecane-7,10-dione

**Ib-107**


4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid

**Ib-108**

4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedial

**Ib-109**


4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid dimethyl ester



5

Ib-110


4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid diphenyl ester



10

Ib-111


4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid dibenzyl ester



15

Ib-112

3,3,12,12-Tetramethyl-6,9-dioxo-tetradecane-1,14-disulfonic acid




20

Ib-113

Phosphoric acid mono-(3,3,12,12-tetramethyl-6,9-dioxo-14-phosphonooxy-tetradecyl) ester

25




30

Ib-114

1,14-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione


35



5

Ib-115

1,14-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione




10

Ib-116

4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid dicyanimide


15



20

Ib-117


Phosphoramidic acid mono-[14-(amino-hydroxy-phosphoryloxy)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl] ester



25

Ib-118

3,3,12,12-Tetramethyl-1,14-bis-(amino-hydroxy-phosphoryloxy)-tetradecane-6,9-dione




30

Ib-119

1,12-Dihydroxy-2,2,11,11-tetramethyl-dodecane-5,8-dione


35



5

Ib-120


2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid



10

Ib-121


2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedial



15

Ib-122


2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dimethyl ester



20

Ib-123

2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid diphenyl ester




30


Ib-124

2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dibenzyl ester


35

**Ib-125**


2,11-Dimethyl-5,8-dioxo-dodecane-2,11-disulfonic acid

**Ib-126**


Phosphoric acid mono-(1,1,10-trimethyl-4,7-dioxo-10-phosphonooxy-undecyl) ester

**Ib-127**


2,11-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,11-dimethyl-dodecane-5,8-dione

**Ib-128**

2,11-Bis-(4,6-dithio-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,11-dimethyl-dodecane-5,8-dione

**Ib-129**

2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dicyanimide




5

Ib-130


Phosphoramidic acid mono-[10-(amino-hydroxy-phosphoryloxy)-1,1,10-trimethyl-4,7-dioxo-undecyl] ester

10

**Ib-131**


2,2,11,11-Tetramethyl-1,12-(amino-hydroxy-phosphoryloxy)-dodecane-5,8-dione

15

**Ib-132**

20

3,3,12,12-Tetramethyl-1,14-bis-tetrazol-1-yl-tetradecane-6,9-dione




25

Ib-133

3,3,12,12-Tetramethyl-1,14-bis-(1H-tetrazol-5-yl)-tetradecane-6,9-dione


30



35

Ib-134


1,14-Bis-(3-hydroxy-isoxazol-5-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione



5

Ib-135

1,14-Bis-(3-hydroxy-isoxazol-4-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione




10

Ib-136

1-(5-Hydroxy-4-oxo-4H-pyran-2-yl)-14-(5-hydroxy-4-oxo-4H-pyran-3-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione

15




20

Ib-137

1,14-Bis-(5-hydroxy-4-oxo-4H-pyran-2-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione

25




30


Ib-138

1,14-Bis-(5-hydroxy-4-oxo-4H-pyran-3-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione


35

**Ib-139**


1-Ethyl-3-[14-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl]-imidazolidine-2,4-dione

**Ib-140**


1-Ethyl-3-[14-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl]-imidazolidine-2,4-dione

**Ib-141**

1-Ethyl-3-[14-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl]-imidazolidine-2,4-dithione


**Ib-142**

1,14-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione




Ib-143


1,14-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione

**Ib-144**


1,17-Dihydroxy-3,3,15,15-tetramethyl-heptadecane-7,11-dione

**Ib-145**


3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedial

**Ib-146**


3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid dimethyl ester

**Ib-147**


1,17-Dihydroxy-3,3,15,15-tetramethyl-heptadecane-7,11-dione

**Ib-148**

3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid diphenyl ester

**Ib-149**


3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid dibenzyl ester



5

Ib-150

2,11-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,11-dimethyldodecane-5,8-dione




10

Ib-151

2,11-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,11-dimethyldodecane-5,8-dione


15



20

Ib-152

2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dicyanamide




25

Ib-153

Phosphoramidic acid mono-[10-(amino-hydroxy-phosphoryloxy)-1,1,10-trimethyl-4,7-dioxo-undecyl] ester

30


35



5

Ib-154


2,11-Dimethyl-2,11-bis-(amino-hydroxy-phosphoryloxy)-dodecane-5,8-dione



10

Ib-155


2,11-Dimethyl-2,11-bis-tetrazol-1-yl-dodecane-5,8-dione



15

Ib-156


2,11-Dimethyl-2,11-bis-(1H-tetrazol-5-yl)-dodecane-5,8-dione



25

Ib-157


2,2,14,14-Tetramethyl-6,10-dioxo-pentadecane-1,15-disulfonic acid



30

Ib-158Phosphoric acid mono-(2,2,14,14-tetramethyl-6,10-dioxo-15-phosphonooxy-pentadecyl)
ester

35




5

Ib-159

1,15-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione

10




15

Ib-160


1,15-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione

20

**Ib-161**

3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid dicyanamide

25




30

Ib-162

Phosphoramidic acid mono-[16-(amino-hydroxy-phosphoryloxy)-4,4,15,15-tetramethyl-7,11-dioxo-hexadecyl] ester

35




5

Ib-163


2,2,14,14-Tetramethyl-1,15-bis-(amino-hydroxy-phosphoryloxy)-pentadecane-6,10-dione

10

**Ib-164**


2,2,14,14-Tetramethyl-1,15-bis-tetrazol-1-yl-pentadecane-6,10-dione

15

**Ib-165**

2,2,14,14-Tetramethyl-1,15-bis-(1H-tetrazol-5-yl)-pentadecane-6,10-dione

20




25

Ib-166


1,15-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione

30

**Ib-167**

1,15-Bis-(3-hydroxy-isoxazol-4-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione


35



5

Ib-168


1-(5-Hydroxy-4-oxo-4H-pyran-3-yl)-15-(5-hydroxy-4-oxo-4H-pyran-2-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione



10

Ib-169


1,15-Bis-(5-hydroxy-4-oxo-4H-pyran-2-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione



15

Ib-170

1,15-Bis-(5-hydroxy-4-oxo-4H-pyran-3-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione




25

Ib-171


1,15-Bis-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione

30


35

**Ib-172**


1-Ethyl-3-[15-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-6,10-dioxo-pentadecyl]-imidazolidine-2,4-dione

**Ib-173**


1,15-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione

**Ib-174**

1,15-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione


**Ib-175**

1,15-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione

**Ic-1**


1,9-Bis-(tetrahydro-pyran-2-yloxy)-nonane-3,7-dione

5

**Ic-2**


1,9-Bis-(4-oxo-oxetan-2-yl)-nonane-3,7-dione

10

**Ic-3**


1,9-Bis-(2-oxo-oxetan-3-yl)-nonane-3,7-dione

15

**Ic-4**

1,9-Bis-(5-oxo-tetrahydrofuran-2-yl)-nonane-3,7-dione

20


**Ic-5**

1,9-Bis-(5-oxo-tetrahydrofuran-3-yl)-nonane-3,7-dione

25

30


35



5

Ic-6

1,9-Bis-(2-oxo-tetrahydrofuran-3-yl)-nonane-3,7-dione




10

Ic-7

{2-[9-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-3,7-dioxo-nonyl]-4-hydroxy-6-oxo-tetrahydropyran-4-yl}-acetic acid


15



20

Ic-8

1,9-Bis-(6-oxo-tetrahydropyran-2-yl)-nonane-3,7-dione




25

Ic-9


1,9-Bis-(6-oxo-tetrahydropyran-3-yl)-nonane-3,7-dione

30


35

**Ic-10**


1,9-Bis-(2-oxo-tetrahydropyran-4-yl)-nonane-3,7-dione

**Ic-11**


1,9-Bis-(2-oxo-tetrahydropyran-3-yl)-nonane-3,7-dione

**Ic-12**


1,11-Bis-(tetrahydro-pyran-2-yloxy)-undecane-4,8-dione

**Ic-13**

1,11-Bis-(2-oxo-oxetan-3-yl)-undecane-4,8-dione

**Ic-14**


1,11-Bis-(2-oxo-oxetan-3-yl)-undecane-4,8-dione



5

Ic-15


1,11-Bis-(5-oxo-tetrahydrofuran-2-yl)-undecane-4,8-dione



10

Ic-16


1,11-Bis-(5-oxo-tetrahydrofuran-3-yl)-undecane-4,8-dione



15

Ic-17

1,11-Bis-(2-oxo-tetrahydrofuran-3-yl)-undecane-4,8-dione




20

Ic-18

{2-[11-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-4,8-dioxo-undecyl]-4-hydroxy-6-oxo-tetrahydropyran-4-yl}-acetic acid

25




30


Ic-19

1,11-Bis-(6-oxo-tetrahydropyran-2-yl)-undecane-4,8-dione


35

**Ic-20**

1,11-Bis-(6-oxo-tetrahydropyran-3-yl)-undecane-4,8-dione


**Ic-21**

1,11-Bis-(2-oxo-tetrahydropyran-4-yl)-undecane-4,8-dione

**Ic-22**


1,11-Bis-(2-oxo-tetrahydropyran-3-yl)-undecane-4,8-dione

5

**IC-23**


1,8-Bis-(tetrahydropyran-2-yloxy)-octane-3,6-dione

10

**IC-24**

1,8-Bis-(4-oxo-oxetan-2-yl)-octane-3,6-dione

15




20

IC-25

1,8-Bis-(2-oxo-oxetan-3-yl)-octane-3,6-dione

25




30

IC-26

1,8-Bis-(5-oxo-tetrahydro-furan-2-yl)-octane-3,6-dione


35



5

IC-27


1,8-Bis-(5-oxo-tetrahydro-furan-3-yl)-octane-3,6-dione



10

IC-28

1,8-Bis-(2-oxo-tetrahydro-furan-3-yl)-octane-3,6-dione




15

20

IC-29

{2-[8-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-3,6-dioxo-octyl]-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl}-acetic acid

25




30

IC-30

1,8-Bis-(6-oxo-tetrahydropyran-2-yl)-octane-3,6-dione


35



5

IC-31


1,8-Bis-(6-oxo-tetrahydropyran-3-yl)-octane-3,6-dione



10

IC-32

1,8-Bis-(2-oxo-tetrahydropyran-4-yl)-octane-3,6-dione



15

20


IC-33

1,8-Bis-(2-oxo-tetrahydropyran-3-yl)-octane-3,6-dione


25

30


35

**II-1**


1,13-Dihydroxy-2,2,12,12-tetramethyl-tridecan-7-one

**II-2**


12-Hydroxy-2,2,12-trimethyl-7-oxo-tridecanoic acid; compound with formaldehyde

**II-3**


11-Hydroperoxy-2,2,10,10-tetramethyl-6-oxo-undecanoic acid

**II-4**

1,11-Dihydroxy-2,2,10,10-tetramethyl-undecan-6-one


**II-5**

11-Hydroxy-2,2,10,10-tetramethyl-6-oxo-undecanoic acid

**II-6**

5


2,2,10,10-Tetramethyl-6-oxo-undecanedioic acid



10

II-7


1,15-Dihydroxy-2,2,14,14-tetramethyl-pentadecan-8-one



15

II-8


15-Hydroxy-2,2,14,14-tetramethyl-8-oxo-pentadecanoic acid



20

II-9

2,2,14,14-Tetramethyl-8-oxo-pentadecanedioic acid




25

II-10

2,2,12,12-Tetramethyl-7-oxo-tridecanedial

30


35



5

II-11


2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid dimethyl ester



10

II-12


2,2,12,12-Tetramethyl-1,13-diphenyl-tridecane-1,7,13-trione



15

II-13


3,3,13,13-Tetramethyl-1,15-diphenyl-pentadecane-2,8,14-trione



20

II-14

2,12-Dimethyl-7-oxo-tridecane-2,12-disulfonic acid




25

II-15


Phosphoric acid mono-(1,1,11-trimethyl-6-oxo-11-phosphonooxy-dodecyl) ester

35

**II-16**


2,2,14,14-Tetramethyl-8-oxo-pentadecanedial

5

**II-17**

2,2,14,14-Tetramethyl-8-oxo-pentadecanedioic acid dimethyl ester

10




15

II-18


2,2,14,14-Tetramethyl-1,15-diphenyl-pentadecane-1,8,15-trione

20

**II-19**

3,3,15,15-Tetramethyl-1,17-diphenyl-heptadecane-2,9,16-trione


25

**II-20**

2,14-Dimethyl-8-oxo-pentadecane-2,14-disulfonic acid

30


35



5

II-21


Phosphoric acid mono-(1,1,13-trimethyl-7-oxo-13-phosphonooxy-tetradecyl) ester



10

II-22


1,15-Dihydroxy-3,3,13,13-tetramethyl-pentadecan-8-one



15

II-23


15-Hydroxy-3,3,13,13-tetramethyl-8-oxo-pentadecanoic acid



20

II-24

3,3,13,13-Tetramethyl-8-oxo-pentadecanedioic acid




25

II-25


1,13-Dihydroxy-3,3,11,11-tetramethyl-tridecan-7-one

30


35

**II-26**


13-Hydroxy-3,3,11,11-tetramethyl-7-oxo-tridecanoic acid

**II-27**


3,3,11,11-Tetramethyl-7-oxo-tridecanedioic acid

**II-28**


1,17-Dihydroxy-3,3,15,15-tetramethyl-heptadecan-9-one

**II-29**

17-Hydroxy-3,3,15,15-tetramethyl-9-oxo-heptadecanoic acid

**II-30**


3,3,15,15-Tetramethyl-9-oxo-heptadecanedioic acid



5

II-31


1,17-Dihydroxy-4,4,14,14-tetramethyl-heptadecan-9-one



10

II-32


17-Hydroxy-4,4,14,14-tetramethyl-9-oxo-heptadecanoic acid



15

II-33


4,4,14,14-Tetramethyl-heptadecan-9-oxo-1,17-dicarboxylic acid



20

II-34

1,15-Dihydroxy-4,4,14,14-tetramethyl-pentadecan-8-one




30


II-35

15-Hydroxy-4,4,12,12-tetramethyl-8-oxo-pentadecanoic acid


35

**II-36**


4,4,12,12-Tetramethyl-8-oxo-pentadecanedioic acid

**II-37**


1,19-Dihydroxy-4,4,16,16-tetramethyl-nonadecan-10-one

**II-38**


19-Hydroxy-4,4,16,16-tetramethyl-10-oxo-nonadecanoic acid

**II-39**

4,4,16,16-Tetramethyl-10-oxo-nonadecanedioic acid

**II-40**

5-[9-(4-Mercapto-3-methyl-2,6-dioxo-3,6-dihydro-2H-pyridin-1-yl)-1,1,9-trimethyl-5-oxo-decyl]-3,3a-dihydro-2H-thieno[3,2-c]pyridine-4,6-dione




5

II-41


2,10-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,10-dimethyl-undecan-6-one

10

**II-42**

2,2,10,10-Tetramethyl-6-oxo-undecanedioic acid bis-cyanoamide

15




20

II-43

Phosphoramidic acid mono-[9-(amino-hydroxy-phosphoryloxy)-1,1,9-trimethyl-5-oxo-decyl] ester


25

**II-44**

Phosphoramidic acid mono-[9-(amino-hydroxy-phosphoryloxy)-1,1,9-trimethyl-5-oxo-decyl] ester

30


35



5

II-45


2,12-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,12-dimethyl-tridecan-7-one



10

II-46


2,12-Bis-(4,6-dithio-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,12-dimethyl-tridecan-7-one



20

II-47

2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid bis-cyanoamide




25

II-48

Phosphoramidic acid mono-[11-(amino-hydroxy-phosphoryloxy)-1,1,11-trimethyl-6-oxo-dodecyl] ester

30

35




5

II-49


Phosphoramidic acid mono-[11(amino-hydroxy-phosphoryloxy)-1,1,11-trimethyl-6-oxo-dodecyl] ester

10

**II-50**

2,12-Dimethyl-2,12-bis-tetrazol-1-yl-tridecan-7-one


15

**II-51**

20

2,12-Dimethyl-2,12-bis-(1H-tetrazol-5-yl)-tridecan-7-one

25


**II-52**

2,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,12-dimethyl-tridecan-7-one

30


35

5

**II-53**


2,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,12-dimethyl-tridecan-7-one

10

**II-54**


4-[11-(4-oxo-oxetan-2-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-oxetan-2-one

15

**II-55**

3-[11-(4-oxo-oxetan-2-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-oxetan-2-one

20




25

II-56

5-[11-(5-oxo-tetrahydro-furan-3-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-dihydro-furan-2-one


30

**II-57**

3-[11-(5-oxo-tetrahydro-furan-3-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-dihydro-furan-2-one


35

5

**II-58**


4-[11-(5-oxo-tetrahydro-furan-3-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-dihydro-furan-2-one

10

**II-59**

2,12-Dimethyl-2,12-bis-(tetrahydro-pyran-2-yloxy)-tridecan-7-one

15

**II-60**


20

{2-[11-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-1,1,11-trimethyl-6-oxo-dodecyl]-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl}-acetic acid


25

30


35

**IIa-1**


1,15-Dihydroxy-2,14-dimethyl-2,14-diphenyl-pentadecan-8-one

**IIa-2**


15-Hydroxy-2,14-dimethyl-8-oxo-2,14-diphenyl-pentadecanoic acid

**IIa-3**


2,14-Dimethyl-8-oxo-2,14-diphenyl-pentadecanedioic acid

**IIa-4**

1,13-Dihydroxy-2,12-dimethyl-2,12-diphenyl-tridecan-7-one

**IIa-5**


13-Hydroxy-2,12-dimethyl-7-oxo-2,12-diphenyl-tridecanoic acid



5

IIa-6


2,12-Dimethyl-7-oxo-2,12-diphenyl-tridecanedioic acid



10

IIa-7


1,11-Dihydroxy-2,10-dimethyl-2,10-diphenyl-undecan-6-one



20

IIa-8


11-Hydroxy-2,10-dimethyl-6-oxo-2,10-diphenyl-undecanoic acid



25

IIa-9

2,10-Dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid




30

IIa-10

2,14-Dimethyl-8-oxo-2,14-diphenyl-pentadecanediol


35



5

IIa-11

2,14-Dimethyl-8-oxo-2,14-diphenyl-pentadecanedioic acid dimethyl ester




10

IIa-12

2,14-Dimethyl-1,2,14,15-tetraphenyl-pentadecane-1,8,15-trione


15



20

IIa-13


3,15-Dimethyl-1,3,15,17-tetraphenyl-heptadecane-2,9,16-trione



25

IIa-14

8-Oxo-2,14-diphenyl-pentadecane-2,14-disulfonic acid




30

IIa-15

Phosphoric acid mono-(1-methyl-7-oxo-1,13-diphenyl-13-phosphonooxy-tetradecyl) ester


35



5

IIa-16


1,17-Dihydroxy-3,15-dimethyl-3,15-diphenyl-heptadecan-9-one



10

IIa-17


17-Hydroxy-3,15-dimethyl-9-oxo-3,15-diphenyl-heptadecanoic acid



15

IIa-18


3,15-Dimethyl-9-oxo-3,15-diphenyl-heptadecanedioic acid



25

IIa-19

1,15-Dihydroxy-3,13-dimethyl-3,13-diphenyl-pentadecan-8-one




30


IIa-20

15-Hydroxy-3,13-dimethyl-8-oxo-3,13-diphenyl-pentadecanoic acid


35

**IIa-21**


3,13-Dimethyl-8-oxo-3,13-diphenyl-pentadecanedioic acid

**IIa-22**


1,13-Dihydroxy-3,11-dimethyl-3,11-diphenyl-tridecan-7-one

**IIa-23**


13-Hydroxy-3,11-dimethyl-7-oxo-3,11-diphenyl-tridecanoic acid

**IIa-24**

3,11-Dimethyl-7-oxo-3,11-diphenyl-tridecanedioic acid

**IIa-25**


13-Hydroxy-3,11-dimethyl-7-oxo-3,11-diphenyl-tridecanoic acid



5

IIa-26


3,11-Dimethyl-7-oxo-3,11-diphenyl-tridecanedioic acid



10

IIa-27


1,19-Dihydroxy-4,16-dimethyl-4,16-diphenyl-nonadecan-10-one



15

IIa-28


19-Hydroxy-4,16-dimethyl-10-oxo-4,16-diphenyl-nonadecanoic acid



25

IIa-29

4,16-Dimethyl-10-oxo-4,16-diphenyl-nonadecanedioic acid




30

IIa-30

1,17-Dihydroxy-4,14-dimethyl-4,14-diphenyl-heptadecan-9-one


35



5

IIa-31

17-Hydroxy-4,14-dimethyl-9-oxo-4,14-diphenyl-heptadecanoic acid




10

IIa-32

4,14-Dimethyl-9-oxo-4,14-diphenyl-heptadecanedioic acid


15



20

IIa-33

1,15-Dihydroxy-4,12-dimethyl-4,12-diphenyl-pentadecan-8-one




25

IIa-34

15-Hydroxy-4,12-dimethyl-8-oxo-4,12-diphenyl-pentadecanoic acid

30

35




5

IIa-35

4,12-Dimethyl-8-oxo-4,12-diphenyl-pentadecanedioic acid


10

**IIa-36**

15

2,12-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,12-diphenyl-tridecan-7-one

20

**IIa-37**


25

2,12-Bis-(4,6-dithio-2,3,3a,6-tetrahydro-4H-thieno[3,2-c]pyridin-5-yl)-2,12-diphenyl-tridecan-7-one

30


35

5

**IIa-38**

2,12-Dimethyl-2,12-diphenyl-7-oxo-tridecanedioic acid bis-cyanoamide


10




15

IIa-39Phosphoramidic acid mono-[11-(amino-hydroxy-phosphoryloxy)-
1-methyl-6-oxo-1,11-diphenyl-dodecyl] ester

20

**IIa-40**25 Phosphoramidic acid mono-[11-(amino-hydroxy-phosphoryloxy)-1,11-diphenyl-1-methyl-6-
oxo-dodecyl] ester


30

**IIa-41**

2,12-Diphenyl-2,12-bis-tetrazol-1-yl-tridecan-7-one


35

5

**IIa-42**

2,12-Diphenyl-2,12-bis-(1H-tetrazol-5-yl)-tridecan-7-one

10




15

IIa-43


2,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,12-diphenyl-tridecan-7-one

20

**IIa-44**

2,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,12-diphenyl-tridecan-7-one

25




30

IIa-45

2,12-Diphenyl-2,12-bis-(tetrahydro-pyran-2-yloxy)-tridecan-7-one

35




5

IIa-46

5-[11-(5-oxo-tetrahydro-furan-2-yl)-1,11-Diphenyl-1-methyl-6-oxo-dodecyl]-dihydro-furan-2-one

10




15

IIa-47

4-[11-(4-oxo-oxetan-2-yl)-1,11-diphenyl-1-methyl-6-oxo-dodecyl]-oxetan-2-one

20




25

IIa-48

4-[11-(5-oxo-tetrahydro-furan-2-yl)-1,11-Diphenyl-1-methyl-6-oxo-dodecyl]-dihydro-furan-2-one

30




35

IIa-49

3-[11-(5-oxo-tetrahydro-furan-2-yl)-1,11-Diphenyl-1-methyl-6-oxo-dodecyl]-dihydro-furan-2-one

5



10

IIa-50

{2-[11-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-1-methyl-6-oxo-1,11-diphenyl-dodecyl]-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl}-acetic acid


15

20

25

30

35




5

III-1

5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol


10

**III-2**

15


5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

20

**III-3**

5-(6-{3-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid


25

**III-4**


30

5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol


35

**III-5**


5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

**III-6**


5-(6-{3-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

**III-7**

6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol

**III-8**

6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid




5

III-9


6-(6-{3-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

10

**III-10**


6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol

15

**III-11**

6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid


20

**III-12**

6-(6-{3-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

30


35



5

III-13

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol




10

III-14


6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid

15

**III-15**

6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid

20




25

III-16

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol

30

35




5

III-17


6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

10

**III-18**

6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

15




20

III-19

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol

25




30


III-20

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

35

**III-21**

5 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-
4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid




10

III-22


5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-
cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol

15

**III-23**


20 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-
cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid

25

**III-24**

30 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-
2-yl)-2,2-dimethyl-pentanoic acid

35




5

III-25

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol


10

**III-26**

15

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid


20

**III-27**

25


5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

30


**III-28**

35

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol

**III-29**

5 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

**III-30**

10 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid


15

20

25

30

35




5

III-31

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol


10

**III-32**

15


6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

20

**III-33**


6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

25

**III-34**

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol


35



5

III-35

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid




10

III-36

6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

15




20

III-37

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol

25




30

III-38

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

35




5

III-39


5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

10

**III-40**


15 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol

20

**III-41**


5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

25

**III-42**

30 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

35




5

III-43


6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol

10

**III-44**

15

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid




20

III-45

6-(6-{2-[6-(6-Carboxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid


25

**III-46**

30

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol

35




5

III-47

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

10




15

III-48

6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid


20

**III-49**

25


6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol

30

**III-50**

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

35




5

III-51


6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid

10

**III-52**

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol


15

**III-53**

20

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid

25


**III-54**

5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid

30


35

5

**III-55**

5-(6-{2-[6-(5-Hydroxy-4-methyl-pentyl)-1,4-dioxo-cyclohex-2-yl]-phenyl}-1,4-dioxo-cyclohex-2-yl)-2,2-dimethyl-pentan-1-ol

10




15

III-56

5-(6-{2-[6-(5-Hydroxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

20




25

III-57


5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

30

**III-58**

35

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol




5

III-59


5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

10

**III-60**


15

5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid

**III-61**

20


5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentan-1-ol



25

III-62

5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid




30


III-63

5-(5-{3-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid

35

**III-64**


5 6-(5-{3-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexan-1-ol



10

III-65

6-(5-{3-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid




15


III-66

6-(5-{3-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid

20

**III-67**


25 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexan-1-ol

**III-68**

30 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid


35

5

**III-69**


6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid

10

**III-70**


6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexan-1-ol

15

**III-71**


20 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid

25


**III-72**

6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid


30

**III-73**


35 5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentan-1-ol

**III-74**


5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid

**III-75**


5-(5-{2-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid

**III-76**


5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentan-1-ol

**III-77**


5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid

**III-78**


5-(5-{2-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid

**III-79**


5 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexan-1-ol

**III-80**


10 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid

**III-81**

15 6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid


**III-82**

20 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexan-1-ol

**III-83**

25 30 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid

35




5

III-84


6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid

10

**III-85**

5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-ethyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentan-1-ol


15

**III-86**

20

5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-ethyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid


25

**III-87**


5-(5-{2-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentadien-2-yl]-ethyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid

30


35

**IIIa-1**


5- (6- {3- [6- (5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-propyl} -1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol

**IIIa-2**


5- (6- {3- [6- (4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-propyl} -1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid

**IIIa-3**


5- (6- {3- [6- (4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-propyl} -1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid

**IIIa-4**


6- (6- {3- [6- (6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-propyl} -1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol

**IIIa-5**


6- (6- {3- [6- (6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-propyl} -1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid

**IIIa-6**


6-(6-{3-[6-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid

**IIIa-7**


6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol

**IIIa-8**

6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid

**IIIa-9**

6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid




5

IIIa-10


5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol

10

**IIIa-11**

5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid

15




20

IIIa-12


5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid

25

**IIIa-13**


5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-propyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentan-1-ol

30

**IIIa-14**

5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-propyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid

35

**IIIa-15**

5-(5-{3-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentan-2-yl]-propyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid

5

10

15

20

25

30

35

4.1. Definitions and Abbreviations

Apo(a): apolipoprotein(a)

Apo A-I: apolipoprotein A-I

5 Apo B: apolipoprotein B

Apo E: apolipoprotein E

FH: Familial hypercholesterolemia

FCH: Familial combined hyperlipidemia

GDM: Gestational diabetes mellitus

10 HDL: High density lipoprotein

IDL: Intermediate density lipoprotein

IDDM: Insulin dependent diabetes mellitus

LDH: Lactate dehydrogenase

LDL: Low density lipoprotein

15 Lp(a): Lipoprotein (a)

MODY: Maturity onset diabetes of the young


NIDDM: Non-insulin dependent diabetes mellitus

PPAR: Peroxisome proliferator activated receptor

RXR: Retinoid X receptor

20 VLDL: Very low density lipoprotein

The term "compound A" means the compound 1,13-dihydroxy-2,2,12,12-tetramethyl-tridecan-7-one having the structure:



Compound A

1,13-Dihydroxy-2,2,12,12-tetramethyl-tridecan-7-one

25 The compounds of the invention can contain one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as double-bond isomers (*i.e.*, geometric isomers), enantiomers, or diastereomers. According to the invention, the chemical structures depicted herein, and therefore the compounds of the invention, encompass all of the corresponding compound's enantiomers and stereoisomers, that is,

both the stereomerically pure form (*e.g.*, geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric and stereoisomeric mixtures.

A compound of the invention is considered optically active or enantiomerically pure (*i.e.*, substantially the R-form or substantially the S-form) with respect to a chiral center when the compound is about 90% ee (enantiomeric excess) or greater, preferably, equal to or greater than 95% ee with respect to a particular chiral center. A compound of the invention is considered to be in enantiomerically-enriched form when the compound has an enantiomeric excess of greater than about 80% ee with respect to a particular chiral center. A compound of the invention is considered diastereomerically pure with respect to multiple chiral centers when the compound is about 90% de (diastereomeric excess) or greater, preferably, equal to or greater than 95% de with respect to a particular chiral center. A compound of the invention is considered to be in diastereomerically-enriched form when the compound has an diastereomeric excess of greater than about 80% de with respect to a particular chiral center. As used herein, a racemic mixture means about 50% of one enantiomer and about 50% of its corresponding enantiomer relative to all chiral centers in the molecule. Thus, the invention encompasses all enantiomerically-pure, enantiomerically-enriched, diastereomerically pure, diastereomerically enriched, and racemic mixtures of compounds of Formulas I through III.

Enantiomeric and diastereomeric mixtures can be resolved into their component enantiomers or stereoisomers by well known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent. Enantiomers and diastereomers can also be obtained from diastereomerically- or enantiomerically-pure intermediates, reagents, and catalysts by well known asymmetric synthetic methods.

The compounds of the invention are defined herein by their chemical structures and/or chemical names. Where a compound is referred to by both a chemical structure and a chemical name, and the chemical structure and chemical name conflict, the chemical structure is determinative of the compound's identity.

When administered to a patient, *e.g.*, to an animal for veterinary use or for improvement of livestock, or to a human for clinical use, the compounds of the invention are administered in isolated form or as the isolated form in a pharmaceutical composition. As used herein, "isolated" means that the compounds of the invention are separated from other components of either (a) a natural source, such as a plant or cell, preferably bacterial culture, or (b) a synthetic organic chemical reaction mixture. Preferably, via conventional

techniques, the compounds of the invention are purified. As used herein, "purified" means that when isolated, the isolate contains at least 95%, preferably at least 98%, of a single ether compound of the invention by weight of the isolate.

The phrase "pharmaceutically acceptable salt(s)," as used herein includes, but are not limited to, salts of acidic or basic groups that may be present in the compounds of the invention. Compounds that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, *i.e.*, salts containing pharmacologically acceptable anions, including but not limited to sulfuric, citric, maleic, acetic, oxalic, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (*i.e.*, 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Compounds of the invention that include an amino moiety also can form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above. Compounds of the invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium lithium, zinc, potassium, and iron salts.

As used herein, the term "solvate" means a compound of the invention or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. Preferred solvents are volatile, non-toxic, and/or acceptable for administration to humans in trace amounts.

As used herein, the term "hydrate" means a compound of the invention or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.

As used herein, the term "clathrate" means a compound of the invention or a salt thereof in the form of a crystal lattice that contains spaces (*e.g.*, channels) that have a guest molecule (*e.g.*, a solvent or water) trapped within.

"Altering lipid metabolism" indicates an observable (measurable) change in at least one aspect of lipid metabolism, including but not limited to total blood lipid content, blood HDL cholesterol, blood LDL cholesterol, blood VLDL cholesterol, blood triglyceride, blood Lp(a), blood apo A-I, blood apo E and blood non-esterified fatty acids.

"Altering glucose metabolism" indicates an observable (measurable) change in at least one aspect of glucose metabolism, including but not limited to total blood glucose content, blood insulin, the blood insulin to blood glucose ratio, insulin sensitivity, and oxygen consumption.

5 As used herein, the term "alkyl group" means a saturated, monovalent unbranched or branched hydrocarbon chain. Examples of alkyl groups include, but are not limited to, (C₁–C₆)alkyl groups, such as methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, *t*-butyl, pentyl, isopentyl, neopentyl, and hexyl, and longer alkyl groups, such as heptyl, and octyl. An alkyl group can be unsubstituted or substituted with one or two suitable substituents.

15 An "alkenyl group" means a monovalent unbranched or branched hydrocarbon chain having one or more double bonds therein. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Suitable alkenyl groups include, but are not limited to (C₂–C₆)alkenyl groups, such as vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, 4-(2-methyl-3-butene)-pentenyl. An alkenyl group can be unsubstituted or substituted with one or two suitable substituents.

20 An "alkynyl group" means monovalent unbranched or branched hydrocarbon chain having one or more triple bonds therein. The triple bond of an alkynyl group can be unconjugated or conjugated to another unsaturated group. Suitable alkynyl groups include, but are not limited to, (C₂–C₆)alkynyl groups, such as ethynyl, propynyl, butynyl, pentynyl, 25 hexynyl, methylpropynyl, 4-methyl-1-butynyl, 4-propyl-2-pentynyl, and 4-butyl-2-hexynyl. An alkynyl group can be unsubstituted or substituted with one or two suitable substituents.

30 An "aryl group" means a monocyclic or polycyclic-aromatic radical comprising carbon and hydrogen atoms. Examples of suitable aryl groups include, but are not limited to, phenyl, tolyl, anthacenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl. An aryl group can be unsubstituted or substituted with one or two suitable substituents. Preferably, the aryl group is a monocyclic ring, wherein the ring comprises 6 carbon atoms, referred to herein as "(C₆)aryl".

35 A "heteroaryl group" means a monocyclic- or polycyclic aromatic ring comprising carbon atoms, hydrogen atoms, and one or more heteroatoms, preferably 1 to 3 heteroatoms,

independently selected from nitrogen, oxygen, and sulfur. Illustrative examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrimidinyl, pyrazyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3)- and (1,2,4)-triazolyl, pyrazinyl, pyrimidinyl, tetrazolyl, furyl, thiophenyl, isoxazolyl, thiazolyl, furyl, phenyl, isoxazolyl, and oxazolyl. A heteroaryl group can be unsubstituted or substituted with one or two suitable substituents. Preferably, a heteroaryl group is a monocyclic ring, wherein the ring comprises 2 to 5 carbon atoms and 1 to 3 heteroatoms, referred to herein as “(C₂–C₅)heteroaryl”.

A “cycloalkyl group” means a monocyclic or polycyclic saturated ring comprising carbon and hydrogen atoms and having no carbon-carbon multiple bonds. Examples of cycloalkyl groups include, but are not limited to, (C₃–C₇)cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, and saturated cyclic and bicyclic terpenes. A cycloalkyl group can be unsubstituted or substituted by one or two suitable substituents. Preferably, the cycloalkyl group is a monocyclic ring or bicyclic ring.

A “heterocycloalkyl group” means a monocyclic or polycyclic ring comprising carbon and hydrogen atoms and at least one heteroatom, preferably, 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, and having no unsaturation. Examples of heterocycloalkyl groups include pyrrolidinyl, pyrrolidino, piperidinyl, piperidino, piperazinyl, piperazino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, and pyranlyl. A heterocycloalkyl group can be unsubstituted or substituted with one or two suitable substituents. Preferably, the heterocycloalkyl group is a monocyclic or bicyclic ring, more preferably, a monocyclic ring, wherein the ring comprises from 3 to 6 carbon atoms and from 1 to 3 heteroatoms, referred to herein as (C₁–C₆)heterocycloalkyl.

As used herein a “heterocyclic radical” or “heterocyclic ring” means a heterocycloalkyl group or a heteroaryl group.

The term “alkoxy group” means an –O–alkyl group, wherein alkyl is as defined above. An alkoxy group can be unsubstituted or substituted with one or two suitable substituents. Preferably, the alkyl chain of an alkoxy group is from 1 to 6 carbon atoms in length, referred to herein as “(C₁–C₆)alkoxy”.

The term “aryloxy group” means an –O–aryl group, wherein aryl is as defined above. An aryloxy group can be unsubstituted or substituted with one or two suitable substituents. Preferably, the aryl ring of an aryloxy group is a monocyclic ring, wherein the ring comprises 6 carbon atoms, referred to herein as “(C₆)aryloxy”.

The term “benzyl” means –CH₂–phenyl.

The term "phenyl" means $-C_6H_5$. A phenyl group can be unsubstituted or substituted with one or two suitable substituents.

A "hydrocarbyl" group means a monovalent group selected from (C_1-C_8) alkyl, (C_2-C_8) alkenyl, and (C_2-C_8) alkynyl, optionally substituted with one or two suitable substituents. Preferably, the hydrocarbon chain of a hydrocarbyl group is from 1 to 6 carbon atoms in length, referred to herein as " (C_1-C_6) hydrocarbyl".

A "carbonyl" group is a divalent group of the formula $-C(O)-$.

An "alkoxycarbonyl" group means a monovalent group of the formula $-C(O)-$ alkoxy. Preferably, the hydrocarbon chain of an alkoxycarbonyl group is from 1 to 8 carbon atoms in length, referred to herein as a "lower alkoxycarbonyl" group.

A "carbamoyl" group means the radical $-C(O)N(R')_2$, wherein R' is chosen from the group consisting of hydrogen, alkyl, and aryl.

As used herein, "halogen" means fluorine, chlorine, bromine, or iodine. Correspondingly, the meaning of the terms "halo" and "Hal" encompass fluoro, chloro, bromo, and iodo.

As used herein, a "suitable substituent" means a group that does not nullify the synthetic or pharmaceutical utility of the compounds of the invention or the intermediates useful for preparing them. Examples of suitable substituents include, but are not limited to: (C_1-C_8) alkyl; (C_1-C_8) alkenyl; (C_1-C_8) alkynyl; (C_6) aryl; (C_2-C_5) heteroaryl; (C_3-C_7) cycloalkyl; (C_1-C_8) alkoxy; (C_6) aryloxy; $-CN$; $-OH$; oxo; halo, $-CO_2H$; $-NH_2$; $-NH((C_1-C_8)alkyl)$; $-N((C_1-C_8)alkyl)_2$; $-NH((C_6)aryl)$; $-N((C_6)aryl)_2$; $-CHO$; $-CO((C_1-C_8)alkyl)$; $-CO((C_6)aryl)$; $-CO_2((C_1-C_8)alkyl)$; and $-CO_2((C_6)aryl)$. One of skill in the art can readily choose a suitable substituent based on the stability and pharmacological and synthetic activity of the compound of the invention.

4.2. Synthesis of the Compounds of the Invention

The compounds of the invention can be obtained via the synthetic methodology illustrated in Schemes 1-13. Starting materials useful for preparing the compounds of the invention and intermediates thereof, are commercially available or can be prepared from commercially available materials using known synthetic methods and reagents.


Scheme 1 illustrates the synthesis of mono-protected diols of the formula **X**, wherein n is an integer ranging from 0 to 4 and R^1 and R^2 are as defined above, and E is a leaving group as defined below. Scheme 1 first outlines the synthesis of mono-protected diols **X**, wherein n is 0, where esters **4** are successively reacted with a first $((R^1)_p-M)$ then a second $((R^2)_p-M)$ organometallic reagent providing ketones **5** and alcohols **6**, respectively. M is a

metal group and p is the metal's valency value (e.g., the valency of Li is 1 and that of Zn is 2). Suitable metals include, but are not limited to, Zn, Na, Li, and $-Mg-Hal$, wherein Hal is a halide selected from iodo, bromo, or chloro. Preferably, M is $-Mg-Hal$, in which case the organometallic reagents, $(R^1)_p-Mg-Hal$ and $(R^2)_p-Mg-Hal$, are known in the art as a

- 5 Grignard reagents. Esters 4 are available commercially (e.g., Aldrich Chemical Co., Milwaukee, Wisconsin) or can be prepared by well-known synthetic methods, for example, *via* esterification of the appropriate 5-halovaleric acid (commercially available, e.g., Aldrich Chemical Co., Milwaukee, Wisconsin). Both $(R^1)_p-M$ and $(R^2)_p-M$ are available
- 10 commercially (e.g., Aldrich Chemical Co., Milwaukee, Wisconsin) or can be prepared by well-known methods (see e.g., Kharasch *et al.*, *Grignard Reactions of Non-Metallic Substances*; Prentice-Hall, Englewood Cliffs, NJ, pp. 138-528 (1954) and Hartley; Patai, *The Chemistry of the Metal-Carbon Bond*, Vol. 4, Wiley: New York, pp. 159-306 and pp. 162-175 (1989), both citations are hereby expressly incorporated herein by reference).

15

Scheme 1: Synthesis of Compounds of Formula X



The reaction of a first $((\text{R}^1)_p-\text{M})$ then a second $((\text{R}^2)_p-\text{M})$ organometallic reagent with esters 4 can be performed using the general procedures referenced in March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 920-929 and Eicher, Patai, *The Chemistry of the Carbonyl Group*, pt. 1, pp. 621-693; Wiley: New York, (1966), hereby expressly incorporated herein by reference. For example, the

synthetic procedure described in Comins *et al.*, 1981, *Tetrahedron Lett.* 22:1085, hereby expressly incorporated herein by reference, can be used. As one example, the reaction can be performed by adding an organic solution of $(R^1)_p-M$ (about 0.5 to about 1 equivalents) to a stirred, cooled (about 0°C to about -80°C) solution comprising esters 4, under an inert atmosphere (*e.g.*, nitrogen) to give a reaction mixture comprising ketones 5. Preferably, $(R^1)_p-M$ is added at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. The progress of the reaction can be followed by using an appropriate analytical method, such as thin-layer chromatography or high-performance-liquid chromatography. Next, an organic solution of $(R^2)_p-M$ (about 0.5 to about 1 equivalent) is added to the reaction mixture comprising ketones 5 in the same manner used to add $(R^1)_p-M$. After the reaction providing alcohols 6 is substantially complete, the reaction mixture can be quenched and the product can be isolated by workup. Suitable solvents for obtaining alcohols 6 include, but are not limited to, dichloromethane, diethyl ether, tetrahydrofuran, benzene, toluene, xylene, hydrocarbon solvents (*e.g.*, pentane, hexane, and heptane), and mixtures thereof. Preferably, the organic solvent is diethyl ether or tetrahydrofuran. Next, alcohols 6 are converted to mono-protected diols X, wherein n is 0, using the well-known Williamson ether synthesis. This involves reacting alcohols 6 with ^-O-PG , wherein -PG is a hydroxy-protecting group. For a general discussion of the Williamson ether synthesis, See March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 386-387, and for a list of procedures and reagents useful in the Williamson ether synthesis, See, for example, Larock *Comprehensive Organic Transformations*; VCH: New York, 1989, pp. 446-448, both of which references are incorporated herein by reference. As used herein, a "hydroxy-protecting group" means a group that is reversibly attached to a hydroxy moiety that renders the hydroxy moiety unreactive during a subsequent reaction(s) and that can be selectively cleaved to regenerate the hydroxy moiety once its protecting purpose has been served. Examples of hydroxy-protecting groups are found in Greene, T.W., *Protective Groups in Organic Synthesis*, 3rd edition 17-237 (1999), hereby expressly incorporated herein by reference. Preferably, the hydroxy-protecting group is stable in a basic reaction medium, but can be cleaved by acid. Examples of suitable base-stable acid-labile hydroxy-protecting groups suitable for use with the invention include, but are not limited to, ethers, such as methyl, methoxy methyl, methylthiomethyl, methoxyethoxymethyl, *bis*(2-chloroethoxy)methyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl, tetrahydrothiofuranyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, *t*-butyl, allyl, benzyl, *o*-nitrobenzyl, triphenylmethyl, α -naphthylidiphenylmethyl, *p*-methoxyphenyldiphenylmethyl,

9-(9-phenyl-10-oxo)anthranyl, trimethylsilyl, isopropyldimethylsilyl, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl, tribenzylsilyl, and triisopropylsilyl; and esters, such as pivaloate, adamantoate, and 2,4,6-trimethylbenzoate. Ethers are preferred, particularly straight chain ethers, such as methyl ether, methoxymethyl ether, methylthiomethyl ether,

- 5 methoxyethoxymethyl ether, *bis*(2-chloroethoxy)methyl ether. Preferably -PG is methoxymethyl (CH₃OCH₂-). Reaction of alcohols 6 with ⁻O-PG under the conditions of the Williamson ether synthesis involves adding a base to a stirred organic solution comprising HO-PG (*e.g.*, methoxymethanol), maintained at a constant temperature within the range of about 0°C to about 80°C, preferably at about room temperature. Preferably, the
- 10 base is added at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. The base can be added as an organic solution or in undiluted form. Preferably, the base will have a base strength sufficient to deprotonate a proton, wherein the proton has a pK_a of greater than about 15, preferably greater than about 20. As is well known in the art, the pK_a is a measure of the
- 15 acidity of an acid H-A, according to the equation pK_a = -log K_a, wherein K_a is the equilibrium constant for the proton transfer. The acidity of an acid H-A is proportional to the stability of its conjugate base ⁻A. For tables listing pK_a values for various organic acids and a discussion on pK_a measurement, see March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 248-272, incorporated herein by
- 20 reference. Suitable bases include, but are not limited to, alkylmetal bases such as methyl lithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium
- 25 hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride. The preferred base is lithium diisopropylamide. Solvents suitable for reacting alcohols 6 with -OPG include, but are not limited, to dimethyl sulfoxide, dichloromethane, ethers, and mixtures thereof, preferably tetrahydrofuran. After addition of the base, the reaction mixture can be adjusted to within a temperature range of about 0°C to about room
- 30 temperature and alcohols 6 can be added, preferably at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. Alcohols 6 can be diluted in an organic solvent or added in their undiluted form. The resulting reaction mixture is stirred until the reaction is substantially complete as determined by using an appropriate analytical method, preferably by gas chromatography,
- 35 then the mono-protected diols X can be isolated by workup and purification.

Next, Scheme 1 outlines a method useful for synthesizing mono-protected diols X, wherein n is 1. First, compounds 7, wherein E is a suitable leaving group, are reacted with compounds 8, wherein R¹ and R² are as defined above and R⁸ is H, (C₁–C₆)alkyl or (C₆)aryl, providing compounds 9. Suitable leaving groups are well known in the art, for example, but not limited to halides, such as chloride, bromide, and iodide; aryl- or alkylsulfonyloxy, substituted arylsulfonyloxy (e.g., tosyloxy or mesyloxy); substituted alkylsulfonyloxy (e.g., haloalkylsulfonyloxy); (C₆)aryloxy or substituted (C₆)aryloxy; and acyloxy groups. Compounds 7 are available commercially (e.g., Aldrich Chemical Co., Milwaukee, Wisconsin) or can be prepared by well-known methods such as halogenation or sulfonation of butanediol. Compounds 8 are also available commercially (e.g., Aldrich Chemical Co., Milwaukee, Wisconsin) or by well-known methods, such as those listed in Larock *Comprehensive Organic Transformations*; Wiley-VCH: New York, 1999, pp. 1754-1755 and 1765. A review on alkylation of esters of type 8 is given by J. Mulzer in *Comprehensive Organic Functional Transformations*, Pergamon, Oxford 1995, pp. 148-151 and exemplary synthetic procedures for reacting compounds 7 with compounds 8 are described in United States Patent No. 5,648,387, column 6 and Ackerly, *et al.*, *J. Med. Chem.* **1995**, pp. 1608, all of which citations are hereby expressly incorporated herein by reference. The reaction requires the presence of a suitable base. Preferably, a suitable base will have a pK_a of greater than about 25, more preferably greater than about 30. Suitable bases include, but are not limited to, alkylmetal bases such as methyllithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium hexamethyldisilazide; hydride bases such as sodium hydride and potassium hydride. Metal amide bases, such as lithium diisopropylamide are preferred. Preferably, to react compounds 7 with compounds 8, a solution of about 1 to about 2 equivalents of a suitable base is added to a stirred solution comprising esters 8 and a suitable organic solvent, under an inert atmosphere, the solution maintained at a constant temperature within the range of about –95 °C to about room temperature, preferably at about –78 °C to about –20°C. Preferably, the base is diluted in a suitable organic solvent before addition. Preferably, the base is added at a rate of about 1.5 moles per hour. Organic solvents suitable for the reaction of compounds 7 with the compounds 8 include, but are not limited to, dichloromethane, diethyl ether, tetrahydrofuran, dimethylformamide, dimethyl sulfoxide, benzene, toluene, xylene, hydrocarbon solvents (e.g., pentane, hexane, and heptane), and mixtures thereof. After

addition of the base, the reaction mixture is allowed to stir for about 1 to about 2 hours, and a compound 7, preferably dissolved in a suitable organic solvent, is added, preferably at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. After addition of compounds 7, the reaction-

5 mixture temperature can be adjusted to within a temperature range of about -20°C to about room temperature, preferably to about room temperature, and the reaction mixture is allowed to stir until the reaction is substantially complete as determined by using an appropriated analytical method, preferably thin-layer chromatography or high-performance liquid chromatography. Then the reaction mixture is quenched and compounds 9, wherein n

10 is 1 can be isolated by workup. Compounds 10 are then synthesized by reacting compounds 9 with $^-\text{O}-\text{PG}$ according to the protocol described above for reacting alcohols 6 with $^-\text{O}-\text{PG}$. Next, compounds 10 can be converted to mono-protected diols X, wherein n is 1, by reduction of the ester group of compounds 10 to an alcohol group with a suitable reducing agent. A wide variety of reagents are available for reduction of such esters to

15 alcohols, *e.g.*, see M. Hudlicky, *Reductions in Organic Chemistry*, 2nd ed., 1996 pp. 212-217, hereby expressly incorporated herein by reference. Preferably, the reduction is effected with a hydride type reducing agent, for example, lithium aluminum hydride, lithium borohydride, lithium triethyl borohydride, diisobutylaluminum hydride, lithium trimethoxyaluminum hydride, or sodium *bis*(2-methoxy)aluminum hydride. For exemplary

20 procedures for reducing esters to alcohols, see Nystrom *et al.*, 1947, *J. Am. Chem. Soc.* 69:1197; and Moffet *et al.*, 1963, *Org. Synth., Collect.* 834(4), lithium aluminum hydride; Brown *et al.*, 1965, *J. Am. Chem. Soc.* 87:5614, lithium trimethoxyaluminum hydride; Cerny *et al.*, 1969, *Collect. Czech. Chem. Commun.* 34:1025, sodium *bis*(2-methoxy)aluminum hydride; Nystrom *et al.*, 1949, *J. Am. Chem.* 71:245, lithium borohydride; and Brown *et al.*,

25 1980, *J. Org. Chem.* 45:1, lithium triethyl borohydride, all of which citations are hereby expressly incorporated herein by reference. Preferably, the reduction is conducted by adding an organic solution of compounds 10 to a stirred mixture comprising a reducing agent, preferably lithium aluminum hydride, and an organic solvent. During the addition, the reaction mixture is maintained at a constant temperature within the range of about -20°C to

30 about 80°C , preferably at about room temperature. Organic solvents suitable for reacting 9 with $-\text{OPG}$ include, but are not limited to, dichloromethane, diethyl ether, tetrahydrofuran or mixtures thereof, preferably tetrahydrofuran. After the addition, the reaction mixture is stirred at a constant temperature within the range of about room temperature to about 60°C , until the reaction is substantially complete as determined by using an appropriate analytical


35 method, preferably thin-layer chromatography or high-performance-liquid chromatography.

Then the reaction mixture can be quenched and mono-protected diols **X**, wherein *n* is 1, can be isolated by workup and purification.

Scheme 1 next illustrates a three step synthetic sequence for homologating mono-protected diols **X** comprising: (a) halogenation (converting $-\text{CH}_2\text{OH}$ to $-\text{CH}_2-\text{Hal}$);
5 (b) carbonylation (replacing $-\text{Hal}$ with $-\text{CHO}$); and (c) reduction (converting $-\text{CHO}$ to $-\text{CH}_2\text{OH}$), wherein a reaction sequence of (a), (b), and (c) increases the value of *n* by 1. In step (a) protected halo-alcohols **11**, wherein Hal is a halide selected from the group of chloro, bromo, or iodo, preferably iodo, can be prepared by halogenating mono-protected diols **X**, by using well-known methods (for a discussion of various methods for conversion
10 of alcohols to halides see March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 431-433, hereby expressly incorporated herein by reference). For example, protected iodo-alcohols **11** can be synthesized starting from mono-protected diols **X** by treatment with $\text{Ph}_3\text{I}/\text{imidazole}$ (Garegg *et al.*, 1980, *J.C.S Perkin I* 2866); 1,2-diphenylene phosphorochloridite/ I_2 (Corey *et al.*, 1967, *J. Org. Chem.* 82:4160); or preferably with $\text{Me}_3\text{SiCl}/\text{NaI}$ (Olah *et al.*, 1979, *J. Org. Chem.* 44:8, 1247), all
15 of which citations are hereby expressly incorporated herein by reference. Step (b); carbonylation of alkyl halides, such as protected halo-alcohols **11**, is reviewed in Olah *et al.*, 1987, *Chem Rev.* 87:4, 671; and March, J., *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 483-484, both of which are hereby expressly
20 incorporated herein by reference). Protected halo-alcohols **11** can be carbonylated with $\text{Li}(\text{BF}_3 \cdot \text{Et}_2\text{O})/\text{HCONMe}_2$ using the procedure described in Maddaford *et al.*, 1993, *J. Org. Chem.* 58:4132; Becker *et al.*, 1982, *J. Org. Chem.* 3297; or Myers *et al.*, 1992, *J. Am. Chem. Soc.* 114:9369 or, alternatively, with an organometallic/*N*-formylmorpholine using the procedure described in Olah *et al.*, 1984, *J. Org. Chem.* 49:3856 or Vogtle *et al.*, 1987, *J.*
25 *Org. Chem.* 52:5560, all of which citations are hereby expressly incorporated herein by reference. The method described in Olah *et al.*, 1984, *J. Org. Chem.* 49:3856 is preferred. Reduction step (c) useful for synthesizing mono-protected diols **X** from aldehydes **12**, can be accomplished by well-known methods in the art for reduction of aldehydes to the corresponding alcohols (for a discussion see M. Hudlicky, *Reductions in Organic*
30 *Chemistry*, 2nd ed., 1996 pp 137-139), for example, by catalytic hydrogenation (*see e.g.*, Carothers, 1949, *J. Am. Chem. Soc.* 46:1675) or, preferably by reacting aldehydes **12** with a hydride reducing agent, such as lithium aluminum hydride, lithium borohydride, sodium borohydride (*see e.g.*, the procedures described in Chaikin *et al.*, 1949, *J. Am. Chem. Soc.* 71:3245; Nystrom *et al.*, 1947, *J. Am. Chem. Soc.* 69:1197; and Nystrom *et al.*, 1949, *J. Am.*

Chem. 71:3245, all of which are hereby expressly incorporated herein by reference).
Reduction with lithium aluminum hydride is preferred.

5 **Scheme 2: Synthesis of Compounds of Formula 12a, which correspond to Compounds $W^{(1)(2)}-Z_m-OH$, Wherein $W^{(1)(2)}$ is $C(R^1)(R^2)-Y$**



Scheme 2 outlines the method for the synthesis of protected alcohols 12a wherein Y, R¹, R², Z, and m are defined as above. Protected alcohols 12a correspond to compounds of the formula $W^{(1)(2)}-Z_m-OH$, wherein $W^{(1)(2)}$ is $C(R^1)(R^2)-Y$.


- 10 Protected alcohols 16, wherein Y comprises a $-COOH$ group, can be synthesized by oxidizing mono-protected diols X with an agent suitable for oxidizing a primary alcohol to a carboxylic acid (for a discussion see M. Hudlicky, *Oxidations in Organic Chemistry*, ACS Monograph 186, 1990, pp. 127-130, hereby expressly incorporated herein by reference). Suitable oxidizing agents include, but are not limited to, pyridinium dichromate (Corey *et al.*, 1979, *Tetrahedron Lett.* 399); manganese dioxide (Ahrens *et al.*, 1967, *J. Heterocycl. Chem.* 4:625); sodium permanganate monohydrate (Menger *et al.*, 1981, *Tetrahedron Lett.* 22:1655); and potassium permanganate (Sam *et al.*, 1972, *J. Am. Chem. Soc.* 94:4024), all of which citations are hereby expressly incorporated herein by reference. The preferred oxidizing reagent is pyridinium dichromate. In an alternative synthetic procedure, protected
- 15 alcohols 16, wherein Y comprises a $-COOH$ group, can be synthesized by treatment of protected halo-alcohols 14, wherein X is iodo, with CO or CO₂, as described in Bailey *et al.*, 1990, *J. Org. Chem.* 55:5404 and Yanagisawa *et al.*, 1994, *J. Am. Chem. Soc.* 116:6130,
- 20

the two of which citations are hereby expressly incorporated herein by reference. Protected alcohols **16**, wherein Y comprises $-C(O)OR^5$, wherein R^5 is as defined above, can be synthesized by oxidation of mono-protected diols **X** in the presence of R^5OH (see generally, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 1196). An exemplary procedure for such an oxidation is described in Stevens *et al.*, 1982, *Tetrahedron Lett.* 23:4647 (HOCl); Sundararaman *et al.*, 1978, *Tetrahedron Lett.* 1627 (O_3/KOH); Wilson *et al.*, 1982, *J. Org. Chem.* 47:1360 ($t-BuOOH/Et_3N$); and Williams *et al.*, 1988, *Tetrahedron Lett.* 29:5087 (Br_2), the four of which citations are hereby expressly incorporated herein by reference. Preferably, protected alcohols **16**, wherein Y comprises a $-C(O)OR^5$ group are synthesized from the corresponding carboxylic acid (*i.e.*, **16**, wherein Y comprises $-COOH$) by esterification with R^5OH (*e.g.*, see March, J., *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 393-394, hereby expressly incorporated herein by reference). In another alternative synthesis, protected alcohols **16**, wherein Y comprises $-C(O)OR^5$, can be prepared from protected halo-alcohols **14** by carbonylation with transition metal complexes (*see e.g.*, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 484-486; Urata *et al.*, 1991, *Tetrahedron Lett.* 32:36, 4733); and Ogata *et al.*, 1969, *J. Org. Chem.* 3985, the three of which citations are hereby expressly incorporated herein by reference).


Protected alcohols **16**, wherein Y comprises $-OC(O)R^5$, wherein R^5 is as defined above, can be prepared by acylation of mono-protected diols **X** with a carboxylate equivalent such as an acyl halide (*i.e.*, $R^5C(O)-Hal$, wherein Hal is iodo, bromo, or chloro, *see e.g.*, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 392 and *Org. Synth. Coll.* Vol. III, Wiley, NY, pp. 142, 144, 167, and 187 (1955)) or an anhydride (*i.e.*, $R^5C(O)-O-(O)CR^5$, *see e.g.*, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 392-393 and *Org. Synth. Coll.* Vol. III, Wiley, NY, pp. 11, 127, 141, 169, 237, 281, 428, 432, 690, and 833 (1955), all of which citations are hereby expressly incorporated herein by reference). Preferably, the reaction is conducted by adding a base to a solution comprising mono-protected diols **X**, a carboxylate equivalent, and an organic solvent, which solution is preferably maintained at a constant temperature within the range of $0^\circ C$ to about room temperature. Solvents suitable for reacting mono-protected diols **X** with a carboxylate equivalent include, but are not limited to, dichloromethane, toluene, and ether, preferably dichloromethane. Suitable bases include, but are not limited to, hydroxide sources, such as sodium hydroxide, potassium hydroxide, sodium carbonate, or potassium carbonate; or an amine such as triethylamine, pyridine, or dimethylaminopyridine, amines are preferred. The progress of the reaction can

be followed by using an appropriate analytical technique, such as thin layer chromatography or high performance liquid chromatography and when substantially complete, the product can be isolated by workup and purified if desired.

- 5 Protected alcohols 16, wherein Y comprises one of the following phosphate ester groups




- wherein R^6 is defined as above, can be prepared by phosphorylation of mono-protected diols X according to well-known methods (for a general reviews, see Corbridge *Phosphorus: An Outline of its Chemistry, Biochemistry, and Uses*, Studies in Inorganic Chemistry, 3rd ed., pp. 357-395 (1985); Ramirez *et al.*, 1978, *Acc. Chem. Res.* 11:239; and Kalckare *Biological Phosphorylations*, Prentice-Hall, New York (1969); J. B. Sweeny in *Comprehensive Organic Functional Group Transformations*, A.R. Katritzky, O. Meth-Cohn and C.W. Rees, Eds. Pergamon: Oxford, 1995, vol 2, pp. 104-109, the four of which are hereby expressly incorporated herein by reference). Protected alcohols 16 wherein Y comprises a
- 15 monophosphate group of the formula:




- wherein R^6 is defined as above, can be prepared by treatment of mono-protected diol X with phosphorous oxychloride in a suitable solvent, such as xylene or toluene, at a constant temperature within the range of about 100°C to about 150°C for about 2 hours to about 24
- 20 hours. After the reaction is deemed substantially complete, by using an appropriate analytical method, the reaction mixture is hydrolyzed with $\text{R}^6\text{-OH}$. Suitable procedures are referenced in Houben-Weyl, *Methoden der Organische Chemie*, Georg Thieme Verlag Stuttgart 1964, vol. XII/2, pp. 143-210 and 872-879, hereby expressly incorporated herein by reference. Alternatively, when both R^6 are hydrogen, can be synthesized by reacting
- 25 mono-protected diols X with silyl polyphosphate (Okamoto *et al.*, 1985, *Bull Chem. Soc. Jpn.* 58:3393, hereby expressly incorporated herein by reference) or by hydrogenolysis of their benzyl or phenyl esters (Chen *et al.*, 1998, *J. Org. Chem.* 63:6511, hereby expressly

incorporated herein by reference). In another alternative procedure, when R⁶ is (C₁–C₆)alkyl, (C₂–C₆)alkenyl, or (C₂–C₆)alkynyl, the monophosphate esters can be prepared by reacting mono-protected diols X with appropriately substituted phosphoramidites followed by oxidation of the intermediate with *m*-chloroperbenzoic acid (Yu *et al.*, 1988, *Tetrahedron Lett.* 29:979, hereby expressly incorporated herein by reference) or by reacting mono-protected diols X with dialkyl or diaryl substituted phosphorochloridates (Pop, *et al.*, 1997, *Org. Prep. and Proc. Int.* 29:341, hereby expressly incorporated herein by reference). The phosphoramidites are commercially available (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or readily prepared according to literature procedures (*see e.g.*, Uhlmann *et al.* 1986, *Tetrahedron Lett.* 27:1023 and Tanaka *et al.*, 1988, *Tetrahedron Lett.* 29:199, both of which are hereby expressly incorporated herein by reference). The phosphorochloridates are also commercially available (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or prepared according to literature methods (*e.g.*, Gajda *et al.* 1995, *Synthesis* 25:4099. In still another alternative synthesis, protected alcohols 16, wherein Y comprises a monophosphate group and R⁶ is alkyl or aryl, can be prepared by reacting IP⁺(OR⁶)₃ with mono-protected diols X according to the procedure described in Stowell *et al.*, 1995, *Tetrahedron Lett.* 36:11, 1825 or by alkylation of protected halo alcohols 14 with the appropriate dialkyl or diaryl phosphates (*see e.g.*, Okamoto, 1985, *Bull Chem. Soc. Jpn.* 58:3393, hereby expressly incorporated herein by reference).


Protected alcohols 16 wherein Y comprises a diphosphate group of the formula




wherein R⁶ is defined as above, can be synthesized by reacting the above-discussed monophosphates of the formula:




with a phosphate of the formula




(commercially available, *e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin), in the presence of carbodiimide such as dicyclohexylcarbodiimide, as described in Houben-Weyl, *Methoden der Organische Chemie*, Georg Thieme Verlag Stuttgart 1964, vol. XII/2, pp. 881-885. In the same fashion, protected alcohols **16**, wherein Y comprises a triphosphate group of the formula:



can be synthesized by reacting the above-discussed diphosphate protected alcohols, of the formula:




with a phosphate of the formula:




as described above. Alternatively, when R⁶ is H, protected alcohols **16** wherein Y comprises the triphosphate group, can be prepared by reacting mono-protected diols **X** with salicyl phosphorochloridite and then pyrophosphate and subsequent cleavage of the adduct thus obtained with iodine in pyridine as described in Ludwig *et al.*, 1989, *J. Org. Chem.* 54:631, hereby expressly incorporated herein by reference.

Protected alcohols **16**, wherein Y is -SO₃H or a heterocyclic group selected from the group consisting of:



can be prepared by halide displacement from protected halo-alcohols **14**. Thus, when Y is $-\text{SO}_3\text{H}$, protected alcohols **16** can be synthesized by reacting protected halo-alcohols **14** with sodium sulfite as described in Gilbert *Sulfonation and Related Reactions*; Wiley: New York, 1965, pp. 136-148 and pp. 161-163; *Org. Synth. Coll. Vol. II*, Wiley, NY, 558, 564 (1943); and *Org. Synth. Coll. Vol. IV*, Wiley, NY, 529 (1963), all three of which are hereby expressly incorporated herein by reference. When Y is one of the above-mentioned heterocycles, protected alcohols **16** can be prepared by reacting protected halo-alcohols **14** with the corresponding heterocycle in the presence of a base. The heterocycles are available commercially (e.g., Aldrich Chemical Co., Milwaukee, Wisconsin) or prepared by well-known synthetic methods (see the procedures described in Ware, 1950, *Chem. Rev.* **46**:403-470, hereby expressly incorporated herein by reference). Preferably, the reaction is conducted by stirring a mixture comprising **14**, the heterocycle, and a solvent at a constant temperature within the range of about room temperature to about 100°C , preferably within the range of about 50°C to about 70°C for about 10 to about 48 hours. Suitable bases include hydroxide bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, or potassium carbonate. Preferably, the solvent used in forming protected alcohols **16** is selected from dimethylformamide; formamide; dimethyl sulfoxide; alcohols, such as methanol or ethanol; and mixtures thereof. The progress of the reaction can be followed by using an appropriate analytical technique, such as thin layer chromatography or high performance liquid chromatography and when substantially complete, the product can be isolated by workup and purified if desired.

Protected alcohols **16**, wherein Y is a heteroaryl ring selected from



can be prepared by metallating the suitable heteroaryl ring then reacting the resulting metallated heteroaryl ring with protected halo-alcohols **14** (for a review, see Katritzky *Handbook of Heterocyclic Chemistry*, Pergamon Press: Oxford 1985). The heteroaryl rings

5 are available commercially or prepared by well-known synthetic methods (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995; De Sarlo *et al.*, 1971, *J. Chem. Soc. (C)* **86**; Oster *et al.*, 1983, *J. Org. Chem.* **48**:4307; Iwai *et al.*, 1966, *Chem. Pharm. Bull.* **14**:1277; and United States Patent No. 3,152,148, all of which citations are hereby expressly incorporated herein by reference). As used herein, the term “metallating” means the forming of a carbon-

10 metal bond, which bond may be substantially ionic in character. Metallation can be accomplished by adding about 2 equivalents of strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, to a mixture comprising a suitable organic solvent and the heterocycle. Two equivalents of base are required: one equivalent of the base deprotonates the $-OH$ group or the $-NH$ group, and the

15 second equivalent metallates the heteroaryl ring. Alternatively, the hydroxy group of the heteroaryl ring can be protected with a base-stable, acid-labile protecting group as described in Greene, T.W., *Protective Groups in Organic Synthesis*, 3rd edition 17-237 (1999), hereby expressly incorporated herein by reference. Where the hydroxy group is protected, only one equivalent of base is required. Examples of suitable base-stable, acid-labile hydroxyl-


20 protecting groups, include but are not limited to, ethers, such as methyl, methoxy methyl, methylthiomethyl, methoxyethoxymethyl, *bis*(2-chloroethoxy)methyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuran-2-yl, tetrahydrothiofuran-2-yl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, *t*-butyl, allyl, benzyl, *o*-nitrobenzyl, triphenylmethyl, α -naphthyl, diphenylmethyl, *p*-methoxyphenyldiphenylmethyl, 9-(9-phenyl-10-oxo)anthranyl,

25 trimethylsilyl, isopropyl, dimethylsilyl, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl, tribenzylsilyl, triisopropylsilyl; and esters, such as pivaloate, adamantate, and 2,4,6-trimethylbenzoate. Ethers are preferred, particularly straight chain ethers, such as methyl ether, methoxymethyl ether, methylthiomethyl ether, methoxyethoxymethyl ether, *bis*(2-chloroethoxy)methyl ether. Preferably, the pK_a of the base is higher than the pK_a of the


proton of the heterocycle to be deprotonated. For a listing of pK_a s for various heteroaryl rings, see Fraser *et al.*, 1985, *Can. J. Chem.* 63:3505, hereby expressly incorporated herein by reference. Suitable bases include, but are not limited to, alkylmetal bases such as methylolithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride. If desired, the organometallic base can be activated with a complexing agent, such as *N,N,N',N'*-tetramethylethylenediamine or hexamethylphosphoramide (1970, *J. Am. Chem. Soc.* 92:4664, hereby expressly incorporated herein by reference). Solvents suitable for synthesizing protected alcohols **16**, wherein Y is a heteroaryl ring include, but are not limited to, diethyl ether; tetrahydrofuran; and hydrocarbons, such as pentane. Generally, metallation occurs alpha to the heteroatom due to the inductive effect of the heteroatom, however, modification of conditions, such as the identity of the base and solvents, order of reagent addition, reagent addition times, and reaction and addition temperatures can be modified by one of skill in the art to achieve the desired metallation position (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995, pp. 30-42, hereby expressly incorporated herein by reference). Alternatively, the position of metallation can be controlled by use of a halogenated heteroaryl group, wherein the halogen is located on the position of the heteroaryl ring where metallation is desired (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995, p. 33 and Saulnier *et al.*, 1982, *J. Org. Chem.* 47:757, the two of which citations are hereby expressly incorporated herein by reference). Halogenated heteroaryl groups are available commercially (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or can be prepared by well-known synthetic methods (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995, pp. 78, 85, 122, 193, 234, 261, 280, 308, hereby expressly incorporated herein by reference). After metallation, the reaction mixture comprising the metallated heteroaryl ring is adjusted to within a temperature range of about 0°C to about room temperature and protected halo-alcohols **14** (diluted with a solvent or in undiluted form) are added, preferably at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. After addition of protected halo-alcohols **14**, the reaction mixture is stirred at a constant temperature within the range of about room temperature and about the solvent's boiling temperature and the reaction's progress can be monitored by the appropriate analytical technique, preferably thin-layer chromatography or high-performance liquid chromatography. After the reaction

is substantially complete, protected alcohols **16** can be isolated by workup and purification. It is to be understood that conditions, such as the identity of protected halo-alcohol **14**, the base, solvents, orders of reagent addition, times, and temperatures, can be modified by one of skill in the art to optimize the yield and selectivity. Exemplary procedures that can be used in such a transformation are described in Shirley *et al.*, 1995, *J. Org. Chem.* **20**:225; Chadwick *et al.*, 1979, *J. Chem. Soc., Perkin Trans. 1* **2845**; Rewcastle, 1993, *Adv. Het. Chem.* **56**:208; Katritzky *et al.*, 1993, *Adv. Het. Chem.* **56**:155; and Kessar *et al.*, 1997, *Chem. Rev.* **97**:721.


When Y is



- 10** protected alcohols **16** can be prepared from their corresponding carboxylic acid derivatives (**16**, wherein Y is $-\text{CO}_2\text{H}$) as described in Belletire *et al.*, 1988, *Synthetic Commun.* **18**:2063 or from the corresponding acylchlorides (**16**, wherein Y is $-\text{CO-halo}$) as described in Skinner *et al.*, 1995, *J. Am. Chem. Soc.* **77**:5440, both citations are hereby expressly incorporated herein by reference. The acylhalides can be prepared from the carboxylic acids
- 15** by well known procedures such as those described in March, J., *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 437-438, hereby expressly incorporated herein by reference. When Y is




- wherein R^7 is as defined above, protected alcohols **16** can be prepared by first reacting
- 20** protected halo-alcohols **15** with a trialkyl phosphite according to the procedure described in Kosolapoff, 1951, *Org. React.* **6**:273 followed by reacting the derived phosphonic diester with ammonia according to the procedure described in Smith *et al.*, 1957, *J. Org. Chem.* **22**:265, hereby expressly incorporated herein by reference. When Y is




protected alcohols **16** can be prepared by reacting their sulphonic acid derivatives (*i.e.*, **16**, wherein Y is $-\text{SO}_3\text{H}$) with ammonia as described in Sianesi *et al.*, 1971, *Chem. Ber.* 104:1880 and Campagna *et al.*, 1994, *Farmaco, Ed. Sci.* 49:653, both of which citations are hereby expressly incorporated herein by reference).

5 As further illustrated in Scheme 2, protected alcohols **16** can be deprotected providing alcohols **20a**. The deprotection method depends on the identity of the alcohol-protecting group, *see e.g.*, the procedures listed in Greene, T.W., *Protective Groups in Organic Synthesis*, 3rd edition 17-237 (1999), particularly see pages 48-49, hereby expressly incorporated herein by reference. One of skill in the art will readily be able to choose the
 10 appropriate deprotection procedure. When the alcohol is protected as an ether function (*e.g.*, methoxymethyl ether), the alcohol is preferably deprotected with aqueous or alcoholic acid. Suitable deprotection reagents include, but are not limited to, aqueous hydrochloric acid, *p*-toluenesulfonic acid in methanol, pyridinium-*p*-toluenesulfonate in ethanol, Amberlyst H-15 in methanol, boric acid in ethylene-glycol-monoethylether, acetic acid in a
 15 water-tetrahydrofuran mixture, aqueous hydrochloric acid is preferred. Examples of such procedures are described, respectively, in Bernady *et al.*, 1979, *J. Org. Chem.* 44:1438; Miyashita *et al.*, 1977, *J. Org. Chem.* 42:3772; Johnston *et al.*, 1988, *Synthesis* 393; Bongini *et al.*, 1979, *Synthesis* 618; and Hoyer *et al.*, 1986, *Synthesis* 655; Gigg *et al.*, 1967, *J. Chem. Soc. C*, 431; and Corey *et al.*, 1978, *J. Am. Chem. Soc.* 100:1942, all of which are hereby
 20 expressly incorporated herein by reference.




Scheme 3 depicts the synthesis of protected lactone alcohols **20** and lactone alcohols **13a**. Compounds **20** and **13a** correspond to compounds of the formula $W^{(1)(2)}-Z_m-OPG$ and $W^{(1)(2)}-Z_m-OH$ respectively, wherein $W^{(1)(2)}$ is a lactone group selected from:




- 5 Protected lactone alcohols **20** can be prepared from compounds of the formula **17**, **18**, or **19** by using well-known condensation reactions and variations of the Michael reaction. Methods for the synthesis of lactones are disclosed in Multzer in *Comprehensive Organic Functional Group Transformations*, A.R. Katritzky, O. Meth-Cohn and C.W. Rees, Eds. Pergamon: Oxford, 1995, vol 5, pp. 161-173, hereby expressly incorporated herein by
10 reference. Mono-protected diols **19**, electrophilic protected alcohols **18**, and aldehydes **19** are readily available ether commercially (e.g., Aldrich Chemical Co., Milwaukee, WI) or by well known synthetic procedures.

When $W^{(1)(2)}$ is a beta-lactone group of the formula:




- protected lactone alcohols **20** can be prepared from aldehydes **19** and electrophilic protected
15 alcohols **18**, respectively, by a one-pot-addition-lactonization according to the procedure of
Masamune *et al.*, 1976, *J. Am. Chem. Soc.* 98:7874 and Danheiser *et al.*, 1991, *J. Org. Chem.*
56:1176, both of which are hereby expressly incorporated herein by reference. This one-
pot-addition-lactonization methodology has been reviewed by Multzer in *Comprehensive*

Organic Functional Group Transformations, A.R. Katritzky, O. Meth-Cohn and C.W. Rees, Eds. Pergamon: Oxford, 1995, vol 5, pp. 161, hereby expressly incorporated herein by reference When $W^{(1)(2)}$ is a gamma- or delta-lactone group of the formula:




protected lactone alcohols **20** can be prepared from aldehydes **19** according to well known synthetic methodology. For example, the methodology described in Masuyama *et al.*, 2000, *J. Org. Chem.* 65:494; Eisch *et al.*, 1978, *J. Organo. Met. Chem.* C8 160; Eaton *et al.*, 1947, *J. Org. Chem.* 37:1947; Yunker *et al.*, 1978, *Tetrahedron Lett.* 4651; Bhanot *et al.*, 1977, *J. Org. Chem.* 42:1623; Ehlinger *et al.*, 1980, *J. Am. Chem. Soc.* 102:5004; and Raunio *et al.*, 1957, *J. Org. Chem.* 22:570, all of which citations are hereby expressly incorporated herein by reference. For instance, as described in Masuyama *et al.*, 2000, *J. Org. Chem.* 65:494, aldehydes **19** can be treated with about 1 equivalent of a strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, in a suitable organic solvent to give a reaction mixture. Suitable bases include, but are not limited to, alkylmetal bases such as methyl lithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride, preferably lithium tetramethylpiperidide. Suitable solvents include, but are not limited to, diethyl ether and tetrahydrofuran. The reaction-mixture temperature is adjusted to within the range of about 0°C to about 100°C, preferably about room temperature to about 50°C, and a halide of the formula:




wherein z is 1 or 2 (diluted with a solvent or in undiluted form) is added. The reaction mixture is stirred for a period of about 2 hours to about 48 hours, preferably about 5 to about 10 hours, during which time the reaction's progress can be followed by using an appropriate

analytical technique, such as thin layer chromatography or high performance liquid chromatography. When the reaction is deemed substantially complete, protected lactone alcohols **20** can be isolated by workup and purified if desired. When $W^{(1)(2)}$ is a gamma- or delta-lactone group of the formula:




- 5 protected lactone alcohols **20** can be synthesized by deprotonating the corresponding lactone with a strong base providing the lactone enolate and reacting the enolate with electrophilic protected alcohols **20** (for a detailed discussion of enolate formation of active methylene compounds such as lactones, see House *Modern Synthetic Reactions*; W. A. Benjamin, Inc. Philippines 1972 pp. 492-570, and for a discussion of reaction of lactone enolates with
- 10 electrophiles such as carbonyl compounds, see March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 944-945, both of which are hereby expressly incorporated herein by reference). Lactone-enolate formation can be accomplished by adding about 1 equivalent of a strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, to a mixture
- 15 comprising a suitable organic solvent and the lactone. Suitable bases include, but are not limited to, alkylmetal bases such as methyl lithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium
- 20 hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride, preferably lithium tetramethylpiperidide. Solvents suitable for lactone-enolate formation include, but are not limited to, diethyl ether and tetrahydrofuran. After enolate formation, the reaction-mixture temperature is adjusted to within the range of about -78°C to about room temperature, preferably about -50°C to about
- 25 0°C , and electrophilic protected alcohols **18** (diluted with a solvent or in undiluted form) are added, preferably at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. The reaction mixture is stirred for a period of about 15 minutes to about 5 hours, during which time the reaction's progress can be followed by using an appropriate analytical technique, such as thin layer

chromatography or high performance liquid chromatography. When the reaction is deemed substantially complete, protected lactone alcohols **20** can be isolated by workup and purified if desired. When $W^{(1)(2)}$ is a lactone group of the formula:




protected lactone alcohols **20** can be prepared from aldehydes **19** according to the procedure described in United States Patent No. 4,622,338, hereby expressly incorporated herein by reference.

When $W^{(1)(2)}$ is a gamma- or delta-lactone group of the formula:




protected lactone alcohols **20** can be prepared according to a three step sequence. The first step comprises base-mediated reaction of electrophilic protected alcohols **18** with succinic acid esters (*i.e.*, $R^9O_2CCH_2CH_2CO_2R^9$, wherein R^9 is alkyl) or glutaric acid esters (*i.e.*, $R^9O_2CCH_2CH_2CH_2CO_2R^9$, wherein R^9 is alkyl) providing a diester intermediate of the formula **21**:




21

wherein x is 1 or 2 depending on whether the gamma or delta lactone group is desired. The reaction can be performed by adding about 1 equivalent of a strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, to a mixture comprising a suitable organic solvent and the succinic or glutaric acid ester. Suitable bases include, but are not limited to, alkylmetal bases such as methyllithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium

amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride, preferably lithium tetramethylpiperidide. Suitable solvents include, but are not limited to, diethyl ether and tetrahydrofuran. After enolate formation, the reaction-mixture temperature is adjusted to within the range of about -78°C to about room temperature, preferably about -50°C to about 0°C , and electrophilic protected alcohols **18** (diluted with a solvent or in undiluted form) are added, preferably at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. The reaction mixture is stirred for a period of about 15 minutes to about 5 hours, during which time the reaction's progress can be followed by using an appropriate analytical technique, such as thin layer chromatography or high performance liquid chromatography. When the reaction is deemed substantially complete, the diester intermediate be isolated by workup and purified if desired. In the second step, the intermediate diester can be reduced, with a hydride reducing agent, to yield a diol of the formula **22**:


**22**

The reduction can be performed according to the procedures referenced in March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 1214, hereby expressly incorporated herein by reference). Suitable reducing agents include, but are not limited to, lithium aluminum hydride, diisobutylaluminum hydride, sodium borohydride, and lithium borohydride). In the third step, the diol can be oxidatively cyclized with $\text{RuH}_2(\text{PPh}_3)_4$ to the product protected lactone alcohols **20** according to the procedure of Yoshikawa *et al.*, 1986, *J. Org. Chem.* 51:2034 and Yoshikawa *et al.*, 1983, *Tetrahedron Lett.* 26:2677, both of which citations are hereby expressly incorporated herein by reference. When $\text{W}^{(1)(2)}$ is a lactone group of the formula:



- protected lactone alcohols **20** can be synthesized by reacting the Grignard salts of electrophilic protected alcohols **18**, where E is a halide, with 5,6-dihydro-2H-pyran-2-one, commercially available (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin), in the presence of catalytic amounts of a 1-dimethylaminoacetyl)pyrrolidine-2-yl)methyl-diarylphosphine-copper (I) iodide complex as described in Tomioka *et al.*, 1995, *Tetrahedron Lett.* **36**:4275, hereby expressly incorporated herein by reference.

Scheme 4: Synthesis of Compounds of Formula 14




Scheme 4 outlines methodology for the synthesis of protected alcohols **14**. Compounds **14**, wherein n is an integer ranging from 1 to 5, can be prepared from compounds **11** using general synthetic strategy depicted and adapting the synthetic protocols from those discussed for Scheme 1.

5 Next, Scheme 4 depicts the general strategy for the synthesis of compounds **14** wherein n is 0. First, Esters **27**, wherein R^8 is as defined above, are synthesized by oxidation of mono-protected diols **X** in the presence of R^8OH (see generally, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 1196). An exemplary procedure for such an oxidation is described in Stevens *et al.*, 1982, *Tetrahedron Lett.* 23:4647 (HOCl); Sundararaman *et al.*, 1978, *Tetrahedron Lett.* 1627 (O₃/KOH); Wilson *et al.*, 1982, *J. Org. Chem.* 47:1360 (*t*-BuOOH/Et₃N); and Williams *et al.*, 1988, *Tetrahedron Lett.* 29:5087 (Br₂), the four of which citations are hereby expressly incorporated herein by reference. Compounds **28** are converted to compounds **14** wherein n is 0 by adapting the synthetic procedures depicted in Scheme 1.

15

Scheme 5: Synthesis of Compounds of Formula 15a, which correspond to compounds $W^{(1)(2)}-Z_m-OH$, Where $W^{(1)(2)}$ is $C(R^1)(R^2)-(CH_2)_cC(R^3)(R^4)-Y$




20 Scheme 5 outlines methodology for the synthesis of protected alcohols **29** and alcohols **15a**, which correspond to $W^{(1)(2)}-Z_m-OPG$ and $W^{(1)(2)}-Z_m-OH$, respectively, wherein $W^{(1)(2)}$ is $C(R^1)(R^2)-(CH_2)_cC(R^3)(R^4)-Y$. The synthesis of starting materials **14**, **26**,

and 28 are depicted in Scheme 4 and the synthetic methods and procedures can be adapted from those described for Scheme 2.


5

10

Scheme 6: Synthesis of Compounds of Formula 16, which correspond to compounds $W^{(1)(2)}-Z_m-OH$, Wherein $W^{(1)(2)}$ is $C(R^1)(R^2)(CH_2)_c-V$ where V is a Lactone Group



Scheme 6 depicts the synthesis of protected lactone alcohols 30 and lactone alcohols 16a. Compounds 30 and 16a correspond to compounds of the formula, which correspond to compounds $W^{(1)(2)}-Z_m-OH$, Wherein $W^{(1)(2)}$ is $C(R^1)(R^2)(CH_2)_c-V$ and V is a Group selected from:



As shown in Scheme 6, protected lactone alcohols **30** and lactone alcohols **16a** can be synthesized from compounds of the formula **X**, **11**, or **12** by adaptation of the methods and procedures discussed above for Scheme 3.

5


Scheme 7: Conversion of Alcohols 18 to Halides 18e



Scheme 7 depicts the synthesis of halides **17**. Halides **17** can be synthesized by a variety of methods. One method involves conversion of the alcohol to a leaving group such as a sulfonic ester, such as, for example, tosylate, brosylate, mesylate, or nosylate. This intermediate is then treated with a source of X⁻, wherein X⁻ is I⁻, Br⁻, or Cl⁻ in a solvent such as THF or ether. A general method for converting vinyl and phenyl alcohols to thiols involves initially converting the alcohol to a leaving group (*e.g.*, a tosylate) then treating with a halide nucleophile.


15

Scheme 8: Synthesis of Compounds of Formula I



Scheme 8 outlines the synthesis of compounds **I**. In the first step, compounds **I** are synthesized by reacting compounds **17** (compounds **X 11, 12, 13, 14, 15, and 16** are encompassed by **17**) with compounds **31** under the conditions suitable for the formation of compounds **I**. The conditions and methods discussed in Scheme 1 above for the synthesis of mono-protected diols **X** from alcohols **6** can be adapted for the synthesis of compounds **17**. Compounds **31**, wherein Y is a suitable leaving group as defined above, preferably an anhydride, an ester, or an amide group, are readily obtained commercially (e.g., Aldrich Chemical Co. Milwaukee WI) or by well known synthetic methods. Compounds **I** are obtained by reacting compounds **31** with compounds **17** under the conditions suitable for alkyl-de-acyloxy substitution. (For a review, See Kharasch; Reinmuth, *Grignard Reactions of Nonmetallic Substances*; Prentice Hall: Englewood Cliffs, NJ, 1954, pp. 561-562 and 846-908. In a preferred procedure, the conversion of anhydrides, carboxylic esters, or amides to ketones with organometallic compounds. In a particular procedure, anhydrides and carboxylic esters give ketones when treated using inverse addition of Grignard reagents at low temperature with the solvent HMPA. See Newman, *J. Org. Chem.* **1948**, *13*, 592; Huet; Empotz; Jubier *Tetrahedron* **1973**, *29*, 479; and *Comprehensive Organic Transformations*; VCH: New York, **1989**, pp. 685-686, 693-700. Ketones can also be prepared by the treatment of thioamides with organolithium compounds (alkyl or aryl). See Tominaga; Kohra; Hosomi *Tetrahedron Lett.* **1987**, *28*, 1529. Moreover, alkyllithium compounds have been used to give ketones from carboxylic esters. See Petrov; Kaplan; Tsir *J. Gen. Chem. USSR* **1962**, *32*, 691. The reaction must be carried out in a high-boiling solvent such as toluene. Di-substituted amides also can be used to synthesize ketones. See Evans *J. Chem. Soc.* 1956, 4691; and Wakefield *Organolithium Methods*; Academic Press: New York, **1988**, pp. 82-88.

5


Scheme 9: Synthesis of Compounds of Formula II

- 10 Scheme 9 illustrates the alpha disubstitution of an ester containing a terminal protected hydroxyl moiety. Compounds that contain strong electron withdrawing groups are easily converted to the corresponding enolates. These enolate ions can readily attack an electrophile resulting in alpha substitution. *See Some Modern Methods of Organic Synthesis*, 3rd Ed.; Cambridge University Press: Cambridge, 1986, pp. 1-26, hereby
- 15 expressly incorporated herein by reference. The reaction is successful for primary and secondary alkyl, allylic, and benzylic. The use of polar aprotic solvents, *e.g.*, dimethylformamide or dimethylsulfoxide, are preferred. Phase transfer catalysts can also be

used. See Tundo *et al. J. Chem. Soc., Perkin Trans. 1*, 1987, 2159, which is hereby expressly incorporated herein by reference.

The conversion to a carboxylic acid with an additional carbon is achieved by treating an acyl halide with diazomethane to generate an intermediate diazo ketone, which in the presence of water and silver oxide rearranges through a ketene intermediate to a carboxylic acid with an additional carbon aton 37. If the reaction is done in an alcohol instead of water an ester is recovered. See Meier *et al. Angew. Chem. Int. Ed. Eng.* 1975, 14, 32-43, which is hereby expressly incorporated herein by reference. Alternatively, the carboxylic acid can be esterified by known techniques. The reaction can be repeated to generate methylene groups adjacent to the carboxylic acid.

Scheme 10: Synthesis of Compounds of Formula 42a which correspond to Compounds $W^{(1)(2)}-(CH_2)_4-OH$, wherein $W^{(1)(2)}$ is $C(R^1)(R^2)(CH_2)_nY$



15

Scheme 10 outlines methodology for the synthesis of protected alcohols 42a wherein Y, R^1 , R^2 , Z, and m are defined as above. Protected alcohols 42a correspond to compounds of the formula $W^{(1)(2)}-Zm-OPG$, wherein $W^{(1)(2)}$ is $C(R^1)(R^2)-Y$.


Protected alcohols 42, wherein Y comprises a $-COOH$ group, can be synthesized by oxidizing mono-protected diols 39 with an agent suitable for oxidizing a primary alcohol to a carboxylic acid (for a discussion see M. Hudlicky, *Oxidations in Organic Chemistry*, ACS Monograph 186, 1990, pp. 127-130, hereby expressly incorporated herein by reference).

Suitable oxidizing agents include, but are not limited to, pyridinium dichromate (Corey *et al.*, 1979, *Tetrahedron Lett.* 399); manganese dioxide (Ahrens *et al.*, 1967, *J. Heterocycl. Chem.* 4:625); sodium permanganate monohydrate (Menger *et al.*, 1981, *Tetrahedron Lett.* 22:1655); and potassium permanganate (Sam *et al.*, 1972, *J. Am. Chem. Soc.* 94:4024), all of which citations are hereby expressly incorporated herein by reference. The preferred oxidizing reagent is pyridinium dichromate. In an alternative synthetic procedure, protected alcohols **42**, wherein Y comprises a --COOH group, can be synthesized by treatment of protected halo-alcohols **40**, wherein X is iodo, with CO or CO_2 , as described in Bailey *et al.*, 1990, *J. Org. Chem.* 55:5404 and Yanagisawa *et al.*, 1994, *J. Am. Chem. Soc.* 116:6130, the two of which citations are hereby expressly incorporated herein by reference. Protected alcohols **42**, wherein Y comprises --C(O)OR^5 , wherein R^5 is as defined above, can be synthesized by oxidation of mono-protected diols **39** in the presence of R^5OH (see generally, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 1196). An exemplary procedure for such an oxidation is described in Stevens *et al.*, 1982, *Tetrahedron Lett.* 23:4647 (HOCl); Sundararaman *et al.*, 1978, *Tetrahedron Lett.* 1627 (O_3/KOH); Wilson *et al.*, 1982, *J. Org. Chem.* 47:1360 ($t\text{-BuOOH}/\text{Et}_3\text{N}$); and Williams *et al.*, 1988, *Tetrahedron Lett.* 29:5087 (Br_2), the four of which citations are hereby expressly incorporated herein by reference. Preferably, protected alcohols **42**, wherein Y comprises a --C(O)OR^5 group are synthesized from the corresponding carboxylic acid (*i.e.*, **42**, wherein Y comprises --COOH) by esterification with R^5OH (*e.g.*, see March, J., *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 393-394, hereby expressly incorporated herein by reference). In another alternative synthesis, protected alcohols **42**, wherein Y comprises --C(O)OR^5 , can be prepared from protected halo-alcohols **40** by carbonylation with transition metal complexes (*see e.g.*, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 484-486; Urata *et al.*, 1991, *Tetrahedron Lett.* 32:36, 4733); and Ogata *et al.*, 1969, *J. Org. Chem.* 3985, the three of which citations are hereby expressly incorporated herein by reference).


Protected alcohols **42**, wherein Y comprises --OC(O)R^5 , wherein R^5 is as defined above, can be prepared by acylation of mono-protected diols **39** with a carboxylate equivalent such as an acyl halide (*i.e.*, $\text{R}^5\text{C(O)--Hal}$, wherein Hal is iodo, bromo, or chloro, *see e.g.*, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 392 and *Org. Synth. Coll.* Vol. III, Wiley, NY, pp. 142, 144, 167, and 187 (1955)) or an anhydride (*i.e.*, $\text{R}^5\text{C(O)--O--(O)CR}^5$, *see e.g.*, March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 392-393 and *Org. Synth. Coll.* Vol. III, Wiley, NY, pp. 11, 127, 141, 169, 237, 281, 428, 432, 690, and 833 (1955),

all of which citations are incorporated herein by reference). Preferably, the reaction is conducted by adding a base to a solution comprising mono-protected diols **39**, a carboxylate equivalent, and an organic solvent, which solution is preferably maintained at a constant temperature within the range of 0°C to about room temperature. Solvents suitable for reacting mono-protected diols **39** with a carboxylate equivalent include, but are not limited to, dichloromethane, toluene, and ether, preferably dichloromethane. Suitable bases include, but are not limited to, hydroxide sources, such as sodium hydroxide, potassium hydroxide, sodium carbonate, or potassium carbonate; or an amine such as triethylamine, pyridine, or dimethylaminopyridine, amines are preferred. The progress of the reaction can be followed by using an appropriate analytical technique, such as thin layer chromatography or high performance liquid chromatography and when substantially complete, the product can be isolated by workup and purified if desired.

Protected alcohols **42**, wherein Y comprises one of the following phosphate ester groups



wherein R⁶ is defined as above, can be prepared by phosphorylation of mono-protected diols **X** according to well-known methods (for a general reviews, see Corbridge *Phosphorus: An Outline of its Chemistry, Biochemistry, and Uses*, Studies in Inorganic Chemistry, 3rd ed., pp. 357-395 (1985); Ramirez *et al.*, 1978, *Acc. Chem. Res.* **11**:239; and Kalckare *Biological Phosphorylations*, Prentice-Hall, New York (1969); J. B. Sweeny in *Comprehensive Organic Functional Group Transformations*, A.R. Katritzky, O. Meth-Cohn and C.W. Rees, Eds. Pergamon: Oxford, 1995, vol 2, pp. 104-109, the four of which are hereby expressly incorporated herein by reference). Protected alcohols **42** wherein Y comprises a monophosphate group of the formula:



wherein R⁶ is defined as above, can be prepared by treatment of mono-protected diol **39** with phosphorous oxychloride in a suitable solvent, such as xylene or toluene, at a constant

temperature within the range of about 100°C to about 150°C for about 2 hours to about 24 hours. After the reaction is deemed substantially complete, by using an appropriate analytical method, the reaction mixture is hydrolyzed with R⁶-OH. Suitable procedures are referenced in Houben-Weyl, Methoden der Organische Chemie, Georg Thieme Verlag


5 Stuttgart 1964, vol. XII/2, pp. 143-210 and 872-879, hereby expressly incorporated herein by reference. Alternatively, when both R⁶ are hydrogen, can be synthesized by reacting mono-protected diols X with silyl polyphosphate (Okamoto *et al.*, 1985, *Bull Chem. Soc. Jpn.* 58:3393, hereby expressly incorporated herein by reference) or by hydrogenolysis of their benzyl or phenyl esters (Chen *et al.*, 1998, *J. Org. Chem.* 63:6511, incorporated herein

10 by reference). In another alternative procedure, when R⁶ is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, or (C₂-C₆)alkynyl, the monophosphate esters can be prepared by reacting mono-protected diols 39 with appropriately substituted phosphoramidites followed by oxidation of the intermediate with *m*-chloroperbenzoic acid (Yu *et al.*, 1988, *Tetrahedron Lett.* 29:979, incorporated herein by reference) or by reacting mono-protected diols 39 with dialkyl or


15 diaryl substituted phosphorochloridates (Pop, *et al.*, 1997, *Org. Prep. and Proc. Int.* 29:341, incorporated herein by reference). The phosphoramidites are commercially available (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or readily prepared according to literature procedures (*see e.g.*, Uhlmann *et al.* 1986, *Tetrahedron Lett.* 27:1023 and Tanaka *et al.*, 1988, *Tetrahedron Lett.* 29:199, both of which are incorporated herein by reference). The

20 phosphorochloridates are also commercially available (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or prepared according to literature methods (*e.g.*, Gajda *et al.*, 1995, *Synthesis* 25:4099. In still another alternative synthesis, protected alcohols 42, wherein Y comprises a monophosphate group and R⁶ is alkyl or aryl, can be prepared by reacting IP⁺(OR⁶)₃ with mono-protected diols 39 according to the procedure described in Stowell *et al.*, 1995, *Tetrahedron Lett.* 36:11, 1825 or by alkylation of protected halo alcohols 40 with the appropriate dialkyl or diaryl phosphates (*see e.g.*, Okamoto, 1985, *Bull Chem. Soc. Jpn.* 58:3393, incorporated herein by reference).


Protected alcohols 42 wherein Y comprises a diphosphate group of the formula




30 wherein R⁶ is defined as above, can be synthesized by reacting the above-discussed monophosphates of the formula:




with a phosphate of the formula




(commercially available, *e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin), in the presence of carbodiimide such as dicyclohexylcarbodiimide, as described in Houben-Weyl, 5 *Methoden der Organische Chemie*, Georg Thieme Verlag Stuttgart 1964, vol. XII/2, pp. 881-885. In the same fashion, protected alcohols **42**, wherein Y comprises a triphosphate group of the formula:



- 10 can be synthesized by reacting the above-discussed diphosphate protected alcohols, of the formula:




with a phosphate of the formula:



- 15 as described above. Alternatively, when R⁶ is H, protected alcohols **42** wherein Y comprises the triphosphate group, can be prepared by reacting mono-protected diols **39** with salicyl phosphorochloridite and then pyrophosphate and subsequent cleavage of the adduct


thus obtained with iodine in pyridine as described in Ludwig *et al.*, 1989, *J. Org. Chem.* 54:631, incorporated herein by reference.

Protected alcohols **42**, wherein Y is $-\text{SO}_3\text{H}$ or a heterocyclic group selected from the group consisting of:



- 5 can be prepared by halide displacement from protected halo-alcohols **40**. Thus, when Y is $-\text{SO}_3\text{H}$, protected alcohols **42** can be synthesized by reacting protected halo-alcohols **40** with sodium sulfite as described in Gilbert *Sulfonation and Related Reactions*; Wiley: New York, 1965, pp. 136-148 and pp. 161-163; *Org. Synth. Coll.* Vol. II, Wiley, NY, 558, 564 (1943); and *Org. Synth. Coll.* Vol. IV, Wiley, NY, 529 (1963), all three of which are
- 10 incorporated herein by reference. When Y is one of the above-mentioned heterocycles, protected alcohols **42** can be prepared by reacting protected halo-alcohols **40** with the corresponding heterocycle in the presence of a base. The heterocycles are available commercially (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or prepared by well-known synthetic methods (see the procedures described in Ware, 1950, *Chem. Rev.* 46:403-
- 15 470, incorporated herein by reference). Preferably, the reaction is conducted by stirring a mixture comprising **40**, the heterocycle, and a solvent at a constant temperature within the range of about room temperature to about 100°C , preferably within the range of about 50°C to about 70°C for about 10 to about 48 hours. Suitable bases include hydroxide bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, or potassium carbonate.
- 20 Preferably, the solvent used in forming protected alcohols **42** is selected from dimethylformamide; formamide; dimethyl sulfoxide; alcohols, such as methanol or ethanol; and mixtures thereof. The progress of the reaction can be followed by using an appropriate analytical technique, such as thin layer chromatography or high performance liquid chromatography and when substantially complete, the product can be isolated by workup
- 25 and purified if desired.

Protected alcohols **42**, wherein Y is a heteroaryl ring selected from




can be prepared by metallating the suitable heteroaryl ring then reacting the resulting metallated heteroaryl ring with protected halo-alcohols **40** (for a review, see Katritzky

- 5 *Handbook of Heterocyclic Chemistry*, Pergamon Press: Oxford 1985). The heteroaryl rings are available commercially or prepared by well-known synthetic methods (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995; De Sarlo *et al.*, 1971, *J. Chem. Soc. (C)* **86**; Oster *et al.*, 1983, *J. Org. Chem.* **48**:4307; Iwai *et al.*, 1966, *Chem. Pharm. Bull.* **14**:1277; and United States Patent No. 3,152,148, all of which citations are incorporated herein by
- 10 reference). As used herein, the term “metallating” means the forming of a carbon-metal bond, which bond may be substantially ionic in character. Metallation can be accomplished by adding about 2 equivalents of strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, to a mixture comprising a suitable organic solvent and the heterocycle. Two equivalents of base are required: one
- 15 equivalent of the base deprotonates the $-OH$ group or the $-NH$ group, and the second equivalent metallates the heteroaryl ring. Alternatively, the hydroxy group of the heteroaryl ring can be protected with a base-stable, acid-labile protecting group as described in Greene, T.W., *Protective Groups in Organic Synthesis*, 3rd edition 17-237 (1999), hereby expressly incorporated herein by reference. Where the hydroxy group is protected, only one
- 20 equivalent of base is required. Examples of suitable base-stable, acid-labile hydroxyl-protecting groups, include but are not limited to, ethers, such as methyl, methoxy methyl, methylthiomethyl, methoxyethoxymethyl, *bis*(2-chloroethoxy)methyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl, tetrahydrothiofuranyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, *t*-butyl, allyl, benzyl, *o*-nitrobenzyl, triphenylmethyl, α -
- 25 naphthyl, diphenylmethyl, *p*-methoxyphenyldiphenylmethyl, 9-(9-phenyl-10-oxo)anthranyl, trimethylsilyl, isopropyl, dimethylsilyl, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl, tribenzylsilyl, triisopropylsilyl; and esters, such as pivaloate, adamantate, and 2,4,6-trimethylbenzoate. Ethers are preferred, particularly straight chain ethers, such as methyl ether, methoxymethyl ether, methylthiomethyl ether, methoxyethoxymethyl ether, *bis*(2-chloroethoxy)methyl ether. Preferably, the pK_a of the base is higher than the pK_a of the
- 30


proton of the heterocycle to be deprotonated. For a listing of pK_a s for various heteroaryl rings, see Fraser *et al.*, 1985, *Can. J. Chem.* **63**:3505, incorporated herein by reference. Suitable bases include, but are not limited to, alkylmetal bases such as methyllithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride. If desired, the organometallic base can be activated with a complexing agent, such as *N,N,N',N'*-tetramethylethylenediamine or hexamethylphosphoramide (1970, *J. Am. Chem. Soc.* **92**:4664, hereby expressly incorporated herein by reference). Solvents suitable for synthesizing protected alcohols **42**, wherein Y is a heteroaryl ring include, but are not limited to, diethyl ether; tetrahydrofuran; and hydrocarbons, such as pentane. Generally, metallation occurs alpha to the heteroatom due to the inductive effect of the heteroatom, however, modification of conditions, such as the identity of the base and solvents, order of reagent addition, reagent addition times, and reaction and addition temperatures can be modified by one of skill in the art to achieve the desired metallation position (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995, pp. 30-42, hereby expressly incorporated herein by reference). Alternatively, the position of metallation can be controlled by use of a halogenated heteroaryl group, wherein the halogen is located on the position of the heteroaryl ring where metallation is desired (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995, p. 33 and Saulnier *et al.*, 1982, *J. Org. Chem.* **47**:757, the two of which citations are hereby expressly incorporated herein by reference). Halogenated heteroaryl groups are available commercially (*e.g.*, Aldrich Chemical Co., Milwaukee, Wisconsin) or can be prepared by well-known synthetic methods (*see e.g.*, Joule *et al.*, *Heterocyclic Chemistry*, 3rd ed., 1995, pp. 78, 85, 122, 193, 234, 261, 280, 308, hereby expressly incorporated herein by reference). After metallation, the reaction mixture comprising the metallated heteroaryl ring is adjusted to within a temperature range of about 0°C to about room temperature and protected halo-alcohols **40** (diluted with a solvent or in undiluted form) are added, preferably at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. After addition of protected halo-alcohols **40**, the reaction mixture is stirred at a constant temperature within the range of about room temperature and about the solvent's boiling temperature and the reaction's progress can be monitored by the appropriate analytical technique, preferably thin-layer chromatography or high-performance liquid chromatography. After the reaction

is substantially complete, protected alcohols **42** can be isolated by workup and purification. It is to be understood that conditions, such as the identity of protected halo-alcohol **40**, the base, solvents, orders of reagent addition, times, and temperatures, can be modified by one of skill in the art to optimize the yield and selectivity. Exemplary procedures that can be used in such a transformation are described in Shirley *et al.*, 1995, *J. Org. Chem.* **20**:225; Chadwick *et al.*, 1979, *J. Chem. Soc., Perkin Trans. 1* **2845**; Rewcastle, 1993, *Adv. Het. Chem.* **56**:208; Katritzky *et al.*, 1993, *Adv. Het. Chem.* **56**:155; and Kessar *et al.*, 1997, *Chem. Rev.* **97**:721.


When Y is



protected alcohols **42** can be prepared from their corresponding carboxylic acid derivatives (**42**, wherein Y is $-\text{CO}_2\text{H}$) as described in Belletire *et al.*, 1988, *Synthetic Commun.* **18**:2063 or from the corresponding acylchlorides (**42**, wherein Y is $-\text{CO}-\text{halo}$) as described in Skinner *et al.*, 1995, *J. Am. Chem. Soc.* **77**:5440, both citations are incorporated herein by reference. The acylhalides can be prepared from the carboxylic acids by well known procedures such as those described in March, J., *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 437-438, hereby expressly incorporated herein by reference. When Y is




wherein R^7 is as defined above, protected alcohols **42** can be prepared by first reacting protected halo-alcohols **40** with a trialkyl phosphite according to the procedure described in Kosolapoff, 1951, *Org. React.* **6**:273 followed by reacting the derived phosphonic diester with ammonia according to the procedure described in Smith *et al.*, 1957, *J. Org. Chem.* **22**:265, incorporated herein by reference. When Y is



protected alcohols **42** can be prepared by reacting their sulphonic acid derivatives (*i.e.*, **42**, wherein Y is $-\text{SO}_3\text{H}$) with ammonia as described in Sianesi *et al.*, 1971, *Chem. Ber.* 104:1880 and Campagna *et al.*, 1994, *Farmaco, Ed. Sci.* 49:653, both of which citations are incorporated herein by reference).

5

Scheme 11: Synthesis of Compounds of Formula 46 which correspond to Compounds $\text{W}^{(1)(2)}-(\text{CH}_2)_4-\text{OH}$, wherein $\text{W}^{(1)(2)}$ is $\text{C}(\text{R}^1)(\text{R}^2)(\text{CH}_2)_n$ -Lactone




As further illustrated in Scheme 11, protected alcohols **42** can be deprotected providing alcohols **42a**. The deprotection method depends on the identity of the alcohol-protecting group, *see e.g.*, the procedures listed in Greene, T.W., *Protective Groups in Organic Synthesis*, 3rd edition 17-237 (1999), particularly see pages 48-49, incorporated herein by reference. One of skill in the art will readily be able to choose the appropriate deprotection procedure. When the alcohol is protected as an ether function (*e.g.*, methoxymethyl ether), the alcohol is preferably deprotected with aqueous or alcoholic acid. Suitable deprotection reagents include, but are not limited to, aqueous hydrochloric acid, *p*-toluenesulfonic acid in methanol, pyridinium-*p*-toluenesulfonate in ethanol, Amberlyst H-15 in methanol, boric acid in ethylene-glycol-monoethylether, acetic acid in a water-tetrahydrofuran mixture, aqueous hydrochloric acid is preferred. Examples of such procedures are described, respectively, in Bernady *et al.*, 1979, *J. Org. Chem.* 44:1438; Miyashita *et al.*, 1977, *J. Org. Chem.* 42:3772; Johnston *et al.*, 1988, *Synthesis* 393; Bongini *et al.*, 1979, *Synthesis* 618; and Hoyer *et al.*, 1986, *Synthesis* 655; Gigg *et al.*, 1967, *J. Chem.*

Soc. C, 431; and Corey *et al.*, 1978, *J. Am. Chem. Soc.* 100:1942, all of which are incorporated herein by reference.

Scheme 11 depicts the synthesis of protected lactone alcohols **46** and lactone. Compound **46** corresponds to compounds of the formula $W^{(1)(2)}-Zm-OPG$ and , wherein

5 $W^{(1)(2)}$ is a lactone group selected from:




Protected lactone alcohols **46** can be prepared from compounds of the formula **46**, **45**, or **44** by using well-known condensation reactions and variations of the Michael reaction.

Methods for the synthesis of lactones are disclosed in Multzer in *Comprehensive Organic*


10 *Functional Group Transformations*, A.R. Katritzky, O. Meth-Cohn and C.W. Rees, Eds. Pergamon: Oxford, 1995, vol 5, pp. 161-173, incorporated herein by reference. Mono-protected diols **43**, electrophilic protected alcohols **44**, and aldehydes **45** are readily available ether commercially (e.g., Aldrich Chemical Co., Milwaukee, WI) or by well known synthetic procedures.

15 When $W^{(1)(2)}$ is a beta-lactone group of the formula:




protected lactone alcohols **46** can be prepared from aldehydes **45** and electrophilic protected alcohols **44**, respectively, by a one-pot-addition-lactonization according to the procedure of Masamune *et al.*, 1976, *J. Am. Chem. Soc.* 98:7874 and Danheiser *et al.*, 1991, *J. Org. Chem.*


56:1176, both of which are incorporated herein by reference. This one-pot-addition-lactonization methodology has been reviewed by Miltzer in *Comprehensive Organic Functional Group Transformations*, A.R. Katritzky, O. Meth-Cohn and C.W. Rees, Eds. Pergamon: Oxford, 1995, vol 5, pp. 161, incorporated herein by reference When W⁽¹⁾⁽²⁾ is a
 5 gamma- or delta-lactone group of the formula:



protected lactone alcohols 46 can be prepared from aldehydes 45 according to well known synthetic methodology. For example, the methodology described in Masuyama *et al.*, 2000, *J. Org. Chem.* 65:494; Eisch *et al.*, 1978, *J. Organo. Met. Chem.* C8 160; Eaton *et al.*, 1947, *J. Org. Chem.* 37:1947; Yunker *et al.*, 1978, *Tetrahedron Lett.* 4651; Bhanot *et al.*, 1977, *J.*
 10 *Org. Chem.* 42:1623; Ehlinger *et al.*, 1980, *J. Am. Chem. Soc.* 102:5004; and Raunio *et al.*, 1957, *J. Org. Chem.* 22:570, all of which citations are incorporated herein by reference. For instance, as described in Masuyama *et al.*, 2000, *J. Org. Chem.* 65:494, aldehydes 45 can be treated with about 1 equivalent of a strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, in a suitable organic
 15 solvent to give a reaction mixture. Suitable bases include, but are not limited to, alkylmetal bases such as methyllithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium
 20 hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride, preferably lithium tetramethylpiperidide. Suitable solvents include, but are not limited to, diethyl ether and tetrahydrofuran. The reaction-mixture temperature is adjusted to within the range of about 0°C to about 100°C, preferably about room temperature to about 50°C, and a halide of the formula:




wherein z is 1 or 2 (diluted with a solvent or in undiluted form) is added. The reaction mixture is stirred for a period of about 2 hours to about 48 hours, preferably about 5 to about 10 hours, during which time the reaction's progress can be followed by using an appropriate analytical technique, such as thin layer chromatography or high performance liquid chromatography. When the reaction is deemed substantially complete, protected lactone alcohols **46** can be isolated by workup and purified if desired. When $W^{(1)(2)}$ is a gamma- or delta-lactone group of the formula:




protected lactone alcohols **46** can be synthesized by deprotonating the corresponding lactone with a strong base providing the lactone enolate and reacting the enolate with electrophilic protected alcohols **44** (for a detailed discussion of enolate formation of active methylene compounds such as lactones, see House *Modern Synthetic Reactions*; W. A. Benjamin, Inc. Philippines 1972 pp. 492-570, and for a discussion of reaction of lactone enolates with electrophiles such as carbonyl compounds, see March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 944-945, both of which are incorporated herein by reference). Lactone-enolate formation can be accomplished by adding about 1 equivalent of a strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, to a mixture comprising a suitable organic solvent and the lactone. Suitable bases include, but are not limited to, alkylmetal bases such as methyllithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride, preferably lithium tetramethylpiperidide. Solvents suitable for lactone-enolate formation include, but are not limited to, diethyl ether and tetrahydrofuran. After enolate formation, the reaction-mixture temperature is adjusted to within the range of about -78°C to about room temperature, preferably about -50°C to about 0°C , and electrophilic protected alcohols **44** (diluted with a solvent or in undiluted form) are added, preferably at a rate such that the reaction-mixture temperature remains within about

- one to two degrees of the initial reaction-mixture temperature. The reaction mixture is stirred for a period of about 15 minutes to about 5 hours, during which time the reaction's progress can be followed by using an appropriate analytical technique, such as thin layer chromatography or high performance liquid chromatography. When the reaction is deemed substantially complete, protected lactone alcohols **46** can be isolated by workup and purified if desired. When $W^{(1)(2)}$ is a lactone group of the formula:




protected lactone alcohols **46** can be prepared from aldehydes **45** according to the procedure described in United States Patent No. 4,622,338, hereby expressly incorporated herein by reference.

- When $W^{(1)(2)}$ is a gamma- or delta-lactone group of the formula:




- protected lactone alcohols **46** can be prepared according to a three step sequence. The first step comprises base-mediated reaction of electrophilic protected alcohols **44** with succinic acid esters (*i.e.*, $R^9O_2CCH_2CH_2CO_2R^9$, wherein R^9 is alkyl) or glutaric acid esters (*i.e.*, $R^9O_2CCH_2CH_2CH_2CO_2R^9$, wherein R^9 is alkyl) providing a diester intermediate of the formula **44i**:




44i

- wherein x is 1 or 2 depending on whether the gamma or delta lactone group is desired. The reaction can be performed by adding about 1 equivalent of a strong organometallic base, preferably with a pK_a of about 25 or more, more preferably with a pK_a of greater than about 35, to a mixture comprising a suitable organic solvent and the succinic or glutaric acid ester.

Suitable bases include, but are not limited to, alkylmetal bases such as methyllithium, *n*-butyllithium, *tert*-butyllithium, *sec*-butyllithium, phenyllithium, phenyl sodium, and phenyl potassium; metal amide bases such as lithium amide, sodium amide, potassium amide, lithium tetramethylpiperidide, lithium diisopropylamide, lithium diethylamide, lithium dicyclohexylamide, sodium hexamethyldisilazide, and lithium hexamethyldisilazide; and hydride bases such as sodium hydride and potassium hydride, preferably lithium tetramethylpiperidide. Suitable solvents include, but are not limited to, diethyl ether and tetrahydrofuran. After enolate formation, the reaction-mixture temperature is adjusted to within the range of about -78°C to about room temperature, preferably about -50°C to about 0°C , and electrophilic protected alcohols **44** (diluted with a solvent or in undiluted form) are added, preferably at a rate such that the reaction-mixture temperature remains within about one to two degrees of the initial reaction-mixture temperature. The reaction mixture is stirred for a period of about 15 minutes to about 5 hours, during which time the reaction's progress can be followed by using an appropriate analytical technique, such as thin layer chromatography or high performance liquid chromatography. When the reaction is deemed substantially complete, the diester intermediate be isolated by workup and purified if desired. In the second step, the intermediate diester can be reduced, with a hydride reducing agent, to yield a diol:




The reduction can be performed according to the procedures referenced in March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, p. 1214, incorporated herein by reference). Suitable reducing agents include, but are not limited to, lithium aluminum hydride, diisobutylaluminum hydride, sodium borohydride, and lithium borohydride). In the third step, the diol can be oxidatively cyclized with $\text{RuH}_2(\text{PPh}_3)_4$ to the product protected lactone alcohols **46** according to the procedure of Yoshikawa *et al.*, 1986, *J. Org. Chem.* **51**:2034 and Yoshikawa *et al.*, 1983, *Tetrahedron Lett.* **26**:2677, both of which citations are incorporated herein by reference. When $\text{W}^{(1)(2)}$ is a lactone group of the formula:



- protected lactone alcohols **46** can be synthesized by reacting the Grignard salts of electrophilic protected alcohols **44**, where E is a halide, with 5,6-dihydro-2H-pyran-2-one, commercially available (e.g., Aldrich Chemical Co., Milwaukee, Wisconsin), in the presence of catalytic amounts of a 1-dimethylaminoacetylpyrrolidine-2-yl)methyl-diarylphosphine-copper (I) iodide complex as described in Tomioka *et al.*, 1995, *Tetrahedron Lett.* **36**:4275, incorporated herein by reference.

Scheme 12: Synthesis of Compounds of Formula II




- Scheme 12 illustrates the synthesis of ketone **II**. The alcohol **47** is initially converted to a halogen **48**. See Larock, *Comprehensive Organic Transformations*, VCH: New York, **1989**, pp. 360-362; all references disclosed therein are incorporated herein by reference. The halide **48** is then converted to a carboxylic acid **49** with subsequent conversion to an acyl halide **50**. See Larock, *Comprehensive Organic Transformations*, VCH: New York, **1989**, pp. 850-851, 855-856, 859-860, 977, 980, and 985; all references disclosed therein are incorporated herein by reference. The acyl halide **50** is then coupled with the halide to afford compound **II**. See Rappoport, *The Chemistry of the Functional Groups*, Supp. D, pt. 2; Wiley: New York, **1983**; House, *Modern Synthetic Reactions*, 2nd

Ed. Benjamin: New York, 1972, pp. 691-694, 734-765, which are incorporated herein by reference.

Scheme 13 depicts the synthesis of compounds **IIIa**, that is, compounds **III** where a double bond is not present in the ring. In the first step, compounds **53**, prepared as discussed in Schemes 1 to 6 above, can be converted to compounds **54** by standard oxidation of the primary alcohol to an aldehyde group. Such oxidations are described in M. Hudlicky, *Oxidations in Organic Chemistry*, ACS Monograph 186, 1990, pp. 114-127, hereby expressly incorporated herein by reference. In the next step Grignard reaction of **54** with **55** followed by standard OH protection gives **57**. Compounds **55** are commercially available (e.g., from Aldrich Chemical Co. Milwaukee, WI) or readily prepared by standard synthetic methodology. For exemplary procedures for Grignard reaction see March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 920-929, incorporated herein by reference. Similarly, in the next step, the Grignard salt of **57** is condensed with **58** to provide **59**. Next **59** is oxidized and then cyclized to **60**. When p is one, exemplary cyclization procedures are found in Friedrichsen, W. in *Comprehensive Heterocyclic Chemistry II*; Katritzky, A. R.; Rees, W. C.; Scriven, E. F. V. Eds.; Pergamon Press: Oxford, 1996; Vol.2, p 351, and *Comprehensive Heterocyclic Chemistry*; Katritzky, A. R.; Rees, W. C. Eds.; Pergamon Press: Oxford, 1986; Vol.3. When p is 0, cyclization procedures are found in Hepworth, J. D. in *Comprehensive Heterocyclic Chemistry II*; Katritzky, A. R.; Rees, W. C.; Scriven, E. F. V. Eds.; Pergamon Press: Oxford, 1996; Vol.5, p 351 and *Comprehensive Heterocyclic Chemistry*; Katritzky, A. R.; Rees, W. C. Eds.; Pergamon Press: Oxford, 1986; Vol.3, all of which citations are hereby expressly incorporated herein by reference.

Scheme 13: Synthesis of Compounds III



- The hydroxy ketone is subjected to cyclization, as described in the above Hepworth, J. D. in *Comprehensive Heterocyclic Chemistry II*; Katritzky, A. R.; Rees, W. C.; Scriven, E. F. V. Eds.; Pergamon Press: Oxford, 1996; Vol.5, p 386. For compounds **III** where $\text{W}^{(1)(2)}$ is $\text{HO}(\text{CH}_2)_n\text{-R}^1\text{R}^2$: The hydroxy group is first deprotected as described in Greene, T.W., *Protective Groups in Organic Synthesis*, 3rd edition(1999). For other structures, where Y is a group such as an acid, aldehydes, *etc.*, protection is needed (acids as esters, preferably pivaloyl, aldehydes as silyl derivatives such as TIPS, stable in both basic and acidic conditions). When $\text{W}^{(1)(2)}$ is a Lactone it can be introduced as discussed in Scheme 3 above. The compounds are then coupled to afford compound of the formula **IIIa**.

The reactions are performed under similar conditions for substituted cyclic compounds. After the formation of the mono-cyclic compounds, they are *in situ* reacted with electrophiles (*e.g.*, MeI) at temperatures between -40°C to $+60^\circ\text{C}$, for a reaction time of 1 hr to 5 days. In addition, *ing* double bonds can be selectively added or reduced or

otherwise manipulated by well known synthetic methods to give compounds **III** having one or two selectively-placed double bonds (*i.e.*, the double bond(s) can be positioned in the desired location within the ring), for example, the methods disclosed in March, J. *Advanced Organic Chemistry; Reactions Mechanisms, and Structure*, 4th ed., 1992, pp. 771-780, incorporated herein by reference.

4.3. Therapeutic Uses of Compounds or Compositions of the Invention

In accordance with the invention, a compound of the invention or a composition of the invention, comprising a compound of the invention and a pharmaceutically acceptable vehicle, is administered to a patient, preferably a human, with or at risk of cardiovascular disease, a dyslipidemia, a dyslipoproteinemia, a disorder of glucose metabolism, Alzheimer's Disease, Syndrome X, a PPAR-associated disorder, septicemia, a thrombotic disorder, obesity, pancreatitis, hypertension, a renal disease, cancer, inflammation, or impotence. In one embodiment, "treatment" or "treating" refers to an amelioration of a disease or disorder, or at least one discernible symptom thereof. In another embodiment, "treatment" or "treating" refers to inhibiting the progression of a disease or disorder, either physically, *e.g.*, stabilization of a discernible symptom, physiologically, *e.g.*, stabilization of a physical parameter, or both.

In certain embodiments, the compounds of the invention or the compositions of the invention are administered to a patient, preferably a human, as a preventative measure against such diseases. As used herein, "prevention" or "preventing" refers to a reduction of the risk of acquiring a given disease or disorder. In a preferred mode of the embodiment, the compositions of the present invention are administered as a preventative measure to a patient, preferably a human having a genetic predisposition to a cardiovascular disease, a dyslipidemia, a dyslipoproteinemia, a disorder of glucose metabolism, Alzheimer's Disease, Syndrome X, a PPAR-associated disorder, septicemia, a thrombotic disorder, obesity, pancreatitis, hypertension, a renal disease, cancer, inflammation, or impotence. Examples of such genetic predispositions include but are not limited to the $\epsilon 4$ allele of apolipoprotein E, which increases the likelihood of Alzheimer's Disease; a loss of function or null mutation in the lipoprotein lipase gene coding region or promoter (*e.g.*, mutations in the coding regions resulting in the substitutions D9N and N291S; for a review of genetic mutations in the lipoprotein lipase gene that increase the risk of cardiovascular diseases, dyslipidemias and dyslipoproteinemias, see Hayden and Ma, 1992, *Mol. Cell Biochem.* **113**:171-176); and familial combined hyperlipidemia and familial hypercholesterolemia.

In another preferred mode of the embodiment, the compounds of the invention or compositions of the invention are administered as a preventative measure to a patient having a non-genetic predisposition to a cardiovascular disease, a dyslipidemia, a dyslipoproteinemia, a disorder of glucose metabolism, Alzheimer's Disease, Syndrome X, a PPAR-associated disorder, septicemia, a thrombotic disorder, obesity, pancreatitis, hypertension, a renal disease, cancer, inflammation, or impotence. Examples of such non-genetic predispositions include but are not limited to cardiac bypass surgery and percutaneous transluminal coronary angioplasty, which often lead to restenosis, an accelerated form of atherosclerosis; diabetes in women, which often leads to polycystic ovarian disease; and cardiovascular disease, which often leads to impotence. Accordingly, the compositions of the invention may be used for the prevention of one disease or disorder and concurrently treating another (*e.g.*, prevention of polycystic ovarian disease while treating diabetes; prevention of impotence while treating a cardiovascular disease).

4.3.1. Cardiovascular Diseases for Treatment or Prevention

The present invention provides methods for the treatment or prevention of a cardiovascular disease, comprising administering to a patient a therapeutically effective amount of a compound or a composition comprising a compound of the invention and a pharmaceutically acceptable vehicle. As used herein, the term "cardiovascular diseases" refers to diseases of the heart and circulatory system. These diseases are often associated with dyslipoproteinemias and/or dyslipidemias. Cardiovascular diseases which the compositions of the present invention are useful for preventing or treating include but are not limited to arteriosclerosis; atherosclerosis; stroke; ischemia; endothelium dysfunctions, in particular those dysfunctions affecting blood vessel elasticity; peripheral vascular disease; coronary heart disease; myocardial infarction; cerebral infarction and restenosis.

4.3.2. Dyslipidemias for Treatment or Prevention

The present invention provides methods for the treatment or prevention of a dyslipidemia comprising administering to a patient a therapeutically effective amount of a compound or a composition comprising a compound of the invention and a pharmaceutically acceptable vehicle.

As used herein, the term "dyslipidemias" refers to disorders that lead to or are manifested by aberrant levels of circulating lipids. To the extent that levels of lipids in the blood are too high, the compositions of the invention are administered to a patient to restore

normal levels. Normal levels of lipids are reported in medical treatises known to those of skill in the art. For example, recommended blood levels of LDL, HDL, free triglycerides and others parameters relating to lipid metabolism can be found at the web site of the American Heart Association and that of the National Cholesterol Education Program of the National Heart, Lung and Blood Institute (http://www.americanheart.org/cholesterol/about_level.html and http://www.nhlbi.nih.gov/health/public/heart/chol/hbc_what.html, respectively). At the present time, the recommended level of HDL cholesterol in the blood is above 35 mg/dL; the recommended level of LDL cholesterol in the blood is below 130 mg/dL; the recommended LDL:HDL cholesterol ratio in the blood is below 5:1, ideally 3.5:1; and the recommended level of free triglycerides in the blood is less than 200 mg/dL.

Dyslipidemias which the compositions of the present invention are useful for preventing or treating include but are not limited to hyperlipidemia and low blood levels of high density lipoprotein (HDL) cholesterol. In certain embodiments, the hyperlipidemia for prevention or treatment by the compounds of the present invention is familial hypercholesterolemia; familial combined hyperlipidemia; reduced or deficient lipoprotein lipase levels or activity, including reductions or deficiencies resulting from lipoprotein lipase mutations; hypertriglyceridemia; hypercholesterolemia; high blood levels of ketone bodies (*e.g.* β -OH butyric acid); high blood levels of Lp(a) cholesterol; high blood levels of low density lipoprotein (LDL) cholesterol; high blood levels of very low density lipoprotein (VLDL) cholesterol and high blood levels of non-esterified fatty acids.

The present invention further provides methods for altering lipid metabolism in a patient, *e.g.*, reducing LDL in the blood of a patient, reducing free triglycerides in the blood of a patient, increasing the ratio of HDL to LDL in the blood of a patient, and inhibiting saponified and/or non-saponified fatty acid synthesis, said methods comprising administering to the patient a compound or a composition comprising a compound of the invention in an amount effective alter lipid metabolism.

4.3.3. Dyslipoproteinemias for Treatment or Prevention

The present invention provides methods for the treatment or prevention of a dyslipoproteinemia comprising administering to a patient a therapeutically effective amount of a compound or a composition comprising a compound of the invention and a pharmaceutically acceptable vehicle.

As used herein, the term "dyslipoproteinemias" refers to disorders that lead to or are manifested by aberrant levels of circulating lipoproteins. To the extent that levels of

lipoproteins in the blood are too high, the compositions of the invention are administered to a patient to restore normal levels. Conversely, to the extent that levels of lipoproteins in the blood are too low, the compositions of the invention are administered to a patient to restore normal levels. Normal levels of lipoproteins are reported in medical treatises known to those of skill in the art.

Dyslipoproteinemias which the compositions of the present invention are useful for preventing or treating include but are not limited to high blood levels of LDL; high blood levels of apolipoprotein B (apo B); high blood levels of Lp(a); high blood levels of apo(a); high blood levels of VLDL; low blood levels of HDL; reduced or deficient lipoprotein lipase levels or activity, including reductions or deficiencies resulting from lipoprotein lipase mutations; hypoalphalipoproteinemia; lipoprotein abnormalities associated with diabetes; lipoprotein abnormalities associated with obesity; lipoprotein abnormalities associated with Alzheimer's Disease; and familial combined hyperlipidemia.

The present invention further provides methods for reducing apo C-II levels in the blood of a patient; reducing apo C-III levels in the blood of a patient; elevating the levels of HDL associated proteins, including but not limited to apo A-I, apo A-II, apo A-IV and apo E in the blood of a patient; elevating the levels of apo E in the blood of a patient, and promoting clearance of triglycerides from the blood of a patient, said methods comprising administering to the patient a compound or a composition comprising a compound of the invention in an amount effective to bring about said reduction, elevation or promotion, respectively.

4.3.4. Glucose Metabolism Disorders for Treatment or Prevention

The present invention provides methods for the treatment or prevention of a glucose metabolism disorder, comprising administering to a patient a therapeutically effective amount of a compound or a composition comprising a compound of the invention and a pharmaceutically acceptable vehicle. As used herein, the term "glucose metabolism disorders" refers to disorders that lead to or are manifested by aberrant glucose storage and/or utilization. To the extent that indicia of glucose metabolism (*i.e.*, blood insulin, blood glucose) are too high, the compositions of the invention are administered to a patient to restore normal levels. Conversely, to the extent that indicia of glucose metabolism are too low, the compositions of the invention are administered to a patient to restore normal levels. Normal indicia of glucose metabolism are reported in medical treatises known to those of skill in the art.

Glucose metabolism disorders which the compositions of the present invention are useful for preventing or treating include but are not limited to impaired glucose tolerance; insulin resistance; insulin resistance related breast, colon or prostate cancer; diabetes, including but not limited to non-insulin dependent diabetes mellitus (NIDDM), insulin
5 dependent diabetes mellitus (IDDM), gestational diabetes mellitus (GDM), and maturity onset diabetes of the young (MODY); pancreatitis; hypertension; polycystic ovarian disease; and high levels of blood insulin and/or glucose.

The present invention further provides methods for altering glucose metabolism in a patient, for example to increase insulin sensitivity and/or oxygen consumption of a patient,
10 said methods comprising administering to the patient a compound or a composition comprising a compound of the invention in an amount effective to alter glucose metabolism.

4.3.5. PPAR Associated Disorders for Treatment or Prevention

The present invention provides methods for the treatment or prevention of a PPAR-
15 associated disorder, comprising administering to a patient a therapeutically effective amount of a compound or a composition comprising a compound of the invention and a pharmaceutically acceptable vehicle. As used herein, "treatment or prevention of PPAR associated disorders" encompasses treatment or prevention of rheumatoid arthritis; multiple sclerosis; psoriasis; inflammatory bowel diseases; breast; colon or prostate cancer; low
20 levels of blood HDL; low levels of blood, lymph and/or cerebrospinal fluid apo E; low blood, lymph and/or cerebrospinal fluid levels of apo A-I; high levels of blood VLDL; high levels of blood LDL; high levels of blood triglyceride; high levels of blood apo B; high levels of blood apo C-III and reduced ratio of post-heparin hepatic lipase to lipoprotein lipase activity. HDL may be elevated in lymph and/or cerebral fluid.

4.3.6. Renal Diseases for Treatment or Prevention

The present invention provides methods for the treatment or prevention of a renal disease, comprising administering to a patient a therapeutically effective amount of a compound or a composition comprising a compound of the invention and a
30 pharmaceutically acceptable vehicle. Renal diseases that can be treated by the compounds of the present invention include glomerular diseases (including but not limited to acute and chronic glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis, glomerular lesions associated with systemic disease, such as systemic lupus erythematosus, Goodpasture's syndrome, multiple myeloma,
35 diabetes, neoplasia, sickle cell disease, and chronic inflammatory diseases), tubular diseases

(including but not limited to acute tubular necrosis and acute renal failure, polycystic renal diseasemedullary sponge kidney, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis), tubulointerstitial diseases (including but not limited to pyelonephritis, drug and toxin induced tubulointerstitial nephritis, hypercalcemic nephropathy, and hypokalemic nephropathy) acute and rapidly progressive renal failure, chronic renal failure, nephrolithiasis, or tumors (including but not limited to renal cell carcinoma and nephroblastoma). In a most preferred embodiment, renal diseases that are treated by the compounds of the present invention are vascular diseases, including but not limited to hypertension, nephrosclerosis, microangiopathic hemolytic anemia, atheroembolic renal disease, diffuse cortical necrosis, and renal infarcts.

4.3.7. Cancers for Treatment or Prevention

The present invention provides methods for the treatment or prevention of cancer, comprising administering to a patient a therapeutically effective amount of a compound or a composition comprising a compound of the invention and a pharmaceutically acceptable vehicle. Cancers that can be treated or prevented by administering the compounds or the compositions of the invention include, but are not limited to, human sarcomas and carcinomas, *e.g.*, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma; leukemias, *e.g.*, acute lymphocytic leukemia and acute myelocytic leukemia (myeloblastic, promyelocytic, myelomonocytic, monocytic and erythroleukemia); chronic leukemia (chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia); and polycythemia vera, lymphoma (Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenström's macroglobulinemia, and heavy chain disease. In a most preferred embodiment, cancers that are treated or prevented by administering the compounds of the

present invention are insulin resistance or Syndrome X related cancers, including but not limited to breast, prostate and colon cancer.

4.3.8. Other Diseases for Treatment or Prevention

5 The present invention provides methods for the treatment or prevention of Alzheimer's Disease, Syndrome X, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, inflammation, and impotence, comprising administering to a patient a therapeutically effective amount of a compound or a composition comprising a compound of the invention and a pharmaceutically acceptable vehicle.

10 As used herein, "treatment or prevention of Alzheimer's Disease" encompasses treatment or prevention of lipoprotein abnormalities associated with Alzheimer's Disease.

As used herein, "treatment or prevention of Syndrome X or Metabolic Syndrome" encompasses treatment or prevention of a symptom thereof, including but not limited to impaired glucose tolerance, hypertension and dyslipidemia/dyslipoproteinemia.

15 As used herein, "treatment or prevention of septicemia" encompasses treatment or prevention of septic shock.

As used herein, "treatment or prevention of thrombotic disorders" encompasses treatment or prevention of high blood levels of fibrinogen and promotion of fibrinolysis.

20 In addition to treating or preventing obesity, the compositions of the invention can be administered to an individual to promote weight reduction of the individual.

4.4. Surgical Uses

Cardiovascular diseases such as atherosclerosis often require surgical procedures such as angioplasty. Angioplasty is often accompanied by the placement of a reinforcing a
25 metallic tube-shaped structure known as a "stent" into a damaged coronary artery. For more serious conditions, open heart surgery such as coronary bypass surgery may be required. These surgical procedures entail using invasive surgical devices and/or implants, and are associated with a high risk of restenosis and thrombosis. Accordingly, the compounds and compositions of the invention may be used as coatings on surgical devices (*e.g.*, catheters)
30 and implants (*e.g.*, stents) to reduce the risk of restenosis and thrombosis associated with invasive procedures used in the treatment of cardiovascular diseases.

35

4.5. Veterinary and Livestock Uses

A composition of the invention can be administered to a non-human animal for a veterinary use for treating or preventing a disease or disorder disclosed herein.

In a specific embodiment, the non-human animal is a household pet. In another specific embodiment, the non-human animal is a livestock animal. In a preferred,

5 embodiment, the non-human animal is a mammal, most preferably a cow, horse, sheep, pig, cat, dog, mouse, rat, rabbit, or guinea pig. In another preferred embodiment, the non-human animal is a fowl species, most preferably a chicken, turkey, duck, goose, or quail.

In addition to veterinary uses, the compounds and compositions of the invention can be used to reduce the fat content of livestock to produce leaner meats. Alternatively, the
10 compounds and compositions of the invention can be used to reduce the cholesterol content of eggs by administering the compounds to a chicken, quail, or duck hen. For non-human animal uses, the compounds and compositions of the invention can be administered via the animals' feed or orally as a drench composition.

15 **4.6. Therapeutic/Prophylactic Administration and Compositions**

Due to the activity of the compounds and compositions of the invention, they are useful in veterinary and human medicine. As described above, the compounds and compositions of the invention are useful for the treatment or prevention of cardiovascular diseases, dyslipidemias, dyslipoproteinemias, glucose metabolism disorders, Alzheimer's
20 Disease, Syndrome X, PPAR-associated disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence.

The invention provides methods of treatment and prophylaxis by administration to a patient of a therapeutically effective amount of a compound or a composition comprising a compound of the invention. The patient is an animal, including, but not limited, to an
25 animal such a cow, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit, guinea pig, *etc.*, and is more preferably a mammal, and most preferably a human.

The compounds and compositions of the invention, are preferably administered orally. The compounds and compositions of the invention may also be administered by any other convenient route, for example, by intravenous infusion or bolus injection, by
30 absorption through epithelial or mucocutaneous linings (*e.g.*, oral mucosa, rectal and intestinal mucosa, *etc.*) and may be administered together with another biologically active agent. Administration can be systemic or local. Various delivery systems are known, *e.g.*, encapsulation in liposomes, microparticles, microcapsules, capsules, *etc.*, and can be used to administer a compound of the invention. In certain embodiments, more than one compound
35 of the invention is administered to a patient. Methods of administration include but are not

limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intranasal, intracerebral, intravaginal, transdermal, rectally, by inhalation, or topically, particularly to the ears, nose, eyes, or skin. The preferred mode of administration is left to the discretion of the practitioner, and will depend in-part upon the site of the medical condition. In most instances, administration will result in the release of the compounds of the invention into the bloodstream.

In specific embodiments, it may be desirable to administer one or more compounds of the invention locally to the area in need of treatment. This may be achieved, for example, and not by way of limitation, by local infusion during surgery, topical application, *e.g.*, in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) of an atherosclerotic plaque tissue.

In certain embodiments, for example, for the treatment of Alzheimer's Disease, it may be desirable to introduce one or more compounds of the invention into the central nervous system by any suitable route, including intraventricular, intrathecal and epidural injection. Intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.

Pulmonary administration can also be employed, *e.g.*, by use of an inhaler or nebulizer, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon or synthetic pulmonary surfactant. In certain embodiments, the compounds of the invention can be formulated as a suppository, with traditional binders and vehicles such as triglycerides.

In another embodiment, the compounds and compositions of the invention can be delivered in a vesicle, in particular a liposome (*see* Langer, 1990, *Science* 249:1527-1533; Treat *et al.*, in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; *see generally ibid.*).

In yet another embodiment, the compounds and compositions of the invention can be delivered in a controlled release system. In one embodiment, a pump may be used (*see* Langer, *supra*; Sefton, 1987, *CRC Crit. Ref. Biomed. Eng.* 14:201; Buchwald *et al.*, 1980, *Surgery* 88:507 Saudek *et al.*, 1989, *N. Engl. J. Med.* 321:574). In another embodiment, polymeric materials can be used (*see* Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability,

Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61; see also Levy et al., 1985, *Science* 228:190; During et al., 1989, *Ann. Neurol.* 25:351; Howard et al., 1989, *J. Neurosurg.* 71:105). In yet another embodiment, a controlled-release system can be placed in proximity of the target area to be treated, e.g., the liver, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, *supra*, vol. 2, pp. 115-138 (1984)). Other controlled-release systems discussed in the review by Langer, 1990, *Science* 249:1527-1533) may be used.

The present compositions will contain a therapeutically effective amount of a compound of the invention, optionally more than one compound of the invention, preferably in purified form, together with a suitable amount of a pharmaceutically acceptable vehicle so as to provide the form for proper administration to the patient.

In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S.

Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "vehicle" refers to a diluent, adjuvant, excipient, or carrier with which a compound of the invention is administered. Such pharmaceutical vehicles can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical vehicles can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents may be used. When administered to a patient, the compounds and compositions of the invention and pharmaceutically acceptable vehicles are preferably sterile. Water is a preferred vehicle when the compound of the invention is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid vehicles, particularly for injectable solutions. Suitable pharmaceutical vehicles also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.

The present compositions can take the form of solutions, suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. In one embodiment, the pharmaceutically acceptable vehicle is a capsule

(see *e.g.*, U.S. Patent No. 5,698,155). Other examples of suitable pharmaceutical vehicles are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.

In a preferred embodiment, the compounds and compositions of the invention are formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compounds and compositions of the invention for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the compositions may also include a solubilizing agent. Compositions for intravenous administration may optionally include a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the compound of the invention is to be administered by intravenous infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the compound of the invention is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

Compounds and compositions of the invention for oral delivery may be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs. Compounds and compositions of the invention for oral delivery can also be formulated in foods and food mixes. Orally administered compositions may contain one or more optionally agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the compositions may be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active driving compound are also suitable for orally administered compounds and compositions of the invention. In these later platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time delay material such as glycerol monostearate or glycerol stearate may also be used. Oral compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, *etc.* Such vehicles are preferably of pharmaceutical grade.

The amount of a compound of the invention that will be effective in the treatment of a particular disorder or condition disclosed herein will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, *in vitro* or *in vivo* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the compositions will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for oral administration are generally about 0.001 milligram to 200 milligrams of a compound of the invention per kilogram body weight. In specific preferred embodiments of the invention, the oral dose is 0.01 milligram to 70 milligrams per kilogram body weight, more preferably 0.1 milligram to 50 milligrams per kilogram body weight, more preferably 0.5 milligram to 20 milligrams per kilogram body weight, and yet more preferably 1 milligram to 10 milligrams per kilogram body weight. In a most preferred embodiment, the oral dose is 5 milligrams of a compound of the invention per kilogram body weight. The dosage amounts described herein refer to total amounts administered; that is, if more than one compound of the invention is administered, the preferred dosages correspond to the total amount of the compounds of the invention administered. Oral compositions preferably contain 10% to 95% active ingredient by weight.

Suitable dosage ranges for intravenous (i.v.) administration are 0.01 milligram to 100 milligrams per kilogram body weight, 0.1 milligram to 35 milligrams per kilogram body weight, and 1 milligram to 10 milligrams per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Suppositories generally contain 0.01 milligram to 50 milligrams of a compound of the invention per kilogram body weight and comprise active ingredient in the range of 0.5% to 10% by weight. Recommended dosages for intradermal, intramuscular, intraperitoneal, subcutaneous, epidural, sublingual, intracerebral, intravaginal, transdermal administration or administration by inhalation are in the range of 0.001 milligram to 200 milligrams per kilogram of body weight. Suitable doses of the compounds of the invention for topical administration are in the range of 0.001 milligram to 1 milligram, depending on the area to which the compound is administered. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems. Such animal models and systems are well known in the art.

The invention also provides pharmaceutical packs or kits comprising one or more containers filled with one or more compounds of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency

regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In a certain embodiment, the kit contains more than one compound of the invention. In another embodiment, the kit comprises a compound of the invention and another lipid-

5 mediating compound, including but not limited to a statin, a thiazolidinedione, or a fibrate.

The compounds of the invention are preferably assayed *in vitro* and *in vivo*, for the desired therapeutic or prophylactic activity, prior to use in humans. For example, *in vitro* assays can be used to determine whether administration of a specific compound of the invention or a combination of compounds of the invention is preferred for lowering fatty

10 acid synthesis. The compounds and compositions of the invention may also be demonstrated to be effective and safe using animal model systems.

Other methods will be known to the skilled artisan and are within the scope of the invention.

15 4.7. Combination Therapy

In certain embodiments of the present invention, the compounds and compositions of the invention can be used in combination therapy with at least one other therapeutic agent. The compound of the invention and the therapeutic agent can act additively or, more preferably, synergistically. In a preferred embodiment, a compound or a composition

20 comprising a compound of the invention is administered concurrently with the administration of another therapeutic agent, which can be part of the same composition as the compound of the invention or a different composition. In another embodiment, a compound or a composition comprising a compound of the invention is administered prior or subsequent to administration of another therapeutic agent. As many of the disorders for

25 which the compounds and compositions of the invention are useful in treating are chronic disorders, in one embodiment combination therapy involves alternating between administering a compound or a composition comprising a compound of the invention and a composition comprising another therapeutic agent, *e.g.*, to minimize the toxicity associated with a particular drug. The duration of administration of each drug or therapeutic agent can

30 be, *e.g.*, one month, three months, six months, or a year. In certain embodiments, when a composition of the invention is administered concurrently with another therapeutic agent that potentially produces adverse side effects including but not limited to toxicity, the therapeutic agent can advantageously be administered at a dose that falls below the threshold at which the adverse side is elicited.

The present compositions can be administered together with a statin. Statins for use in combination with the compounds and compositions of the invention include but are not limited to atorvastatin, pravastatin, fluvastatin, lovastatin, simvastatin, and cerivastatin.

The present compositions can also be administered together with a PPAR agonist, for example a thiazolidinedione or a fibrate. Thiazolidinediones for use in combination with the compounds and compositions of the invention include but are not limited to 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione, troglitazone, pioglitazone, ciglitazone, WAY-120,744, englitazone, AD 5075, darglitazone, and rosiglitazone. Fibrates for use in combination with the compounds and compositions of the invention include but are not limited to gemfibrozil, fenofibrate, clofibrate, or ciprofibrate. As mentioned previously, a therapeutically effective amount of a fibrate or thiazolidinedione often has toxic side effects. Accordingly, in a preferred embodiment of the present invention, when a composition of the invention is administered in combination with a PPAR agonist, the dosage of the PPAR agonist is below that which is accompanied by toxic side effects.

The present compositions can also be administered together with a bile-acid-binding resin. Bile-acid-binding resins for use in combination with the compounds and compositions of the invention include but are not limited to cholestyramine and colestipol hydrochloride. The present compositions can also be administered together with niacin or nicotinic acid. The present compositions can also be administered together with a RXR agonist. RXR agonists for use in combination with the compounds of the invention include but are not limited to LG 100268, LGD 1069, 9-cis retinoic acid, 2-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-cyclopropyl)-pyridine-5-carboxylic acid, or 4-((3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)2-carbonyl)-benzoic acid. The present compositions can also be administered together with an anti-obesity drug. Anti-obesity drugs for use in combination with the compounds of the invention include but are not limited to β -adrenergic receptor agonists, preferably β -3 receptor agonists, fenfluramine, dexfenfluramine, sibutramine, bupropion, fluoxetine, and phentermine. The present compositions can also be administered together with a hormone. Hormones for use in combination with the compounds of the invention include but are not limited to thyroid hormone, estrogen and insulin. Preferred insulins include but are not limited to injectable insulin, transdermal insulin, inhaled insulin, or any combination thereof. As an alternative to insulin, an insulin derivative, secretagogue, sensitizer or mimetic may be used. Insulin secretagogues for use in combination with the compounds of

the invention include but are not limited to forskolin, dibutryl cAMP or isobutylmethylxanthine (IBMX).

5 The present compositions can also be administered together with a tyrophostine or an analog thereof. Tyrophostines for use in combination with the compounds of the invention include but are not limited to tryophostine 51.

10 The present compositions can also be administered together with sulfonylurea-based drugs. Sulfonylurea-based drugs for use in combination with the compounds of the invention include, but are not limited to, glisoxepid, glyburide, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbutamide, and tolcyclamide. The present compositions can also be administered together with a biguanide. Biguanides for use in combination with the compounds of the invention include but are not limited to metformin, phenformin and buformin.

15 The present compositions can also be administered together with an α -glucosidase inhibitor. α -glucosidase inhibitors for use in combination with the compounds of the invention include but are not limited to acarbose and miglitol.

20 The present compositions can also be administered together with an apo A-I agonist. In one embodiment, the apo A-I agonist is the Milano form of apo A-I (apo A-IM). In a preferred mode of the embodiment, the apo A-IM for administration in conjunction with the compounds of the invention is produced by the method of U.S. Patent No. 5,721,114 to Abrahamsen. In a more preferred embodiment, the apo A-I agonist is a peptide agonist. In a preferred mode of the embodiment, the apo A-I peptide agonist for administration in conjunction with the compounds of the invention is a peptide of U.S. Patent No. 6,004,925 or 6,037,323 to Dasseux.

25 The present compositions can also be administered together with apolipoprotein E (apo E). In a preferred mode of the embodiment, the apoE for administration in conjunction with the compounds of the invention is produced by the method of U.S. Patent No. 5,834,596 to Ageland.

30 In yet other embodiments, the present compositions can be administered together with an HDL-raising drug; an HDL enhancer; or a regulator of the apolipoprotein A-I, apolipoprotein A-IV and/or apolipoprotein genes.

4.8. Combination Therapy with Cardiovascular Drugs

35 The present compositions can be administered together with a known cardiovascular drug. Cardiovascular drugs for use in combination with the compounds of the invention to

prevent or treat cardiovascular diseases include but are not limited to peripheral antiadrenergic drugs, centrally acting antihypertensive drugs (*e.g.*, methyl dopa, methyl dopa HCl), antihypertensive direct vasodilators (*e.g.*, diazoxide, hydralazine HCl), drugs affecting renin-angiotensin system, peripheral vasodilators, phentolamine, antianginal drugs, cardiac glycosides, inodilators (*e.g.*, amrinone, milrinone, enoximone, fenoximone, imazodan, sulmazole), antidysrhythmic drugs, calcium entry blockers, ranitine, bosentan, and rezulin.

4.9. Combination Therapy for Cancer Treatment

The present compositions can be administered together with treatment with irradiation or one or more chemotherapeutic agents. For irradiation treatment, the irradiation can be gamma rays or X-rays. For a general overview of radiation therapy, see Hellman, Chapter 12: Principles of Radiation Therapy Cancer, in: Principles and Practice of Oncology, DeVita *et al.*, eds., 2nd. Ed., J.B. Lippencott Company, Philadelphia. Useful chemotherapeutic agents include methotrexate, taxol, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbazine, etoposides, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, asparaginase, vinblastine, vincristine, vinorelbine, paclitaxel, and docetaxel. In a specific embodiment, a composition of the invention further comprises one or more chemotherapeutic agents and/or is administered concurrently with radiation therapy. In another specific embodiment, chemotherapy or radiation therapy is administered prior or subsequent to administration of a present composition, preferably at least an hour, five hours, 12 hours, a day, a week, a month, more preferably several months (*e.g.*, up to three months), subsequent to administration of a composition of the invention.


5

10

5. EXAMPLES

15

5.1.a. Synthesis of 1,13-Dihydroxy-2,2,12,12-tetramethyl-tridecan-7-one also known as **Compound A**



1,13-Dihydroxy-2,2,12,12-tetramethyl-tridecan-7-one

20

To a solution of 2-(6-bromo-2,2-dimethyl-hexyloxy)-tetrahydro-pyran (13.0 g, 44.33 mmol) and p-toluenesulphonylmethyl isocyanide (4.33 g, 22.17 mmol) in anhydrous DMSO (50 ml) and anhydrous diethyl ether (50 ml) was added sodium hydride (60% dispersion in mineral oil, 2.13 g, 53.20 mmol) at rt under N₂ atmosphere. After solidification of the


reaction mixture, additional anhydrous DMSO (50 ml) was added. After stirring for 5.5 h at room temperature, tetrabutylammonium iodide (1.64 g, 4.43 mmol) was added and the mixture stirred for additional 22.5 h at rt. The reaction mixture was carefully hydrolyzed with water (10 ml), diluted with water (200 ml), and extracted with diethyl ether (200 ml).

- 5 The organic layer was washed with saturated NaCl solution (100 ml), dried over MgSO_4 , and concentrated *in vacuo* to give crude 2-[7-isocyano-2,2,12,12-tetramethyl-13-(tetrahydro-pyran-2-yloxy)-7-(toluene-4-sulfonyl)-tridecyloxy]-tetrahydro-pyran (15.5 g) as an oil.

- 10 The crude material (14.8 g) was dissolved in methanol (180 ml), concentrated HCl (20 ml), and water (40 ml) and heated to reflux for 2 h. The reaction mixture was poured into CH_2Cl_2 (200 ml) and saturated NaCl solution (200 ml). The layers were separated and the aqueous layer was extracted with CH_2Cl_2 (200 ml). The combined organic layers were washed with saturated NaHCO_3 solution (2 x 100 ml) and brine (100 ml), dried over anhydrous MgSO_4 , and concentrated *in vacuo*. The resulting crude oil was purified by flash
15 chromatography (silica; hexanes/ethyl acetate = 1/1) to give the pure product (4.3 g, 71 % over two steps) as a colorless oil. ^1H NMR (CDCl_3 , 300 MHz) δ = 3.28 (s, 4 H); 2.80 (m, 2 H); 2.42 (t, 4 H, J = 7.3); 1.54 (m, 4 H); 1.25 (m, 8 H); 0.84 (s, 12 H). ^{13}C NMR (CDCl_3 , 75 MHz) 212.06, 71.24, 42.47, 38.11, 34.76, 24.45, 23.72, 23.25.

20

5.1.b. Synthesis of 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid diethyl ester also referred to herein as Compound B diethyl ester



Compound B diethyl ester


2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid diethyl ester

2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid diethyl ester

Under N₂ atmosphere, to a solution of ethyl-(5-bromo-2,2-dimethyl-pentanoate (11.1 g, 44.2 mol) in DMSO (150 ml, dried over 4 Å molecular sieves) was added *p*-toluenesulphonylmethyl isocyanide (4.31 g, 22.1 mmol), sodium hydride (60 % w/w in mineral oil, 2.12 g, 53.02 mmol), and tetra-*n*-butyl ammonium iodide at rt. The reaction mixture was stirred for 18 h at rt, then cooled to 0 °C, carefully hydrolyzed with water (10 ml), and then diluted with additional water (250 ml). The solution was extracted with diethyl ether (3 x 150 ml). The combined organic layers were washed with saturated NaCl solution (2 x 100 ml), dried over anhydrous MgSO₄, concentrated *in vacuo*, and dried in high *vacuo* to give the *p*-toluenesulphonyl intermediate (11.1 g, 93 %) as an oil. ¹H NMR (CDCl₃, 300 MHz): δ = 7.85 (d, 2 H, J = 8.3); 7.43 (d, 2 H, J = 8.3); 4.12 (q, 4 H, J = 7.0); 2.49 (s, 3 H); 1.94 (m, 4 H); 1.60 - 1.34 (m, 8 H); 1.30 - 1.15 (m, 4 H); 1.25 (t, 6 H, J = 7.0); 1.15 (s, 12 H). ¹³C NMR (CDCl₃, 75 MHz): δ = 177.77, 164.08, 146.43, 131.20, 130.34, 129.96, 81.78, 60.37, 42.12, 40.27, 33.21, 25.25, 25.19, 24.97, 24.26, 21.86, 14.34.

To a solution intermediate (11.0 g, 20.53 mmol) in CH₂Cl₂ (250 ml) was added concentrated HCl (50 ml) and the reaction mixture was stirred for 30 min at rt. The solution was diluted with water (200 ml) and the layers were separated. The aqueous layer was extracted with CH₂Cl₂ (200 ml). The combined organic layers were washed with saturated NaHCO₃ solution (2 x 100 ml), half-saturated NaCl solution (100 ml), and saturated NaCl solution. The organic phases were dried over MgSO₄, concentrated *in vacuo*, and dried in high *vacuo* to furnish crude compound B ethyl ester (8.2 g, 108 %) as an oil. ¹H NMR (CDCl₃, 300 MHz): δ = 4.03 (q, 4 H, J = 7.1); 2.31 (t, 4 H, J = 7.5); 1.45 (m, 8 H); 1.20 - 1.08 (m, 4 H); 1.16 (t, 6 H, J = 7.1); 1.07 (s, 12 H). ¹³C NMR (CDCl₃, 75 MHz): δ = 211.14, 178.05, 60.34, 42.69, 42.20, 40.52, 25.24, 24.71, 24.30, 14.35.

5.1.c. Synthesis of 1,11-Dihydroxy-2,2,10,10-tetramethyl-undecan-6-one



5-Bromo-2,2-dimethylpentan-1-ol

In a 1-L 3-neck round-bottomed flask fitted with condenser, dropping funnel pressure equalizer and magnetic stirrer were placed dichloromethane (300 mL) and lithium borohydride (12.97 g, 0.595 moles). The mixture was heated to 28-30 °C, then the heating was discontinued and methanol (19.04 g, 0.595 moles) was added, at a rate that maintained the temperature below 30 °C. To this solution, ethyl 5-bromo-2,2-dimethylpentanoate (94 g, 0.397 mol) in dichloromethane (100 mL) was added under argon atmosphere, allowing a gentle reflux during the addition. After the completion of the addition, the mixture was heated to 36-40 °C until no more starting material was detected by GC. The reaction mixture was cooled to 0 °C and was treated with crushed ice (130 g) under vigorous stirring until the effervescence ceased. The reaction mixture was treated with saturated aqueous NH_4Cl (120 mL), stirred for 25 min, and warmed to above 15 °C. The organic layer was separated and the aqueous layer was extracted with dichloromethane (2 × 100 mL). The combined organic phases were washed with saturated aqueous NH_4Cl (2 × 100 mL). The organic phase was dried (MgSO_4) and the solvent was evaporated under reduced pressure to give 5-bromo-2,2-dimethylpentan-1-ol (78 g, 88.1 % yield). ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm) 5.02 (s, 1 H), 3.39-3.34 (t, $J = 14$, 2 H), 3.33 (s, 2 H), 1.85-1.75 (m, 2 H), 1.38-1.31 (m, 2 H), 0.88 (s, 6 H). ^{13}C NMR (75 MHz, $\text{CDCl}_3 = 77.0$ ppm /TMS): δ (ppm) 71.5, 37.1, 34.8, 34.6, 27.6, 23.8.

5-Bromo-1-(tetrahydropyranyloxy)-2,2-dimethylpentane

To a solution of 5-bromo-2,2-dimethyl-1-pentanol (78 g, 0.35 mol) and *p*-toluenesulfonic acid (0.42 g) in dichloromethane (0.5 L) was added 3,4-dihydro-2H-pyran (45 mL) slowly at 0 °C. The reaction mixture was stirred at rt overnight, or until no more starting material was evidenced by TLC. The mixture was filtered through aluminum oxide and was washed with dichloromethane (300 mL). The filtrate was evaporated under vacuum to produce 5-bromo-1-(tetrahydropyranyloxy)-2,2-dimethylpentane (101 g, 94.7 % yield) as a pale-yellow oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 4.48 - 4.52 (m, 1 H), 3.90 - 3.75 (m, 1 H), 3.50 - 3.35 (m, 4 H), 2.95 (d, *J* = 12 Hz, 1 H), 1.90 - 1.20 (m, 10 H), 0.90 (s, 6 H). ¹³C NMR (75 MHz, CDCl₃ = 77.0 ppm/TMS): δ (ppm) 99.2, 76.3, 62.0, 38.0, 34.9, 34.2, 30.7, 28.0, 25.7, 24.8, 24.7, 19.3.

1,11-Dihydroxy-2,2,10,10-tetramethyl-undecan-6-one

Under N₂ atmosphere, to a solution of 5-bromo-1-(tetrahydropyranyloxy)-2,2-dimethylpentane (40.0 g, 0.143 mol) and *p*-toluenesulphonylmethyl isocyanide (TosMIC; 13.99 g, 0.072 mol) in anhydrous DMSO (400 mL) was added sodium hydride (60% dispersion in mineral oil, 6.86 g, 0.173 mol) under cooling in a water-bath. Tetra-*n*-butylammonium iodide (5.28 g, 0.0143 mol) was then added while cooling in a water-bath. The mixture was stirred for 6 h at rt., then carefully hydrolyzed by drop-wise addition of water (100 mL) under cooling in a water-bath. The reaction mixture was diluted with dichloromethane (100 mL), additional water (100 mL), and dichloromethane (100 mL). The layers were separated and the aqueous layer was extracted with dichloromethane (3 × 100 mL). The combined organic layers were washed with water (2 × 200 mL) and saturated NaCl solution (100 mL), dried over MgSO₄, concentrated *in vacuo*, and dried in high *vacuo* to give crude 2-[6-isocyano-2,2,10,10-tetramethyl-11-(tetrahydropyran-2-yloxy)-6-(toluene-4-sulfonyl)-undecyloxy]-tetrahydropyran (47.9 g) as a brownish, viscous oil. This crude oil (47.0 g) was dissolved in methanol (200 mL) and water (40 mL). Concentrated sulfuric acid (20 mL) was added drop-wise over 10 min whereupon the solution warmed up to ca. 30 °C. The reaction mixture was stirred at rt for ca. 150 min and then diluted with water (200 mL). The mixture was extracted with CH₂Cl₂ (2 × 200 mL, 1 × 100 mL) and the combined organic layers were washed with water (200 mL), 10 % potassium hydroxide solution (3 × 200 mL), water (200 mL), and brine (160 mL). The organic extracts were dried over MgSO₄, concentrated *in vacuo*, and dried in high *vacuo* to furnish crude 1,11-dihydroxy-2,2,10,10-tetramethyl-undecan-6-one (26.0 g) as a brown oil. The crude product was purified by chromatography (silica, 330 g, hexanes/ethyl acetate = 90/10, 70/30, 50/50) to


obtain three fractions: A: 1.1 g, 93.5 % purity by HPLC, 5.6 % yield; B: 3.0 g, ca. 96.7 % purity by HPLC, 16 % yield, and C: 4.0 g, ≥ 90 % purity by NMR, 19.5 %. Fraction C was again purified by chromatography (silica, 150 g, hexanes/ethyl acetate = 60/40) to give clean product (1.5 g, purity by HPLC: 96.3 %). Overall yield: 5.6 g, 30.3 % over two steps. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm) 3.25 (s, 4 H), 2.60 (br., 2 H), 2.32 (t, 4 H, $J = 7.2$), 1.45 (m, 4 H), 1.12 (m, 4 H), 0.79 (s, 12 H). ^{13}C NMR (75 MHz, $\text{CDCl}_3 = 77.0$ ppm/TMS): δ (ppm) 212.25, 70.99, 43.15, 37.69, 34.94, 23.89, 17.91. HRMS (LSIMS, gly): Calcd for $\text{C}_{15}\text{H}_{29}\text{O}_2$ ($\text{MH}^+ - \text{H}_2\text{O}$): 241.2168, found: 241.2169.

10

15

20

5.1.d. Synthesis of 2,12-Dimethyl-7-oxo-2,12-di-*p*-tolyl-tridecanedioic acid



2-p-Tolyl-propionic acid ethyl ester

Under N₂ atmosphere, a solution of ethyl *p*-tolyl-acetate (2.72 g, 15.2 mmol) in anhydrous THF (70 mL) was cooled to -40 °C and a solution of LDA (7.6 mL, 15.25 mmol) was added drop-wise over 30 minutes. The reaction mixture was stirred for 1 h, and methyl iodide (3.03 g, 21.30 mmol) was added drop-wise, followed by the addition of DMPU (1 mL). The reaction mixture was allowed to warm to rt, after 1 h and stirred overnight. The reaction mixture was poured into water (30 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with saturated NH₄Cl solution (10 mL), 1 M HCl (10 mL), saturated NaHCO₃ solution (10 mL), and brine (10 mL), then dried over MgSO₄, and concentrated *in vacuo*. The residue was distilled in high *vacuo* (bp. 59 - 63 °C/0.2 mmHg) to furnish 2-*p*-tolyl-propionic acid ethyl ester (2.5 g, 86.0%) as an oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.18 (d, 2 H, *J* = 8.1), 7.10 (d, 2 H, *J* = 8.1), 4.09 (m, 2 H), 3.67 (q, 1 H, *J* = 7.2), 2.29 (s, 3 H), 1.47 (d, *J* = 7.2 Hz, 3 H), 1.20 (t, *J* = 5.7 Hz, 3 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 174.71, 137.80, 136.63, 129.33, 129.14, 127.36, 60.66, 45.18, 21.05, 18.70, 14.15. [Lit. ref.: Ghosh, S.; Pardo, S. N.; Salomon, R. G. *J. Org. Chem.* **1982**, *47*, 4692 - 4702.].

6-Bromo-2-methyl-2-*p*-tolyl-hexanoic acid ethyl ester

Under N₂ atmosphere, LDA (54.5 mL, 110 mmol) was added drop-wise to a stirred solution of 2-*p*-tolyl-propionic acid ethyl ester (21 g, 110 mmol) in anhydrous THF (190 mL) at -78 °C. After 1 h, the reaction mixture was added to a solution of 1,4-dibromobutane (38 g, 176 mmol) in THF (50 mL) at -78 °C, followed by addition of DMPU (20 mL). The reaction mixture was stirred for 2 h, then warmed to rt overnight. The resulting mixture was poured into saturated NH₄Cl solution (1000 mL), and extracted with ethyl acetate (4 × 250 mL). The combined organic layers were washed with brine (300 mL), 1 M HCl (200 mL), saturated NaHCO₃ solution (300 mL), and brine (200 mL). The organic layer was dried over MgSO₄ and concentrated *in vacuo*. The residue was distilled in high *vacuo* (bp. 128 - 130 °C/0.2 mmHg) to furnish 6-bromo-2-methyl-2-*p*-tolyl-hexanoic acid ethyl ester (22 g, 89.5 %) as an oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.19 (d, 2 H, *J* = 8.2 Hz), 7.12 (d, 2 H, *J* = 8.2 Hz), 4.13 (q, 2 H, *J* = 7.2 Hz), 3.37 (t, *J* = 6.6 Hz, 2 H), 2.32 (s, 3 H), 2.10 - 1.80 (m, 4 H), 1.54 (s, 3 H), 1.36 (m, 2 H), 1.19 (t, *J* = 7.2 Hz, 3 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 176.26, 140.92, 136.35, 129.21, 125.89, 60.88, 49.82, 38.53, 33.61, 33.33, 23.59, 22.78, 21.07, 14.25. HRMS (LSIMS, nba): Calcd. for (C₁₆H₂₃BrO₂) 327.0959, found 327.0975.

2,12-Dimethyl-7-oxo-2,12-di-*p*-tolyl-tridecanedioic acid diethyl ester


To a solution of 6-bromo-2-methyl-2-*p*-tolyl-hexanoic acid ethyl ester (21 g, 64.22 mmol), tetra-*n*-butylammonium iodide (2.37 g, 6.42 mmol), and *p*-toluene-sulphonylmethyl isocyanide (TosMIC, 6.26g, 32.11 mmol) in anhydrous DMSO (320 mL) and anhydrous diethyl ether (110 mL) was added sodium hydride (60% dispersion in mineral oil, 3.24 g, 80.92 mmol) at rt under N₂ atmosphere. The reaction mixture was stirred for 24 h at rt, then carefully hydrolyzed with ice-water (600 mL) and extracted with diethyl ether (2 × 300 mL). The combined organic layers were washed with brine (2 × 300 mL), dried over MgSO₄, and concentrated to furnish a crude 2,12-dimethyl-7-isocyano-2,12-di-*p*-tolyl-7-(toluene-4-sulfonyl)-tridecanedioic acid diethyl ester. A solution of this crude intermediate in CH₂Cl₂ (500 mL) and concd HCl (140 mL) was stirred for 2 h at rt. The reaction mixture was diluted with water (500 mL) and the layers were separated. The aqueous layer was extracted with CH₂Cl₂ (2 × 200 mL). The combined organic layers were washed with saturated NaHCO₃ solution (150 mL), and brine (150 mL), dried over MgSO₄, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography (silica gel, ethyl acetate/hexanes = 1/20, 1/10) to furnish 2,12-dimethyl-7-oxo-2,12-di-*p*-tolyl-tridecanedioic acid diethyl ester (9.0 g, 67.12%) as a light yellowish oil. ¹H NMR (300 MHz,

CDCl₃/TMS): δ (ppm) 7.10 (d, 4 H, $J = 7.9$ Hz), 7.02 (d, 4 H, $J = 7.9$ Hz), 4.05 (q, 4 H, $J = 7.0$ Hz), 2.25 (t, $J = 9$ Hz, 4 H), 2.20 (s, 6 H), 1.95 - 1.70 (m, 4 H), 1.42 (s, 6 H), 1.50 - 1.05 (m, 8 H), 1.08 (t, 6 H, $J = 7.0$ Hz). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 211.10, 176.00, 141.00, 135.80, 128.50, 124.51, 60.50, 49.50, 42.01, 39.50, 24.05, 22.10, 20.50, 13.00. HRMS (LSIMS, nba): Calcd. for C₃₃H₄₇O₅ (MH⁺): 523.3424, found: 523.3405.

2,12-Dimethyl-7-oxo-2,12-di-*p*-tolyl-tridecanedioic acid

2,12-Dimethyl-7-oxo-2,12-di-*p*-tolyl-tridecanedioic acid diethyl ester (9.0 g, 17.24 mmol) was added to a homogenous solution of KOH (85%, 4.0 g, 60.34 mmol) in water (10 mL) and ethanol (30 mL). The reaction mixture was heated to reflux for 6 h. The ethanol was removed under reduced pressure. The residue was diluted with water (30 mL) and the solution was acidified with concd. HCl (12 mL) to pH 1, then extracted with CH₂Cl₂ (3 \times 80 mL). The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, concentrated, and purified by flash chromatography (silica gel, ethyl acetate/hexanes = 1/20, 1/10, 1/2) to furnish 2,12-dimethyl-7-oxo-2,12-di-*p*-tolyl-tridecanedioic acid (3.1 g, 38.8%) as a white solid. Mp.: 48 - 50 °C. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 9.69 (br, 2 H), 7.22 (d, 4 H, $J = 8.1$), 7.12 (d, 4 H, $J = 8.1$), 2.36 (t, $J = 7.5$ Hz, 4 H), 2.31 (s, 6 H), 1.98 - 1.80 (m, 4 H), 1.56 - 1.44 (m, 4 H), 1.51 (s, 6 H), 1.24 - 1.15 (m, 4 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 211.63, 183.07, 140.40, 137.00, 129.58, 126.43, 50.02, 42.82, 39.10, 24.74, 24.50, 22.82, 21.39. HRMS (LSIMS, nba): Calcd. for C₂₉H₃₉O₅ (MH⁺): 467.2797, found: 467.2785.

5.1.e. Synthesis of 1,13-Dihydroxy-2,12-dimethyl-2,12-di-*p*-tolyl-tridecan-7-one



6-Bromo-2-methyl-2-*p*-tolyl-hexan-1-ol

5 Methanol (3.14 g, 98.22 mmol) was added drop-wise to a stirred suspension of LiBH₄ (2.19 g, 101 mmol) in anhydrous CH₂Cl₂ (50 mL) under N₂ atmosphere. After the addition of ethyl 6-bromo-2-methyl-2-*p*-tolyl-hexanoate (22 g, 67.28 mmol), the reaction mixture was heated to reflux overnight. The reaction mixture was cooled to 5 °C and hydrolyzed with ice (ca. 40 g) and saturated NH₄Cl solution (150 mL) for 1 h. The layers
10 were separated and the aqueous layer was extracted with CH₂Cl₂ (3 × 200 mL). The combined organic layers were washed with saturated NH₄Cl solution (3 × 150 mL), dried over anhydrous MgSO₄ and concentrated in vacuo to furnish 6-bromo-2-methyl-2-*p*-tolyl-hexan-1-ol (18.44 g, 96.2 %) as an oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.25 - 7.00 (m, 4 H), 3.68 - 3.50 (m, 1 H), 3.49 - 3.35 (m, 1 H), 3.34 - 3.21 (t, *J* = 6.9 Hz, 2 H),
15 2.31 (s, 3 H), 1.88 - 1.51 (m, 4 H), 1.51 - 1.40 (m, 2 H), 1.31 (s, 3 H), 1.20 - 1.00 (m, 1 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 141.49, 135.74, 129.47, 126.63, 72.54, 43.03, 37.53, 33.69, 33.51, 22.66, 21.58, 20.98. HRMS (LSIMS, nba): Calcd. for C₁₄H₂₀Br (MH⁺ - H₂O): 267.0748, found: 267.0750.

2-(6-Bromo-2-methyl-2-*p*-tolyl-hexyloxy)-tetrahydropyran


20 Under N₂ atmosphere, 3,4-dihydro-2*H*-pyran (6.39 g, 76.09 mmol) was added drop-wise to a stirred solution of 6-bromo-2-methyl-2-*p*-tolyl-hexan-1-ol (18.20 g, 63.86 mmol) and *p*-toluenesulfonic acid hydrate (0.43 g, 2.26 mmol) in dichloromethane (300 mL) at - 5 °C. The reaction mixture was allowed to warm to rt and stirred for 3 h. The solution was
25 filtered through aluminum oxide (160 g), which was washed with CH₂Cl₂ (500 mL). The filtrate was concentrated *in vacuo* to furnish 2-(6-bromo-2-methyl-2-*p*-tolyl-hexyloxy)-tetrahydropyran (22 g, 93.4 %) as an oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.25 - 7.05 (m, 4 H), 4.60 - 4.48 (m, 1 H), 3.82 (m, 2 H), 3.48 - 3.37 (m, 2 H), 3.35 - 3.26 (m, 2 H), 2.30 (s, 3 H), 1.90 - 1.40 (m, 11 H), 1.40 - 1.33 (s, 3 H), 1.40 - 1.08 (m, 1 H). ¹³C NMR
30 (75 MHz, CDCl₃/TMS): δ (ppm) 142.78, 135.22, 128.81, 126.39, 99.09, 61.99, 41.67, 38.12, 37.87, 33.68, 30.99, 25.96, 23.08, 22.89, 21.12, 20.97, 19.41. HRMS (LSIMS, nba): Calcd. for C₁₉H₃₀O₂Br (MH⁺): 369.1429, found: 369.1451.

1,13-Dihydroxy-2,12-dimethyl-2,12-di-*p*-tolyl-tridecan-7-one

To a solution of 2-(6-bromo-2-methyl-2-*p*-tolyl-hexyloxy)-tetrahydropyran (21.5 g, 58.27 mmol), tetra-*n*-butylammonium iodide (2.36 g, 6.41 mmol), and *p*-toluenesulphonyl-methyl isocyanide (TosMIC, 5.68 g, 29.14 mmol) in anhydrous DMSO (300 mL) and anhydrous diethyl ether (100 mL) was added sodium hydride (60% dispersion in mineral oil, 2.94 g, 73.42 mmol) at rt under N₂ atmosphere. The mixture was stirred for 24 h at rt. The reaction mixture was carefully hydrolyzed with ice-water (500 mL) and extracted with diethyl ether (2 × 300 mL). The organic layer was washed with brine (2 × 300 mL), dried over anhydrous MgSO₄, and concentrated in vacuo to furnish crude 2-[7-isocyano-2,12-dimethyl-2,12-di-*p*-tolyl-13-(tetrahydropyran-2-yloxy)-7-(toluene-4-sulfonyl)-tridecanyloxy]-tetrahydropyran (18.44 g) as a brown oil. A solution of this crude intermediate (18 g) in methanol (300 mL), concd. HCl (36 mL), and water (70 mL) was heated to reflux for 3 h. The reaction mixture was poured into CH₂Cl₂ (250 mL) and ice-water (250 mL). The layers were separated and the aqueous layer was extracted with CH₂Cl₂ (3 × 100 mL). The combined organic layers were washed with saturated NaHCO₃ solution (3 × 100 mL) and brine (150 mL), dried over anhydrous MgSO₄ and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography (silica gel, ethyl acetate/hexanes = 20/1, 15/1, 10/1, 5/1, and 1/1) to furnish 1,13-dihydroxy-2,12-dimethyl-2,12-di-*p*-tolyl-tridecan-7-one (2.72 g, 26.2 % over two steps) as a colorless oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.18 (d, 4 H, *J* = 8.1 Hz), 7.12 (d, 4 H, *J* = 8.1 Hz), 3.63 (d, *J* = 11.0 Hz, 2 H), 3.49 (d, *J* = 11.0 Hz, 2 H), 2.31 (s, 6 H), 2.26 (t, *J* = 7.8 Hz, 4 H), 1.78-1.40 (m, 10 H), 1.28 (s, 6 H), 1.24 - 0.82 (m, 4 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 211.51, 141.75, 135.64, 129.23, 126.64, 72.54, 43.06, 42.65, 38.28, 24.53, 23.59, 21.66, 20.98. HRMS (LSIMS, nba): Calcd. for C₂₉H₄₃O₃ (MH⁺): 439.3212, found: 439.3222.

5

5.1.f. Synthesis of 2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-oxo-tridecanedioic acid



10

6-Bromo-2-(4-isobutyl-phenyl)-2-methyl-hexanoic acid ethyl ester

Ethyl (4-isobutyl-phenyl)-acetate (10.5 g, 44.8 mmol) was dissolved in freshly distilled tetrahydrofuran (150 mL) and cooled to -78°C . Lithium diisopropylamide (2 N, 28 mL, 56 mmol) was added and the solution stirred for 1 hour at -78°C under a nitrogen atmosphere. 1,4-Dibromobutane (25 mL, 37.5 g, 175 mmol) was then added drop-wise over 30 minutes. The solution was allowed to warm to room temperature over five hours. After stirring at room temperature for an additional 16 hours, the reaction was quenched with water (100 mL) and extracted with diethyl ether (2×100 mL). The ether was washed with 10% hydrochloric acid (2×100 mL), saturated sodium bicarbonate (100 mL) and water

(100 mL). After drying with sodium sulfate (5 g), filtration and concentration, the product was purified by flash chromatography on silica gel (200 g), eluting with 5% ethyl acetate/hexanes. The product was then heated to 150 °C under vacuum (0.5 mm Hg) for 30 minutes to remove excess 1,4-dibromobutane. The reaction yielded 6-bromo-2-(4-isobutyl-phenyl)-2-methyl-hexanoic acid ethyl ester (14.49 g, 87.5% yield) as a clear, viscous oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm): 7.19 (d, 2H, *J*= 8.0 Hz), 7.08 (d, 2H, *J*= 8.0 Hz), 4.11 (q, 2H, *J*= 7.0 Hz), 3.35 (t, 2H, *J*= 6.8 Hz), 2.43 (d, 2H, *J*= 7.3 Hz), 2.10 - 1.92 (m, 1H), 1.92 - 1.78 (m, 4H), 1.53 (s, 3H), 1.40 - 1.28 (m, 2H), 1.17 (t, 3H, *J*= 7.0 Hz), 0.88 (d, 6H, *J*= 6.8). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 176.17, 141.12, 140.04, 129.14, 125.64, 60.77, 49.80, 44.99, 38.52, 33.51, 33.26, 30.22, 23.55, 22.69, 22.50, 14.19. HRMS (LSIMS, nba): Calcd. for C₁₉H₃₀O₂Br (MH⁺): 369.1429, found: 369.1445.

2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-oxo-tridecanedioic acid diethyl ester

6-Bromo-2-(4-isobutyl-phenyl)-2-methyl-hexanoic acid ethyl ester (14.13 g, 38.2 mmol) was dissolved in freshly distilled methylsulfoxide (200 mL) and TosMIC (3.73 g, 19.1 mmol), tetra-*n*-butylammonium iodide (1.30 g, 3.5 mmol), and sodium hydride (2.0 g 60%, 19.1 mmol) were added at room temperature under a nitrogen atmosphere. After stirring for 18 hours at room temperature, the reaction was quenched by the slow addition of water (200 mL). Dichloromethane (100 mL) was added and the layers were separated. The aqueous fraction was then extracted with additional dichloromethane (2 × 50 mL). The dichloromethane fractions were combined and washed with water (100 mL) and brine (100 mL) before drying with sodium sulfate. After filtration, concentration and drying under high vacuum, the crude intermediate was dissolved in dichloromethane (100 mL) and concentrated hydrochloric acid (50 mL). After stirring for one hour at room temperature, cold water (200 mL) was added and the layers were separated. The aqueous portion was extracted with additional dichloromethane (100 mL). The dichloromethane fractions were combined, dried with sodium sulfate, filtered and concentrated. The product was purified by flash chromatography on silica gel (300 g), eluting with 10% ethyl acetate/hexanes (2 L) followed by 20 % ethyl acetate/hexanes (1 L). The reaction yielded 2,12-*bis*-(4-isobutyl-phenyl)-2,12-dimethyl-7-oxo-tridecanedioic acid diethyl ester (9.49 g, 82% yield) as a colorless oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.18 (d, 4H, *J*= 8.0 Hz), 7.07 (d, 4H, *J*= 8.0 Hz), 4.10 (q, 4H, *J*= 7.0 Hz), 2.43 (d, 4H, *J*= 7.0 Hz), 2.34 (t, 4H, *J*= 7.6 Hz), 2.10-1.92 (m, 2H), 1.92-1.78 (m, 4H), 1.60-1.50 (m, 4H), 1.50 (s, 6H), 1.19-1.11 (m, 5H), 1.17 (t, 3H, *J*= 7.0 Hz), 0.88 (d, 12H, *J*= 6.6 Hz). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 211.06, 176.39, 141.36, 140.04, 129.16, 125.71, 60.77, 49.90, 45.06, 42.66, 39.18,


30.27, 24.59, 24.35, 22.86, 22.56, 14.23. HRMS (LSIMS, nba): Calcd. for $C_{39}H_{59}O_5$ (MH^+): 607.4362, found: 607.4337.

2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-oxo-tridecanedioic acid

- 5 2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-oxo-tridecanedioic acid diethyl ester (3.0 g, 4.95 mmol) was dissolved in ethanol (40 mL) and water (10 mL) with potassium hydroxide (4.4 g 85%). The solution was heated to reflux for six hours, cooled and concentrated. After the ethanol was removed, water (200 mL) was added and the solution was extracted with diethyl ether (100 mL). The aqueous fraction was acidified with
- 10 concentrated hydrochloric acid (10 mL, to pH = 1). The product was then extracted with diethyl ether (2 × 100 mL). The ether fractions were combined and dried with sodium sulfate (5 g). After filtration, concentration and drying under high vacuum, the reaction yielded 2,12-bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-oxo-tridecanedioic acid (2.35 g, 82% yield) as a light yellow foam. 1H NMR (300 MHz, $CDCl_3/TMS$): δ (ppm) 10.02 (bs, 2H),
- 15 7.24 (d, 4H, $J = 8.0$ Hz), 7.09 (d, 4H, $J = 8.0$ Hz), 2.43 (d, 4H, $J = 7.0$ Hz), 2.33 (t, 4H, $J = 7.3$ Hz), 2.05-1.88 (m, 2H), 1.96-1.77 (m, 4H), 1.55-1.42 (m, 10H), 1.22-1.08 (m, 4H), 0.88 (d, 12H, $J = 6.6$). ^{13}C NMR (75 MHz, $CDCl_3/TMS$): δ (ppm): 211.48, 182.94, 140.43, 140.24, 129.27, 125.94, 49.71, 45.06, 42.58, 42.58, 38.91, 30.25, 24.45, 24.24, 22.58, 22.40. HRMS (LSIMS, nba): Calcd. for $C_{35}H_{50}O_5Na$ (MNa^+): 573.3555, found: 573.3459.

20

**5.1.g. Synthesis of 1,13-Dihydroxy-
2,12-bis-(4-isobutyl-phenyl)-2,12-dimethyl-tridecan-7-one**



2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-([1,3]dithianyl)-tridecanedioic acid diethyl ester

- 5 2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-oxo-tridecanedioic acid diethyl ester (5.50 g, 9.0 mmol) was dissolved in freshly distilled dichloromethane (60 mL) with borontrifluoride etherate (0.45 mL) and 1,3-propanedithiol (1.0 mL, 0.98 g, 9.0 mmol). The solution was stirred for three hours at room temperature under a nitrogen atmosphere. After three hours, an additional volume of dichloromethane (100 mL) was added and the solution
- 10 was extracted with 5% sodium hydroxide solution (2 × 50 mL) and water (100 mL). After drying with sodium sulfate, filtration, and concentration, the product was purified by flash chromatography on silica gel (130 g), eluting with 10% ethyl acetate/hexanes. The reaction yielded 2,12-bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-([1,3]dithianyl)-tridecanedioic acid diethyl ester (6.16 g, 98% yield) as a colorless oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ
- 15 (ppm) 7.20 (d, 4H, *J* = 8.0 Hz), 7.07 (d, 4H, *J* = 8.0 Hz), 4.10 (q, 4H, *J* = 7.0 Hz), 2.76 (t, 4H, *J* = 5.3 Hz), 2.43 (d, 4H, *J* = 7.0 Hz), 2.09-1.95 (m, 2H), 1.94-1.78 (m, 10H), 1.51 (s, 6H), 1.46-1.36 (m, 4H), 1.25-1.12 (m, 4 H), 1.18 (t, 6 H, *J* = 7.0 Hz), 0.88 (d, 12H, *J* = 6.5 Hz). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 176.42, 141.43, 140.00, 129.14, 125.74, 60.74, 53.30, 49.97, 45.05, 39.22, 38.29, 30.26, 26.10, 25.64, 25.17, 24.76, 22.99, 22.56, 14.26.
- 20 HRMS (LSIMS, nba): Calcd. for C₄₂H₆₅O₄S₂ (MH⁺): 696.4246, found: 696.4234.

2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-([1,3]dithianyl)-tridecane-1,13-diol

- 25 2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-([1,3]dithianyl)-tridecanedioic acid diethyl ester (5.81 g, 8.33 mmol) was dissolved in freshly distilled tetrahydrofuran (THF, 50 mL) and added to lithium aluminum hydride (1.0 g, 26.3 mmol) in THF (50 mL) at -78 °C under a nitrogen atmosphere. The solution was warmed to room temperature over four
- 30 hours. The reaction was then cooled back to -78 °C and quenched with ethyl acetate (5.0 mL). After warming to room temperature, water (100 mL) was added and the product was extracted with diethyl ether (2 × 100 mL). The ether extracts were combined, dried with sodium sulfate, filtered, and concentrated. After drying under high vacuum for four hours, the reaction yielded 2,12-bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-([1,3]dithianyl)-tridecane-
- 35 1,13-diol (4.80 g, 94% yield) as a colorless oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.20 (d, 4H, *J* = 8.0 Hz), 7.09 (d, 4H, *J* = 8.0 Hz), 3.64 (d, 2H, *J* = 10.7 Hz), 3.48 (d, 2H, *J* = 10.7 Hz), 2.71 (t, 4H, *J* = 5.1 Hz), 2.50 - 2.35 (m br., 2 H), 2.43 (d, 4H, *J* = 7.0 Hz), 1.90-1.80

(m, 4H), 1.80-1.68 (m, 6H), 1.58-1.42 (m, 2H), 1.38-1.25 (m, 4H), 1.30 (s, 6H), 1.26-1.10 (m, 2H), 1.10-0.95 (m, 2H), 0.89 (d, 12H, $J=6.6$ Hz). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm) 141.94, 139.39, 129.20, 126.44, 72.48, 53.30, 44.97, 43.09, 38.45, 38.18, 30.21, 26.01, 25.64, 24.84, 24.09, 22.55, 21.64. HRMS (LSIMS, nba): Calcd. for $\text{C}_{38}\text{H}_{61}\text{O}_2\text{S}_2$ (MH^+): 613.4113, found: 613.4075.


10

1,13-Dihydroxy-2,12-bis-(4-isobutyl-phenyl)-2,12-dimethyl-tridecan-7-one

2,12-Bis-(4-isobutyl-phenyl)-2,12-dimethyl-7-([1,3]dithianyl)-tridecane-1,13-diol (4.50 g, 7.35 mmol) was dissolved in dimethoxyethane (DME, 50 mL) with concentrated hydrochloric acid (10 mL). Methylsulfoxide (DMSO, 5.0 mL) was added drop-wise over five minutes and the solution was stirred for thirty minutes at room temperature. The reaction was then slowly poured into saturated sodium bicarbonate solution (100 mL) and extracted with diethyl ether (2×100 mL). The ether fractions were combined, dried with sodium sulfate, filtered, and concentrated. The product was purified by flash chromatography on silica gel (100 g), eluting with 30 % ethyl acetate/hexanes. The reaction yielded 1,13-dihydroxy-2,12-bis-(4-isobutyl-phenyl)-2,12-dimethyl-tridecan-7-one (3.2 g, 83.5 %) as a colorless oil. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm): 7.19 (d, 4H, $J=8.0$ Hz), 7.09 (d, 4H, $J=8.0$ Hz), 3.63 (d, 2H, $J=11.0$ Hz), 3.49 (d, 2H, $J=11.0$ Hz), 2.43 (d, 4H, $J=7.0$ Hz), 2.26 (t, 4H, $J=7.3$ Hz), 1.88-1.66 (m, 4H), 1.52-1.41 (m, 8H), 1.29 (s, 6H), 1.15-1.10 (m, 2H), 0.98-0.88 (m, 2H), 0.89 (d, 12H, $J=6.6$ Hz). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ = 211.47, 141.97, 139.51, 129.28, 126.45, 72.53, 45.02, 43.11, 42.69, 38.36, 30.26, 24.57, 23.63, 22.58, 21.72. HRMS (LSIMS, nba): Calcd. for $\text{C}_{35}\text{H}_{55}\text{O}_3$ (MH^+): 523.4151, found: 523.4144.

30

5.1.h. Synthesis of 2,10-Dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid




2,10-Dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid diethyl ester

To a solution of ethyl 5-bromo-2-methyl-2-phenylpentanoate (25 g, 75.25 mmol), tetra-*n*-butylammonium iodide (2.78 g, 7.53 mmol), and *p*-toluenesulphonylmethyl isocyanide (TosMIC, 7.34 g, 37.63 mmol) in anhydrous DMSO (400 mL) and anhydrous diethyl ether (150 mL) was added sodium hydride (60% dispersion in mineral oil, 3.80 g, 95 mmol) at rt under N₂ atmosphere. The reaction mixture was stirred for 24 h at rt, then carefully hydrolized with ice-water (600 mL), and extracted with diethyl ether (2 × 300 mL). The organic layer was washed with brine (2 × 300 mL) dried over anhydrous MgSO₄, concentrated in vacuo to furnish crude 2,10-dimethyl-6-isocyano-6-(4-tolyl-sulfonyl)-2,10-diphenyl-undecanedioic acid diethyl ester (28 g) as a brown oil. A solution of this crude intermediate (25 g) was dissolved in CH₂Cl₂ (500 mL) and concd. HCl (140 mL) and stirred for 2 h at rt. The reaction mixture was diluted with water (500 mL) and the layers were separated. The aqueous layer was extracted with CH₂Cl₂ (2 × 200 mL). The combined layers were washed with saturated NaHCO₃ solution (150 mL), and brine (150 mL), dried over MgSO₄, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography (silica gel, ethyl acetate/hexanes = 1/20, 1/10) to furnish 2,10-dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid diethyl ester (9.5 g, 50.3 %) as a light yellowish oil.

¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.40 - 7.10 (m, 10 H), 4.20 - 4.05 (m, 4 H), 2.38 (m, 4 H), 2.05 - 1.80 (m, 4 H), 1.60 (s, 6 H), 1.50 - 1.20 (m, 4 H), 1.22 (m, 6 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 210.24, 176.06, 143.71, 128.42, 126.72, 125.97, 60.83, 50.13, 42.97, 38.91, 22.73, 22.47, 19.09, 14.13. HRMS (LSIMS, nba): Calcd. for C₂₉H₃₉O₅ (MH⁺): 467.2797, found: 467.2772.

2,10-Dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid

To a homogenous solution of KOH (85%, 7.17 g, 108.90 mmol) in water (15 mL) and ethanol (45 mL) was added 2,10-dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid diethyl ester (14.5 g, 31.12 mmol). The reaction solution was heated to reflux for 6 h. The ethanol was removed in reduced pressure and the residue was diluted with water (300 mL). The solution was acidified with concd. HCl (18 mL) to pH 1 and extracted with CH₂Cl₂ (3 × 100 mL). The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄ and purified by flash chromatography (silica gel, ethyl acetate/hexanes = 1/20, 1/10, 1/2) to furnish 2,10-dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid (4 g, 31.4 %) as a white solid. Mp.: 44 - 46 °C. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 10.25 (br, 2 H), 7.35 - 7.22 (m, 10 H), 2.32 (m, 4 H), 1.94 - 1.86 (m, 4 H), 1.57 (s, 6 H), 1.51 - 1.22 (m, 4 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 210.64, 182.66, 142.69, 128.66, 127.18, 126.29, 50.07, 42.97, 38.62, 22.20, 19.11. HRMS (LSIMS, nba): Calcd. for C₂₅H₃₁O₅ (MH⁺): 411.2171, found: 411.2144.

5.1.i. Synthesis of 1,11-Dihydroxy-2,10-dimethyl-2,10-diphenyl-undecan-6-one**5-Bromo-2-methyl-2-phenyl-pentan-1-ol**

Methanol (5.24 g, 164 mmol) was added drop-wise to a stirred suspension of LiBH₄ (3.45 g, 150 mmol) in anhydrous CH₂Cl₂ (150 mL) under N₂ atmosphere. After the addition of ethyl 5-bromo-2-methyl-2-phenyl-pentanoate (23.70 g, 106 mmol), the reaction mixture was heated to reflux overnight. The reaction mixture was cooled to 5 °C and hydrolyzed

with ice (ca. 30 g) and NH_4Cl solution (150 mL) for 1 h. The layers were separated and the aqueous layer was extracted with CH_2Cl_2 (3×150 mL). The combined organic layers were washed with NH_4Cl solution (3×100 mL), dried over MgSO_4 and concentrated in vacuo to furnish 5-bromo-2-methyl-2-phenyl-pentan-1-ol (20 g, 96.8 %) as an oil. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm) 7.34 - 7.14 (m, 5 H), 3.60 (m, 1 H), 3.48 (m, 1 H), 3.29 (t, $J = 6.0$ Hz, 2 H), 1.96 - 1.44 (m, 5 H), 1.32 (s, 3 H). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm) 144.25, 128.59, 126.71, 126.41, 72.44, 43.15, 37.06, 34.64, 27.58, 21.61. HRMS (LSIMS, nba): Calcd. for $\text{C}_{12}\text{H}_{16}\text{Br}$ ($\text{MH}^+ - \text{H}_2\text{O}$): 239.0435, found: 239.0444.

10

2-(5-Bromo-2-methyl-2-phenyl-pentyloxy)-tetrahydropyran

Under N_2 atmosphere, 3,4-dihydro-2H-pyran (8.19 g, 98 mmol) was added dropwise to a stirred solution of 5-bromo-2-methyl-2-phenyl-pentan-1-ol (20 g, 78 mmol) at -5°C . The reaction mixture was allowed to warm to rt and stirred for 5 h. The solution was filtered through aluminum oxide (100 g), which was washed with CH_2Cl_2 (500 mL). The filtrate was concentrated in vacuo to furnish 2-(5-bromo-2-methyl-2-phenyl-pentyloxy)-tetrahydropyran (25.23 g, 96.2 %) as an oil. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm) 7.26 - 7.08 (m, 5 H), 4.45 (m, 1 H), 3.72 (m, 1 H), 3.58 (m, 1 H), 3.35 - 3.05 (m, 2 H), 3.28 (t, $J = 6.6$, 2 H), 1.95 - 1.39 (m, 10 H), 1.25 (s, 3 H). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm) 145.37, 128.14, 126.51, 126.03, 99.06, 98.92, 61.91, 61.80, 41.82, 41.74, 37.58, 37.43, 34.65, 30.61, 27.88, 25.58, 23.03, 22.89, 19.39, 19.32. HRMS (HR, LSIMS, nba): Calcd. for $\text{C}_{17}\text{H}_{26}\text{O}_2\text{Br}$ (MH^+): 341.1116, found: 341.1127.

15

20

1,11-Dihydroxy-2,10-dimethyl-2,10-diphenyl-undecan-6-one

To a solution of 2-(5-bromo-2-methyl-2-phenyl-pentyloxy)-tetrahydropyran (25 g, 74.18 mmol), tetra-*n*-butylammonium iodide (3.0 g, 8.16 mmol), and *p*-toluenesulfonylmethyl isocyanide (TosMIC, 7.23 g, 37.09 mmol) in anhydrous DMSO (350 mL) and anhydrous diethyl ether (100 mL) was added sodium hydride (60% dispersion in mineral oil, 3.73 g, 1.26 mmol) at rt under N_2 atmosphere. The reaction mixture was allowed to stir for 24 h at this temperature, then was carefully hydrolyzed with ice and water (600 mL) and extracted with diethyl ether (2×300 mL). The combined organic layers were washed with brine (2×300 mL), dried over MgSO_4 , and concentrated in vacuo to furnish 6-isocyano-6-(4-tolyl-sulfonyl)-2,10-dimethyl-2,10-diphenyl-11-(tetrahydropyran-2-yloxy)-undecanyloxy-tetrahydropyran (28 g) as a brown oil. A solution of this crude intermediate (28 g, 41.12 mmol) was dissolved in methanol (500 mL), concd. HCl (60 mL), and water (120 mL) and heated to reflux for 3 h. The reaction mixture was poured into CH_2Cl_2 (300 mL) and ice and

25


30

35

water (300 g). The layers were separated and the aqueous layer was extracted with CH_2Cl_2 ($3 \times 150 \text{ mL}$). The combined organic layers were washed with saturated NaHCO_3 solution ($3 \times 150 \text{ mL}$) and brine (150 mL), dried over MgSO_4 , and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography (silica gel; hexanes, then ethyl

acetate/hexanes = 1/20, 1/10, 1/2, 1/1) to furnish 1,11-dihydroxy-2,10-dimethyl-2,10-diphenyl-undecan-6-one (5.3 g, 34 %) as a light yellowish oil. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm) 7.38 - 7.30 (m, 8 H), 7.26 - 7.18 (m, 2 H), 3.62 (d, $J = 10.5 \text{ Hz}$, 2 H), 3.48 (d, $J = 10.5 \text{ Hz}$, 2 H), 2.25 (m, 6 H) 1.76 - 1.64 (m, 2 H), 1.58 - 1.16 (m, 6 H), 1.32 (s, 6 H). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm) 211.43, 144.84, 128.32, 126.58, 126.03, 71.79, 43.11, 42.89, 37.61, 21.68, 18.12. HRMS (LSIMS, nba): Calcd. for $\text{C}_{25}\text{H}_{33}\text{O}_2$ ($\text{MH}^+ - \text{H}_2\text{O}$): 365.2481, found: 365.2482.

5.1.j. Synthesis of 9-Hydroxy-3-(6-hydroxy-5,5-dimethyl-hexyl)-8,8-dimethyl-nonan-2-one



2,2-Bis-[5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl]-malonic acid diethyl ester

Under nitrogen atmosphere, to a solution of 2-(6-bromo-2,2-dimethyl-hexyloxy)-tetrahydropyran (17.6 g, 60 mmol) and diethyl malonate (4.8 g, 30 mmol) in anhydrous DMSO (145 mL) was added sodium hydride (60 % dispersion in mineral oil, 2.88 g, 72 mmol) under cooling with a water-bath. Tetra-*n*-butylammonium iodide (2.1 g, 3.6 mmol) was then added. The mixture was stirred for 16 h at room temperature. Water (140 mL) was added carefully to the reaction mixture under cooling with water-bath. The product was extracted with diethyl ether (3 × 60 mL) and the combined organic layers were washed with water (4 × 50 mL) and brine (50 mL). The solution was dried over sodium sulfate and concentrated in vacuo to give 2,2-*bis*-[5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl]-malonic acid diethyl ester (17.3 g, 82.3 %) as an oil. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 4.41 (t, *J* = 3.1 Hz, 2H), 4.01 (q, *J* = 7.0 Hz, 4 H), 3.82 - 3.70 (m, 2 H), 3.50 - 3.30 (m, 4 H), 2.87 (d, *J* = 9.1 Hz, 2 H), 1.80 - 1.35 (m, 16 H), 1.30 - 0.95 (m, 18 H), 0.88 - 0.74 (m, 12 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 172.0, 99.1, 76.6, 61.9, 60.9, 57.6, 39.2, 34.3, 32.3, 30.7, 25.7, 25.0, 24.6, 24.6, 24.3, 19.5, 14.2.

2,2-Bis(6-hydroxy-5,5-dimethyl-hexyl)-malonic acid diethyl ester

A solution of 2,2-*bis*-[5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl]-malonic acid diethyl ester (2.92 g, 5mmol) in concentrated HCl (2.4 mL) and water (1.6 mL) was refluxed for 1 h. Ethanol (8.2 mL) was added and the reaction mixture was heated to reflux for 3 h. The reaction mixture was diluted with water (20 mL) and extracted with diethyl ether (3 × 20 mL). The combined organic layers were washed with water (20 mL), brine (20 mL), and dried over Na₂SO₄. The solution was concentrated to furnish 2,2-*bis*(6-hydroxy-5,5-dimethyl-hexyl)-malonic acid diethyl ester (1.74 g, 84 %). ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 4.13 (q, *J* = 7.2 Hz, 4 H), 3.25 (s, 4 H), 2.42 (s, 2 H), 1.90 - 1.75 (m, 4 H), 1.30 - 1.12 (m, 18 H), 0.84 (s, 12 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 172.0, 71.7, 60.9, 57.4, 38.2, 34.9, 32.1, 24.8, 24.0, 23.7, 14.0.

2,2-Bis-(6-hydroxy-5,5-dimethyl-hexyl)-malonic acid

To a stirred solution of KOH (4.83 g, 75 mmol) in water (4.2 mL) and ethanol (15 mL) was added 2,2-*bis*(6-hydroxy-5,5-dimethyl-hexyl)-malonic acid diethyl ester (15 g). The reaction mixture was heated to reflux for 14 h, then concentrated *in vacuo*, and extracted with chloroform. The aqueous layer was acidified with HCl until pH 1 and extracted with diethyl ether (3 × 50 mL). The ethereal solution was dried over anhydrous MgSO₄ and concentrated *in vacuo* to afford get 2,2-*bis*-(6-hydroxy-5,5-dimethyl-hexyl)-malonic acid (7.8 g, 82.3 %) as a yellow solid. ¹H NMR (300 MHz, CD₃OD/TMS): δ (ppm)

4.86 (s, 4 H), 3.22 (s, 4 H), 1.9 - 1.8 (m, 4 H), 1.36 - 1.10 (m, 12 H), 0.84 (s, 12 H). ¹³C NMR (75 MHz, CD₃OD/TMS): δ (ppm) 176.0, 72.0, 58.7, 39.8, 36.0, 34.1, 26.5, 25.5, 24.5. Mp.: 178 - 180 °C.


5 8-Hydroxy-2-(6-hydroxy-5,5-dimethyl-hexyl)-7,7-dimethyl-octanoic acid

2,2-Bis-(6-hydroxy-5,5-dimethyl-hexyl)-malonic acid was heated to 200 °C using an oil-bath. This temperature was kept for 30 minutes until the effervescence ceased. 8-Hydroxy-2-(6-hydroxy-5,5-dimethyl-hexyl)-7,7-dimethyl-octanoic acid was obtained as an oil (4.04 g, 98 %). ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 4.88 (s, 3 H), 3.22 (s, 4 H), 2.29 (m, 1 H), 1.70 - 1.40 (m, 4 H), 1.4 - 1.1 (m, 12 H), 0.84 (s, 12 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 180.5, 72.1, 47.1, 39.9, 36.0, 33.8, 29.7, 25.0, 24.6.

9-Hydroxy-3-(6-hydroxy-5,5-dimethyl-hexyl)-8,8-dimethyl-nonan-2-one

8-Hydroxy-2-(6-hydroxy-5,5-dimethyl-hexyl)-7,7-dimethyl-octanoic acid (1.0 g, 3.16 mmol) was dissolved in THF (40 mL) and cooled in an ice-water bath. Methyl lithium (27 mL) was then added at once. The reaction was continued for 2 h at 0 °C. The reaction mixture was poured into dilute hydrochloric acid (5 mL concentrated hydrochloric acid in 60 mL water). The organic layer was separated and the aqueous layer was extracted with diethyl ether (2 × 50 mL). The combined organic layers were dried over sodium sulfate and concentrated in vacuo to give the crude product (1.0 g). The crude product was purified by column chromatography (hexanes : ethyl acetate = 4 : 1, then 1 : 1) to give 9-hydroxy-3-(6-hydroxy-5,5-dimethyl-hexyl)-8,8-dimethyl-nonan-2-one (0.41 g, yield 41 %) and 7-(1-hydroxy-1-methylethyl)-2,2,12,12-tetramethyltridecan-1,13-diol (0.4 g, 38 %, not shown) as a by-product. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 3.46 (s, 4 H), 2.65 - 2.50 (m, 1 H), 2.28 (s, 3 H), 2.60 (br., 2 H), 1.82 - 1.50 (m, 4 H), 1.50 - 1.25 (m, 12 H), 1.02 (s, 12 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm) 213.4, 71.7, 53.2, 38.3, 34.9, 31.6, 28.7, 28.3, 23.8. HRMS (LSIMS, nba): Calcd. for C₁₉H₃₉O₃ (MH⁺): 315.2899, found: 315.2866.

5.1.k. Synthesis of Bis[3-(3-hydroxy-2,2-dimethylpropyl)phenyl]methanone



**3-{3-[3-(2-Ethoxycarbonyl-2-methyl-propyl)-
benzoyl]-phenyl}-2,2-dimethyl-propionic acid ethyl ester**

5

A solution of lithium diisopropylamide (LDA, 2.0 M in heptane/THF, ethyl benzene, 42.2 mL, 84.4 mmol) was added drop-wise to a solution of ethyl isobutyrate (9.78 g, 84.3 mmol) in anhydrous THF (30 mL) at -78°C . The mixture was allowed to stir at -78°C for 1 h, before 3,3'-bis(bromomethyl)benzophenone ((prepared according to Shultz, D.A.; Fox, M. A. *J. Am. Chem. Soc.* **1989**, *16*, 6311, from 3-bromobenzyl methyl ether (Friedman, L.; Shechter, H. *J. Org. Chem.* **1961**, *26*, 2522), 10.34 g, 28.1 mmol) was added, followed by addition of DMPU (2.7 g, 17 mmol). The mixture was stirred for 30 min at -78°C , allowed to warm to rt, and stirred for 30 min. The THF was removed under reduced pressure and the residue was diluted with saturated NH_4Cl (280 mL). The aqueous layer was extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with brine (200 mL), 5 % HCl (100 mL), and saturated NaHCO_3 solution (50 mL), then dried over anhydrous Na_2SO_4 and concentrated *in vacuo* to furnish 3-{3-[3-(2-ethoxycarbonyl-2-methyl-propyl)-benzoyl]-phenyl}-2,2-dimethyl-propionic acid ethyl ester (11.0 g, 90%) as an oil. ^1H NMR (300 MHz, CDCl_3): δ (ppm): 7.8 - 7.2 (m, 8 H), 3.98 (q, J

10

15

= 6.9 Hz, 4 H), 2.83 (s, 4 H), 1.2 - 0.8 (m, 18 H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm): 196.5, 176.8, 138.1, 137.2, 134.0, 131.4, 128.1, 127.7, 60.3, 45.7, 43.3, 24.8, 13.9.

5 **3-(3-{2-[3-(2-Ethoxycarbonyl-2-methyl-propyl)-phenyl]-[1,3]dithian-2-yl}-phenyl)-2,2-dimethyl-propanoic acid ethyl ester**

To a solution of 3-{3-[3-(2-ethoxycarbonyl-2-methyl-propyl)-benzoyl]-phenyl}-2,2-dimethyl-propionic acid ethyl ester (6.2 g, 14 mmol) in dichloromethane (100 mL) was added 1,3-propanedithiol (1.9 g, 17.5 mmol) and borontrifluoride etherate (0.52 mL). The solution was stirred at room temperature overnight and 5 % sodium hydroxide solution (17.5 mL) was added. The organic layer was separated, washed with water (50 mL), dried over sodium sulfate, and evaporated to afford 3-(3-{2-[3-(2-ethoxycarbonyl-2-methyl-propyl)-phenyl]-[1,3]dithian-2-yl}-phenyl)-2,2-dimethyl-propanoic acid ethyl ester (6.5 g, 86 %) as an oil. ¹H NMR (300 MHz, CDCl₃): δ (ppm): 7.58 - 6.96 (m, 8 H), 4.10 (q, *J* = 7.2 Hz, 4 H), 2.85 (s, 4 H), 2.76 (t, *J* = 5.6 Hz, 4 H), 1.98 (m, 2 H), 1.25 - 1.14 (m, 18 H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm): 177.2, 142.2, 138.1, 131.1, 129.3, 127.8, 127.3, 60.4, 46.2, 43.5, 29.4, 24.9, 24.5, 14.1.

20 **3-(3-{2-[3-(3-Hydroxy-2,2-dimethyl-propyl)-phenyl]-[1,3]dithian-2-yl}-phenyl)-2,2-dimethyl-propan-1-ol**


To a suspension of LiBH₄ (0.78 g, 33 mmol) in dichloromethane (55 mL) was added methanol (1.04 g, 33 mmol) at rt. After the addition of 3-(3-{2-[3-(2-ethoxycarbonyl-2-methyl-propyl)-phenyl]-[1,3]dithian-2-yl}-phenyl)-2,2-dimethyl-propanoic acid ethyl ester (6.5 g, 12.2 mmol), the reaction mixture was heated to reflux for 6 h. After cooling to rt, saturated ammonium chloride solution (20 mL) and dichloromethane (15 mL) were added. The layers were separated and the aqueous layer was extracted with dichloromethane (2 × 10 mL). The combined organic phases were dried over sodium sulfate and concentrated in vacuo to afford crude 3-(3-{2-[3-(3-hydroxy-2,2-dimethyl-propyl)-phenyl]-[1,3]dithian-2-yl}-phenyl)-2,2-dimethyl-propan-1-ol (4.66 g, 85 %) as an oil. ¹H NMR (300 MHz, CDCl₃): δ (ppm): 7.6 - 6.8 (m, 8 H), 3.63 (s, 4 H), 3.16 (s, 4 H), 2.95 - 2.60 (m, 4 H), 2.0 - 1.8 (m, 2 H), 1.61 (s, 2 H), 0.75 (s, 12 H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm): 142.4, 139.2, 131.7, 128.9, 128.1, 127.0, 71.1, 44.9, 43.7, 36.7, 29.6, 27.3, 24.2.

35

Bis-[3-(3-hydroxy-2,2-dimethylpropyl)-phenyl]-methanone

A three-necked flask fitted with a magnetic stirring bar, a condenser, and a pressure-equalizing dropping funnel was charged with copper(II)oxide (0.96 g, 12 mmol), anhydrous copper(II)chloride (3.2 g, 24 mmol) and acetone (80 mL). The resulting suspension was brought to reflux with vigorous stirring, and a solution of 3-(3-{2-[3-(3-hydroxy-2,2-dimethyl-propyl)-phenyl]-[1,3]dithian-2-yl}-phenyl)-2,2-dimethyl-propan-1-ol (4.44 g, 10 mmol) in acetone (20 mL) and DMF (1.2 mL) was added over five min. Reflux temperature was maintained for 90 min. The reaction mixture was cooled and filtered. The insoluble materials were washed with dichloromethane (3 × 20 mL) and the combined organic solutions were washed with aqueous 2 N sodium carbonate solution (50 mL), dried over sodium sulfate, and filtered. Concentration in vacuo gave crude *bis*-[3-(3-hydroxy-2,2-dimethylpropyl)-phenyl]-methanone, which was purified by chromatography on silica (hexanes : acetone = 4:1) to yield an oil (2.5 g, 70.6 %). ¹H NMR (300 MHz, CDCl₃): δ (ppm): 7.68 - 7.30 (m, 8 H), 3.31 (s, 4 H), 3.03 (s, 2 H), 2.65 (s, 4 H), 0.88 (s, 12 H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm): 197.4, 139.1, 137.0, 134.6, 131.9, 127.8, 127.6, 70.4, 44.1, 36.3, 23.8. HRMS (LSIMS, gly): Calcd. for C₂₃H₃₁O₃ (MH⁺): 355.2273, found: 355.2273.

5.1.1. Synthesis of 3-{3-[3-(2-Carboxy-2-methylpropyl)-benzoyl]-phenyl}-2,2-dimethyl-propanoic acid




3-{3-[3-(2-Carboxy-2-methylpropyl)benzoyl]-phenyl}-2,2-dimethyl-propanoic acid

To a solution of potassium hydroxide (1.57 g, 28 mmol) in water (1.5 mL) and absolute ethanol (5 mL) was added 3-{3-[3-(2-ethoxycarbonyl-2-methylpropyl)-benzoyl]-phenyl}-2,2-dimethyl-propionic acid ethyl ester (4.38 g, 10 mmol) in portions. The mixture was heated to reflux for 3 h and the ethanol was distilled off under reduced pressure on a water-bath. The residual aqueous solution was extracted with chloroform (2 × 50 mL), then cooled with an ice-bath, and acidified with hydrochloric acid to pH 1. The mixture was extracted with diethyl ether (3 × 50 mL). The ethereal extracts were dried over sodium

sulfate and concentrated in vacuo to give 3-{3-[3-(2-carboxy-2-methylpropyl)benzoyl]-phenyl}-2,2-dimethyl-propanoic acid (3.88 g, 100 %) as a solid. Mp.: 46 - 48 °C. ¹H NMR (300 MHz, CDCl₃): δ (ppm): 7.8 - 7.2 (m, 8 H), 2.83 (s, 4 H), 1.25 (s 12 H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm): 198.02, 184.0, 139.2, 137.3, 134.5, 129.5, 128.4, 128.3, 127.6, 43.8, 24.7. HRMS (LSIMS, gly): Calcd. for C₂₃H₂₇O₅ (MH⁺): 383.1858, found: 383.1858.

5.1.m. Synthesis of 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid *bis*-methylamide



6-[2-(5-Ethoxycarbonyl-5-methyl-hexyl)-[1,3]dithian-2-yl]-2,2-dimethyl-hexanoic acid ethyl ester

10

Under N₂ atmosphere, to a solution of 2,2,12,12-tetramethyl-7-oxo-tridecanedioic acid diethyl ester (1.0 g, 2.70 mmol) and 1,3-propanedithiol (361 mg, 361 μL, 3.24 mmol) in dichloromethane (20 mL; dried with Aluminum oxide, activated, neutral, Brockmann I) was added boron trifluoride diethyl etherate (100 μL) at rt. The reaction mixture was stirred for 3 h, diluted with dichloromethane (100 mL), and extracted with 5 % NaOH solution (100 mL) and water (75 mL). The organic phase was dried over MgSO₄, concentrated in vacuo, and dried in high vacuo to furnish 6-[2-(5-ethoxycarbonyl-5-methyl-hexyl)-[1,3]dithian-2-yl]-2,2-dimethyl-hexanoic acid ethyl ester (1.0 g, 80 %) as a yellowish oil. ¹H

15

- NMR (300 MHz, CDCl_3/TMS): δ (ppm): 4.11 (q, 4 H, $J = 7.1$), 2.79 (t, 4 H, $J = 5.6$), 1.94 (m, 2 H), 1.84 (m, 4 H), 1.54 (m, 4 H), 1.39 (m, 4 H), 1.24 (t, 6 H, $J = 7.1$), 1.30 – 1.20 (m, 4 H), 1.16 (s, 12 H). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm): 178.08, 60.33, 53.32, 42.27, 40.69, 38.28, 26.14, 25.67, 25.28, 24.71, 14.41. HRMS (LSIMS, nba): Calcd. for $\text{C}_{24}\text{H}_{45}\text{S}_2\text{O}_4$ (MH^+): 461.2759, found 461.2774.

6-[2-(5-Carboxy-5-methyl-hexyl)-[1,3]dithian-2-yl]-2,2-dimethyl-hexanoic acid

- A solution of 6-[2-(5-ethoxycarbonyl-5-methyl-hexyl)-[1,3]dithian-2-yl]-2,2-dimethyl-hexanoic acid ethyl ester (870 mg, 1.89 mmol) and potassium hydroxide (85 %, 750 mg, 11.33 mmol) in ethanol (16 mL) and water (4 mL) was heated under reflux for 3 h. The reaction mixture was diluted with water (100 mL) and acidified to pH 4 with 1 N HCl (8 mL). The emulsion was extracted with dichloromethane (3×75 mL). The combined organic phases were washed with water (50 mL), dried over MgSO_4 , concentrated in vacuo, and dried in high vacuo to furnish 6-[2-(5-carboxy-5-methyl-hexyl)-[1,3]dithian-2-yl]-2,2-dimethyl-hexanoic acid (730 mg, 95 %) as a viscous, yellowish oil. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm): 2.80 (m, 4 H), 1.94 (m, 2 H), 1.85 (m, 4 H), 1.56 (m, 4 H), 1.41 (m, 4 H), 1.30 (m, 4 H), 1.19 (s, 12 H). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm): 185.08, 53.36, 42.28, 40.52, 38.27, 26.18, 25.69, 25.23, 25.11, 24.73. HRMS (LSIMS, nba): Calcd. for $\text{C}_{20}\text{H}_{37}\text{O}_4\text{S}_2$ (MH^+): 405.2133, found: 405.2115.

2,2-Dimethyl-6-[2-(5-methyl-5-methylcarbamoyl-hexyl)-[1,3]dithian-2-yl]-hexanoic acid methylamide


- Under N_2 atmosphere, to a solution of 6-[2-(5-carboxy-5-methyl-hexyl)-[1,3]dithian-2-yl]-2,2-dimethyl-hexanoic acid (280 mg, 0.67 mmol) and *N*-hydroxysuccinimide (170 mg, 1.47 mmol) in dichloromethane (5 mL; dried with Aluminum oxide, neutral, Brockmann I) was added dicyclohexyl carbodiimide (305 mg, 1.47 mmol). The reaction mixture was stirred at rt for 2 h, the urea was removed by filtration and washed with dichloromethane (2 mL). The filtrate was concentrated in vacuo and dried in high vacuo to give crude 6-[2-[5-(2,5-dioxo-pyrrolidin-1-yl)oxycarbonyl]-5-methyl-hexyl]-[1,3]dithian-2-yl]-2,2-dimethyl-hexanoic acid 2,5-dioxo-pyrrolidin-1-yl ester (500 mg, 125 %) as a foamy, yellow oil. Under N_2 atmosphere, to a solution of this crude intermediate (370 mg, 0.62 mmol) in anhydrous THF (10 mL) was added a solution of methylamine in anhydrous THF (5 mL, 10 mmol, 2.0 M in THF), resulting in the immediate formation of a white precipitate. The reaction mixture was stirred at rt for 1.5 h, then diluted with dichloromethane (100 mL), and

extracted with saturated NaHCO_3 solution (2×50 mL), water (50 mL), 1 N HCl (50 mL), and saturated NaCl solution. The organic phase was concentrated in vacuo and the residue purified by flash chromatography (silica, hexanes/ethyl acetate = 50/50, then 25/75, then 0/100) to furnish 2,2-dimethyl-6-[2-(5-methyl-5-methylcarbamoyl-hexyl)-[1,3]dithian-2-yl]-hexanoic acid methylamide (100 mg, 37 %) as a colorless oil. Mp.: 104 - 106 °C. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm): 5.92 (m br, 2 H), 2.81 (d, 6 H, $J = 4.6$), 2.78 (m, 4 H), 1.94 (m, 2 H), 1.82 (m, 4 H), 1.52 (m, 4 H), 1.37 (m, 4 H), 1.30 – 1.14 (m, 4 H), 1.17 (s, 12 H). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm): 178.46, 53.23, 42.10, 41.32, 38.18, 26.56, 26.08, 25.62, 25.56, 25.16, 24.64. HRMS (LSIMS, nba): Calcd. for $\text{C}_{22}\text{H}_{43}\text{N}_2\text{S}_2\text{O}_2$ (MH^+): 431.2766, found: 431.2762.

2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid bis-methylamide

A suspension of 2,2-dimethyl-6-[2-(5-methyl-5-methylcarbamoyl-hexyl)-[1,3]dithian-2-yl]-hexanoic acid methylamide (3.30 g, 7.66 mmol), paraformaldehyde (6.9 g), and Amberlyst 15 (3.85 g) in acetone (100 mL) and water (10 mL) was heated to reflux for 16 h. The acetone was removed under reduced pressure, the reaction mixture was filtered, and the resin was washed with ethyl acetate (3×75 mL). The combined layers were extracted with saturated NaHCO_3 solution (30 mL) and saturated NaCl solution (30 mL), dried over MgSO_4 , and concentrated *in vacuo*. The residue was purified by flash chromatography (silica; ethyl acetate, then ethyl acetate/ethanol = 50/50) to furnish 2,2,12,12-tetramethyl-7-oxo-tridecanedioic acid bis-methylamide (2.45 g, 94 %) as a colorless, viscous oil that solidified on standing. Mp.: 91.5 – 93.5 °C. ^1H NMR (300 MHz, CDCl_3/TMS): δ (ppm): 6.05 (d br., 2 H, $J = 4.6$), 2.78 (d, 6 H, $J = 4.6$), 2.36 (t, 4 H, $J = 7.3$), 1.58 – 1.45 (m, 8 H), 1.27 – 1.12 (m, 4 H), 1.15 (s, 12 H). ^{13}C NMR (75 MHz, CDCl_3/TMS): δ (ppm): 211.50, 178.43, 42.56, 41.99, 41.03, 26.52, 25.48, 24.48, 24.20. HRMS (LSIMS, nba): Calcd. for $\text{C}_{19}\text{H}_{37}\text{N}_2\text{O}_3$ (MH^+): 341.2804, found: 341.2804.

5.1.n. Synthesis of 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid bis-phenylamide




2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid bis-phenylamide

Under N₂ atmosphere, to a stirred solution of 2,2,12,12-tetramethyl-7-oxo-tridecanedioic acid (3.40 g, 10.9 mmol) in acetonitrile (50 ml) was added *N*-methyl-morpholine (2.42 g, 2.63 ml, 23.9 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (4.20 g, 23.9 mmol) at rt. After 20 h, aniline (5.08 g, 5.0 ml, 54.5 mmol) was added and the reaction mixture was stirred for 26 h. The reaction mixture was diluted with ethyl acetate (100 mL) and extracted with ice-cold 1 N HCl (2 × 100 mL), saturated NaCl solution (100 mL), saturated NaHCO₃ solution (2 × 100 mL), and saturated NaCl solution (100 mL). The organic layer was dried over MgSO₄, concentrated in vacuo, and dried in high vacuo to give a viscous, crude oil (4.50 g). 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid bis-phenylamide and 2,2,12-trimethyl-7-oxo-12-phenylcarbamoyl-tridecanoic acid were isolated from this crude product mixture by flash chromatography (silica; chloroform, then chloroform/acetone = 98/2, then chloroform/acetone = 95/5). Additional purification of 2,2,12,12-tetramethyl-7-oxo-tridecanedioic acid bis-phenylamide by crystallization (1.0 g oil in ca. 7.5 ml hexanes/chloroform/ethanol = 10/4/1) was necessary to give the clean bis-amide (290 mg, 6 %) as a white solid. Mp.: 113 – 114 °C. ¹H NMR (300 MHz, CDCl₃): δ (ppm): 7.52 (d, 2 H, *J* = 7.5), 7.50 (s, 2 H), 7.27 (t, 4 H, *J* = 7.5), 7.07 (t, 2 H, *J* = 7.5), 2.34 (t, 4 H, *J* = 7.3), 1.64 – 1.44 (m, 8 H), 1.34 – 1.14 (m, 4 H), 1.24 (s, 12 H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm): 211.31, 176.08, 138.09, 128.93, 124.28, 120.36, 42.96, 42.84, 41.13, 25.58, 24.53, 24.20. HRMS (LSIMS, nba): Calcd. for C₂₉H₄₀N₂O₃ (MH⁺): 465.3118, found: 465.3129.

2,2,12-Trimethyl-7-oxo-12-phenylcarbamoyl-tridecanoic acid

Viscous oil (1.15 g, 25 %). ¹H NMR (300 MHz, CDCl₃): δ (ppm): 8.90 (m br., 1 H), 7.57 (s br, 1 H), 7.51 (d, 2 H, *J* = 7.9), 7.28 (m, 2 H), 7.08 (t, 1 H, *J* = 7.3), 2.38 (t, 2 H, *J* = 7.2), 2.36 (t, 2 H, *J* = 7.2 H), 1.53 (m, 8 H), 1.34 – 1.20 (m, 4 H), 1.26 (s, 6 H), 1.16 (s, 6 H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm): 211.54, 183.74, 176.28, 138.02, 128.92, 124.35, 120.46, 42.97, 42.55, 42.53, 42.06, 41.12, 40.21, 25.56, 25.05, 24.55, 24.52, 24.21, 24.17. HRMS (LSIMS, nba): Calcd. for C₂₃H₃₆NO₄ (MH⁺): 390.2644, found: 390.2650.

5.1.o. Synthesis of 7-Oxo-2,12-dimethyl-2,12-diphenyl-tridecanedioic acid

5

7-Oxo-2,12-dimethyl-2,12-diphenyl-tridecanedioic acid diethyl ester

Under N₂-atmosphere, to a solution of ethyl 6-bromo-2-methyl-2-phenyl-hexanoate (9.59 g, 30 mmol) in DMSO (50 mL, dried over 4 Å molecular sieves) was added *p*-toluenesulphonylmethyl isocyanide (TosMIC, 3.02 g, 15 mmol), sodium hydride (60 % w/w in mineral oil, 1.44 g, 36 mmol), and tetra-*n*-butyl ammonium iodide (1.10 g, 3.0 mmol) under cooling with an ice-bath. After the addition, the reaction mixture was stirred for 96 h at rt, then cooled to 0 °C, and carefully hydrolyzed with water (100 mL). The product was extracted with dichloromethane (2 × 100 mL, 50 mL). The combined organic layers were washed with water (50 mL), dried over MgSO₄ and concentrated in *vacuo* to give an oil (30.0 g). To a solution of this oil (30.0 g) in CH₂Cl₂ (300 mL) was added concd. HCl (40 mL) and the reaction mixture was stirred for 2 h at rt. The solution was diluted with water (150 mL) and the layers were separated. The aqueous layer was extracted with CH₂Cl₂ (3 × 50 mL). The combined organic layers were washed with saturated NaHCO₃ solution (30 mL) and saturated NaCl solution (30 mL). The organic phases were dried over MgSO₄, concentrated in *vacuo* to give an oil (11.2 g). The product was purified by flash chromatography (silica; hexanes/ethyl acetate = 91/9) to furnish 7-oxo-2,12-dimethyl-2,12-diphenyl-tridecanedioic acid diethyl ester (5.0 g, 67 %) as a clear oil and 1.17 g (16%) of less pure fraction. ¹H NMR (300 MHz, CDCl₃/TMS): δ (ppm) 7.40 - 7.10 (m, 10 H), 4.11 (q, *J* = 7.0 Hz, 4 H), 2.34 (t, *J* = 7.1 Hz, 4 H), 2.10 - 1.70 (m, 4 H), 1.6 - 1.4 (m, 10 H), 1.30 - 1.00 (m, 10 H). ¹³C NMR (75 MHz, CDCl₃/TMS): δ (ppm): 210.7, 176.0, 143.8, 128.2,

126.5, 125.8, 60.6, 50.0, 42.4, 38.9, 24.3, 24.1, 22.6, 14.0. HRMS (LSIMS, nba): Calcd. for $C_{31}H_{42}O_5$ (MH^+): 495.3110, found 495.3106.

5

7-Oxo-2,12-dimethyl-2,12-diphenyl-tridecanedioic acid

To a solution of 7-oxo-2,12-dimethyl-2,12-diphenyl-tridecanedioic acid diethyl ester (3.93 g, 7.55 mmol) in ethanol (60 mL) was added a solution of KOH (4.0 g, 85%, 60 mmol) in water (10 mL). The reaction mixture was heated under reflux for 3 h and then
10 kept overnight at rt. The solution was concentrated under reduced pressure. The residue was dissolved in water (100 mL) and washed with ether (2×75 mL). The aqueous layer was acidified with concd. HCl (ca. 12 mL) until pH 1. The product was extracted with diethyl ether (3×75 mL). The combined organic extracts were dried over $MgSO_4$, filtered, and concentrated in *vacuo* to give 7-oxo-2,12-dimethyl-2,12-diphenyl-tridecanedioic acid as
15 an oil (3.0 g, 90 %). 1H NMR (300 MHz, $CDCl_3$ /TMS): δ (ppm): 7.40 - 7.10 (m, 10 H), 2.32 (t, $J = 7.2$ Hz, 4 H), 2.10 - 1.80 (m, 4 H), 1.6 - 1.45 (m, 10 H), 1.25 - 1.10 (m, 4 H). ^{13}C NMR (75 MHz, $CDCl_3$ /TMS): δ (ppm): 211.1, 182.5, 142.8, 128.4, 126.9, 126.0, 49.9, 42.3, 38.7, 24.2, 24.0, 22.3. HRMS (LSIMS, nba): Calcd. for $C_{27}H_{35}O_5$ (MH^+): 439.2484, found 439.2497.

20

5.2. LDL-Cholesterol, HDL-Cholesterol and Triglyceride Levels in Male Sprague-Dawley Rats

Illustrative compounds of the invention are administered daily at a dose of 100
25 mg/kg to chow fed male Sprague-Dawley rats for seven days in the morning by oral gavage in 1.5% carboxymethylcellulose/0.2% Tween-20 (dosing vehicle). Animals are weighed daily. Animals are allowed free access to rodent chow and water throughout the study. After the seventh dose, animals are sacrificed in the evening and blood serum is assayed for lipoprotein cholesterol profiles, serum triglycerides, total cholesterol VLDL, LDL, and HDL
30 cholesterol, and the ratio of HDL cholesterol to that of VLDL plus LDL cholesterol, apolipoproteins A-I, C-II, C-III, and E by immunoelectrophoresis, and percent weight gain.

35

5.3. LDL-Cholesterol, HDL-Cholesterol and Triglyceride Levels in Obese Female Zucker Rats

5.3.a. Experiment A

Dosing vehicle, Compound A (86 mg/kg of body weight) or troglitazone (120 mg/kg of body weight) is administered to eight week old female obese Zucker rats daily for seven days in the morning by oral gavage in 1.5% carboxymethylcellulose/0.2% Tween-20. Troglitazone is obtained commercially. Finely crushed tablets are suspended in vehicle for dosing. Orbital blood samples are obtained following a six-hour fast prior to the initial dose and also following the seventh dose.

Blood serum is assayed for total cholesterol and triglycerides, lipoprotein cholesterol profiles, VLDL plus LDL cholesterol combined (also referred to as apo B containing lipoprotein cholesterol or non-HDL cholesterol), HDL cholesterol, and the ratio of HDL cholesterol to that of VLDL plus LDL cholesterol, serum glucose, and non-esterified fatty acids, and percent weight gain.

5.3.b. Experiments B, C, D, & E

In a number of different experiments, illustrative compounds of the invention and troglitazone are administered daily at various doses to 10 week old chow fed obese female Zucker rats for 14 days in the morning by oral gavage in 1.5% carboxymethylcellulose/0.2% Tween-20 (dosing vehicle). Animals are weighed daily. Animals are allowed free access to rodent chow and water throughout the study. Blood glucose is determined after a 6-hour fast in the afternoon without anesthesia from a tail vein. Serum is also prepared from a blood sample subsequently obtained from the orbital venous plexus (with O₂/CO₂ anesthesia) prior to and after one week treatment and used lipid and insulin determinations.

At two weeks, blood glucose is again determined after a 6-hour fast without anesthesia from a tail vein. Soon thereafter, animals are sacrificed by CO₂ inhalation in the evening and cardiac blood serum is collected and assessed for various lipids and insulin. Body weight is determined daily prior to dosing and at the time of euthanasia. Blood glucose and serum insulin levels are determined from fasted rats just prior to and following one and two weeks of treatment. Percent liver to body weight is determined after two weeks of treatment at the time of sacrifice.

5.4. Lipoprotein Cholesterol Profile in LDL Receptor-Deficient Mice

Homozygous familial hypercholesterolemia is a rare human disease (~1/1,000,000) characterized by absent or defective LDL receptors, markedly elevated serum LDL cholesterol levels and very early and severe onset of atherosclerosis. The more common form of this disease in humans, heterozygous familial hypercholesterolemia, occurs in

about one in every 500 humans. Patients with the heterozygous form of this disease also present with elevated LDL levels and early onset of atherosclerosis.

The effect on LDL levels in a murine model of homozygous familial hypercholesterolemia can be studied according to the methods described in Ishibashi *et al.*, 1993, *J. Clin. Invest.* 92:883-893; Ishibashi *et al.*, 1994, *J. Clin. Invest.* 93:1885-1893, hereby expressly incorporated herein by reference. LDL receptor-deficient mice have elevated LDL cholesterol relative to wild type mice when fed a chow diet. When fed cholesterol-enriched diets, these mice develop atherosclerosis.

5.5. Synthesis of Non-Saponified and Saponified Lipids in Hepatocytes Isolated from a Male Sprague-Dawley Rat

Washout buffer containing; 149 mM sodium chloride, 9.2 mM sodium *N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid, 1.7 mM fructose, 0.5 mM EGTA, 10 U/mL heparin at pH 7.5 and digestion buffer containing; 6.7 mM potassium chloride, 143 mM sodium chloride, 9.2 mM sodium *N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid, 5 mM calcium chloride-dihydrate, 1.7 mM fructose, 0.2% bovine serum albumin, 100 U/mL collagenase Type 1, 93 U/mL Hyaluronidase, 160 BAEE/mL trypsin inhibitor at pH 7.5 were prepared. Solutions were oxygenate prior to perfusion. Wash buffer containing Dulbecco's Modified Eagle Medium (DMEM) containing 4.5 gm/L D-glucose, 2 mM GlutMax-1, 0.2% BSA, 5% fetal bovine serum (FBS), 12 nM insulin, 1.2 μ M hydrocortisone and DMEM+HS solution containing DMEM, 2 mM GlutMax-1, 20 nM delta-aminolevulinic acid, 17.4 mM MEM non-essential amino acids, 20% EBS, 12 nM insulin and 1.2 μ M hydrocortisone was prepared. DMEM- solution containing DMEM, 2 mM GlutMax-1, 20 nM delta-aminolevulinic acid and 17.4 mM MEM non-essential amino acids were prepared. Male Sprague-Dawley rats weighing 125-250 gms were maintained on a standard rodent chow diet and freely given water. On the evening prior to cell isolation, selected healthy animals were fed restricted. The rat was anesthetized with a 50 mg/kg intraperitoneal administration of sodium pentobarbital. Clotting was minimized with intraperitoneal administer of heparin at 1000 IU/kg body weight. The abdominal cavity was opened and the portal vein was surgical isolated. The angiocatheter was inserted into the portal vein at the general location of the lineal branch and connected to a perfusion pump, The in situ perfusion was performed at (~30 mL/min) with washout buffer, equilibrated with annosphere gases at a temperature of 37°C. The internal iliac artery was cut to allow pressure equilibration. The caustal area of the diaphragm was excised to provide access to the caudal vena cava and the aorta, using curved forceps both vessels were occluded. About

200 mL of buffer was needed to clear the liver. Digestion buffer was circulated at the same flow rate for about 7 minutes after the initial entry of digestion buffer into the liver. When the liver had significantly increased in size, and consistency, and started to leak perfusate the perfusion was discontinued. The liver was rinsed in situ with sterile saline and surgical removed from the animal to a sterile beaker. Additional digestion solution was dispensed into the beaker and cap with foil. The liver tissue was gently shaken using sterile forceps to free hepatocyte cells. Cells were filtered through presterilized stainless steels mesh sieves of pore sizes 250, 106 and 75 μm . Cells were diluted in with ice-cold wash buffer, pipetted successively to assist the disassociation of the cells and transferred to a 50 mL tube. The cells are centrifuged for about 4 minutes at 50 x g to form a loosely packed pellet. The supernatant is discarded and the pelleted cells were resuspend in ice-cold wash buffer. The washing procedure was repeated twice for a total of three washes. The final pellet was suspended in 50 mL of wash buffer and held on wet-ice. The viability and cell number was checked by diluting duplicate 100 μL aliquots of cell suspension with 400 μL of wash buffer and 500 μL of 0.4% trypan blue in isotonic buffer. The cell concentration was determined in several fields on the hemocytometer. The cell viability (those that exclude die) was 85% or greater. Cells were diluted in DMEM+HS to a final concentration to ensure plating at a density of 150,000 cells/ cm^2 on collagen coated 6- or 12-well plates. Four hours after plating change the media was changed with DMEM- and culture overnight. Solutions of lovastatin, and illustrative compounds were prepared at 30 mM with DMSO. To obtain a compound solution mixtures were vortexed and sonicated.

To evaluate the effect of reference and illustrative compounds on saponified and non-saponified lipid synthesis, the monolayer cultures were exposed to compounds formulated in DMEM- containing ^{14}C -acetate. All cells were exposed to 1% DMSO. Metabolic labeling with ^{14}C -acetate continued for 4 hr at 37°C. After labeling, cells were washed twice with 1 mL of PBS followed by lysing in 1 mL deionized water. Cells were scraped from the dishes and transferred to glass tubes at which point they were sonicated. 2.5 mL of 2:1 chloroform/methanol mixture was added followed by 1.5 mL of Phosphate Buffered Saline (PBS). To correct for extraction efficiency in the upcoming extractions, 3000 dpm of ^3H -cholesterol was added to each tube. Tubes were shaken for 30 min. to extract lipids into the organic phase followed by centrifugation for 10 minutes at 1000 x g to separate the organic and aqueous phases. The lower organic phase containing total lipids was removed and placed in a new tube. The organic solution was evaporated under N_2 . Resuspend the dry lipid extract in 1 mL of 93% ethanol containing 1 M KOH and placed at 70°C for 2.5 hours. After the reaction and cooling, 2 mL of hexane and 2.5 mL of water was

added to each tube followed by rigorous shaking for 10 min. Tubes were centrifuged for 10 mm at 1000 x g and the organic (top) layer containing the non-saponified lipids was transferred to a new tube followed by evaporation of the organic solvent under N₂. The aqueous phase containing the saponified lipids was also transferred to a new tube. The non-saponified lipid extract, after drying, was suspended in toluene and an aliquot added to scintillation cocktail followed by radioactive counting. ¹⁴C counts representing the incorporation of ¹⁴C acetate into non-saponified lipids was corrected by the ³H counts, which represented the extraction efficiency of the procedure as, noted above by the addition of ³H cholesterol. To isolate saponified lipids, 1.5 mL of aqueous phase solution was mixed with 400ul of 1M HCl and then lipids extracted by the addition of 2.5 mL of 2:1 chloroform: methanol, 1.5 ml. of PBS, and 1 mL of water followed by rigorous shaking and isolation of the organic phase. Resuspend the N₂ dried organic phase extraction in toluene, and measure radioactivity using liquid scintillant method. The rate of ¹⁴C-acetate incorporation into saponified and non-saponified lipids is reported.

Figure 5 shows the rates of saponified, non-saponified lipid synthesis following treatment with lovastatin and illustrative compounds of the invention. Data are represented as a percent of no compound treatment (Vehicle control). Data are represented as the mean of three measurements +/- one standard deviation. The data indicate that the illustrative compounds of the invention are useful for inhibition of lipid synthesis. In particular, compound A at 30 μM reduced the rates of both saponifiable and non-saponifiable lipid synthesis by at least 97% in the rat hepatocyte cells. Compound B also reduced the rates of both saponified and non-saponified lipids by at least 65% in the rat hepatocyte cells. Accordingly, Compounds A and B, or a pharmaceutically acceptable salt thereof, is useful for inhibiting the synthesis of saponified lipids.

5.6. Cytotoxicity

To evaluate cytotoxicity, monolayer hepatocyte cultures are exposed to increasing concentrations of up to 250 μM Compound A in DMEM for 24 hours. Control cells are exposed to the same media lacking a test compound. All cells are exposed to 0.1% DMSO. The measure of cytotoxicity, release of lactate dehydrogenase (LDH) from the cytosolic compartment of hepatocyte monolayer cultures, reflects damage to the plasma membrane. The assay, is based on the method of Wroblewski and LaDue, 1955, *Proc. Soc. Exp. Biol. Med.* 90:210-213; see also Ulrich *et al.*, 1995, *Toxicol. Lett.* 82/83:107-115, describing the use of hepatocytes as models for hepatic toxicity), and measures the LDH activity in tissue culture medium and a cell homogenate. Briefly, all the media are removed from plates and

transferred to a separate plate. Following removal of media, attached cells are lysed with a hypotonic Tris/Glycerol/EDTA buffer (0.1 M Tris, 20% glycerol, 1 mM EDTA pH 7.3). Activity of LDH in medium and cells is measured spectrophotometrically by monitoring the rate of pyruvate reduction to lactate, coupled with oxidation of NADH; the rate of absorbance change is measured at 340 nm. Cytotoxicity is expressed as a ratio using the following equation: $(\text{LDH in medium} / (\text{LDH in medium} + \text{LDH in solubilized hepatocytes})) = R$.

5.7. Insulin Sensitization Effects

Effects of Compound A on rate of differentiation of 3T3-L1 cells from a “committed pre-adipocyte” to an “adipocyte” phenotype in the absence or presence of insulin can be tested. The differentiation of 3T3-L1 cells to an adipocyte-like phenotype is highly dependent upon insulin. This insulin-dependent changes in cellular morphology and metabolism, including: expression of adipocyte-specific genes, greatly increased levels of glucose uptake and metabolism, induction of GLUT4 (and increased expression of GLUT1) glucose transporters, greatly increased lipid synthesis and deposition of intracellular lipid droplets. In this assay the degree of differentiation is a reflection of the rate of lipid synthesis, as measured through incorporation of ^{14}C -acetate over 2 hours. Thus the ability of a compound to stimulate a submaximal insulin response would suggest an insulin-sensitizing activity (Kletzein *et al.*, 1991, *Molecular Pharm.* 41:393-398).

3T3-L1 stem cells are induced to differentiate with dexamethasone, isobutylmethylxanthine and insulin (Green and Kehinde, 1975, *Cell* 5:19-27). Cells are plated in Dulbecco's modified Eagle medium containing 10% calf serum and grown to confluence. Cells are then refreshed with 10% fetal calf serum, and treated with 0.5 mM isobutylmethylxanthine and 250 nM dexamethasone, but no additional insulin, for 48 hours. This treatment induces the differentiation of 3T3-L1 cells into pre-adipocytes. Conversion of preadipocytes to adipocyte phenotype requires the removal of dexamethasone and the presence of insulin, which stimulates differentiation of preadipocytes into adipocytes in a concentration- and time-dependent manner. A maximal insulin effect occurs at about 100 nM insulin, and leads to nearly complete (95-100%) conversion to adipocytes within 4 days.

The preadipocytes are then treated for 4 days with various concentrations of a test compound in 5% fetal calf serum in Dulbecco's modified Eagles medium, with or without a submaximal concentration of insulin (30 nM). Following this four-day treatment, the predipocytes are pulsed with 0.1 mCi ^{14}C -acetate per well for 2 hours. Cell are then washed with phosphate buffered saline, lysed with 0.1 N NaOH, and ^{14}C -acetate incorporation into lipids is determined using phase separation and liquid scintillation counting.

5.8. *In Vivo* Test Results

Compound A was administered daily at a dose of 100 mg/kg to chow-fed male Sprague-Dawley rats for 7 days in the morning by oral gavage in 1.5 percent carboxymethylcellulose/0.2 percent tween-20 (dosing vehicle). Animals were weighed daily. Animals were allowed free access to rodent chow and water throughout the study period. After the seventh dose, animals were sacrificed in the evening and blood serum was assayed for lipoprotein cholesterol profiles (Figure 2), serum total cholesterol and serum triglycerides (Figure 3). Values for VLDL, LDL and HDL cholesterol, and the ratio of HDL cholesterol to that of VLDL plus LDL cholesterol (Figure 3) were derived from the lipoprotein cholesterol profile (*i.e.*, Figure 2) and the independently determined total cholesterol value (Figure 3). Lipoprotein cholesterol profiles (Figure 2) shows treatment with Compound A results in a 72 percent reduction in VLDL cholesterol ($p < 0.0005$), an 88 percent reduction of LDL cholesterol ($p < 0.0001$), and a non-significant 3 percent increase of HDL cholesterol when compared to animals treated with the dosing vehicle alone. Compound A treatment also reduces total serum cholesterol by 30 percent ($p < 0.0005$) and serum triglycerides by 64 percent ($p < 0.0005$) (Figure 2). The change in total cholesterol as reflected by the reduction in VLDL plus LDL cholesterol and the slight elevation in HDL cholesterol resulted in a HDL to VLDL plus LDL cholesterol ratio from 1.7 ± 0.1 (control) to 17.0 ± 6.9 (Compound A treated); a 9.9 fold improvement in the ratio (Figure 2). Compared to pretreatment body weights, Compound A caused a reduction in body weight gain (30.4 ± 0.6 percent weight gain) compared to the control group (34.3 ± 0.7 percent weight gain) after seven days.

Dosing vehicle or Compound A (93 mg/kg) was administered to 9-10 week old female obese Zucker rats (*i.e.* the fa/fa or leptin receptor deficient rat) daily for 14 days in the morning by oral gavage in 1.5 percent carboxymethylcellulose/0.2 percent tween-20. Tail vein blood for glucose determinations (without anesthesia) and orbital blood samples for serum (with anesthesia for all other determinations) were obtained following a 6 hour fast prior to the initial dose and after one and two weeks of dosing.

Blood serum were assayed for insulin, non-esterified fatty acids, β -hydroxy butyrate, total cholesterol, and triglycerides (Figure 5). Glucose was determined in whole blood (Figure 5). Blood serum was also used to produce lipoprotein cholesterol profiles (Figure 4), and used to determine VLDL plus LDL cholesterol combined (also referred to as apoB containing lipoprotein cholesterol or non-HDL cholesterol), HDL cholesterol, and the ratio of HDL cholesterol to that of VLDL plus LDL cholesterol (Figure 5). In addition, the effect of Compound A on weight gain after 14 days and the liver to body weight ratio at sacrifice are shown in Figure 5.

In the Zucker rat. Compound A increased total serum cholesterol by 33, and 79 percent after one and two weeks of treatment, respectively. Vehicle treatment resulted in only a -10 and 10 change of total serum cholesterol after one and two weeks of treatment, respectively (Figure 5). Serum triglycerides were reduced by 60 and 62 percent with ESP31015 treatment after one and two weeks of treatment (Figure 5).

Lipoprotein cholesterol profiles shows treatment with Compound A resulted in a marked alteration in the distribution of cholesterol among lipoproteins (Figure 4). In particular, Compound A caused a marked elevation in HDL cholesterol after one week of treatment, which was further elevated after two weeks of treatment. Using the serum total cholesterol values (Figure 5) and the lipoprotein cholesterol distribution (Figure 4), the amount of cholesterol associated with non-HDL (i.e. VLDL plus LDL cholesterol) and HDL cholesterol were determined (Figure 5). Compound A decreased non-HDL cholesterol by 58 and 27 percent, and markedly increased HDL cholesterol 2.3-fold and 3.2-fold after one and two weeks treatment, respectively. When these data are expressed as a ratio of HDL/non-HDL cholesterol, it can be clearly seen Compound A markedly improves the ratio from 0.83 (pretreatment) to 2.97 and 3.45 after one-week and two-weeks of treatment, respectively.


Impaired glucose tolerance is the metabolic symptom beginning at about 8-12 weeks of age in obese female Zucker rats and therefore the animals are able to maintain normal glucose levels at the expense of elevated insulin levels. As shown in Figure 5, pretreatment and posttreatment blood glucose levels were similar after one and two weeks of Compound A treatment. An indication of an improved diabetic state is the reduction of non-esterified fatty acids from 2.51 to 0.77 mmol/L after two weeks of Compound A coupled to an elevation in β -hydroxy butyrate. These data may reflect an enhanced hepatic β -oxidation of excess fatty acids resulting from the reduction of serum non-esterified fatty acids and triglycerides (Figure 5). Compound A treatment did not induce a hypoglycemic state.

The present invention is not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the invention and any embodiments which are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the appended claims.

THE CLAIMS

What is claimed is:

1. A compound of a formula **I**:




I


or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

- (a) each occurrence of Z is independently CH₂, CH=CH, or phenyl, where each occurrence of m is independently an integer ranging from 1 to 9, but when Z is phenyl then its associated m is 1;

- (b) G is $(\text{CH}_2)_x$, $\text{CH}_2\text{CH}=\text{CHCH}_2$, $\text{CH}=\text{CH}$, CH_2 -phenyl- CH_2 , or phenyl, where x is 2, 3, or 4;
- (c) W^1 and W^2 are independently L, V, $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_c-\text{C}(\text{R}^3)(\text{R}^4)-(\text{CH}_2)_n-\text{Y}$, or $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_c-\text{V}$ where c is 1 or 2 and n is an independent integer ranging from 0 to 4;
- (d) each occurrence of R^1 or R^2 is independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl or when one or both of W^1 and W^2 is $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_c-\text{C}(\text{R}^3)(\text{R}^4)-(\text{CH}_2)_n-\text{Y}$, then R^1 and R^2 can both be H to form a methylene group;
- (e) R^3 is H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_1-C_6) alkoxy, phenyl, benzyl, Cl, Br, CN, NO_2 , or CF_3 ;
- (f) R^4 is OH, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_1-C_6) alkoxy, phenyl, benzyl, Cl, Br, CN, NO_2 , or CF_3 ;
- (g) L is $\text{C}(\text{R}^1)(\text{R}^2)-(\text{CH}_2)_n-\text{Y}$ where n is an independent integer ranging from 0 to 4;
- (h) V is



- (i) each occurrence of Y is independently OH, COOH, CHO, COOR⁵, SO₃H,



5

where

- (i) R⁵ is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C₁-C₆)alkoxy, or phenyl groups,

10

(ii) each occurrence of R^6 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, (C_1-C_6) alkoxy, or phenyl groups, and

5 (iii) each occurrence of R^7 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;

provided that:

- 10 (i) if G is $(CH_2)_x$, x is 4, each occurrence of Z is CH_2 , each occurrence of m is 4, and W^1 is $-CH(CH_3)CO_2H$, then W^2 is not the same as W^1 ;
- (ii) if G is CH_2 -phenyl- CH_2 , each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(CH_3)_2CH(CO_2CH_2CH_3)_2$, then W^2 is not the same as W^1 ;
- 15 (iii) if G is CH_2 -phenyl- CH_2 , each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(CH_3)_2CH_2(CO_2CH_2CH_3)$, then W^2 is not the same as W^1 ;
- (iv) if G is CH_2 -phenyl- CH_2 , each occurrence of Z is CH_2 , each occurrence of m is 1, and W^1 is $-COCH_2C(CH_3)_2CH_2CO_2H$, then W^2 is not the same as W^1 ;
- 20 (v) if G is $(CH_2)_x$, x is 4, each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(phenyl)_2CH_2CO_2H$, then W^2 is not the same as W^1 ;
- (vi) if G is $CH=CH$, each occurrence of Z is CH_2 , each occurrence of m is 1, and W^1 is $-C(CH_3)_2CH_2(CO_2H)$, then W^2 is not the same as W^1 ; and
- 25 (vii) if G is phenyl, each occurrence of Z is CH_2 , each occurrence of m is 1, and W^1 is $-C(phenyl)_2CO_2H$, then W^2 is not the same as W^1 .

30

2. The compound of claim 1, wherein:

- (a) W^1 and W^2 are independently L, V, or $C(R^1)(R^2)-(CH_2)_c-V$ where c is 1 or 2; and
- (b) R^1 or R^2 are independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl.
- 35

3. The compound of claim 1, wherein W^1 is L.

4. The compound of claim 1, wherein W^1 is V.


5. The compound of claim 1, wherein W^1 is $C(R^1)(R^2)-(CH_2)_c-C(R^3)(R^4)-(CH_2)_n-Y$.

6. The compound of claim 1, wherein W^1 is $C(R^1)(R^2)-(CH_2)_c-V$.

7. The compound of claim 1, wherein W^1 and W^2 are independent L groups.

8. The compound of claim 7, wherein each occurrence of Y is independently OH, $COOR^5$, or COOH.

9. A compound of the formula **Ia**:



Ia


or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

(a) each occurrence of Z is independently CH_2 or $CH=CH$, where each occurrence of m is independently an integer ranging from 1 to 9;


(b) G is $(CH_2)_x$, $CH_2CH=CHCH_2$, or $CH=CH$, where x is 2, 3, or 4;

(c) W^1 and W^2 are independently L, V, or $C(R^1)(R^2)-(CH_2)_c-V$ where c is 1 or 2;

- (d) each occurrence of R^1 or R^2 is independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl;
- (e) L is $C(R^1)(R^2)-(CH_2)_n-Y$ where n is an independent integer ranging from 0 to 4;
- (f) V is




- (g) each occurrence of Y is independently OH, COOH, CHO, $COOR^3$, SO_3H ,



where:

- 5 (i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,



- 10 (ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, (C_1-C_6) alkoxy, or phenyl groups, and

- (iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;

provided that:

- 15 (i) if x is 4, each occurrence of Z is CH_2 , each occurrence of m is 4, and W^1 is $-CH(CH_3)CO_2H$, then W^2 is not the same as W^1 ; and
- (ii) if x is 4, each occurrence of Z is CH_2 , each occurrence of m is 2, and W^1 is $-C(phenyl)_2CH_2CO_2H$, then W^2 is not the same as W^1 .
- 20

10. The compound of claim 9, wherein W^1 is L.

11. The compound of claim 9, wherein W^1 is V.


12. The compound of claim 9, wherein W^1 is $C(R^1)(R^2)-(CH_2)_c-V$.

13. The compound of claim 9, wherein W^1 and W^2 are independent L groups.

5 14. The compound of claim 13, wherein each occurrence of Y is independently OH, $COOR^3$, or $COOH$.

15. A compound of the formula **Ib**

10



Ib

15 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:


(a) each occurrence of m is independently an integer ranging from 1 to 9;


20 (b) x is 2, 3, or 4;

(c) each occurrence of n is independently an integer ranging from 0 to 4;

25 (d) each occurrence of R^1 or R^2 is independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl; and

(e) each occurrence of Y is independently OH, $COOH$, CHO , $COOR^3$, SO_3H ,





where:

- 5 (i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- 10 (ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups; and
- (iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;

15 provided that:


- (i) if x is 4 each occurrence of m is 4, and W^1 is $-\text{CH}(\text{CH}_3)\text{CO}_2\text{H}$, then W^2 is not the same as W^1 ; and
- (ii) if x is 4 occurrence of m is 2, and W^1 is $-\text{C}(\text{phenyl})_2\text{CH}_2\text{CO}_2\text{H}$, then W^2 is not the same as W^1 .

5

16. The compound of claim 15, wherein each occurrence of Y is independently OH, COOR^3 , or COOH.

10 17. The compound of claim 16, wherein each R^1 or R^2 is the same or different (C_1-C_6) alkyl group.


18. A compound of the formula **Ic**

**Ic**

15 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

- (a) each occurrence of m is an independent integer ranging from 1 to 9;
- 20 (b) x is 2, 3, or 4;

25 (c) V is



provided that:

- (i) if x is 4 each occurrence of m is 4, and W^1 is $-\text{CH}(\text{CH}_3)\text{CO}_2\text{H}$, then W^2 is not the same as W^1 ; and

5


- (ii) if x is 4 each occurrence of m is 2, and W^1 is $-\text{C}(\text{phenyl})_2\text{CH}_2\text{CO}_2\text{H}$, then W^2 is not the same as W^1 .

19. A compound according to claim 1, having the formula

5-[2-(5-hydroxy-4,4-dimethyl-pentyloxy)-ethoxy]-2,2-dimethyl-pentan-1-ol or

10 4-[3-(3,3-Dimethyl-4-oxo-butoxy)-propoxy]-2,2-dimethyl-butyric acid.

20. A compound of the formula **II**:



II

15


or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

- (a) R^1 and R^2 are independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl; or R^1 , R^2 , and the carbon to which they are both attached are taken together to form a (C_3-C_7) cycloalkyl group;

5 (b) n is an integer ranging from 1 to 5;

(c) each occurrence of m is independently an integer ranging from 0 to 4;


(d) each occurrence of W^1 and W^2 is independently CH_2OH , $COOH$, CHO , $OC(O)R^3$,
 10 $C(O)OR^3$, SO_3H ,



where:

(i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,

(ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted




with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups,

(iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl; and

(iv) each occurrence of n is independently an integer ranging from 0 to 4.


21. A compound of the formula **IIa**:



IIa

5 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

(a) R^1 and R^2 are OH, COOH, CHO, COOR⁷, SO₃H,



10

where:

(i) R^7 is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C₁-C₆)alkoxy, or phenyl groups,

15

(ii) each occurrence of R^8 is independently H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, or (C₂-C₆)alkynyl and is unsubstituted or substituted with one or two halo, OH, C₁-C₆ alkoxy, or phenyl groups,

(iii) each occurrence of R^9 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl;

(b) R^3 and R^4 are (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl;

(c) R^5 and R^6 are hydrogen, halogen, (C_1-C_4) alkyl, (C_1-C_4) alkoxy, (C_6) aryloxy, CN, or NO_2 , $N(R^5)_2$ where R^5 is H, (C_1-C_4) alkyl, phenyl, or benzyl;

(d) each occurrence of m is independently an integer ranging from 1 to 5;

(e) each occurrence of n is independently an integer ranging from 0 to 4; and

(f) C^{*1} and C^{*2} each represent independent chiral-carbon centers, wherein each center may independently be R or S.


22. The compound of claim 21 wherein C^{*1} is a chiral-carbon center of the stereochemical configuration R or substantially R.

23. The compound of claim 21 wherein C^{*1} is a chiral-center of the stereochemical configuration S or substantially S.

24. The compound of claim 21 wherein C^{*2} is a chiral-carbon center of the stereochemical configuration R or substantially R.

25. The compound of claim 21 wherein C^{*2} is a chiral-center of the stereochemical configuration S or substantially S.


26. A compound of the formula **III**:




III

or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:

- 5 (a) each occurrence of Z is independently CH₂, CH=CH, or phenyl, where each occurrence of m is independently an integer ranging from 1 to 5, but when Z is phenyl then its associated m is 1;
- 10 (b) G is (CH₂)_x, CH₂CH=CHCH₂, CH=CH, CH₂-phenyl-CH₂, or phenyl, where x is an integer ranging from 1 to 4;
- (c) W¹ and W² are independently C(R¹)(R²)-(CH₂)_n-Y where n is an independent integer ranging from 0 to 4;



- 15 (d) each occurrence of R¹ or R² is independently (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl, or where R¹ and R² are both hydrogen;
- (e) each occurrence of R⁶ and R⁷ are independently H, (C₁-C₆)alkyl, or where R⁶ and R⁷ are taken together to form a carbonyl group;
- 20 (f) each occurrence of Y is independently OH, COOH, CHO, COOR³, SO₃H,



where:

5

(i) R³ is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C₁-C₆)alkoxy, or phenyl groups,

10

(ii) each occurrence of R⁴ is independently H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, or (C₂-C₆)alkynyl and is unsubstituted or substituted with one or two halo, OH, C₁-C₆ alkoxy, or phenyl groups,

(iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl, and

- 5 (g) each occurrence of p is independently 0 or 1 where the broken line represents an optional presence of one or more additional carbon-carbon bonds that when present complete one or more carbon-carbon double bonds.


10 27. The compound of claim 26, wherein W^1 and W^2 are independent $C(R^1)(R^2)-(CH_2)_n-Y$ groups, where n is an independent integer ranging from 0 to 4, and each occurrence of Y is independently OH, $COOR^4$, or COOH.

28. The compound of claim 26, wherein p is 0.

15 29. The compound of claim 26, wherein p is 1.

30. The compound of claim 26 wherein each occurrence of R_6 and R_7 is hydrogen;

31. A compound of the formula **IIIa**:




IIIa

20 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, stereoisomer, geometric isomer or mixtures thereof wherein:


25 (a) each occurrence of m is independently an integer ranging from 1 to 5;


(b) x is an integer ranging from 1 to 4;

(c) W^1 and W^2 are independently $C(R^1)(R^2)-(CH_2)_n-Y$ where n is an integer from 0 to 4,



- (d) each occurrence of R¹ or R² is independently (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl;
- 5 (e) each occurrence of Y is independently OH, COOH, CHO, COOR³, SO₃H,





where

(i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,

(ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups,

(iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl, and

(f) each occurrence of p is independently 0 or 1.

32. The compound of claim 31, wherein W^1 and W^2 are independent $C(R^1)(R^2)-(CH_2)_n-Y$ groups, and each occurrence of Y is independently $-(CH_2)_nOH$, $-(CH_2)_nCOOR^3$, or $-(CH_2)_nCOOH$.

33. The compound of claim 31, wherein p is 0.

34. The compound of claim 31, wherein p is 1.

35. A compound having the formula:

- I-1** 5-Hydroxy-1-[4-(5-hydroxy-5-methyl-2-oxo-hexyl)-phenyl]-5-methyl-hexan-2-one;
- 5 I-2** 6-Hydroxy-1-[4-(6-hydroxy-5,5-dimethyl-2-oxo-hexyl)-phenyl]-5,5-dimethyl-hexan-2-one;
- I-3** 6-[4-(5-Carboxy-5-methyl-2-oxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanoic acid;
- 10 I-4** 6-[4-(5,5-Dimethyl-2,6-dioxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanal;
- I-5** 6-[4-(5-Methoxycarbonyl-5-methyl-2-oxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanoic acid methyl ester;
- 15 I-6** 2,2-Dimethyl-6-[4-(5-methyl-2-oxo-5-phenoxy-carbonyl-hexyl)-phenyl]-5-oxo-hexanoic acid phenyl ester;
- I-7** 6-[4-(5-Benzoyloxycarbonyl-5-methyl-2-oxo-hexyl)-phenyl]-2,2-dimethyl-5-oxo-hexanoic acid benzyl ester;
- 20 I-8** 2-Methyl-6-[4-(5-methyl-2-oxo-5-sulfo-hexyl)-phenyl]-5-oxo-hexane-2-sulfonic acid;
- 25 I-9** Phosphoric acid mono-{1,1-dimethyl-5-[4-(5-methyl-2-oxo-5-phosphonooxy-hexyl)-phenyl]-4-oxo-pentyl} ester;
- I-10** 4-Hydroxy-1-[4-(4-hydroxy-4-methyl-pentanoyl)-phenyl]-4-methyl-pentan-1-one;
- 30 I-11** 5-Hydroxy-1-[4-(5-hydroxy-4,4-dimethyl-pentanoyl)-phenyl]-4,4-dimethyl-pentan-1-one;
- I-12** 5-[4-(4-Carboxy-4-methyl-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanoic acid;
- 35 I-13** 5-[4-(4,4-Dimethyl-5-oxo-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanal;
- I-14** 5-[4-(4-Methoxycarbonyl-4-methyl-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanoic acid methyl ester;
- 40 I-15** 2,2-Dimethyl-6-[4-(5-methyl-2-oxo-5-phenoxy-carbonyl-hexyl)-phenyl]-5-oxo-hexanoic acid phenyl ester;
- I-16** 5-[4-(4-Benzoyloxycarbonyl-4-methyl-pentanoyl)-phenyl]-2,2-dimethyl-5-oxo-pentanoic acid benzyl ester;
- 45 I-17** 2-Methyl-5-[4-(4-methyl-4-sulfo-pentanoyl)-phenyl]-5-oxo-pentane-2-sulfonic acid;
- I-18** Phosphoric acid mono-{1,1-dimethyl-4-[4-(4-methyl-4-phosphonooxy-pentanoyl)-phenyl]-4-oxo-butyl} ester;
- 50 Ib-1** 2,12-Dihydroxy-2,12-dimethyl-tridecane-5,9-dione;

- Ib-2** 1,13-Dihydroxy-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-3** 2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid;
- 5 **Ib-4** 2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedial;
- Ib-5** 2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid dimethyl ester;
- 10 **Ib-6** 2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid diphenyl ester;
- Ib-7** 2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid dibenzyl ester;
- Ib-8** 2,12-Dimethyl-5,9-dioxo-tridecane-2,12-disulfonic acid;
- 15 **Ib-9** Phosphoric acid mono-(1,1,11-trimethyl-4,8-dioxo-11-phosphonooxy-dodecyl) ester;
- Ib-10** 2,12-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,12-dimethyl-tridecane-5,9-dione;
- 20 **Ib-11** 2,12-Bis-(4,6-dithio-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,12-dimethyl-tridecane-5,9-dione;
- Ib-12** 2,2,12,12-Tetramethyl-5,9-dioxo-tridecanedioic acid dicyanimide
- 25 **Ib-13** Phosphoramidic acid mono-[11-(amino-hydroxy-phosphoryloxy)-1,1,11-trimethyl-4,8-dioxo-dodecyl] ester;
- Ib-14** 2,12-Dimethyl-2,12-bis-(amino-hydroxy-phosphoryloxy)-tridecane-5,9-dione;
- 30 **Ib-15** 2,12-Dimethyl-2,12-bis-tetrazol-1-yl-tridecane-5,9-dione;
- Ib-16** 2,12-Dimethyl-2,12-bis-(1*H*-tetrazol-5-yl)-tridecane-5,9-dione;
- 35 **Ib-17** 2,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,12-dimethyl-tridecane-5,9-dione;
- Ib-18** 2,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,12-dimethyl-tridecane-5,9-dione;
- Ib-19** 2,12-Bis-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-2,12-dimethyl-tridecane-5,9-dione;
- 40 **Ib-20** 2,12-Bis-(5-hydroxy-4-oxo-4*H*-pyran-2-yl)-2,12-dimethyl-tridecane-5,9-dione;
- Ib-21** 1-Ethyl-3-[11-(3-ethyl-2,5-dithio-2-oxo-1,2,4-imidazolidin-1-yl)-1,1,11-trimethyl-4,8-dioxo-dodecyl]-imidazolidine-2,4-dione;
- 45 **Ib-22** 2,12-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,12-dimethyl-tridecane-5,9-dione;
- Ib-23** 2,12-Bis-(3-ethyl-5-oxo-2-thio-2-oxo-1,2,4-imidazolidin-1-yl)-2,12-dimethyl-tridecane-5,9-dione;
- 50 **Ib-24** 2,12-Bis-(3-ethyl-2-oxo-5-thio-2-oxo-1,2,4-imidazolidin-1-yl)-2,12-dimethyl-tridecane-5,9-dione;

- Ib-25** 1,15-Dihydroxy-3,3,13,13-tetramethyl-pentadecane-6,10-dione;
- Ib-26** 3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedioic acid;
- 5 **Ib-27** 3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedial;
- Ib-28** 3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedioic acid dimethyl ester;
- 10 **Ib-29** 2,2,12,12-Tetramethyl-5,9-dioxo-tetradecanedioic acid diphenyl ester;
- Ib-30** 3,3,13,13-Tetramethyl-6,10,14-trioxo-16-phenyl-hexadecanoic acid benzyl ester;
- Ib-31** 2,2,12,12-Tetramethyl-5,9-dioxo-tridecane-1,13-disulfonic acid;
- 15 **Ib-32** Phosphoric acid mono-(2,2,12,12-tetramethyl-5,9-dioxo-13-phosphonooxy-tridecyl) ester;
- Ib-33** 1,13-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- 20 **Ib-34** 1,13-Bis-(4,6-dithio-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-35** 3,3,13,13-Tetramethyl-6,10-dioxo-pentadecanedioic acid dicyanamide
- 25 **Ib-36** Phosphoramidic acid mono-[13-(amino-hydroxy-phosphoryloxy)-2,2,12,12-tetramethyl-6,9-dioxo-tridecyl] ester;
- Ib-37** Phosphoramidic acid mono-[11-(amino-hydroxy-phosphoryloxy)-1,1,11-trimethyl-4,8-dioxo-dodecyl] ester;
- 30 **Ib-38** 2,2,12,12-Tetramethyl-1,13-bis-tetrazol-1-yl-tridecane-5,9-dione;
- Ib-39** 1,13-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- 35 **Ib-40** 1,13-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-41** 1,13-Bis-(3-hydroxy-isoxazol-4-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- 40 **Ib-42** 1-(5-Hydroxy-4-oxo-4*H*-pyran-3-yl)-13-(5-hydroxy-4-oxo-4*H*-pyran-2-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-43** 1,13-Bis-(5-hydroxy-4-oxo-4*H*-pyran-2-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- 45 **Ib-44** 1,13-Bis-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-45** 1-Ethyl-3-[13-(3-ethyl-2,5-dithio-imidazolidin-1-yl)-2,2,12,12-tetramethyl-5,9-dioxo-tridecyl]-imidazolidine-2,4-dione;
- 50

- Ib-46** 1,13-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-47** 1,13-Bis-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-48** 1,13-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-49** 1,13-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,2,12,12-tetramethyl-tridecane-5,9-dione;
- Ib-50** 2,11-Dihydroxy-2,11-dimethyl-dodecane-5,8-dione;
- Ib-51** 1,12-Dihydroxy-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- Ib-52** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid;
- Ib-53** 2,11-Dimethyl-5,8-dioxo-dodecane-2,11-disulfonic acid;
- Ib-54** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedial;
- Ib-55** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dimethyl ester;
- Ib-56** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid diphenyl ester;
- Ib-57** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dibenzyl ester;
- Ib-58** Phosphoric acid mono-(1,1,10-trimethyl-4,7-dioxo-10-phosphonooxy-undecyl) ester;
- Ib-59** 2,14-Dihydroxy-2,14-dimethyl-pentadecane-6,10-dione;
- Ib-60** 1,15-Dihydroxy-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- Ib-61** 2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedioic acid;
- Ib-62** 2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedial;
- Ib-63** 2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedioic acid dimethyl ester;
- Ib-64** 2,2,14,14-Tetramethyl-6,10-dioxo-hexadecanedioic acid diphenyl ester;
- Ib-65** 2,2,14,14-Tetramethyl-6,10-dioxo-hexadecanedioic acid dibenzyl ester;
- Ib-66** 2,14-Dimethyl-6,10-dioxo-pentadecane-2,14-disulfonic acid;
- Ib-67** Phosphoric acid mono-(1,1,13-trimethyl-5,9-dioxo-13-phosphonooxy-tetradecyl) ester;
- Ib-68** 2,14-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,14-dimethyl-pentadecane-6,10-dione;

- Ib-69** 2,14-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- Ib-70** 2,2,14,14-Tetramethyl-6,10-dioxo-pentadecanedioic acid dicyanimide
- Ib-71** Phosphoramidic acid mono-[13-(amino-hydroxy-phosphoryloxy)-1,1,13-trimethyl-5,9-dioxo-tetradecyl] ester;
- Ib-72** 2,14-Dimethyl-2,14-bis-(amino-hydroxy-phosphoryloxy)-pentadecane-6,10-dione;
- Ib-73** 2,14-Dimethyl-2,14-bis-tetrazol-1-yl-pentadecane-6,10-dione;
- Ib-74** 2,14-Dimethyl-2,14-bis-(1*H*-tetrazol-5-yl)-pentadecane-6,10-dione;
- Ib-75** 2,14-Bis-(3-hydroxy-isoxazol-5-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- Ib-76** 2,14-Bis-(3-hydroxy-isoxazol-4-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- Ib-77** 2,14-Bis-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- Ib-78** 2-(5-Hydroxy-4-oxo-4*H*-pyran-2-yl)-2,14-dimethyl-14-(5-methyl-4-oxo-4*H*-pyran-2-yl)-pentadecane-6,10-dione;
- Ib-79** 2,14-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- Ib-80** 2,14-Bis-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- Ib-81** 2,14-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- Ib-82** 2,14-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,14-dimethyl-pentadecane-6,10-dione;
- Ib-83** 1,14-Dihydroxy-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- Ib-84** 3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid;
- Ib-85** 3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedial;
- Ib-86** 3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid dimethyl ester;
- Ib-87** 3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid diphenyl ester;
- Ib-88** 3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid dibenzyl ester;
- Ib-89** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecane-1,12-disulfonic acid;
- Ib-90** Phosphoric acid mono-(2,2,11,11-tetramethyl-5,8-dioxo-12-phosphonooxy-dodecyl) ester;

- Ib-91** 1,12-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- 5 **Ib-92** 1,12-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dithione;
- Ib-93** 3,3,12,12-Tetramethyl-6,9-dioxo-tetradecanedioic acid dicyanimide
- 10 **Ib-94** Phosphoramidic acid mono-[12-(amino-hydroxy-phosphoryloxy)-2,2,11,11-tetramethyl-5,8-dioxo-dodecyl] ester;
- Ib-95** 2,2,11,11-Tetramethyl-1,12-bis-(aminohydroxyphosphoryloxy)-dodecane-5,8-dione;
- 15 **Ib-96** 2,2,11,11-Tetramethyl-1,12-bis-(1*H*-tetrazol-5-yl)-dodecane-5,8-dione;
- Ib-97** 1,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- Ib-98** 1,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- 20 **Ib-99** 1-(5-Hydroxy-4-oxo-4*H*-pyran-3-yl)-12-(5-hydroxy-4-oxo-4*H*-pyran-2-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- Ib-100** 1,12-Bis-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- 25 **Ib-101** 1,12-Bis-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- Ib-102** 1-Ethyl-3-[12-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-5,8-dioxo-dodecyl]-imidazolidine-2,4-dione;
- 30 **Ib-103** 1-Ethyl-3-[12-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-5,8-dioxo-dodecyl]-imidazolidine-2,4-dione;
- Ib-104** 1,12-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- 35 **Ib-105** 1,12-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- 40 **Ib-106** 1,16-Dihydroxy-4,4,13,13-tetramethyl-hexadecane-7,10-dione;
- Ib-107** 4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid;
- 45 **Ib-108** 4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedial;
- Ib-109** 4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid dimethyl ester;
- Ib-110** 4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid diphenyl ester;
- 50 **Ib-111** 4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid dibenzyl ester;

- Ib-112** 3,3,12,12-Tetramethyl-6,9-dioxo-tetradecane-1,14-disulfonic acid;
- Ib-113** Phosphoric acid mono-(3,3,12,12-tetramethyl-6,9-dioxo-14-phosphonooxy-tetradecyl) ester;
- 5 **Ib-114** 1,14-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- 10 **Ib-115** 1,14-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- Ib-116** 4,4,13,13-Tetramethyl-7,10-dioxo-hexadecanedioic acid dicyanimide
- 15 **Ib-117** Phosphoramidic acid mono-[14-(amino-hydroxy-phosphoryloxy)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl] ester;
- Ib-118** 3,3,12,12-Tetramethyl-1,14-bis-(amino-hydroxy-phosphoryloxy)-tetradecane-6,9-dione;
- 20 **Ib-119** 1,12-Dihydroxy-2,2,11,11-tetramethyl-dodecane-5,8-dione;
- Ib-120** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid;
- Ib-121** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedial;
- 25 **Ib-122** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dimethyl ester;
- Ib-123** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid diphenyl ester;
- 30 **Ib-124** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dibenzyl ester;
- Ib-125** 2,11-Dimethyl-5,8-dioxo-dodecane-2,11-disulfonic acid;
- 35 **Ib-126** Phosphoric acid mono-(1,1,10-trimethyl-4,7-dioxo-10-phosphonooxy-undecyl) ester;
- Ib-127** 2,11-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,11-dimethyl-dodecane-5,8-dione;
- 40 **Ib-128** 2,11-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,11-dimethyl-dodecane-5,8-dione;
- Ib-129** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dicyanimide
- 45 **Ib-130** Phosphoramidic acid mono-[10-(amino-hydroxy-phosphoryloxy)-1,1,10-trimethyl-4,7-dioxo-undecyl] ester;
- Ib-131** 2,2,11,11-Tetramethyl-1,12-(amino-hydroxy-phosphoryloxy)-dodecane-5,8-dione;
- 50 **Ib-132** 3,3,12,12-Tetramethyl-1,14-bis-tetrazol-1-yl-tetradecane-6,9-dione;
- Ib-133** 3,3,12,12-Tetramethyl-1,14-bis-(1*H*-tetrazol-5-yl)-tetradecane-6,9-dione;

- Ib-134** 1,14-Bis-(3-hydroxy-isoxazol-5-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- Ib-135** 1,14-Bis-(3-hydroxy-isoxazol-4-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- 5 **Ib-136** 1-(5-Hydroxy-4-oxo-4*H*-pyran-2-yl)-14-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- Ib-137** 1,14-Bis-(5-hydroxy-4-oxo-4*H*-pyran-2-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- 10 **Ib-138** 1,14-Bis-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- 15 **Ib-139** 1-Ethyl-3-[14-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl]-imidazolidine-2,4-dione;
- Ib-140** 1-Ethyl-3-[14-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl]-imidazolidine-2,4-dione;
- 20 **Ib-141** 1-Ethyl-3-[14-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-6,9-dioxo-tetradecyl]-imidazolidine-2,4-dithione;
- Ib-142** 1,14-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- 25 **Ib-143** 1,14-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-3,3,12,12-tetramethyl-tetradecane-6,9-dione;
- 30 **Ib-144** 1,17-Dihydroxy-3,3,15,15-tetramethyl-heptadecane-7,11-dione;
- Ib-145** 3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedial;
- Ib-146** 3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid dimethyl ester;
- 35 **Ib-147** 1,17-Dihydroxy-3,3,15,15-tetramethyl-heptadecane-7,11-dione;
- Ib-148** 3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid diphenyl ester;
- 40 **Ib-149** 3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid dibenzyl ester;
- Ib-150** 2,11-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,11-dimethyl-dodecane-5,8-dione;
- 45 **Ib-151** 2,11-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,11-dimethyl-dodecane-5,8-dione;
- Ib-152** 2,2,11,11-Tetramethyl-5,8-dioxo-dodecanedioic acid dicyanamide;
- 50 **Ib-153** Phosphoramidic acid mono-[10-(amino-hydroxy-phosphoryloxy)-1,1,10-trimethyl-4,7-dioxo-undecyl] ester;

- Ib-154** 2,11-Dimethyl-2,11-bis-(amino-hydroxy-phosphoryloxy)-dodecane-5,8-dione;
- Ib-155** 2,11-Dimethyl-2,11-bis-tetrazol-1-yl-dodecane-5,8-dione;
- 5 **Ib-156** 2,11-Dimethyl-2,11-bis-(1*H*-tetrazol-5-yl)-dodecane-5,8-dione;
- Ib-157** 2,2,14,14-Tetramethyl-6,10-dioxo-pentadecane-1,15-disulfonic acid;
- 10 **Ib-158** Phosphoric acid mono-(2,2,14,14-tetramethyl-6,10-dioxo-15-phosphonooxy-pentadecyl) ester;
- Ib-159** 1,15-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- 15 **Ib-160** 1,15-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- Ib-161** 3,3,15,15-Tetramethyl-7,11-dioxo-heptadecanedioic acid dicyanamide;
- 20 **Ib-162** Phosphoramidic acid mono-[16-(amino-hydroxy-phosphoryloxy)-4,4,15,15-tetramethyl-7,11-dioxo-hexadecyl] ester;
- Ib-163** 2,2,14,14-Tetramethyl-1,15-bis-(amino-hydroxy-phosphoryloxy)-pentadecane-6,10-dione;
- 25 **Ib-164** 2,2,14,14-Tetramethyl-1,15-bis-tetrazol-1-yl-pentadecane-6,10-dione;
- Ib-165** 2,2,14,14-Tetramethyl-1,15-bis-(1*H*-tetrazol-5-yl)-pentadecane-6,10-dione;
- 30 **Ib-166** 1,15-Bis-(3-hydroxy-isoxazol-5-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- Ib-167** 1,15-Bis-(3-hydroxy-isoxazol-4-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- 35 **Ib-168** 1-(5-Hydroxy-4-oxo-4*H*-pyran-3-yl)-15-(5-hydroxy-4-oxo-4*H*-pyran-2-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- Ib-169** 1,15-Bis-(5-hydroxy-4-oxo-4*H*-pyran-2-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- 40 **Ib-170** 1,15-Bis-(5-hydroxy-4-oxo-4*H*-pyran-3-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- Ib-171** 1,15-Bis-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- 45 **Ib-172** 1-Ethyl-3-[15-(3-ethyl-2,5-dithioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-6,10-dioxo-pentadecyl]-imidazolidine-2,4-dione;
- 50 **Ib-173** 1,15-Bis-(3-ethyl-2,5-dioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;

- Ib-174** 1,15-Bis-(3-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- Ib-175** 1,15-Bis-(3-ethyl-2-oxo-5-thioxo-imidazolidin-1-yl)-2,2,14,14-tetramethyl-pentadecane-6,10-dione;
- Ic-1** 1,9-Bis-(tetrahydro-pyran-2-yloxy)-nonane-3,7-dione;
- Ic-2** 1,9-Bis-(4-oxo-oxetan-2-yl)-nonane-3,7-dione;
- Ic-3** 1,9-Bis-(2-oxo-oxetan-3-yl)-nonane-3,7-dione;
- Ic-4** 1,9-Bis-(5-oxo-tetrahydrofuran-2-yl)-nonane-3,7-dione;
- Ic-5** 1,9-Bis-(5-oxo-tetrahydrofuran-3-yl)-nonane-3,7-dione;
- Ic-6** 1,9-Bis-(2-oxo-tetrahydrofuran-3-yl)-nonane-3,7-dione;
- Ic-7** {2-[9-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-3,7-dioxo-nonyl]-4-hydroxy-6-oxo-tetrahydropyran-4-yl}-acetic acid;
- Ic-8** 1,9-Bis-(6-oxo-tetrahydropyran-2-yl)-nonane-3,7-dione;
- Ic-9** 1,9-Bis-(6-oxo-tetrahydropyran-3-yl)-nonane-3,7-dione;
- Ic-10** 1,9-Bis-(2-oxo-tetrahydropyran-4-yl)-nonane-3,7-dione;
- Ic-11** 1,9-Bis-(2-oxo-tetrahydropyran-3-yl)-nonane-3,7-dione;
- Ic-12** 1,11-Bis-(tetrahydro-pyran-2-yloxy)-undecane-4,8-dione;
- Ic-13** 1,11-Bis-(2-oxo-oxetan-3-yl)-undecane-4,8-dione;
- Ic-14** 1,11-Bis-(2-oxo-oxetan-3-yl)-undecane-4,8-dione;
- Ic-15** 1,11-Bis-(5-oxo-tetrahydrofuran-2-yl)-undecane-4,8-dione;
- Ic-16** 1,11-Bis-(5-oxo-tetrahydrofuran-3-yl)-undecane-4,8-dione;
- Ic-17** 1,11-Bis-(2-oxo-tetrahydrofuran-3-yl)-undecane-4,8-dione;
- Ic-18** {2-[11-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-4,8-dioxo-undecyl]-4-hydroxy-6-oxo-tetrahydropyran-4-yl}-acetic acid;
- Ic-19** 1,11-Bis-(6-oxo-tetrahydropyran-2-yl)-undecane-4,8-dione;
- Ic-20** 1,11-Bis-(6-oxo-tetrahydropyran-3-yl)-undecane-4,8-dione;
- Ic-21** 1,11-Bis-(2-oxo-tetrahydropyran-4-yl)-undecane-4,8-dione;
- Ic-22** 1,11-Bis-(2-oxo-tetrahydropyran-3-yl)-undecane-4,8-dione;

- Ic-23** 1,8-Bis-(tetrahydropyran-2-yloxy)-octane-3,6-dione;
- Ic-24** 1,8-Bis-(4-oxo-oxetan-2-yl)-octane-3,6-dione;
- 5 Ic-25** 1,8-Bis-(2-oxo-oxetan-3-yl)-octane-3,6-dione;
- Ic-26** 1,8-Bis-(5-oxo-tetrahydro-furan-2-yl)-octane-3,6-dione;
- Ic-27** 1,8-Bis-(5-oxo-tetrahydro-furan-3-yl)-octane-3,6-dione;
- 10 Ic-28** 1,8-Bis-(2-oxo-tetrahydro-furan-3-yl)-octane-3,6-dione;
- Ic-29** {2-[8-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-3,6-dioxo-octyl]-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl}-acetic acid;
- 15 Ic-30** 1,8-Bis-(6-oxo-tetrahydropyran-2-yl)-octane-3,6-dione;
- Ic-31** 1,8-Bis-(6-oxo-tetrahydropyran-3-yl)-octane-3,6-dione;
- 20 Ic-32** 1,8-Bis-(2-oxo-tetrahydropyran-4-yl)-octane-3,6-dione;
- Ic-33** 1,8-Bis-(2-oxo-tetrahydropyran-3-yl)-octane-3,6-dione;
- 25 II-1** 1,13-Dihydroxy-2,2,12,12-tetramethyl-tridecan-7-one;
- II-2** 13-Hydroxy-2,2,12,12-tetramethyl-7-oxo-tridecanoic acid;
- II-3** 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid;
- 30 II-4** 1,11-Dihydroxy-2,2,10,10-tetramethyl-undecan-6-one;
- II-5** 11-Hydroxy-2,2,10,10-tetramethyl-6-oxo-undecanoic acid;
- II-6** 2,2,10,10-Tetramethyl-6-oxo-undecanedioic acid;
- 35 II-7** 1,15-Dihydroxy-2,2,14,14-tetramethyl-pentadecan-8-one;
- II-8** 15-Hydroxy-2,2,14,14-tetramethyl-8-oxo-pentadecanoic acid;
- 40 II-9** 2,2,14,14-Tetramethyl-8-oxo-pentadecanedioic acid;
- II-10** 2,2,12,12-Tetramethyl-7-oxo-tridecanedial;
- II-11** 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid dimethyl ester;
- 45 II-12** 2,2,12,12-Tetramethyl-1,13-diphenyl-tridecane-1,7,13-trione;
- II-13** 3,3,13,13-Tetramethyl-1,15-diphenyl-pentadecane-2,8,14-trione;
- 50 II-14** 2,12-Dimethyl-7-oxo-tridecane-2,12-disulfonic acid;
- II-15** Phosphoric acid mono-(1,1,11-trimethyl-6-oxo-11-phosphonooxy-dodecyl) ester;

	II-16	2,2,14,14-Tetramethyl-8-oxo-pentadecanedial;
	II-17	2,2,14,14-Tetramethyl-8-oxo-pentadecanedioic acid dimethyl ester;
5	II-18	2,2,14,14-Tetramethyl-1,15-diphenyl-pentadecane-1,8,15-trione;
	II-19	3,3,15,15-Tetramethyl-1,17-diphenyl-heptadecane-2,9,16-trione;
	II-20	2,14-Dimethyl-8-oxo-pentadecane-2,14-disulfonic acid;
10	II-21	Phosphoric acid mono-(1,1,13-trimethyl-7-oxo-13-phosphonooxy-tetradecyl) ester;
	II-22	1,15-Dihydroxy-3,3,13,13-tetramethyl-pentadecan-8-one;
15	II-23	15-Hydroxy-3,3,13,13-tetramethyl-8-oxo-pentadecanoic acid;
	II-24	1,13-Dihydroxy-3,3,11,11-tetramethyl-tridecan-7-one;
20	II-25	1,13-Dihydroxy-3,3,11,11-tetramethyl-tridecan-7-one;
	II-26	13-Hydroxy-3,3,11,11-tetramethyl-7-oxo-tridecanoic acid;
	II-27	3,3,11,11-Tetramethyl-7-oxo-tridecanedioic acid;
25	II-28	1,17-Dihydroxy-3,3,15,15-tetramethyl-heptadecan-9-one;
	II-29	17-Hydroxy-3,3,15,15-tetramethyl-9-oxo-heptadecanoic acid;
30	II-30	3,3,15,15-Tetramethyl-9-oxo-heptadecanedioic acid;
	II-31	1,17-Dihydroxy-4,4,14,14-tetramethyl-heptadecan-9-one;
	II-32	17-Hydroxy-4,4,14,14-tetramethyl-9-oxo-heptadecanoic acid;
35	II-33	4,4,14,14-Tetramethyl-heptadecan-9-oxo-1,17-dicarboxylic acid;
	II-34	1,15-Dihydroxy-4,4,14,14-tetramethyl-pentadecan-8-one;
40	II-35	15-Hydroxy-4,4,12,12-tetramethyl-8-oxo-pentadecanoic acid;
	II-36	4,4,12,12-Tetramethyl-8-oxo-pentadecanedioic acid;
	II-37	1,19-Dihydroxy-4,4,16,16-tetramethyl-nonadecan-10-one;
45	II-38	19-Hydroxy-4,4,16,16-tetramethyl-10-oxo-nonadecanoic acid;
	II-39	4,4,16,16-Tetramethyl-10-oxo-nonadecanedioic acid;
50	II-40	2,10-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4 <i>H</i> -thieno[3,2- <i>c</i>]pyridin-5-yl)-2,10-dimethyl-undecan-6-one;

- 5
10
15
20
25
30
35
40
45
50
- II-41 2,10-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,10-dimethyl-undecan-6-one;
 - II-42 2,2,10,10-Tetramethyl-6-oxo-undecanedioic acid bis-cyanamide;
 - II-43 Phosphoramidic acid mono-[9-(amino-hydroxy-phosphoryloxy)-1,1,9-trimethyl-5-oxo-decyl] ester;
 - II-44 Phosphoramidic acid mono-[9-(amino-hydroxy-phosphoryloxy)-1,1,9-trimethyl-5-oxo-decyl] ester;
 - II-45 2,12-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,12-dimethyl-tridecan-7-one;
 - II-46 2,12-Bis-(4,6-dithioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,12-dimethyl-tridecan-7-one;
 - II-47 2,2,12,12-Tetramethyl-7-oxo-tridecanedioic acid bis-cyanamide;
 - II-48 Phosphoramidic acid mono-[11-(amino-hydroxy-phosphoryloxy)-1,1,11-trimethyl-6-oxo-dodecyl] ester;
 - II-49 Phosphoramidic acid mono-[11(amino-hydroxy-phosphoryloxy)-1,1,11-trimethyl-6-oxo-dodecyl] ester;
 - II-50 2,12-Dimethyl-2,12-bis-tetrazol-1-yl-tridecan-7-one;
 - II-51 2,12-Dimethyl-2,12-bis-(1*H*-tetrazol-5-yl)-tridecan-7-one;
 - II-52 2,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,12-dimethyl-tridecan-7-one;
 - II-53 2,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,12-dimethyl-tridecan-7-one;
 - II-54 4-[11-(4-oxo-oxetan-2-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-oxetan-2-one;
 - II-55 3-[11-(4-oxo-oxetan-2-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-oxetan-2-one;
 - II-56 5-[11-(5-oxo-tetrahydro-furan-3-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-dihydro-furan-2-one;
 - II-57 3-[11-(5-oxo-tetrahydro-furan-3-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-dihydro-furan-2-one;
 - II-58 4-[11-(5-oxo-tetrahydro-furan-3-yl)-1,1,11-Trimethyl-6-oxo-dodecyl]-dihydro-furan-2-one;
 - II-59 2,12-Dimethyl-2,12-bis-(tetrahydro-pyran-2-yloxy)-tridecan-7-one;
 - II-60 {2-[9-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-1,1,9-trimethyl-5-oxo-decyl]-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl}-acetic acid;
 - IIa-1 1,15-Dihydroxy-2,14-dimethyl-2,14-diphenyl-pentadecan-8-one;

- IIa-2** 15-Hydroxy-2,14-dimethyl-8-oxo-2,14-diphenyl-pentadecanoic acid;
- IIa-3** 2,14-Dimethyl-8-oxo-2,14-diphenyl-pentadecanedioic acid;
- 5 IIa-4** 1,13-Dihydroxy-2,12-dimethyl-2,12-diphenyl-tridecan-7-one;
- IIa-5** 13-Hydroxy-2,12-dimethyl-7-oxo-2,12-diphenyl-tridecanoic acid;
- 10 IIa-6** 2,12-Dimethyl-7-oxo-2,12-diphenyl-tridecanedioic acid;
- IIa-7** 1,11-Dihydroxy-2,10-dimethyl-2,10-diphenyl-undecan-6-one;
- IIa-8** 11-Hydroxy-2,10-dimethyl-6-oxo-2,10-diphenyl-undecanoic acid;
- 15 IIa-9** 2,10-Dimethyl-6-oxo-2,10-diphenyl-undecanedioic acid;
- IIa-10** 2,14-Dimethyl-8-oxo-2,14-diphenyl-pentadecanedial;
- 20 IIa-11** 2,14-Dimethyl-8-oxo-2,14-diphenyl-pentadecanedioic acid dimethyl ester;
- IIa-12** 2,14-Dimethyl-1,2,14,15-tetraphenyl-pentadecane-1,8,15-trione;
- IIa-13** 3,15-Dimethyl-1,3,15,17-tetraphenyl-heptadecane-2,9,16-trione;
- 25 IIa-14** 8-Oxo-2,14-diphenyl-pentadecane-2,14-disulfonic acid;
- IIa-15** Phosphoric acid mono-(1-methyl-7-oxo-1,13-diphenyl-13-phosphonooxy-tetradecyl) ester;
- 30 IIa-16** 1,17-Dihydroxy-3,15-dimethyl-3,15-diphenyl-heptadecan-9-one;
- IIa-17** 17-Hydroxy-3,15-dimethyl-9-oxo-3,15-diphenyl-heptadecanoic acid;
- 35 IIa-18** 3,15-Dimethyl-9-oxo-3,15-diphenyl-heptadecanedioic acid;
- IIa-19** 1,15-Dihydroxy-3,13-dimethyl-3,13-diphenyl-pentadecan-8-one;
- IIa-20** 15-Hydroxy-3,13-dimethyl-8-oxo-3,13-diphenyl-pentadecanoic acid;
- 40 IIa-21** 3,13-Dimethyl-8-oxo-3,13-diphenyl-pentadecanedioic acid;
- IIa-22** 1,13-Dihydroxy-3,11-dimethyl-3,11-diphenyl-tridecan-7-one;
- 45 IIa-23** 13-Hydroxy-3,11-dimethyl-7-oxo-3,11-diphenyl-tridecanoic acid;
- IIa-24** 3,11-Dimethyl-7-oxo-3,11-diphenyl-tridecanedioic acid;
- IIa-25** 13-Hydroxy-3,11-dimethyl-7-oxo-3,11-diphenyl-tridecanoic acid;
- 50 IIa-26** 3,11-Dimethyl-7-oxo-3,11-diphenyl-tridecanedioic acid;
- IIa-27** 1,19-Dihydroxy-4,16-dimethyl-4,16-diphenyl-nonadecan-10-one;

- IIa-28** 19-Hydroxy-4,16-dimethyl-10-oxo-4,16-diphenyl-nonadecanoic acid;
- IIa-29** 4,16-Dimethyl-10-oxo-4,16-diphenyl-nonadecanedioic acid;
- 5 **IIa-30** 1,17-Dihydroxy-4,14-dimethyl-4,14-diphenyl-heptadecan-9-one;
- IIa-31** 17-Hydroxy-4,14-dimethyl-9-oxo-4,14-diphenyl-heptadecanoic acid;
- 10 **IIa-32** 4,14-Dimethyl-9-oxo-4,14-diphenyl-heptadecanedioic acid;
- IIa-33** 1,15-Dihydroxy-4,12-dimethyl-4,12-diphenyl-pentadecan-8-one;
- IIa-34** 15-Hydroxy-4,12-dimethyl-8-oxo-4,12-diphenyl-pentadecanoic acid;
- 15 **IIa-35** 4,12-Dimethyl-8-oxo-4,12-diphenyl-pentadecanedioic acid;
- IIa-36** 2,12-Bis-(4,6-dioxo-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,12-diphenyl-tridecan-7-one;
- 20 **IIa-37** 2,12-Bis-(4,6-dithio-2,3,3a,6-tetrahydro-4*H*-thieno[3,2-*c*]pyridin-5-yl)-2,12-diphenyl-tridecan-7-one;
- IIa-38** 2,12-Dimethyl-2,12-diphenyl-7-oxo-tridecanedioic acid bis-cyanamide;
- 25 **IIa-39** Phosphoramidic acid mono-(amino-hydroxy-phosphoryloxy)-1-methyl-6-oxo-1,11-diphenyl-dodecyl] ester;
- IIa-40** Phosphoramidic acid mono-[11(amino-hydroxy-phosphoryloxy)-1,11-diphenyl-1-methyl-6-oxo-dodecyl] ester;
- 30 **IIa-41** 2,12-Diphenyl-2,12-bis-tetrazol-1-yl-tridecan-7-one;
- IIa-42** 2,12-Diphenyl-2,12-bis-(1*H*-tetrazol-5-yl)-tridecan-7-one;
- 35 **IIa-43** 2,12-Bis-(3-hydroxy-isoxazol-5-yl)-2,12-diphenyl-tridecan-7-one;
- IIa-44** 2,12-Bis-(3-hydroxy-isoxazol-4-yl)-2,12-diphenyl-tridecan-7-one;
- 40 **IIa-45** 2,12-Diphenyl-2,12-bis-(tetrahydro-pyran-2-yl)-tridecan-7-one;
- IIa-46** 5-[11-(5-oxo-tetrahydro-furan-2-yl)-1,11-Diphenyl-1-methyl-6-oxo-dodecyl]-dihydro-furan-2-one;
- 45 **IIa-47** 4-[11-(4-oxo-oxetan-2-yl)-1,11-diphenyl-1-methyl-6-oxo-dodecyl]-oxetan-2-one;
- IIa-48** 4-[11-(5-oxo-tetrahydro-furan-2-yl)-1,11-Diphenyl-1-methyl-6-oxo-dodecyl]-dihydro-furan-2-one;
- 50 **IIa-49** 3-[11-(5-oxo-tetrahydro-furan-2-yl)-1,11-Diphenyl-1-methyl-6-oxo-dodecyl]-dihydro-furan-2-one;

- IIa-50** {2-[11-(4-Carboxymethyl-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-1-methyl-6-oxo-1,11-diphenyl-dodecyl]-4-hydroxy-6-oxo-tetrahydro-pyran-4-yl}-acetic acid;
- 5 III-1** 5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-2** 5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 10 III-3** 5-(6-{3-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 15 III-4** 5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-5** 5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 20 III-6** 5-(6-{3-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-7** 6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- 25 III-8** 6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 30 III-9** 6-(6-{3-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-propyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-10** 6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- 35 III-11** 6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-12** 6-(6-{3-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-propyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 40 III-13** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol;
- III-14** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- 45 III-15** 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- 50 III-16** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol;

- III-17** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 5 III-18** 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-19** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- 10 III-20** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-21** 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 15 III-22** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-23** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- 20 III-24** 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-vinyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- 25 III-25** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-26** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 30 III-27** 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-vinyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-28** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- 35 III-29** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 40 III-30** 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-vinyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-31** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- 45 III-32** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-33** 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 50**

- III-34** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- 5** **III-35** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-36** 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 10** **III-37** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-38** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 15** **III-39** 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-ethyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 20** **III-40** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-41** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 25** **III-42** 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-ethyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-43** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol;
- 30** **III-44** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- 35** **III-45** 6-(6-{2-[6-(6-Carboxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- III-46** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol;
- 40** **III-47** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-48** 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 45** **III-49** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- 50** **III-50** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;

- III-51** 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-52** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-53** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- III-54** 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-phenyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- III-55** 5-(6-{2-[6-(5-Hydroxy-4-methyl-pentyl)-1,4-dioxo-cyclohex-2-yl]-phenyl}-1,4-dioxo-cyclohex-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-56** 5-(6-{2-[6-(5-Hydroxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-57** 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1,4-dioxo-cyclohexadien-2-yl]-phenyl}-1,4-dioxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-58** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-59** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-60** 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-4,4-dimethyl-1-oxo-cyclohexadien-2-yl]-phenyl}-4,4-dimethyl-1-oxo-cyclohexadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-61** 5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-62** 5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-63** 5-(5-{3-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-64** 6-(5-{3-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- III-65** 6-(5-{3-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-66** 6-(5-{3-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentadien-2-yl]-propyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-67** 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexan-1-ol;

- III-68** 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid;
- 5** **III-69** 6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid;
- III-70** 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- 10** **III-71** 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid;
- III-72** 6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 15** **III-73** 5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentan-1-ol;
- 20** **III-74** 5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid;
- III-75** 5-(5-{2-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid;
- 25** **III-76** 5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- III-77** 5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 30** **III-78** 5-(5-{2-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 35** **III-79** 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexan-1-ol;
- III-80** 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid;
- 40** **III-81** 6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentan-2-yl]-vinyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-hexanoic acid;
- III-82** 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexan-1-ol;
- 45** **III-83** 6-(5-{2-[5-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid;
- 50** **III-84** 6-(5-{2-[5-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclopentadien-2-yl]-vinyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-hexanoic acid;

- III-85** 5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-ethyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentan-1-ol;
- 5 III-86** 5-(5-{2-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentadien-2-yl]-ethyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid;
- III-87** 5-(5-{2-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentadien-2-yl]-ethyl}-1-oxo-cyclopentadien-2-yl)-2,2-dimethyl-pentanoic acid;
- 10 IIIa-1** 5-(6-{3-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol;
- IIIa-2** 5-(6-{3-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- 15 IIIa-3** 5-(6-{3-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- IIIa-4** 6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol;
- 20 IIIa-5** 6-(6-{3-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- 25 IIIa-6** 6-(6-{3-[6-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclohexan-2-yl]-propyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- IIIa-7** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexan-1-ol;
- 30 IIIa-8** 6-(6-{2-[6-(6-Hydroxy-5,5-dimethyl-hexyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- IIIa-9** 6-(6-{2-[6-(5-Carboxy-5-methyl-hexyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-hexanoic acid;
- 35 IIIa-10** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentan-1-ol;
- 40 IIIa-11** 5-(6-{2-[6-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- IIIa-12** 5-(6-{2-[6-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclohexan-2-yl]-ethyl}-1-oxo-cyclohexan-2-yl)-2,2-dimethyl-pentanoic acid;
- 45 IIIa-13** 5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-propyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentan-1-ol;
- 50 IIIa-14** 5-(5-{3-[5-(5-Hydroxy-4,4-dimethyl-pentyl)-1-oxo-cyclopentan-2-yl]-propyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid; or

IIIa-15 5-(5-{3-[5-(4-Carboxy-4-methyl-pentyl)-1-oxo-cyclopentan-2-yl]-propyl}-1-oxo-cyclopentan-2-yl)-2,2-dimethyl-pentanoic acid.

5 36. A pharmaceutical composition comprising a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35 and a pharmaceutically acceptable vehicle, excipient, or diluent.

 37. A pharmaceutical composition comprising the following compound:
6-(5,5-Dimethyl-6-hydroxy-hexane-1-sulfinyl)-2,2-dimethyl-hexan-1-ol or pharmaceutically
10 acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof and a pharmaceutically acceptable vehicle, excipient, or diluent.

 38. A method for treating or preventing a cardiovascular disease in a patient,
15 comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

 39. A method for treating or preventing a dyslipidemia in a patient, comprising
administering to a patient in need of such treatment or prevention a therapeutically effective
20 amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

 40. A method for treating or preventing a dyslipoproteinemia in a patient,
comprising administering to a patient in need of such treatment or prevention a
therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35
25 .

 41. A method for treating or preventing a disorder of glucose metabolism in a
patient, comprising administering to a patient in need of such treatment or prevention a
therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.
30

 42. A method for treating or preventing Alzheimer's Disease in a patient,
comprising administering to a patient in need of such treatment or prevention a
therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

43. A method for treating or preventing Syndrome X or Metabolic Syndrome in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

5 44. A method for treating or preventing septicemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

10 45. A method for treating or preventing a thrombotic disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

15 46. A method for treating or preventing a peroxisome proliferator activated receptor associated disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

20 47. A method for treating or preventing obesity in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

25 48. A method for treating or preventing pancreatitis in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

 49. A method for treating or preventing hypertension in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

30 50. A method for treating or preventing renal disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

51. A method for treating or preventing cancer in a patient, comprising administering to a patient in claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

5 52. A method for treating or preventing inflammation in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

10 53. A method for treating or preventing impotence in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

15 54. A method for reducing the fat content of meat in livestock comprising administering to livestock in need of such reduction a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

55. A method for reducing the cholesterol content of fowl eggs comprising administering to a fowl a therapeutically effective amount of a compound of claim 1, 9, 15, 18, 20, 21, 26, 31 or 35.

20

EFFECT OF ONE WEEK OF DAILY ORAL GAVAGE TREATMENT WITH COMPOUND B ON LIPOPROTEIN
TOTAL CHOLESTEROL IN CHOW-FED MALE SPRAGUE-DAWLEY RATS




FIG.1

EFFECT OF ONE WEEK OF DAILY ORAL GAVAGE TREATMENT WITH COMPOUND B ON SERUM LIPIDS IN CHOW-FED MALE SPRAGUE-DAWLEY RATS




FIG.2

3/5

EFFECT OF TWO WEEKS OF DAILY ORAL GAVAGE TREATMENT WITH
COMPOUND B ON LIPOPROTEIN TOTAL CHOLESTEROL
IN CHOW FED OBESE FEMALE ZUCKER RATS




FIG.3

4/5

EFFECT OF TWO WEEKS OF DAILY ORAL GAVAGE TREATMENT WITH COMPOUND B
IN CHOW-FED OBESE FEMALE ZUCKER RATS

VARIABLE	UNITS	CONTROL n=3			COMPOUND B n=4 97/mg/kg/day		
		Pre	1 Week	2 Week	Pre	1 Week	2 Week
14 Day Percent Weight Gain	Percent	0		13.6	0		14.6
Liver/Body Weight	Percent			4.09			5.70
Blood Glucose	mg/dL	122	98	130	108	116	120
Insulin	ng/mL	12.2	8.7	6.2	10.0	8.7	8.7
Non-Esterified Fatty Acids	mmol/L	1.95	1.27	1.21	2.13	0.60	0.57
β -hydroxy butyrate	mg/dL	2.29	1.62	2.90	1.44	2.56	3.97
Total Cholesterol	mg/dL	62	56	68	59	93	112
Percent HDL Cholesterol (Gain/Loss)	Percent	0	-10	10	0	58	90
VLDL plus LDL Cholesterol	mg/dL	21	26	27	21	17	19
HDL Cholesterol	mg/dL	42	30	41	38	76	93
Percent HDL Cholesterol (Gain/Loss)	Percent	0	-28	0	0	99	143
HDL/(VLDL plus LDL)	Ratio	2.32	1.30	1.77	1.97	4.85	5.47
Triglycerides	mg/dL	999	984	887	861	299	324
Triglycerides (Gain/Loss)	Percent	0	-2	-11	0	-65	.82

FIG. 4

5/5

**¹⁴C-ACETATE INCORPORATION INTO SAPONIFIED
AND NON-SAPONIFIED LIPIDS**




FIG.5

INTERNATIONAL SEARCH REPORT

ational Application No

PCT/US 01/31872

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C49/17 C07C49/245 C07C49/258 C07C49/185 A61K31/12
 A61K31/122 A61K31/185 A61K31/21 A61K31/275 A61K31/095
 A61K31/33 A61K31/66 A61P9/00 C07C49/82 C07C49/86

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D C07F A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NAN F ET AL: "Dual function glutamate-related ligands: discovery of a novel, potent inhibitor of glutamate carboxypeptidase II possessing mGluR3 agonist activity" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 43, no. 5, 9 March 2000 (2000-03-09), pages 772-774, XP002144187 ISSN: 0022-2623 the whole document	1-55
A	US 3 441 605 A (STEPHEN BLAKE) 29 April 1969 (1969-04-29) the whole document	1

-/--

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

17 May 2002

Date of mailing of the international search report

29/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Beslier, L

INTERNATIONAL SEARCH REPORT

ational Application No

PCT/US 01/31872

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C49/782 C07C49/215 C07C49/723 C07C49/743 C07C49/747
 C07C49/507 C07C50/30 C07C261/04 C07F9/09 C07F9/24
 C07F9/44 C07C69/716 C07C69/738 C07C309/24 C07C309/07

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 00 64911 A (GEORGETOWN UNIVERSITY) 2 November 2000 (2000-11-02) the whole document ---	1-55
P,A	WO 01 46110 A (THE UNIVERSITY OF GEORGIA) 28 June 2001 (2001-06-28) the whole document -----	1-55



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

17 May 2002

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Beslier, L

International Application No
PCT/US 01/31872

IPC 7	C07C59/84	C07C59/347	C07C59/90	C07C59/50	C07C59/86
	C07C59/82	C07D309/30	C07D495/04	C07D257/04	C07D261/12
	C07D309/40	C07D233/72	C07D233/84	C07D233/86	C07D309/12

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

P document published prior to the international filing date but later than the priority date claimed

***&** document member of the same patent family

17 May 2002

Date of mailing of the international search report

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Besler, L

INTERNATIONAL SEARCH REPORT

tional Application No

PCT/US 01/31872

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D305/12 C07D307/33

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

17 May 2002

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Beslier, L

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-18, 20-34 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the examples.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/31872

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 3441605	A	29-04-1969	BE 676592 A	16-08-1966
			DE 1543984 A1	05-02-1970
			FR 1471295 A	03-03-1967
			NL 6602087 A	18-08-1966
WO 0064911	A	02-11-2000	AU 4668200 A	10-11-2000
			EP 1177200 A1	06-02-2002
			WO 0064911 A1	02-11-2000
WO 0146110	A	28-06-2001	AU 2291001 A	03-07-2001
			WO 0146110 A2	28-06-2001
			US 2002040029 A1	04-04-2002